PROGRAMME. See you next year in VIENNA April

Transcription

1 PROGRAMME April See you next year in VIENNA

2 DOWNLOAD THE INTERNATIONAL LIVER CONGRESS 2018 APP ON YOUR MOBILE DEVICE! The ILC 2018 app provides full-access to the scientific programme, posters and abstracts, as well as maps of the halls and exhibition area. See who's attending, search the full programme, save your favourite sessions, create notes, and interact with speakers while they are presenting. Download the ILC 2018 app now! Discover all the feature of our congress app at ilc-congress.eu/mobile-app/

3 Use eposter connect to meet an author! Download the app Go to eposter connect Choose a poster and request presentation Plan a meeting with the author Meet at the eposter connect terminals

4 Specialties Cirrhosis and complications Liver tumours General hepatology Metabolism, alcohol and toxicity Viral hepatitis Cholestasis and autoimmune Fields Liver transplant and surgery Public health Basic and translational science Imaging and interventional What s your colour? Follow the colour codes and pictogrammes throughout this book to find the sessions of interest to you!

5 11-15 APRIL 2018 PARIS, FRANCE ORGANISED BY EASL The Home of Hepatology European Association for the Study of the Liver Rue Daubin 7, 1203 Geneva, Switzerland Tel: +41 (0) REGISTRATION AGENCY Congrex Switzerland On behalf of The International Liver Congress 2018 Peter Merian Strasse 80, 4002 Basel, Switzerland Tel: +41 (0) Congress registration hotline Sunday 08 April: 14:00-18:00 Monday 09 April: 08:00 18:00 Tuesday 10 April: 08:00 19:00 Wednesday 11 Sunday 15 April: during congress hours Tel: +33 (0) HOUSING AGENCY b network 20 rue Royale, Paris, France ILC2018@b-network.com Tel: +33 (0) Tel: +33 (0) THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 3

6 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME TABLE OF CONTENTS Welcome messages... 7 Welcome message from the EASL Secretary General and Vice-Secretary...8 Welcome message from ILC 2018 Honorary President...10 Opening ceremony...11 General congress information...13 Congress venue...14 General site plans...15 Opening hours Registration Young Investigators CME accreditation EASL...29 EASL Governing Board Awards...33 EASL Award ceremonies and awardees Information for presenters...39 For oral presenters For poster presenters...41 Scientific programme overview...45 What s your colour? Scientific highlights Session format description...52 Abstract presentations...55 Daily Wednesday Daily Thursday Daily Friday...62 Daily Saturday Daily Sunday EASL THE HOME OF HEPATOLOGY

7 11-15 APRIL 2018 PARIS, FRANCE Scientific programme...69 Wednesday 11 April...69 Thursday 12 April...85 Friday 13 April Saturday 14 April Sunday 15 April Late-breaker posters Posters Thursday 12 April Friday 13 April Saturday 14 April Acknowledgements Abstract reviewers Sponsors National associations village Industry Satellite symposia Mini-workshops Exhibition Exhibitor s list Meeting rooms Company profiles Association profiles THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 5

8

9 11-15 APRIL 2018 PARIS, FRANCE WELCOME MESSAGES EASL THE HOME OF HEPATOLOGY

10 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME WELCOME MESSAGES WELCOME MESSAGE FROM THE EASL SECRETARY GENERAL AND VICE-SECRETARY Dear Colleagues, Welcome to Paris to The International Liver Congress TM 2018 (ILC 2018), the 53rd annual meeting of the European Association for the Study of the Liver (EASL), the Home of Hepatology! We are delighted to invite you to join the international liver community at the Paris Expo Porte de Versailles Pavillon 7, 1 Place de la Porte de Versailles, Paris, from 11 to 15 April Hepatology is undergoing dramatic changes with highly effective drugs to cure hepatitis C, a major increase of metabolic liver diseases and liver cancer worldwide, and multiple novel innovative treatment concepts for rare liver diseases and hepatitis B emerging. New alliances are forming, for instance, with diabetologists and oncologists, reflecting the multidisciplinary landscape in which EASL remains the hub. It is our great pleasure and honour to welcome you to ILC 2018, where we bring together clinicians, scientists and hepatology associates from all around the world to discuss latest advances at the frontline of hepatology and related disciplines. Complementary to the new tools of digital communication, ILC 2018 provides a unique opportunity to meet and discuss clinical innovation and research challenges but also to interact socially, network and develop future collaborations. The 2018 ILC highlights comprise: Over 1,500 original scientific projects presented from almost 3,000 submitted abstracts Complete tracks within all major topics of hepatology will keep you busy at all times regardless of your interest New tracks in the programme this year: comprehensive public health, surgical and basic science tracks Clinical postgraduate course on Viral hepatitis and basic science seminar on Targetable pathways in liver disease State of the art lectures on Is it time to abandon the diagnosis of cirrhosis? and Beyond albumin and IgG - the unexpected prospects of the neonatal Fc receptor 8 EASL THE HOME OF HEPATOLOGY

11 11-15 APRIL 2018 PARIS, FRANCE For the first time, a comprehensive transplant and surgery postgraduate course Many interactive sessions: breakfast morning rounds, grand rounds, Meet the experts workshops, a comprehensive skills-learning track and a new Research Think Tank concept Major EASL Clinical Practice Guidelines releases, including hepatocellular carcinoma, decompensated cirrhosis, alcoholic liver diseases and updated recommendations on hepatitis C Evolving the Home of Hepatology concept with collaborative sessions with multiple societies Dedicated arenas for young investigator involvement Selected sessions and posters will be webcasted and made available on the LiverTree TM for EASL members to view. WELCOME MESSAGES Looking forward to seeing you in Paris. Warmest regards, Whether you are a young investigator, clinician, basic scientist, nurse, or a researcher, you will be exposed to the latest data in your specialty and can broaden your horizons at ILC Take part in an exciting week of liver discoveries and exchange. TOM HEMMING KARLSEN EASL Secretary General FRANK TACKE EASL Vice-Secretary THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 9

12 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME WELCOME MESSAGES WELCOME MESSAGE FROM THE ILC 2018 HONORARY PRESIDENT Dear colleagues, visitors and friends, It was a complete surprise when I received a letter from the EASL Governing Board asking me to become Honorary President Not at all convinced that I deserved this honour, I nevertheless accepted with a small degree of vanity, but mostly with gratitude for those who helped me on my journey through medicine, especially through hepatology, and to those who introduced me to EASL almost forty years ago. So welcome to ILC, Paris and EASL, welcome to IPE! Alas, another acronym! I offer you several further solutions (you may also find one of your own): With respect to our congress: Ingredients of hepatology Performance of world experts Efforts of young colleagues With respect to the venue: Île de la Cité Proust Eiffel With respect to science: Irresistible challenge Puzzle of nature Errors to detect With respect to medicine: Invest in patients! Persist in learning! Earn the confidence! Enjoy working on liver diseases! Enjoy science and culture! Enjoy each other! Enjoy the congress! Best wishes, Tilman Sauerbruch, M.D. Honorary President of The International Liver Congress 2018 and Emeritus Professor, University of Bonn, Germany 10 EASL THE HOME OF HEPATOLOGY

13 11-15 APRIL 2018 PARIS, FRANCE OPENING CEREMONY Thursday 12 April at 13:30 in the main plenary hall 7.3. Join us to kickstart the congress week! Opening words by ILC 2018 Honorary President Prof. Tilman Sauerbruch Opening speech by EASL Secretary General Prof. Tom H. Karlsen Speech by Tatjana Reic, President of ELPA, European Liver Patients Association WELCOME MESSAGES Speech by Michael Ninburg, President of WHA, World Hepatitis Alliance THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 11

14 SHARE ZONE BIOTECH VILLAGE CAREER CENTRE EASL COMMUNITY HUB Hall 7.2 NETWORKING LOUNGE

15 11-15 APRIL 2018 PARIS, FRANCE GENERAL CONGRESS INFORMATION EASL THE HOME OF HEPATOLOGY

16 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME CONGRESS VENUE PARIS CONVENTION CENTRE GENERAL CONGRESS INFORMATION Paris Expo Porte de Versailles Pavillon 7 1 Place de la Porte de Versailles, Porte/Gate A Paris France Nearest tramway/metro stops: Porte de Versailles-Parc des Expositions For your security in the congress venue, a full body and luggage check will be carried out upon your arrival in the entrance area of Pavillon 7. It is therefore recommended to arrive at least 30 minutes before your first session. WI-FI INTERNET CONNECTION Network: ILC2018 Password: ilcapril2018 The Wi-Fi connection will be available throughout the congress centre. We ask you to avoid downloading heavy files, movies or music during the congress as it will affect the connection speed for other attendees. 14 EASL THE HOME OF HEPATOLOGY

17 11-15 APRIL 2018 PARIS, FRANCE GENERAL SITE PLANS CONGRESS CENTRE AND MAP GENERAL CONGRESS INFORMATION PAVILLON 7-OVERVIEW 7.4 Private meeting rooms Registration area/easl booth / Plenaries/Press office/meeting rooms Poster area/exhibition Meeting rooms ILC 2018 Main entrance Oceanie meeting rooms in Pavillon 4 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 15

18 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME FLOOR 7.3 GENERAL CONGRESS INFORMATION OVERFLOW AREA EAST 3 EAST 2 EAST 1 SOUTH 4 SOUTH 3 WED & SUN eposters WED & SUN MAIN PLENARY Access to hall 7.2 SOUTH 2 SAT Skills Learning Centre Skills Learning Centre Meet the Experts SOUTH 1 WEST 6 WEST 5 WEST 4 WEST 3 WEST 2 WEST 1 Access to hall 7.2 EXECUTIVE LOUNGE FACULTY REGISTRATION SPEAKERS' READY ROOM REGISTRATION AREA EASL BOOTH SAT NORTH 1 MEETING ROOMS ENTRANCE 16 EASL THE HOME OF HEPATOLOGY

19 11-15 APRIL 2018 PARIS, FRANCE FLOOR 7.2 For detailed exhibition and meeting room plans, see pages MEETING ROOMS b a 817 POSTER AREA 2 Posters POSTER AREA 1 Posters THU-SAT Abbvie 510 Intercept EASL EDUCATION JOURNAL OF HEPATOLOGY EASL APPS eposters Access to hall 7.3 EASL COMMUNITY HUB BIOTECH VILLAGE CAREER CENTRE EASL SHARE ZONE THU-SAT POSTER AREA 3 Posters POSTER AREA 4 Posters Norgine THU-SAT GENERAL CONGRESS INFORMATION THU-SAT Abbvie 410 Access to hall 7.3 Gilead Intercept MSD 310 DELEGATE LOUNGE sponsored by Bristol-Myers Squibb Gilead 240 Gilead THU-SAT Exhibition & meeting rooms help desk ENTRANCE TO MEETING ROOMS ENTRANCE TO EXHIBITION Poster help desk & poster tours meeting points MEETING ROOMS THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 17

20 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME POSTER AREA GENERAL CONGRESS INFORMATION POSTER AREA POSTER AREA POD 2 POD 1 LATE-BREAKERS LBP eposters EASL EDUCATION JOURNAL OF HEPATOLOGY EASL APPS THU-SAT Poster help desk & poster tours meeting points Access to hall EASL THE HOME OF HEPATOLOGY

21 11-15 APRIL 2018 PARIS, FRANCE POSTER AREA 3 POD POSTER AREA 4 POD GENERAL CONGRESS INFORMATION THU-SAT THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 19

22 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME OPENING HOURS PARIS EXPO PORTE DE VERSAILLES Pavillon 7 / Oceanie rooms in Pavillon 4 GENERAL CONGRESS INFORMATION Opening: 30 minutes before the first session each day Closing: 30 minutes after the last session each day For your security in the congress venue, a full body and luggage check will be carried out upon your arrival in the entrance area of Pavillon 7. It is therefore recommended to arrive at least 30 minutes before your first session. FLOOR 7.1, MAIN ENTRANCE CLOAKROOM Wednesday 11 to Saturday 14 April 07:00-20:00 Sunday 15 April 07:00-14:00 EASL waives any responsibility for lost or damaged belongings. All items are left at the owner s own risk. Please make sure to pick-up your belongings before closing. HALL 7.3 REGISTRATION AREA Help desk, hotel desk, congress material, congress app Tuesday 10 April 16:00-19:00 Wednesday 11 to Saturday 14 April 07:00-19:00 Sunday 15 April 07:00-14:00 NEW for EASL members Gain time in Paris. Use fast track lanes for onsite registration and badge pick-up. Group badge pick-up Only for large groups and on special request Monday 9 April 14:00-18:00 Tuesday 10 April 08:00-14:00 20 EASL THE HOME OF HEPATOLOGY

23 11-15 APRIL 2018 PARIS, FRANCE EASL BOOTH EASL membership, future events, social media coffee lounge Tuesday 10 April 16:00-19:00 Wednesday 11 to Saturday 14 April 07:00-19:00 Sunday 15 April 07:00-14:00 EXECUTIVE LOUNGE Faculty registration and speakers ready room Tuesday 10 April 16:00-19:00 Wednesday 11 to Saturday 14 April 07:00-19:00 Sunday 15 April 07:00-14:00 PRESS OFFICE Tuesday 10 April 16:00-19:00 Wednesday 11 to Saturday 14 April 07:00-19:00 Sunday 15 April 07:00-14:00 GENERAL CONGRESS INFORMATION HALL 7.2 POSTER AREA Thursday 12 to Saturday 14 April 09:00-17:00 Poster help desk 09:00-17:30* * Presenters can collect their poster from their dedicated board at the end of their presentation day. If posters are not picked up by the presenter they will be discarded. EASL COMMUNITY HUB Biotech village, share zone & networking lounge, career centre Thursday 12 to Saturday 14 April 09:00-17:00 EASL EDUCATION ZONE Journal of Hepatology, EASL apps, poster help desk, eposters activities and meeting points Thursday 12 to Saturday 14 April 09:00-17:00 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 21

24 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME EXHIBITION Thursday 12 to Saturday 14 April 09:00-17:00 Please refer to the list of exhibitors on for further info. GENERAL CONGRESS INFORMATION MEETING ROOMS Floor 7.2, 7.3, 7.4 & Oceanie rooms in Pavillon 4 Wednesday 11 to Saturday 14 April 07:00-19:00 Sunday 15 April 07:00-14:00 EXHIBITION & MEETING ROOMS HELP DESK Monday 09 to Wednesday 11 April 08:00-20:00 Thursday 12 to Saturday 14 April 08:00-17:00 Sunday 15 April 08:00-18:00 COMPLIMENTARY CATERING EASL will provide a limited amount of complimentary catering during coffee breaks and lunches on a first come first served basis. The serving times are indicated in the daily programmes pages Complimentary lunch and coffee breaks will be served in hall 7.2 and 7.3 as follows: = Lunch =coffee Wednesday 11 April Hall 7.3 Hall 7.2 Thursday 12 April Friday 13 April Saturday 14 April Sunday 15 April 22 EASL THE HOME OF HEPATOLOGY

25 11-15 APRIL 2018 PARIS, FRANCE CATERING OUTLETS The following catering outlets will also be open on-site if you wish to purchase food and beverages. HALL 7.3 HALL 7.2 Wednesday 11 to Saturday 14 April 07:00-18:00 Sunday 15 April 07:00-13:00 Thursday 12 to Saturday 14 April 09:00-17:00 GENERAL CONGRESS INFORMATION THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 23

26 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME REGISTRATION On-site registration, congress material pick-up, and badge collection will be available at the registration area. For opening hours, please refer to pages GENERAL CONGRESS INFORMATION BADGES All delegates and exhibitors are requested to wear their ILC badge at all times in order to be given access to the congress venue. Persons not wearing an ILC badge will not be granted access past the registration area. All congress attendees will be provided with one of the following badge types and coloured ribbons. BADGE CATEGORIES Delegates: Non-Prescribers Prescribers Delegates are admitted into the lecture halls and other scheduled activities, as well as the catering areas. Only delegates who have pre-booked their session in the skills learning centre and to the postgraduate course will be admitted entrance to such sessions. Exhibition area: access to non-prescribers is restricted. Exhibitors Exhibitors are admitted into the exhibition area as well as the catering areas but have no access to the lecture halls. They can also attend the industry satellite symposia of their respective company. Media The media badge gives access to the congress sessions and media areas. Please ensure that you have your ID card or passport with you at all times in case of an identity check. 24 EASL THE HOME OF HEPATOLOGY

27 11-15 APRIL 2018 PARIS, FRANCE LOST BADGES If a badge is lost or forgotten, an administrative fee of EUR (+ 20% VAT) will be charged to reprint the badge once identity verification (passport, driving license or other recognised identification document) is complete. If both badges are returned to the registration desk, the administrative fee will be refunded. COLOURED RIBBONS The coloured ribbons attached to the congress badges indicate the following: EASL member GENERAL CONGRESS INFORMATION Emeritus EASL member New EASL member Faculty Young investigator Nurse EASL Secretary General, EASL Vice-Secretary, ILC Honorary President EASL Governing Board and EASL staff THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 25

28 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME YOUNG INVESTIGATOR BURSARIES To verify physical presence on-site, poster presenters need to check-in before noon at the poster help desk in the EASL education zone (hall 7.2) each day for poster presentations. GENERAL CONGRESS INFORMATION Kindly note that a passport, driving license or other official identification proof will be requested to verify your identity. BURSARY PAYMENT Bursary payments will be made by bank transfer after the congress, however only to those whose presence was verified on-site. Those eligible to claim a bursary will be notified approximately 14 days after the congress. CME ACCREDITATION The International Liver Congress (TM), Paris, France, 11/04/ /04/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME ) with 36 European CME credits (ECMEC s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits TM. Information on the process to convert EACCME credit to AMA credit can be found at Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 26 EASL THE HOME OF HEPATOLOGY

29 11-15 APRIL 2018 PARIS, FRANCE EACCME credits Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC s per day: , , , , ,00 The EACCME awards ECMEC s on the basis of 1 ECMEC for one hour of CME with a maximum of 8 ECMEC s per day. Cf. Chapter X of UEMS GENERAL CONGRESS INFORMATION ATTENDANCE AND CME CERTIFICATE Please note that a completed CME evaluation form is a prerequisite in order to download your ILC 2018 certificate of attendance. The CME evaluation form will only be available as of Monday 16 April and should be completed via the online registration platform. Complete the online survey to activate your certificate. 1- Go to 2- Enter your registration credentials 3- Select the Certificate of Attendance tab 4- Fill in the survey 5- Download your certificate of attendance No printed certificate of attendance will be available on-site in Paris! THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 27

30 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NO SMOKING POLICY Smoking is prohibited at all times in all congress centre areas. Your compliance is appreciated. GENERAL CONGRESS INFORMATION MOBILE PHONES Mobile phones must be switched to silent mode during all sessions. Contribute to the twitter discussion online using #ILC2018. IMAGES AND RECORDINGS As a registered attendee of The International Liver Congress 2018 you grant permission for EASL to use your likeness in a photograph or video in any and all of its publication and presentations, including website entries, without payment or any other consideration. You authorise EASL to edit, alter, copy, exhibit, publish or distribute the photograph or video for purposes of publicising EASL s programmes or for any other lawful purpose. You waive the right to inspect or approve the finished product, including written or electronic copy, wherein your likeness appears. You also agree that these materials will become the property of EASL. Please note that only accredited media can record in the congress premises. 28 EASL THE HOME OF HEPATOLOGY

31 11-15 APRIL 2018 PARIS, FRANCE EASL EASL THE HOME OF HEPATOLOGY

32 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME EASL GOVERNING BOARD SECRETARY GENERAL VICE-SECRETARY TREASURER EASL Prof. Tom Hemming Karlsen Oslo, Norway Prof. Frank Tacke Aachen, Germany Prof. Mauro Bernardi Bologna, Italy SCIENTIFIC COMMITTEE MEMBERS Prof. Analisa Berzigotti Bern, Switzerland Prof. Markus Cornberg Hannover, Germany Dr Alejandro Forner Barcelona, Spain Prof. Marco Marzioni Ancona, Italy Prof. Philip N. Newsome Birmingham, United Kingdom 30 EASL THE HOME OF HEPATOLOGY

33 11-15 APRIL 2018 PARIS, FRANCE EDUCATIONAL COUNCILLORS EU POLICY COUNCILLOR EASL Prof. Francesco Negro Geneva, Switzerland Prof. Massimo Pinzani London, United Kingdom Prof. Helena Cortez-Pinto Lisbon, Portugal ILC 2018 HONORARY PRESIDENT Prof. Tilman Sauerbruch Bonn, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 31

34 2 DAY POSTGRADUATE COURSE ON VIRAL HEPATITIS Wednesday 11, 11:30-17:30 Thursday 12, 08:30-12:00 Download the app Test your knowledge Take part in our interactive session

35 11-15 APRIL 2018 PARIS, FRANCE AWARDS EASL THE HOME OF HEPATOLOGY

36 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME EASL AWARD CEREMONIES FRIDAY 13 APRIL Main Plenary, 08:30-10:30 Award ceremony I EASL Recognition Awards SATURDAY 14 APRIL Main Plenary, 10:00-12:00 AWARDS Award ceremony II EASL Registry Grants EASL Post Graduate Fellowship Sheila Sherlock EASL PhD Studentship Juan Rodes EASL Daniel Alagille Award EASL Mentorship Programme Best Basic and Best Clinical Oral Abstract Awards Best Poster Presentation Awards EASL Young Investigator Awards PSC Partners Award EASL RECOGNITION AWARDS 2018 EASL introduced the Recognition Awards to acknowledge the men and women who are writing the history of EASL. The awards are our way of saying Thank You to the scientists in the liver research field who dedicate their lives and careers to hepatology by providing major scientific contributions. EASL s annual award recognises the outstanding contribution of an individual to liver disease care and research in Europe. The following awards will be presented during the award ceremony I, Friday 13 April in the main plenary: Mario Mondelli, Pavia, Italy Didier Samuel, Paris, France Anna Lok, Ann Arbor, Michigan, United States 34 EASL THE HOME OF HEPATOLOGY

37 11-15 APRIL 2018 PARIS, FRANCE EASL REGISTRY GRANTS Valerio Nobili, Italy The European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD) Cyriel Ponsioen, Netherlands International PSC Registry EASL POST GRADUATE FELLOWSHIP SHEILA SHERLOCK AWARDS Annarein Kerbert, Netherlands Toll-like receptor 4: a novel target for the treatment of hyperammonemia and hepatic encephalopathy Jan Masek, Czech Republic Cracking the Notch code: single-cell receptor-ligand interactions and outcomes in vivo Wenshi Wang, China Surveys on the possible role of SLC- and ABClike membrane transporters as receptor(s) for nonprimate hepatitis B viruses: beyond NTCP EASL PHD STUDENTSHIP JUAN RODES Muhammad Atif, United Kingdom Free fatty acids and their metabolites lead to dysfunctional intrahepatic regulatory T cells which promotes ongoing nonalcoholic steato-hepatitis (NASH) Elisabetta Caon, Italy The fibrogenic and contractile phenotype of human hepatic stellate cells cultured in 3D extracellular matrix scaffolds derived from normal and cirrhotic human liver Roberta Forlano, Italy Prevalence of Non-Alcoholic Fatty Liver Disease in patients with Type 2 Diabetes Mellitus. Screening policy, economic implications and cost analysis THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 35

38 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME EASL DANIEL ALAGILLE AWARD AWARDS Dr Teresa Cardoso Delgado, Spain Targeting the microrna mir-873-5p in paediatric and adult genetic cholestatic diseases EASL YOUNG INVESTIGATOR AWARD EASL introduced the Young Investigator Award in 2015 to recognise the international liver research achievements of young fellows. The EASL Governing Board and Young Investigator Concerted Action Group have selected the following awardees to receive the 2018 award, during the award ceremony II. Prof. Pierre-Emmanuel Rautou, France Dr Jesus M. Banales, Spain 36 EASL THE HOME OF HEPATOLOGY

39 EASL 2018 MENTORSHIP PROGRAMME APRIL 2018 PARIS, FRANCE Mentees Marta Afonso, Portugal Research Institute for Medicines, University of Lisbon Iuliana Nenu, Romania Cluj-Napoca University of Medicine and Pharmacy AWARDS Mentors Dr Peter R. Galle, MD, PhD, Germany First Department of Internal Medicine, University Medical Center, Mainz Prof. Olivier Chazouillères, MD, France Head of the Hepatology Department at Saint-Antoine Hospital in Paris THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 37

40

41 11-15 APRIL 2018 PARIS, FRANCE INFORMATION FOR PRESENTERS EASL THE HOME OF HEPATOLOGY

42 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME FOR ORAL PRESENTERS SPEAKERS READY ROOM The speakers ready room is located in the Executive lounge in hall 7.3 and will be available throughout the congress for invited speakers and oral presenters. Once on-site, you may check, change, or upload your presentation in the speakers ready room at least 3 hours before the start of the session. Our staff, together with you, will take a final look at your material and help you upload it. Technicians will be available to assist speakers during the following hours: INFORMATION FOR PRESENTERS Tuesday 10 April 16:00-19:00 Wednesday 11 to Saturday 14 April 07:00-19:00 Sunday 15 April 07:00-14:00 PRESENTATION TECHNOLOGY Each lecture room is equipped with a laptop and data-projector. Own laptops cannot be connected in the rooms. All presentations must be uploaded in advance to the network. PRESENTATION FORMAT Only presentations in MS-PowerPoint 2013 or earlier versions (*.ppt and*. pptx) will be accepted. The exact screen ratio is 16:9. IMPORTANT: Presentations attached to s cannot be processed. If you are using PowerPoint 2007 or older versions, it is essential that you upload your video files as they cannot be embedded into the presentation. All uploaded material will pass through a technical verification, and detailed online support is available during the upload process. 40 EASL THE HOME OF HEPATOLOGY

43 11-15 APRIL 2018 PARIS, FRANCE DISCLOSURE SLIDE It is mandatory that all oral presenters display a disclosure slide as the first slide of their presentation. During the presentation upload process, you will be required to enter your disclosures in the system. The disclosure slide will be automatically generated and added to your presentation. If you have nothing to disclose, this slide will automatically indicate nothing to disclose. All conflicts of interest must be disclosed, not only the ones related to the presentation. For any technical questions related to your presentation contact: ilc@m-events.com FOR POSTER PRESENTERS Your poster will be displayed on both electronic (eposters) and paper posters at ILC Paper posters will be displayed (hall 7.2) from Thursday 12 to Saturday 14 April. INFORMATION FOR PRESENTERS All eposters will be made available throughout the week via the eposter terminals (hall 7.2 & 7.3), on the ILC app and on the LiverTree. THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 41

44 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME EASL offers poster presenters: Free printing of accepted paper posters Free delivery to the congress venue Free hanging and display of abstracts in the poster board area Free publishing of eposters on the LiverTree PAPER POSTERS Presenters are required to stand next to their posters on their scheduled presentation day (all lunch and coffee breaks). Presenters entitled to a bursary have to check-in at the poster help desk. See page 26. INFORMATION FOR PRESENTERS Each paper poster will be on display for 1 day only. Poster presenters will need to check the programme and the poster identification number (the first 3 letters indicate the day of the presentation. e.g. THU-001 = Thursday, board number 1). Late-breaker paper posters will be on display for 3 days (Thursday 12 to Saturday 14 April). Authors are invited to remove their poster from the poster boards between 17:00-17:30 at the end of their presentation slot. All unremoved posters will be dismantled and destroyed after 17:30. IMPORTANT: Presenters will not be allowed to display their paper poster if they have not submitted their research in eposter format prior to the congress. eposters submitted after 15 March 2018 will not be printed nor displayed by EASL. The concerned authors are responsible to print and display their poster in due time. On-site printing requests are to be done at the poster help desk (2-3 hours delivery time are to be considered). 42 EASL THE HOME OF HEPATOLOGY

45 11-15 APRIL 2018 PARIS, FRANCE eposters Your electronic poster will be available for continuous viewing throughout the congress week on dedicated terminals in hall 7.2 and 7.3, in the mobile app and on the LiverTree. Increase the possibility of presenting your research to the public by using the eposter connect feature. eposter CONNECT You may be asked by a delegate, using the eposter connect feature on the ILC 2018 congress app, to participate in a face-to-face meeting to talk about your research and findings. Poster presenters and delegates will meet at the allocated eposter screen in the the EASL education zone (hall 7.2) or in hall 7.3 for a discussion around the eposter of their interest. Other congress delegates will be able to see when such meetings are scheduled via the ILC 2018 app and can join in at the assigned eposter station. Poster presenters are therefore encouraged to download the ILC 2018 congress app to receive presentation requests from delegates. Look for eposter connect on your app and follow-up on all presentation requests! Tips for presenters using eposter connect: Download the congress app Respond quickly to all presentation requests Make sure to arrive 5 minutes before the scheduled time You do not need to bring anything other than your notes you will be able to view your eposter on the screen Ideally, you should dedicate 10 minutes to the presentation and 5 minutes for questions. INFORMATION FOR PRESENTERS THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 43

46 Use eposter connect to meet an author! Download the app Go to eposter connect Choose a poster and request presentation Plan a meeting with the author Meet at the eposter connect terminals

47 11-15 APRIL 2018 PARIS, FRANCE SCIENTIFIC PROGRAMME OVERVIEW EASL THE HOME OF HEPATOLOGY

48 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME WHAT S YOUR COLOUR? Scientific content is presented in a way that enables you to make informed choices on sessions of interest. The programme indicates specialties, fields and session types. SPECIALTIES SCIENTIFIC PROGRAMME OVERVIEW 46 EASL THE HOME OF HEPATOLOGY

49 11-15 APRIL 2018 PARIS, FRANCE FIELDS Basic and translational science Liver transplant and surgery Imaging and interventional Public health ADDITIONAL ICONS OF INTEREST Webcast session Poster tour Young Investigators session Nurse session Oral eposter session SCIENTIFIC PROGRAMME OVERVIEW THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 47

50 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SCIENTIFIC HIGHLIGHTS BRAND NEW THIS YEAR BREAKFAST MORNING ROUNDS Friday 13 & Sunday 15 April, 07:30-08:20 Come and enjoy a snack and a coffee at any of the four breakfast morning rounds taking place each day in the main plenary hall 7.3. We are sure you will have no problem finding a case that will interest you. EASL has invited KOLs who will attend with their junior peers to present a case and to replicate activities that take place at early morning hospital rounds. A panel of 3 to 4 experts is invited to interact and provide an external view to each case which will undoubtedly animate the discussions. No pre-registration is required. Free sessions open to all! SCIENTIFIC PROGRAMME OVERVIEW MEET THE EXPERTS Thursday 12 to Sunday 15 April, refer to the daily programmes, pages This is the ideal opportunity to meet with some of the biggest names in hepatology in a face to face interactive setting. Invited experts will provide answers to challenging questions during 16 informal workshops in hall 7.3. No pre-registration is required, nevertheless seats are limited and access will be given on a first come first served basis. RESEARCH THINK TANKS Wednesday 11 April, 08:00-11:00 Stimulate your brain at one of the EASL research think tanks through collaborative participation with invited groups. EASL will facilitate discussions between topically related organisations and/or consortia enabling highly interactive sessions that will focus on emerging or developing research trends. Workshops to be held on Wednesday morning will be divided into two sessions; a first session of 90 minutes with 3-4 speakers/experts followed by a coffee break and a 60-minute interactive panel discussion. No registration required, just drop by! 48 EASL THE HOME OF HEPATOLOGY

51 11-15 APRIL 2018 PARIS, FRANCE SKILLS IN HEPATOLOGY This brand-new field is dedicated to different skills in hepatology and is composed of 2 symposia and hands-on sessions. SYMPOSIA On Wednesday 11 April, in the morning, you are invited to attend 2 symposia in room West 3; A session dedicated to ultrasound activities held in collaboration with EFSUMB. EASL thanks EFSUMB for its support. 08:00-09:30 Dissecting meaning and role of elastography in liver disease Chairs: Robert de Knegt, Netherlands Fabio Piscaglia, Italy A symposium on invasive methods and procedures in hepatology. 10:00-11:00 Challenging issues in patients with liver disease undergoing invasive procedures Chairs: Andres Cardenas, Spain Pierre-Emmanuel Rautou, France SKILLS LEARNING CENTRE- HANDS-ON SESSIONS SCIENTIFIC PROGRAMME OVERVIEW Hands-on practical activities will take place every evening from Thursday 12 to Saturday 14 April, 18:30-20:00, in the skills learning centre (hall 7.3, West 5 & 6). Delegates will meet in small groups and can take the opportunity to look, learn, ask questions, and test material used for procedures under the tutelage of experts in the field. The activities are presented in a relaxed and friendly atmosphere during which delegates can talk with experts and ask an array of questions related to the practice of interventions in patients with liver disease. The skills in hepatology sessions are aimed at increasing the awareness of diagnostic and therapeutic techniques and offer delegates the possibility of examining their knowledge and skills. THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 49

52 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME In the skills learning centre hall 7.3 (West 5 & 6) you will have access to 3 distinct areas: EASL-EFSUMB: Non-invasive diagnostic methods Acute medicine in hepatology: Rob de Knegt, Netherlands Sonography Elastography: Rob de Knegt, Netherlands Ultrasound: Fabio Piscaglia, Italy Surveillance with ultrasound + bedside US Doppler US in hepatology and liver transplantation Interventional ultrasound and CEUS Invasive methods: evaluation and procedures Endoscopy: Andreas Cardenas, Spain Endoscopy in patients with cirrhosis and esophageal / gastric varices: Diagnosis and therapy SCIENTIFIC PROGRAMME OVERVIEW Hepatic hemodynamics: Pierre-Emmanuel Rautou, France Skills in liver hemodynamics and transjugular liver biopsy Thermal ablation of focal liver lesions: Christiane Kuhl, Germany TIPS: Fanny Turon, Spain TIPS placement: all you need to know Emerging therapies Alfapump : Andrea de Gottardi, Switzerland Clinical Skills Alfapump Extracorporeal liver assist devices: Rajiv Jalan, United Kingdom MARS Plasma Exchange ELAD ALBUTEC UCL Bioartificial Liver DIALIVE SX-ELLA Danis Stent: Angels Escorsell, Spain 50 EASL THE HOME OF HEPATOLOGY

53 11-15 APRIL 2018 PARIS, FRANCE Acknowledgements: Ernest Belmonte, Thomas Berg, Carrie Breen, Nathan Davies, Laure Elkrief, Cornelius Engelmann, Arnulf Ferlitsch, Alessandro Granito, Peter Isfort, Thomas Karlas, Steffen Mitzner, Sarwa Darwish Murad, Carlos Norohna, Frederico Pedersoli, Bogdan Procopet, Thomas Reiberger, Jeoffrey Schouten, Roxana Sirli, Dave Sprengers, Jan Stange, Horia Stefanescu, Guido Stirnimann, Fin Stoltze Larsen, Pavel Taimr, Christoph Terkamp, Markus Zimmermann ALSO DISCOVER NURSES ABSTRACT CATEGORY This year at ILC 2018 a specific abstract category has been created for nurses. Come and discover their posters: in the poster area (hall 7.2) on Friday 13 April on all eposter terminals throughout the duration of the congress (halls 7.3 and 7.2) SCIENTIFIC PROGRAMME OVERVIEW THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 51

54 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SESSION FORMAT DESCRIPTION BASIC SCIENCE SEMINAR Wednesday 11 April, 11:30-17:30 Thursday 12 April, 08:30-12:00 The basic science seminar aims to foster interaction with the audience and is organised like a workshop, with no classical lectures. The purpose of this seminar is to attract more people from the basic science field and to discuss specific topics where invited speakers have the opportunity not only to present their success stories, but also failures, generating a lively and informative discussion. A second objective is to showcase Young Investigator presentations selected by the invited speaker (typically one of their fellows). The usual format is as follows: SCIENTIFIC PROGRAMME OVERVIEW 10 minute presentation by a Senior Speaker (lecture format) 10 minute presentation by a Young Investigator (abstract format) 10 minute discussion This year s basic science seminar is on targetable pathways in liver disease. BASIC SCIENCE HIGHLIGHTS Friday 13 April, 11:30-12:30 This session runs in parallel to the Grand Rounds and offers a basic science alternative where speakers present selected publications on a current research topic. CRITICAL REFLECTION ON LANDMARK PAPERS 2017 Friday 13 April, 16:00-18:00 A chair will select four recent publications on hot topics and invite the authors to present and discuss with the audience. A specialist from the field will be invited to discuss and debate the paper with the author. 52 EASL THE HOME OF HEPATOLOGY

55 11-15 APRIL 2018 PARIS, FRANCE FELLOWSHIPS AND REGISTRY GRANTS Thursday 12 April, 12:00-13:30 EASL Fellowship awardees and Registry Grant recipients are invited to present their research and findings made possible thanks to the funding provided by EASL. GRAND ROUNDS Friday 13 April, 11:30-12:30 Senior members of major European institutions will present an interesting and challenging case together with a junior member of his/her team. Each case presented will represent a challenge of broad interest to the audience and aims to nurture discussions. A co-chair from another institution will be present with the intention of animating the debate. The objective is to foster interaction with a broad audience of clinicians through lively discussion around interesting clinical cases. NURSES AND ASSOCIATES FORUM Friday 13 April, 10:00-11:30 & 13:30-15:15 The lectures will address the specific needs of this target group. Come and meet the nurses Concerted Action Group at the end of the session! POSTGRADUATE COURSE Wednesday 11 April, 11:30-17:30 SCIENTIFIC PROGRAMME OVERVIEW Thursday 12 April, 08:30-12:00 EASL POSTGRADUATE COURSE VIRAL HEPATITIS APRIL 2018 The postgraduate course highlights many clinical practice dilemmas and engages the audience with world-renowned experts on how to make the best management decisions to help patients with liver disease. A printed course syllabus will be distributed at the entrance of the main plenary hall 7.3 and made available in pdf format on the congress website. See you next year in VIENNA April THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 53

56 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME The postgraduate course is divided into six sessions. At the beginning of each session, a case is presented. Live voting will be available and the audience will be able to reply to questions from chairs through the ILC 2018 mobile app. This year s postgraduate course will discuss viral hepatitis and specialists will provide their input on the presented case. STATE-OF-THE-ART LECTURES Friday 13 April, 10:30-11:00 Saturday 14 April, 12:00-12:30 There are two 30-minute lectures (one clinical and one basic) running without sessions in parallel. SYMPOSIA Friday 13 to Saturday 14 April, 14:00-15:30 SCIENTIFIC PROGRAMME OVERVIEW Sunday 15 April, 10:30-11:30 Symposia belonging to the educational sessions of the congress programme will provide the audience with a comprehensive, updated, and balanced summary of the diagnostic, prognostic, and therapeutic procedures related to the relevant topics. For webcasted sessions, look for the in the scientific programme. 54 EASL THE HOME OF HEPATOLOGY

57 ABSTRACT PRESENTATIONS ORAL PRESENTATIONS General/parallel and late-breaker sessions Presentations based on selected abstracts. POSTER PRESENTATIONS APRIL 2018 PARIS, FRANCE EASL offers abstract presentations in both paper and electronic (eposter) poster formats. Paper posters EASL will present the latest scientific data on boards in hall 7.2, from Thursday 12 to Saturday 14 April, between 09:00-17:00. There will be over 1,500 posters on display over 3 days. Visit the Poster area to see the new data! Late-breaker abstracts A dedicated area has been assigned in the EASL education zone to display latebreaker abstracts. These will be on display from Thursday 12 to Saturday 14 April and will not change. View page 21 for poster area opening hours. Poster tours During lunch and coffee breaks, Key Opinion Leader (KOL) guides will tour the poster area (hall 7.2) with a group of 30 delegates to showcase 3-4 selected paper posters and discuss them with the respective presenters. SCIENTIFIC PROGRAMME OVERVIEW Different tours will be scheduled, allowing 2-3 tours per break. Find out more about the tour topics, tour guides and selected posters in the daily programmes at the glance pages To join a tour, come to the meeting point corresponding to the tour in front of the poster help desk (hall 7.2) at the beginning of the break. Thursday 12 April 10:00-10:30 12:00-13:00 15:30-16:00 Friday 13 April 11:00-11:30 12:30-13:30 15:30-16:00 Saturday 14 April 12:30-14:00 15:30-16:00 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 55

58 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME eposters All electronic posters (eposters) are available throughout the congress from Wednesday to Sunday, on multiple dedicated plasma screens and simultaneously on the ILC 2018 mobile app and the LiverTree. Oral eposter sessions Selected posters will be presented in the 4 pods in the paper poster area in hall 7.2 on Thursday, Friday and Saturday for 6 mins by their author, followed by questions from the audience. Oral eposter sessions last from 30 minutes to 1 hour each and are provided in a very informal set-up allowing you to come and go as you please. There will be 3 different oral eposter sessions to attend on 3 consecutive days during coffee and lunch breaks. See schedule below: SCIENTIFIC PROGRAMME OVERVIEW Thursday 12 April 10:00-10:30 12:00-13:00 15:30-16:00 Friday 13 April 11:00-11:30 15:30-16:00 Saturday 14 April 13:00-14:00 15:30-16:00 eposter connect A unique feature designed to boost your learning and networking experience during The International Liver Congress This Congress App feature allows you to request or join exclusive presentations from any poster presenter whose research is of interest to you. You are encouraged to use the eposter connect feature on the ILC 2018 app to submit requests to poster authors and arrange a face-to-face meeting with any poster author to talk about their research and findings. Poster presenters and delegates will meet next to a designated eposter screen in hall 7.2 or hall 7.3 for a discussion around the eposter of interest. Other congress delegates will be able to see when such meetings are scheduled via the app and can join in at the assigned eposter station. Look for the eposter connect feature on your app! 56 EASL THE HOME OF HEPATOLOGY

59 11-15 APRIL 2018 PARIS, FRANCE HOW DOES IT WORK? BEST POSTER SESSION This session takes place on Sunday at 08:30 and its format is similar to the Sheila Sherlock 100 th year anniversary ILC 2018 wrap up session. Key Opinion Leaders will present their selection of the best posters in each of the main hepatology topics (viral hepatitis, metabolic and cholestasis, hepatocellular carcinoma, and general hepatology). SCIENTIFIC PROGRAMME OVERVIEW THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 57

60 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME DAILY PROGRAMME AT A GLANCE 07:00-07:30 07:30-08:00 08:00-08:30 Research think tanks 08:30-09:00 South 1 Portal hypertension 09:00-09:30 West 1 Autoimmune and cholestatic liver diseases North 1 Chronic liver failure 09:30-10:00 South 4 Liver tumours South 2 NAFLD 10:00-10:30 West 2 Alcoholic liver disease Main Plenary Viral hepatitis 10:30-11:00 South 3 Public health in viral hepatitis SCIENTIFIC PROGRAMME OVERVIEW 11:00-11:30 11:30-12:00 Postgraduate course 12:00-12:30 Main Plenary Viral hepatitis HBV 12:30-13:00 Postgraduate course 13:00-13:30 Main Plenary Viral hepatitis HCV 13:30-14:00 Lunch (hall 7.3) 14:00-14:30 14:30-15:00 15:00-15:30 Postgraduate course Main Plenary Viral hepatitis HDV 15:30-16:00 Coffee break (hall 7.3) 16:00-16:30 16:30-17:00 17:00-17:30 Postgraduate course Main Plenary Viral hepatitis HEV 17:30-18:00 18:00-18:30 18:30-19:00 19:00-19:30 Industry symposia 19:30-20:00 To refer to colour code, see page EASL THE HOME OF HEPATOLOGY

61 11-15 APRIL 2018 PARIS, FRANCE WEDNESDAY 11 APRIL :00-07:30 07:30-08:00 Skills in hepatology (Symposium) West 3 Non-invasive methods: Dissecting meaning and role of elastography in liver disease 08:00-08:30 08:30-09:00 09:00-09:30 Coffee break (hall 7.3) 09:30-10:00 Skills in hepatology (Symposium) West 3 Invasive methods: Challenging issues in patients with liver disease undergoing invasive procedures 10:00-10:30 10:30-11:00 11:00-11:30 Basic science seminar North 1 Targetable pathways in liver disease: Identifying targetable pathways in liver disease Basic science seminar North 1 Targetable pathways in liver disease: New targets in metabolism Basic science seminar North 1 Targetable pathways in liver disease: New targets in inflammation and fibrosis 11:30-12:00 12:00-12:30 12:30-13:00 13:00-13:30 13:30-14:00 14:00-14:30 14:30-15:00 15:00-15:30 15:30-16:00 16:00-16:30 16:30-17:00 17:00-17:30 SCIENTIFIC PROGRAMME OVERVIEW 17:30-18:00 18:00-18:30 18:30-19:00 19:00-19:30 19:30-20:00 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 59

62 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME DAILY PROGRAMME AT A GLANCE 07:30-08:00 08:00-08:30 Industry symposia 08:30-09:00 Postgraduate course 09:00-09:30 09:30-10:00 Main Plenary Viral hepatitis HBV 10:00-10:30 Coffee break (hall 7.2) 10:30-11:00 Postgraduate course 11:00-11:30 Main Plenary Viral hepatitis HCV Basic science seminar North 1 Targetable pathways in liver disease: New targets in liver tumors Basic science seminar Oral eposters North 1 Targetable pathways in liver disease: From targetable pathways to the clinics SCIENTIFIC PROGRAMME OVERVIEW 11:30-12:00 12:00-12:30 Public health 12:30-13:00 13:00-13:30 13:30-14:00 14:00-14:30 14:30-15:00 15:00-15:30 15:30-16:00 EASL clinical practice guidelines North 1 Management of hepatocellular carcinoma South 4 Epidemiology and burden of liver disease in Europe: data from HEPAHEALTH West 3 EASL-CDC symposium: Decentralization and integration of HCV diagnostics, care and treatment services in low- and middle-income countries Workshops South 1 Publishing in JHEP A view from the inside West 1 Women in hepatology Fellowships & registry grants West 2 Fellowship presentations South 3 The role of registries for modern hepatology Main Plenary General session I and opening ceremony Coffee break (hall 7.2) 16:00-16:30 Parallel sessions Poster tours 16:30-17:00 17:00-17:30 17:30-18:00 South 3 Liver transplantation: Clinical West 2 Public health: General West 1 Autoimmune and cholestasis 1 South 1 Cirrhosis and its complications: Experimental and pathophysiology North 1 Clinical management of hepatocellular carcinoma South 2 NAFLD: Experimental and pathophysiology Main Plenary Hepatitis C: Therapy South 4 HBV Cure: Pre-clinical studies 18:00-18:30 18:30-19:00 19:00-19:30 19:30-20:00 Industry symposia To refer to colour code, see page EASL THE HOME OF HEPATOLOGY

63 11-15 APRIL 2018 PARIS, FRANCE THURSDAY 12 APRIL 2018 Industry mini-workshops Meet the experts West 4 Management of autoimmune hepatitis 07:30-08:00 08:00-08:30 08:30-09:00 09:00-09:30 Poster tours Meet the experts West 4 Non-invasive tests in liver diseases 09:30-10:00 10:00-10:30 Meet the experts West 4 Management of HCV infection in patients with HCC 10:30-11:00 11:00-11:30 11:30-12:00 12:00-12:30 Oral eposters Poster tours Meet the experts West 4 Hepatorenal syndrome 12:30-13:00 Lunch (hall 7.2) Oral eposters 13:00-13:30 13:30-14:00 14:00-14:30 14:30-15:00 15:00-15:30 15:30-16:00 SCIENTIFIC PROGRAMME OVERVIEW Meet the experts West 4 Antibiotic stewardship in cirrhosis 16:00-16:30 16:30-17:00 ELPA Symposium West 3 Symptom management across liver diseases: Is there a big picture? Meet the experts West 4 Achieving alcohol abstinence 17:00-17:30 17:30-18:00 Skills in hepatology (Hands-on sessions) West 5 Skills learning centre: Non-invasive diagnostics methods 18:00-18:30 18:30-19:00 19:00-19:30 19:30-20:00 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 61

64 DAILY PROGRAMME AT A GLANCE 07:30-08:00 Breakfast morning rounds 08:00-08:30 08:30-09:00 West 1 Acute liver failure when to list? West 3 Iron overload and hemochromatosis Practical management 09:00-09:30 09:30-10:00 Main Plenary General session II and award ceremony I 10:00-10:30 10:30-11:00 11:00-11:30 Clinical state-of-the-art Main Plenary Jean-Pierre Benhamou clinical state-of-the-art: Is it time to abandon the term cirrhosis? Coffee break (hall 7.2) Oral eposters 11:30-12:00 Grand rounds South 3 Primary biliary cholangitis 12:00-12:30 North 1 Cirrhosis complications Main Plenary Hepatocellular carcinoma in non-cirrhotic liver South 2 Fatty liver in a lean patient South 1 Severe alcoholic hepatitis Poster tours Young investigator seminar West 3 Palliative care in hepatology: an unmet need 12:30-13:00 62 SCIENTIFIC PROGRAMME OVERVIEW To refer to colour code, see page 46 13:00-13:30 13:30-14:00 EASL General Assembly Members only West 2 14:00-14:30 EASL clinical practice guidelines 14:30-15:00 15:00-15:30 15:30-16:00 Main Plenary Decompensated cirrhosis & Nutrition Symposia West 1 Extracellular vesicles and signal transmission North 1 NAFLD management in 2018 South 2 DAA failure and post SVR complications Public health South 3 Alcoholic liver disease: Are we moving in the right direction to reduce the more frequent and preventable liver disease? Coffee break (hall 7.2) Oral eposters 16:00-16:30 Parallel sessions South 3 Liver regeneration and tissue engineering 16:30-17:00 17:00-17:30 17:30-18:00 18:00-18:30 18:30-19:00 19:00-19:30 19:30-20:00 West 3 Experimental hepatology North 1 Cirrhosis: ACLF and critical illness Main Plenary NAFLD: Clinical and therapy South 1 Alcoholic liver disease South 2 HCV: Striving towards elimination West 1 Viral hepatitis: Basic science Industry symposia Industry mini-workshops Lunch (hall 7.2) Fusion hepatology around the world South 1 HCC Critical reflection on landmark papers 2017 West 2 Skills in hepatology (Hands-on sessions) West 6 Skills learning centre: Invasive methods: Evaluation and procedures

65 FRIDAY 13 APRIL 2018 South 1 Common complications in liver cirrhosis West 2 NAFLD How to achieve weight loss 07:30-08:00 08:00-08:30 08:30-09:00 09:00-09:30 09:30-10:00 Nurses and associates forum West 3 Involvement of nurses and associates in liver disease management 10:00-10:30 10:30-11:00 11:00-11:30 Basic science highlights West 1 Immune checkpoints in liver tumours and beyond Workshop East 3 How to succeed in European research grant applications? Meet the experts West 4 Difficult cases of HCV therapy: is there any? 11:30-12:00 12:00-12:30 Poster tours 12:30-13:00 Symposium South 4 Hot topics in liver transplantation Nurses and associates forum West 3 Quality care for people with liver disease West 3 Meet the nurses CAG Poster tours Meet the experts West 4 Prevention of decompensation in cirrhosis Poster tours 13:00-13:30 13:30-14:00 14:00-14:30 14:30-15:00 15:00-15:30 15:30-16:00 SCIENTIFIC PROGRAMME OVERVIEW Meet the experts West 4 Portal vein thrombosis Meet the experts West 4 Alpha-1-Antitrypsin deficiency 16:00-16:30 16:30-17:00 17:00-17:30 17:30-18:00 Skills in hepatology (Hands-on sessions) West 5 Skills learning centre: Non-invasive diagnostics methods Skills in hepatology (Hands-on sessions) West 5 Skills learning centre: Non-invasive diagnostics methods 18:00-18:30 18:30-19:00 19:00-19:30 19:30-20:00 63

66 DAILY PROGRAMME AT A GLANCE 08:00-08:30 Parallel sessions 08:30-09:00 09:00-09:30 09:30-10:00 West 1 Acute liver failure and liver transplantation West 2 Inflammation and fibrosis South 1 Autoimmune and cholestasis 2 North 1 Cirrhosis: Portal hypertension and complication South 3 Liver tumours: Experimental South 2 NAFLD: Diagnostics and non-invasive assessment 10:00-10:30 10:30-11:00 11:00-11:30 11:30-12:00 12:00-12:30 Main Plenary General session III and award ceremony II Basic science state-of-the-art Main Plenary Karl Wilhelm von Kupffer basic state-of-the-art: Beyond albumin and IgG the unexpected prospects of the neonatal Fc receptor 12:30-13:00 13:00-13:30 Industry symposia Lunch (hall 7.2 & 7.3) SCIENTIFIC PROGRAMME OVERVIEW 13:30-14:00 14:00-14:30 Symposia 14:30-15:00 15:00-15:30 West 1 Defining the second line therapy in cholestatic and autoimmune liver disease South 4 Advances in local and systemic therapies for HCC Main Plenary Current management and emerging treatment in HBV West 3 Systems medicine of metabolic liver disease Joint symposia South 1 EASL-EASD symposium: Testing strategies and pathways in NAFLD West 2 EASL-APASL symposium: ACLF and critical care in hepatology South 3 EASL-WHO symposium: Meeting the 2030 Elimination Goals of the WHO Viral Hepatitis Strategy 15:30-16:00 Coffee break (hall 7.2) 16:00-16:30 16:30-17:00 17:00-17:30 17:30-18:00 18:00-18:30 Main Plenary Late-breaker session 18:30-19:00 EASL recommendations on treatment of 19:00-19:30 hepatitis C :30-20:00 Main Plenary Skills in hepatology (Hands-on sessions) West 6 Skills learning centre: Emerging therapies 64 To refer to colour code, see page 46

67 SATURDAY 14 APRIL 2018 West 3 Clinical developments in metabolic and rare disease Main Plenary Clinical impact of HCV cure South 4 HBV and HDV: Current and emerging treatments Meet the experts West 4 Hepatitis B: Should we treat immunotolerant patients? Meet the experts 08:00-08:30 08:30-09:00 09:00-09:30 West 4 Hepatitis B: Coffee break (hall 7.2) When to stop NUC 09:30-10:00 therapy? 10:00-10:30 10:30-11:00 11:00-11:30 11:30-12:00 12:00-12:30 Oral eposters Young investigator fusion Poster tours Meet the experts Poster tours Poster tours East 3 Career opportunities in hepatology: an emerging generation of NAFLD researchers West 4 Cirrhosis after HCV cure Meet the experts West 4 Management of patients with chronic hepatitis E 12:30-13:00 13:00-13:30 13:30-14:00 14:00-14:30 14:30-15:00 15:00-15:30 SCIENTIFIC PROGRAMME OVERVIEW Oral eposters Poster tours 15:30-16:00 Skills in hepatology (Hands-on sessions) West 5 Skills learning centre: Non-invasive diagnostics methods Skills in hepatology (Hands-on sessions) West 5 Skills learning centre: Non-invasive diagnostics methods 16:00-16:30 16:30-17:00 17:00-17:30 17:30-18:00 18:00-18:30 18:30-19:00 19:00-19:30 19:30-20:00 65

68 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME DAILY PROGRAMME AT A GLANCE 07:30-08:00 Breakfast morning rounds 08:00-08:30 08:30-09:00 West 2 Strictures of the bile duct West 3 Cirrhotic patient with a single nodule Diagnostic work-up and best treatment option? 09:00-09:30 09:30-10:00 Best poster summary South 4 10:00-10:30 Coffee break (hall 7.3) 10:30-11:00 Symposia SCIENTIFIC PROGRAMME OVERVIEW 11:00-11:30 11:30-12:00 12:00-12:30 12:30-13:00 13:00-13:30 13:30-14:00 West 3 The gut-liver axis: from concepts to data West 1 Impaired renal function in advanced cirrhosis: diagnosis and management West 2 Multidisciplinary management of alcoholic liver disease Joint symposia South 4 EASL-ALEH symposium: Diagnostic dilemmas in metabolic liver disease North 1 EASL-ESMO symposium: Collaboration between medical oncologists and hepatologists to boost therapeutic advances in liver cancer North 1 Sheila Sherlock 100 th year anniversary ILC 2018 wrap up session Lunch (hall 7.3) To refer to colour code, see page EASL THE HOME OF HEPATOLOGY

69 11-15 APRIL 2018 PARIS, FRANCE SUNDAY 15 APRIL 2018 West 1 Drug-induced liver injury How to diagnose, how to treat? South 1 The difficult to treat patient with chronic hepatitis C 07:30-08:00 08:00-08:30 Viral hepatitis and the community South 3 Dynamics of the viral hepatitis epidemic Meet the experts West 4 Wilson s disease 08:30-09:00 09:00-09:30 09:30-10:00 10:00-10:30 Viral hepatitis and the community South 3 Addressing the continuum of care EASL clinical practice guidelines South 2 HEV & DILI Meet the experts West 4 Hepatitis Delta: Wait for new drugs or treat now with interferon alfa? 10:30-11:00 11:00-11:30 11:30-12:00 12:00-12:30 12:30-13:00 13:00-13:30 13:30-14:00 SCIENTIFIC PROGRAMME OVERVIEW THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 67

70

71 11-15 APRIL 2018 PARIS, FRANCE SCIENTIFIC PROGRAMME WEDNESDAY 11 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

72 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SCIENTIFIC PROGRAMME WEDNESDAY 11 APRIL 2018 Research Think Tank Viral hepatitis Main Plenary Chairs: Markus CORNBERG, Germany Jean-Michel PAWLOTSKY, France 08:00-08:10 Introduction of the concept of the Research Think Tank format Markus CORNBERG, Germany New HBV and HDV therapies: fantasy or reality? 08:10-08:30 New treatments for HDV Heiner WEDEMEYER, Germany SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :30-08:50 New treatments for HBV Jordan FELD, Canada 08:50-09:30 Interactive debate 09:30-10:00 Coffee break Do we need an HCV vaccine? 10:00-10:15 We need an HCV vaccine Eleanor BARNES, United Kingdom 10:15-10:30 We don t need an HCV vaccine Markus CORNBERG, Germany 10:30-11:00 Interactive debate Research Think Tank Chronic liver failure: Predicting events and outcomes in chronic liver failure: the unmet need of biomarkers North 1 Chairs: Paolo ANGELI, Italy Jasmohan S BAJAJ, United States Mauro BERNARDI, Italy Thierry GUSTOT, Belgium 70 EASL THE HOME OF HEPATOLOGY

73 11-15 APRIL 2018 PARIS, FRANCE 08:00-08:10 Introduction of the concept of the Research Think Tank format Mauro BERNARDI, Italy 08:10-08:30 Are we able to predict the development of ACLF and its outcome? Jonel TREBICKA, Germany 08:30-08:50 Refining the diagnosis of bacterial infections in chronic liver failure Javier FERNANDEZ, Spain 08:50-09:10 How to define the phenotypes of acute kidney injury in advanced cirrhosis Elsa SOLÀ, Spain 09:10-09:30 Potential biomarkers to improve current clinical/ testing strategies in hepatic encephalopathy Sara MONTAGNESE, Italy 09:30-10:00 Coffee break 10:00-11:00 Panel dicussion Paolo ANGELI, Italy Jasmohan S BAJAJ, United States Mauro BERNARDI, Italy Javier FERNANDEZ, Spain Thierry GUSTOT, Belgium Sara MONTAGNESE, Italy Elsa SOLÀ, Spain Jonel TREBICKA, Germany Research Think Tank NAFLD: Targets and pharmacotherapy in NASH South 2 Chairs: Quentin ANSTEE, United Kingdom Philip NEWSOME, United Kingdom SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :00-08:10 Introduction of the concept of the Research Think Tank format Philip NEWSOME, United Kingdom THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 71

74 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 08:10-08:30 Lipotoxicity in NASH-from Disease Models to Novel Targets Antonio VIDAL-PUIG, United Kingdom 08:30-08:50 Targeting Nuclear Receptor Pathways in NASH (PPARs & FXR)-Benefits Bart STAELS, France 08:50-09:10 Targeting Nuclear Receptor Pathways in NASH (PPARs & FXR)-Risks Michael TRAUNER, Austria 09:10-09:30 Future Endpoints for Trials-Assessing Biomarker Performance Richard TORSTENSON, Sweden 09:30-10:00 Coffee break SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :00-10:30 Which patients will we be treating in 2020 and how will pharmacotherapy be tailored? Elisabetta BUGIANESI, Italy 10:30-11:00 Panel dicussion: Quentin ANSTEE, United Kingdom Elisabetta BUGIANESI, Italy Philip NEWSOME, United Kingdom Bart STAELS, France Richard TORSTENSON, Sweden Michael TRAUNER, Austria Antonio VIDAL-PUIG, United Kingdom Research Think Tank Liver tumours: Current options and future trends in the management of advanced HCC South 4 Chairs: Sandrine FAIVRE, France Alejandro FORNER, Spain 08:00-08:10 Introduction of the concept of the Research Think Tank format Alejandro FORNER, Spain Current options in the management of advanced HCC 72 EASL THE HOME OF HEPATOLOGY

75 11-15 APRIL 2018 PARIS, FRANCE 08:10-08:30 Current status of treatment in advanced HCC: It is possible to do personalized medicine? Jean Charles NAULT, France 08:30-08:50 Pivotal role of imaging in the management of HCC Irene BARGELLINI, Italy 08:50-09:10 Transarterial radioembolization in HCC: Current status and future trends Riad SALEM, United States 09:10-09:30 Novel treatments for advanced HCC Peter GALLE, Germany 09:30-10:00 Coffee Break Future trends in the management of advanced HCC 10:00-10:20 Immunotherapy in HCC: Impact on HCC management? Bruno SANGRO, Spain 10:20-11:00 Panel dicussion: Trial design: Lessons learned in the last decade Irene BARGELLINI, Italy Sandrine FAIVRE, France Alejandro FORNER, Spain Peter GALLE, Germany Jean Charles NAULT, France Riad SALEM, United States Bruno SANGRO, Spain Research Think Tank Portal hypertension: Coagulation cascade activation as a driver of chronic liver diseases South 1 SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL 2018 Chairs: Agustin ALBILLOS, Spain Annalisa BERZIGOTTI, Switzerland Andrea DE GOTTARDI, Switzerland 08:00-08:10 Introduction of the concept of the Research Think Tank format Annalisa BERZIGOTTI, Switzerland THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 73

76 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 08:10-08:30 Activation of the coagulation cascade in chronic liver diseases: Experimental evidence Jordi GRACIA-SANCHO, Spain 08:30-08:50 Clinical evidence supporting an activation of the coagulation cascade in cirrhosis: Potential benefit of anticoagulation Francesco VIOLI, Italy 08:50-09:10 Intrahepatic and portal vein thrombosis in hepatic vascular disease cause or consequence? Potential benefit of anticoagulation Aurelie PLESSIER, France 09:10-09:30 Pathophysiological basis and clinical experience with direct-acting oral anticoagulants (DOACs) in chronic liver diseases Andrea DE GOTTARDI, Switzerland 09:30-10:00 Coffee break SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :00-11:00 Panel dicussion Agustin ALBILLOS, Spain Annalisa BERZIGOTTI, Switzerland Andrea DE GOTTARDI, Switzerland Juan-Carlos GARCIA-PAGAN, Spain Jordi GRACIA-SANCHO, Spain Aurelie PLESSIER, France Francesco VIOLI, Italy Research Think Tank Public health in viral hepatitis: Integrating care for HCV infection and substance use among people who use drugs: What will be required to achieve HCV elimination by 2030? South 3 Chairs: Julie BRUNEAU, Canada Francesco NEGRO, Switzerland 08:00-08:10 Introduction of the concept of the Research Think Tank format Francesco NEGRO, Switzerland 74 EASL THE HOME OF HEPATOLOGY

77 11-15 APRIL 2018 PARIS, FRANCE 08:10-08:30 Enhancing access to health care for people who use drugs: It is not all about medication Julie BRUNEAU, Canada 08:30-08:50 The importance of improving access to harm reduction to prevent HCV in people who use drugs: A key piece to the HCV elimination puzzle Niklas LUHMANN, France 08:50-09:10 Testing and treatment of HCV infection for people who use drugs: Where to next? Karine LACOMBE, France 09:10-09:30 Integration of services to address substance use and HCV infection: Challenges and opportunities Hannu ALHO, Finland 09:30-10:00 Coffee break 10:00-10:20 HCV treatment: a gateway to improved health for PWID Icro MAREMMANI, Italy 10:20-11:00 Panel dicussion Hannu ALHO, Finland Julie BRUNEAU, Canada Karine LACOMBE, France Niklas LUHMANN, France Luis MENDAO, Portugal Francesco NEGRO, Switzerland Research Think Tank Autoimmune and cholestatic liver diseases: Synergism in research West 1 Chairs: Michael MANNS, Germany Marco MARZIONI, Italy Cyriel PONSIOEN, Netherlands Henk VAN BUUREN, Netherlands SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :00-08:10 Introduction of the concept of the Think Tank format Marco MARZIONI, Italy THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 75

78 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 08:10-08:30 Unmet needs in autoimmune and cholestatic liver diseases: the academic perspective Christoph SCHRAMM, Germany 08:30-08:50 Unmet needs in autoimmune and cholestatic liver diseases: patient s perspective Martine WALMSLEY, United Kingdom 08:50-09:10 Opportunities and challenges for collaborative drug development Michael MANNS, Germany 09:10-09:30 Dissemination and delivery of care: opportunities within the ERN David JONES, United Kingdom 09:30-10:00 Coffee break Interactive session: how to improve synergism in research SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :00-10:10 Update on initiatives within the International PSC Study Group Cyriel PONSIOEN, Netherlands 10:10-10:20 Update on initiatives within the International Autoimmune Hepatitis Group (IAIHG) Diego VERGANI, United Kingdom 10:20-10:30 Update on initiatives within the Global PBC Study Group Henk VAN BUUREN, Netherlands 10:30-11:00 Panel dicussion Michael MANNS, Germany Marco MARZIONI, Italy David JONES, United Kingdom Cyriel PONSIOEN, Netherlands Christoph SCHRAMM, Germany Henk VAN BUUREN, Netherlands Diego VERGANI, United Kingdom Martine WALMSLEY, United Kingdom 76 EASL THE HOME OF HEPATOLOGY

79 11-15 APRIL 2018 PARIS, FRANCE Research Think Tank Alcoholic liver disease: What are the new directions? West 2 Chairs: Helena CORTEZ-PINTO, Portugal Sebastian MUELLER, Germany 08:00-08:10 Introduction of the concept of the Research Think Tank format Helena CORTEZ-PINTO, Portugal 08:10-08:26 Can drugs modulate drinking behaviour? Giovanni ADDOLORATO, Italy 08:26-08:42 In which way genetic loci will change the field? Felix STICKEL, Switzerland 08:42-08:58 Liver histology in ALD: Beyond diagnosis of ASH, what are the implications for prognosis and elucidation of disease progression Karoline LACKNER, Austria 08:58-09:14 Screening at a population level to increase early diagnosis Jerome BOURSIER, France 09:14-09:30 Future therapeutic targets on ALD Claus HELLERBRAND, Germany 09:30-10:00 Coffee break 10:00-11:00 Panel dicussion Giovanni ADDOLORATO, Italy Jerome BOURSIER, France Helena CORTEZ-PINTO, Portugal Claus HELLERBRAND, Germany Karoline LACKNER, Austria Sebastian MUELLER, Germany Felix STICKEL, Switzerland SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 77

80 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Skills in hepatology: Dissecting meaning and role of elastography in liver disease West 3 Chairs: Robert DE KNEGT, Netherlands Fabio PISCAGLIA, Italy 08:00-08:05 Welcome and Introduction 08:05-08:25 Transient elastography, essential part of liver diagnostics and follow up Laurent CASTERA, France 08:25-08:45 Shearwaves: the exchangeable or complementary method to measure elasticity? Mireen FRIEDRICH-RUST, Germany 08:45-09:05 Can elastography be used in all liver diseases? Matteo ROSSELLI, Italy SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :05-09:25 Elastography is more than just fibrosis measurement Giovanna FERRAIOLI, Italy 09:25-09:30 Remarks and conclusions Skills in hepatology: Challenging issues in patients with liver disease undergoing invasive procedures West 3 Chairs: Andres CARDENAS, Spain Pierre-Emmanuel RAUTOU, France 10:00-10:20 Management of coagulation abnormalities and anticoagulants in patients with liver disease undergoing invasive procedures Pierre-Emmanuel RAUTOU, France 10:20-10:40 Endoscopic approaches for patients with refractory portal hypertensive bleeding Andres CARDENAS, Spain 10:40-11:00 Therapy of dominant strictures in patients with PSC Lars AABAKKEN, Norway 78 EASL THE HOME OF HEPATOLOGY

81 11-15 APRIL 2018 PARIS, FRANCE PGC Viral Hepatitis Main Plenary Organisers: Maurizia BRUNETTO, Italy Francesco NEGRO, Switzerland Jean-Michel PAWLOTSKY, France Heiner WEDEMEYER, Germany HBV Chair: Anna LOK, United States 11:30-11:40 Case presentation Anna LOK, United States 11:40-11:55 Where do we stand with diagnosis of HBV infection phase and HBV-induced liver damage in HBeAgpositive carriers? Maria BUTI, Spain 11:55-12:10 When and how to treat a highly viraemic HBeAgpositive patient, and how to monitor and guide the treatment Patrick KENNEDY, United Kingdom 12:10-12:25 How to manage pregnant women to minimize the risk of transmission Henry CHAN, Hong Kong 12:25-12:30 Panel discussion HCV Chair: Alessandra MANGIA, Italy 12:30-12:45 Case presentation Alessandra MANGIA, Italy SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :45-13:00 Difficult-to-cure patients in 2018 Christophe HEZODE, France 13:00-13:15 Retreatment strategies in 2018 Jordan FELD, Canada 13:15-13:30 HCC risk post-daa treatment: a balanced perspective Geoffrey DUSHEIKO, United Kingdom THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 79

82 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 13:30-14:00 Lunch HDV Chair: Mario RIZZETTO, Italy 14:00-14:15 Case presentation Mario RIZZETTO, Italy 14:15-14:30 Assessing liver fibrosis in hepatitis delta virus: invasive vs. non-invasive techniques. Is the liver biopsy still necessary as a diagnostic tool and in long-term surveillance? Benjamin HEIDRICH, Germany 14:30-14:50 Facts and controversies in treatment of hepatitis delta with PegIFNα Cihan YURDAYDIN, Turkey SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :50-15:05 The risk of decompensation and HCC development in patients with HDV-related cirrhosis Grazia NIRO, Italy 15:05-15:20 The role of liver transplantation in hepatitis delta Didier SAMUEL, France 15:20-15:30 Panel discussion 15:30-16:00 Coffee break HEV Chair: Sven PISCHKE, Germany 16:00-16:15 Case presentation Sven PISCHKE, Germany 16:15-16:30 How to become infected with HEV in Europe Robert DE MAN, Netherlands 16:30-16:45 Diagnostics in HEV infection Darius MORADPOUR, Switzerland 16:45-17:00 Hepatitis E: natural history Harry DALTON, United Kingdom 80 EASL THE HOME OF HEPATOLOGY

83 11-15 APRIL 2018 PARIS, FRANCE 17:00-17:15 Treatment of hepatitis E Nassim KAMAR, France 17:15-17:30 Panel discussion Basic Science Seminar Targetable pathways in liver disease North 1 Organisers: Helen Louise REEVES, United Kingdom Cecília M P RODRIGUES, Portugal Frank TACKE, Germany Identifying targetable pathways in liver disease 11:30-12:00 Big data approaches to identify targetable pathways in liver cancer Josep M. LLOVET, United States 12:00-12:30 12:30-13:00 Reclassifying immunology by single-cell approaches Shalev ITZKOVITZ, Israel Paired-cell sequencing reveals zonation of nonparenchymal liver cells Keren BAHAR HALPERN, Israel Discussion How to identify new drug targets in cellular metabolism Peter CARMELIET, Belgium Insights and therapeutic implications of single cell analysis of tumour endothelial cell metabolic signatures Lucas TREPS, Belgium SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :00-13:30 Discussion Imaging of cell-cell communication Gustavo MENEZES, Brazil THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 81

84 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Combination of in vivo imaging and functional analysis reveals major changes in liver immunometabolic profile during newborn development Brenda NAKAGAKI, Brazil Discussion 13:30-14:00 Lunch New targets in Metabolism 14:00-14:30 Glucose sensing and lipid storage in hepatocytes: where are the new drug targets? Catherine POSTIC, France Glucose sensing and lipid storage in hepatocytes: where are the new drug targets?: Fellow lecture Aya Abdul-Wahed KAYALI, France Discussion SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL :30-15:00 Bile acid signaling and related hormones Antonio MOSCHETTA, Italy Nuclear receptor FXR and the enterokine FGF19 in hepatocarcinoma Marica CARIELLO, Italy Discussion 15:00-15:30 Liver disease drug targets in the gut microbiota Jasmohan S BAJAJ, United States Oral-gut-hepatic axis in cirrhosis Chathur ACHARYA, United States Discussion 15:30-16:00 Coffee break New targets in inflammation and fibrosis 16:00-16:30 Modulating danger sensing at the interface to liver inflammation Wajahat MEHAL, United States 82 EASL THE HOME OF HEPATOLOGY

85 11-15 APRIL 2018 PARIS, FRANCE The role of Pyruvate Kinase M2 in regulating liver inflammation Wajahat MEHAL, United States Discussion 16:30-17:00 Drug targets in the dynamics of liver fibrosis Neil HENDERSON, United Kingdom Differential regulation of hepatic fibrosis by mesenchymal subpopulations Ross DOBIE, United Kingdom Discussion 17:00-17:30 A molecular perspective to new treatments in portal hypertension Jordi GRACIA-SANCHO, Spain Liver stiffness: new driver in portal hypertension Sergi GUIXÉ-MUNTET, Switzerland Industry Symposia Discussion 18:00-19:30 Please refer to the industry section for more details, page 348. SCIENTIFIC PROGRAMME / WEDNESDAY 11 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 83

86

87 11-15 APRIL 2018 PARIS, FRANCE SCIENTIFIC PROGRAMME THURSDAY 12 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

88 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SCIENTIFIC PROGRAMME THURSDAY 12 APRIL 2018 Industry Symposia 07:30-08:30 Please refer to the industry section for more details, page 348. Industry Mini-workshops 07:30-08:30 Please refer to the industry section for more details, page 356. PGC Viral Hepatitis Main Plenary SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 Organisers: Maurizia BRUNETTO, Italy Francesco NEGRO, Switzerland Jean-Michel PAWLOTSKY, France Heiner WEDEMEYER, Germany HBV Chair: Rafael ESTEBAN, Spain 08:30-08:45 Case presentation Rafael ESTEBAN, Spain 08:45-09:00 Where do we stand on diagnosising HBV infection phase, and HBV-induced liver damage in HBeAgnegative carriers? George PAPATHEODORIDIS, Greece 09:00-09:15 PegIFN vs. oral therapy in HBeAg-negative CHB patients Pietro LAMPERTICO, Italy 09:15-09:30 Can we stop nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients? Fabien ZOULIM, France 86 EASL THE HOME OF HEPATOLOGY

89 11-15 APRIL 2018 PARIS, FRANCE 09:30-09:45 Management of HBeAg-negative patients who stopped long-term treatment with nucleos(t)ide analogues Thomas BERG, Germany 09:45-10:00 Panel discussion 10:00-10:30 Coffee break HCV Chair: Kosh AGARWAL, United Kingdom 10:30-10:45 Case presentation Kosh AGARWAL, United Kingdom 10:45-11:00 Practical HCV treatment in patients with decompensated cirrhosis Xavier FORNS, Spain 11:00-11:15 Removing patients from the transplant list with anti- HCV treatment Norah TERRAULT, United States 11:15-11:30 HCV treatment in the immunosuppressed patient Alessio AGHEMO, Italy 11:30-11:45 Pros and cons of transplanting HCV-infected organs Marina BERENGUER, Spain 11:45-12:00 Panel discussion Basic Science Seminar Targetable pathways in liver disease North 1 Organisers: Helen Louise REEVES, United Kingdom Cecília RODRIGUES, Portugal Frank TACKE, Germany SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 New targets in liver tumours 08:30-09:00 Interfering with senescence and malignant transformation Lars ZENDER, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 87

90 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Therapy induced senescence and image-guided senolytic targeting for liver cancer treatment Katharina WOLTER, Germany Discussion 09:00-09:30 Cell proliferation and invasiveness in liver cancer Jessica ZUCMAN-ROSSI, France Cell proliferation in liver tumours Stefano CARUSO, France Discussion 09:30-10:00 Adaptive immunity and immune checkpoint inhibition Robert THIMME, Germany Characterization of TAA-specific CD8+ T cells in HCC patients Catrin TAUBER, Germany SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 Discussion 10:00-10:30 Coffee break From targetable pathways to the clinics 10:30-11:00 New drug delivery systems and diagnostics Detlef SCHUPPAN, Germany In vivo antifibrotic therapy in the liver using cell-targeted nanohydrogel particles Leonard KAPS, Germany Discussion 11:00-11:30 Liquid biopsy for liver fibrosis Jelena MANN, United Kingdom Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis Mujat ZEYBEL, United Kingdom Discussion 11:30-12:00 The big picture: from a scientific finding to a clinical trial Scott FRIEDMAN, United States 88 EASL THE HOME OF HEPATOLOGY

91 11-15 APRIL 2018 PARIS, FRANCE Meet the Experts: Management of autoimmune hepatitis West 4 08:30-09:20 Olivier CHAZOUILLERES, France Michael P. MANNS, Germany Meet the Experts: Non-invasive tests in liver diseases West 4 09:30-10:20 Laurent CASTERA, France Massimo PINZANI, United Kingdom Oral eposters 10:00-10:30 Hepatitis B treatment Chair: Benjamin MAASOUMY, Germany Poster pod 1 10:00-10:30 Liver tumours: Experimental Chair: Jesper ANDERSEN, Denmark Poster pod 2 10:00-10:30 Alcohol Chair: Steven DOOLEY, Germany Poster pod 3 10:00-10:30 Gut liver axis Chair: Johannes HOV, Norway Poster pod 4 Poster tours SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :00-10:30 Autoimmune and chronic cholestatic liver disease: Clinical aspects Guide: Douglas THORBURN, United Kingdom Meeting Point 1 10:00-10:30 ACLF and critical illness Guide: Alexander GERBES, Germany Meeting Point 3 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 89

92 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Meet the Experts: Management of HCV infection in patients with HCC West 4 10:30-11:20 Jordi BRUIX, Spain Antonio CRAXI, Italy Epidemiology and burden of liver disease in Europe: data from HEPAHEALTH South 4 Chairs: Helena CORTEZ-PINTO, Portugal Francesco NEGRO, Switzerland 12:00-12:20 Key findings: the true burden of liver disease in Europe Laura PIMPIN, United Kingdom SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :20-12:35 What HEPAHEALTH tells us about liver disease in Central and Eastern Europe Marieta SIMONOVA, Bulgaria 12:35-12:55 Key health determinants for liver disease in Europe Nick SHERON, United Kingdom 12:55-13:10 Policy recommendations arising out of HEPAHEALTH and next steps Helena CORTEZ-PINTO, Portugal 13:10-13:30 Discussion Publishing in JHEP: A view from the inside South 1 Chair: Rajiv JALAN, United Kingdom 12:00-12:05 Introduction to the session Rajiv JALAN, United Kingdom 12:05-12:20 12:20-12:35 Editorial processes at the Journal of Hepatology Jessica ZUCMAN-ROSSI, France How to use neuromarketing techniques to get your paper published Rajiv JALAN, United Kingdom 90 EASL THE HOME OF HEPATOLOGY

93 11-15 APRIL 2018 PARIS, FRANCE 12:35-12:50 Reproducibility in research Thomas BERG, Germany 12:50-13:05 What constitutes research misconduct Richard MOREAU, France 13:05-13:30 Open Session: Questions to the editors from the audience The role of registries for modern hepatology South 3 Chairs: Joost DRENTH, Netherlands Erik SCHRUMPF, Norway 12:00-12:05 Introduction Marco MARZIONI, Italy 12:05-12:25 Why a registry in rare diseases is needed Christian TRAUTWEIN, Germany 12:25-12:45 Difficulties in creating a registry on a heterogenous disease Jesus M. BANALES, Spain 12:45-13:05 Large data collection on viral hepatitis in 2018: Where to go Heiner WEDEMEYER, Germany 13:05-13:25 The role of registries in policy making Philippe MATHURIN, France 13:25-13:30 Discussion Women in Hepatology West 1 SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 Chairs: Annalisa BERZIGOTTI, Switzerland Erica VILLA, Italy 12:00-12:10 Introduction Erica VILLA, Italy 12:10-12:25 Leadership in hepatology: Junior perspective Maja THIELE, Denmark THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 91

94 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 12:25-12:40 Leadership in hepatology: Senior perspective Marina BERENGUER HAYM, Spain 12:40-12:55 Gender medicine: Lessons from the cardiovascular medicine 12:55-13:10 Institution perspective David JONES, United Kingdom 13:10-13:30 Discussion Fellowship presentations West 2 Chairs: Bettina HANSEN, Netherlands Robert THIMME, Germany SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :00-12:15 12:15-12:30 12:30-12:45 12:45-12:55 12:55-13:05 13:05-13:15 EASL support to excellent young investigators: Presentation of the awardee of 2017 and what s new in the fellowship scheme Massimo PINZANI, United Kingdom EASL Pre-doc fellowship Marco DI PASCOLI, Italy EASL Post-doc fellowship Krista ROMBOUTS, United Kingdom EASL Mentorship concept and overview Jaime BOSCH, Spain A EASL mentee experience Bogdan PROCOPET, Romania EASL prizes and masterclass Massimo PINZANI, United Kingdom 13:15-13:30 A novel experimental model for a rare liver disease Emma ANDERSSON, Sweden 92 EASL THE HOME OF HEPATOLOGY

95 11-15 APRIL 2018 PARIS, FRANCE EASL-CDC symposium: Decentralization and integration of HCV diagnostics, care and treatment services in lowand middle-income countries West 3 Chairs: Markus CORNBERG, Germany Muazzam NASRULLAH, United States 12:00-12:10 World Health Organization (WHO) good practice principles for simplified service delivery for HCV testing, care and treatment, with lessons learned from HIV Philippa EASTERBROOK, Switzerland 12:10-12:20 HCV diagnostics, an essential part of decentralization and integration of care Francesco MARINUCCI, Switzerland 12:20-12:30 Training and capacity building for primary care and harm reduction settings Karla THORNTON, United States 12:30-12:40 Scaling up of HCV services in Punjab, India Gagandeep GROVER, India 12:40-12:55 Progress towards decentralization and integration of HCV services in primary care, hospitals and harm reduction settings in Georgia David SERGEENKO, Georgia 12:55-13:05 Challenges and opportunities for decentralization of HCV care and treatment services Francisco AVERHOFF, United States 13:05-13:30 Q & A / Discussion SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 Meet the Experts: Hepatorenal syndrome West 4 12:00-12:50 Paolo ANGELI, Italy Pere GINÈS, Spain THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 93

96 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Oral eposters 12:00-13:00 Hepatitis C therapy: clinical challenges Chair: Tania WELZEL, Germany Poster pod 1 12:00-13:00 Hepatitis A and E Chair: Patrick BEHRENDT, Germany Poster pod 2 12:00-13:00 Cirrhosis Chair: Elsa SOLÀ, Spain Poster pod 3 12:00-13:00 NASH: Experimental Chair: Luca VALENTI, Italy Poster pod 4 SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 Poster tours 12:00-13:00 Public Health Guide: Peter JEPSEN, Denmark Meeting Point 1 12:00-13:00 Viral hepatitis C: Therapy and resistance Guide: Antonio CRAXI, Italy Meeting Point 2 12:00-13:00 NAFLD: Experimental and pathophysiology Guide: Isabelle LECLERQ, Belgium Meeting Point 3 EASL clinical practice guidelines: Management of hepatocellular carcinoma North 1 Chairs: Alejandro FORNER, Spain Peter GALLE, Germany 12:15-12:45 Presentation Peter GALLE, Germany 94 EASL THE HOME OF HEPATOLOGY

97 11-15 APRIL 2018 PARIS, FRANCE 12:45-13:15 Panel Josep M. LLOVET, United States Vincenzo MAZZAFERRO, Italy Fabio PISCAGLIA, Italy Jean-Luc RAOUL, France Peter SCHIRMACHER, Germany General session I and opening ceremony Main Plenary Chairs: Tom Hemming KARLSEN, Norway Tilman SAUERBRUCH, Germany 13:30-14:00 Opening Ceremony 14:00-14:15 GS :15-14:30 GS :30-14:45 GS :45-15:00 GS-004 Epidemiology, predictors and outcomes of multi drug resistant bacterial infections in patients with cirrhosis across the world. Final results of the Global study Salvatore PIANO, Italy Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study Vlad RATZIU, France Sorafenib with versus without concurrent conventional transarterial chemoembolization (ctace) in patients with advanced hepatocellular carcinoma (HCC): Results from a multicenter, openlabel, randomized, controlled phase III STAH trial Joong-Won PARK, Korea, Rep. of South Integrative molecular classification of extrahepatic cholangiocarcinoma Robert MONTAL, Spain SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :00-15:15 GS :15-15:30 GS-006 Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection Heiner WEDEMEYER, Germany Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naïve participants Tarik ASSELAH, France THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 95

98 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Oral eposters 15:30-16:00 Molecular and cell biology Chair: Laura FOUASSIER, France Poster pod 1 15:30-16:00 Autoimmune and cholestatic diseases: clinical Chair: Espen MELUM, Norway Poster pod 2 15:30-16:00 Extrahepatic manifestations in HCV Chair: Anna Linda ZIGNEGO, Italy Poster pod 3 SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :30-16:00 Poster tours NAFLD: Diagnostic and non-invasive Chair: William ALAZAWI, United Kingdom Poster pod 4 15:30-16:00 Liver tumours: Therapy Guide: Maria REIG, Spain Meeting point 1 15:30-16:00 Molecular and cellular biology Guide: Rui CASTRO, Portugal Meeting point 2 15:30-16:00 Viral hepatitis C: Clinical aspects except therapy Guide: Robert FLISIAK, Poland Meeting point 3 Parallel session: Hepatitis C: Therapy Main Plenary Chairs: Alessio AGHEMO, Italy Maria BUTI, Spain 96 EASL THE HOME OF HEPATOLOGY

99 11-15 APRIL 2018 PARIS, FRANCE 16:00-16:15 PS :15-16:30 PS :30-16:45 PS-035 Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort Elizabeth VERNA, United States 8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort Alison BOYLE, United Kingdom Safetyand Efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in Genotype 3 HCV-Infected Patients with Cirrhosis Maria BUTI, Spain 16:45-17:00 PS :00-17:15 PS :15-17:30 PS :30-17:45 PS-039 Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST)-does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R) Stefan CHRISTENSEN, Germany Estimated glomerular filtration rate (egfr) variations and direct acting antivirals (DAA) treatment for chronic hepatitis C (CHC): a retrospective longitudinal study Vincent MALLET, France Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study Hadi KURIRY, Canada NS5A resistance patterns and treatment outcomes in DAA-naive genotype 1a (GT1a) chronic hepatitis C patients with and without baseline resistanceassociated substitutions (RASs) Julia DIETZ, Germany SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :45-18:00 PS-040 Retreatment of patients who failed glecaprevir/ pibrentasvir treatment for hepatitis C virus infection David WYLES, United States THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 97

100 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Parallel session: Clinical management of hepatocellular carcinoma North 1 Chairs: Sandrine FAIVRE, France Markus PECK-RADOSAVLJEVIC, Austria 16:00-16:15 PS :15-16:30 PS-018 Personalized T cell therapy against HBV-related hepatocellularcarcinoma Anthony TAN, Singapore Role of 99mTc-Macroaggregated Albumin SPECT/ CT based dosimetry in predicting survival and tumor response of patients with locally advanced and inoperable hepatocellular carcinoma (HCC) treated by selective intra-arterial radiation therapy (SIRT) with yttrium-90 resin microspheres, a cohort from SARAH study Anne-Laure HERMANN, France SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :30-16:45 PS :45-17:00 PS :00-17:15 PS-021 Pattern of progression determines post-progression survival in patients with hepatocellular carcinoma treated with Radioembolization Carlota JORDAN, Spain Lower compliance to prior HCC surveillance and liver function impairment explain the apparent higher HCC incidence under direct antivirals in HCV compensated cirrhotic patients: the French multicenter prospective ANRS CO12 CirVir cohort experience Pierre NAHON, France Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR Sarah SHILI, France 17:15-17:30 PS-022 Efficacy and safety of REGORAFENIB in real life in the treatment of hepatocellular carcinoma. Multicenter experience Miguel FRAILE, Spain 98 EASL THE HOME OF HEPATOLOGY

101 11-15 APRIL 2018 PARIS, FRANCE 17:30-17:45 PS :45-18:00 PS-024 Pathological characteristics and early post-hepaticresection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: a multicenter cohort study Alessandro VITALE, Italy Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study Tim MEYER, United Kingdom Parallel session: NAFLD: Experimental and pathophysiology South 2 16:00-16:15 PS :15-16:30 PS :30-16:45 PS :45-17:00 PS-052 Chairs: Amalia GASTALDELLI, Italy Jelena MANN, United Kingdom Acceleration of NASH in a mouse model provides novel insights on the mechanisms by which I148M PNPLA3 drives steatohepatitis Bubu BANINI, United States Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD Cyrielle CAUSSY, United States Defective autophagy in liver sinusoidal endothelial cells promotes non alcoholic steatohepatitis and fibrosis development Adel HAMMOUTENE, France Modelling non-alcoholic fatty liver disease using human induced pluripotent stem cells Carola Maria MORELL, United Kingdom SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :00-17:15 PS-053 NLRP6 Inflammasome-mediated intestinal dysbiosis drives steatohepatitis and promotes HCC progression Kai Markus SCHNEIDER, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 99

102 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 17:15-17:30 PS :30-17:45 PS :45-18:00 PS-056 Serum bile acids alteration is associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD Cyrielle CAUSSY, United States Down-regulation of hepatic MBOAT7 by hyperinsulinemia favours steatosis development Marica MERONI, Italy NLRP3 inflammasome activation in hepatocytes results in pyroptotic cell death, release of NLRP3 particles and liver fibrosis Susanne SCHUSTER, United States Parallel session: HBV cure: Pre-clinical studies South 4 SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :00-16:15 PS :15-16:30 PS :30-16:45 PS-027 Chairs: Julie LUCIFORA, France Stephen LOCARNINI, Australia Combinatorial RNAi/vaccination therapy for chronic hepatitis B achieves long-term functional cure in preclinical mouse model Thomas MICHLER, Germany Novel and potent HBV capsid modulator reduces HBeAg and cccdna in core site directed T109I mutant in HepNTCP cells Leda BASSIT, United States Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer Nagraj MANI, United States 16:45-17:00 PS-028 Combination treatment of a TLR7 agonist RO and a capsid assembly modulator RO achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model Lu GAO, China 100 EASL THE HOME OF HEPATOLOGY

103 11-15 APRIL 2018 PARIS, FRANCE 17:00-17:15 PS :15-17:30 PS :30-17:45 PS :45-18:00 PS-032 Durable inhibition of hepatitis B virus replication and antigenemia using a subcutaneously administered sirna agent in preclinical models Amy C.H LEE, Canada Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection Christine WOODDELL, United States T cells grafted with HBV-specific T-cell receptors of high functional avidity achieve functional cure of HBV infection in humanized mice Ulrike PROTZER, Germany Discovery of a novel core inhibitor EP with potent antiviral activity both in vitro and in a humanized mouse model Michael VAINE, United States Parallel session: Cirrhosis and its complications: Experimental and pathophysiology South 1 16:00-16:15 PS :15-16:30 PS-010 Chairs: Wim LALEMAN, Belgium Richard MOREAU, France Stem cells as a new therapeutic strategy for portal hypertension and cirrhosis Anabel FERNÁNDEZ-IGLESIAS, Spain Targeting the nitric-oxide downstream pathway in bile-duct ligated rats to improve portal hypertension and liver fibrosis Philipp SCHWABL, Austria SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :30-16:45 PS-011 Serum concentrations of Macrophage Migration Inhibitory Factor (MIF) and its soluble receptor CD74 predict transplant-free short-term survival in patients with acute decompensation of liver cirrhosis Theresa WIRTZ, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 101

104 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 16:45-17:00 PS :00-17:15 PS :15-17:30 PS-014 Oxidized albumin present in patients with decompensated cirrhosis triggers the inflammatory response in peripheral leukocytes through the p38 MAP kinase pathway José ALCARAZ QUILES, Spain Lessons from ATTIRE feasibility study: differential inflammatory response profiles following treatment with albumin correlate with 6 months survival Natalia BECARES, United Kingdom Acute-on-chronic liver failure is characterised by hepatocyte gasdermin D cleavage and release of the pro-inflammatory Damage Associated Molecular Pattern (DAMP) IL-1a Ugo SOFFIENTINI, United Kingdom SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :30-17:45 PS :45-18:00 PS-016 Gut microbiome is profoundly altered in acute-onchronic liver failure as evaluated by quantitative metagenomics. Relationship with liver cirrhosis severity Cristina SOLE, Spain Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort Jasmohan S BAJAJ, United States Parallel session: Liver transplantation: Clinical South 3 16:00-16:15 PS-041 Chairs: Marina BERENGUER HAYM, Spain Christian TOSO, Switzerland Frequency and outcomes of liver transplantation for non-alcoholic steatohepatitis in Europe Debashis HALDAR, United Kingdom 16:15-16:30 PS-042 Liver transplantation in patients with multiple organ failures is feasible with good outcomes Paul J. THULUVATH, United States 102 EASL THE HOME OF HEPATOLOGY

105 11-15 APRIL 2018 PARIS, FRANCE 16:30-16:45 PS :45-17:00 PS :00-17:15 PS :15-17:30 PS-046 Evaluation of a pocket-sizedspectroscopy for extemporaneous macrosteatosis liver graft assessment Nicolas GOLSE, France Effect of longitudinal exposure to tacrolimus on chronic kidney disease occurrence at one year post liver transplantation Pauline MAUREL, France Donor specific antibodies after liver transplantation- still an underestimated risk? Katharina WILLUWEIT, Germany Severe histological injury of common bile ducts in donation after circulatory death liver transplantation Francesca TINTI, Italy 17:30-17:45 PS :45-18:00 PS-048 Prevalence of subclinical histological lesions and tolerance biomarkers in long-term adult liver transplant recipients considered for immunosuppression withdrawal. Alberto SANCHEZ-FUEYO, United Kingdom 30 years of liver transplantation for metabolic disease in the United States Patrick MCKIERNAN, United States Parallel session: Autoimmune and cholestasis 1 West 1 16:00-16:15 PS-001 Chairs: Frank LAMMERT, Germany Marco MARZIONI, Italy Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial Christophe CORPECHOT, France SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 103

106 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 16:15-16:30 PS :30-16:45 PS :45-17:00 PS-004 Are the Globe and UK-PBC scores also effective for predicting risk in patients treated with bezafibrate in addition to ursodeoxycholic acid?: A validation study in Japan Atsushi TANAKA, Japan Sub-cutaneously delivered mesenchymal stromal cells and down-regulation of activated vascular endothelium-a novel, clinically ready, therapeutic approach to treating cholestatic liver disease Philip NEWSOME, United Kingdom The gut-liver axis is essential for disease progression in the Mdr2-/- mouse model of primary sclerosing cholangitis Lijun LIAO, Germany SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :00-17:15 PS :15-17:30 PS :30-17:45 PS :45-18:00 PS-008 Immunomodulatory mechanisms of the novel therapeutic bile acid 24-nor-ursodeoxycholic acid Ci ZHU, Austria Autoantibodies against Huntingtin-interacting protein 1-related protein are superior to conventinal autoantibodies in diagnosing autoimmune hepatitis in adults Richard TAUBERT, Germany Intestine-specific deletion of Abcg5/g8 leads to hepatobiliary cholesterol overload: pathophysiology of biliary lipid secretion Susanne N WEBER, Germany Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis-even in patients without biochemical improvements Maren HARMS, Netherlands Parallel session: Public health: General West 2 Chairs: Marc BULTERYS, Switzerland Jeffrey LAZARUS, Spain 104 EASL THE HOME OF HEPATOLOGY

107 11-15 APRIL 2018 PARIS, FRANCE 16:00-16:15 PS :15-16:30 PS :30-16:45 PS-059 Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): A large German claims database study Ali CANBAY, Germany Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A pangenotypic cost-effectiveness analysis set in Scotland Brett PINSKY, United States Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics Massimo IAVARONE, Italy 16:45-17:00 PS :00-17:15 PS :15-17:30 PS :30-17:45 PS :45-18:00 PS-064 Food insecurity increases the risk of advanced fibrosis in diabetics with nonalcoholic fatty liver disease Russell ROSENBLATT, United States Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response Hooman FARHANG ZANGNEH, Canada Prevalence and explanatory factors for liver function testing and abnormality in a population-based study of children and young people Wenhao LI, United Kingdom Cases of transfusion-transmitted hepatitis E virus infections at a tertiary referral center Dirk WESTHÖLTER, Germany Analysis of the influence of alcohol abstinence on the risk of developing hepatocellular carcinoma (HCC) in patients with alcoholic liver cirrhosis (ALC) Andrés CASTANO-GARCIA, Spain SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 105

108 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME ELPA Symposium: Symptom management across liver diseases: Is there a big picture? West 3 Chairs: Marko KORENJAK, Slovenia Tatjana REIC, Belgium 16:00-16:10 Welcome and introduction Tatjana REIC, Belgium 16:10-16:25 Fatigue in liver disease Marco CARBONE, Italy 16:25-16:40 Pruritus in liver disease Annarosa FLOREANI, Italy 16:40-16:55 Liver disease and mental health: psychological or physical? Martin SCHAEFER, Germany SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL :55-17:10 Quality of life after liver transplantation Patrizia BURRA, Italy 17:10-17:25 Sexual problems in liver disease Anton GILLESSEN, Germany 17:25-17:40 Impact of self management Robert MITCHELL THAIN, United Kingdom 17:40-17:50 Group discussion Marko KORENJAK, Slovenia 17:50-18:00 Closing remarks Tatjana REIC, Belgium Meet the Experts: Antibiotic stewardship in cirrhosis West 4 16:00-16:50 Raffaele BRUNO, Italy Valentin FUHRMANN, Germany 106 EASL THE HOME OF HEPATOLOGY

109 11-15 APRIL 2018 PARIS, FRANCE Meet the Experts: Achieving alcohol abstinence West 4 17:00-17:50 Antoni GUAL, Spain Maja THIELE, Denmark Skills in hepatology: Non-invasive diagnostics methods: Acute medicine in hepatology West 5 Chair: Robert DE KNEGT, Netherlands 18:30-20:00 Tutors Pavel TAIMR, Netherlands Christoph TERKAMP, Germany Jeoffrey SCHOUTEN, Belgium Dave SPRENGERS, Netherlands Industry Symposia 18:30-20:00 Please refer to the industry section for more details, page 348. SCIENTIFIC PROGRAMME / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 107

110

111 11-15 APRIL 2018 PARIS, FRANCE SCIENTIFIC PROGRAMME FRIDAY 13 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

112 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SCIENTIFIC PROGRAMME FRIDAY 13 APRIL 2018 Breakfast morning rounds: Common complications in liver cirrhosis South 3 Chair: Thomas BERG, Germany 07:30-08:20 Case presentation Cornelius ENGELMANN, United Kingdom Experts Andres CARDENAS, Spain Claire FRANCOZ, France Thomas REIBERGER, Austria SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Breakfast morning rounds: Acute liver failure when to list? West 1 Chair: John O GRADY, United Kingdom 07:30-08:20 Case presentation Upkar GILL, United Kingdom Experts Patrizia BURRA, Italy Frederik NEVENS, Belgium Fuat SANER, Germany Breakfast morning rounds: NAFLD How to achieve weight loss West 2 Chair: Vlad RATZIU, France 07:30-08:20 Case presentation Fabio NASCIMBENI, Italy 110 EASL THE HOME OF HEPATOLOGY

113 11-15 APRIL 2018 PARIS, FRANCE Experts Elisabetta BUGIANESI, Italy Jörn SCHATTENBERG, Germany Shira ZELBER-SAGI, Israel Breakfast morning rounds: Iron overload and hemochromatosis Practical management West 3 Chair: Ger KOEK, Netherlands 07:30-08:20 Case presentation Paulien LIEDORP, Netherlands Experts Elena CORRADINI, Italy Claus NIEDERAU, Germany Felix STICKEL, Switzerland General session II and award ceremony I 08:30-08:45 GS :45-09:00 GS-008 Chairs: Ronald SOKOL, United States Frank TACKE, Germany Main Plenary First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: data from the German Hepatitis C-Registry Thomas BERG, Germany Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up Jeong-Hoon LEE, Korea, Rep. of South SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-09:15 GS-009 MGL-3196, a selective thyroid hormone receptorbeta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study Stephen HARRISON, United Kingdom 09:15-09:45 Award ceremony 1 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 111

114 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 09:45-10:00 GS :00-10:15 GS :15-10:30 GS-012 HEPAHEALTH: The Burden of liver disease in Europe Helena CORTEZ-PINTO, Portugal Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid Gideon HIRSCHFIELD, United Kingdom Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study Tarik ASSELAH, France Jean-Pierre Benhamou Clinical State-of-the-art: Is it time to abandon the term cirrhosis? Main Plenary SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :30-11:00 Jaime Bosch, Spain Guest Professor of Hepatology, Swiss Liver Centre, Inselspital, Department of Biomedical Research, University of Bern, Switzerland Jaime Bosch is clinical hepatologist and worldwide recognised expert in portal hypertension and hemodynamic assessment of liver disease. In this field he authored/coauthored over 400 papers in peer-reviewed journals. He is also Professor of the Faculty of Medicine in the University of Barcelona. Lecture summary: Cirrhosis of the liver is an anatomic diagnosis for a common final phase of several advanced chronic liver diseases. It is characterized by a total remodelling of the normal liver architecture that is substituted by the diffuse formation of regenerative nodules separated by fibrous scar tissue. Cirrhosis may be the consequence, among others, of chronic viral hepatitis (B, D, C, and E), of alcohol abuse, metabolic disorders -either acquired (NAFLD) or congenital (hemochromatosis, 112 EASL THE HOME OF HEPATOLOGY

115 11-15 APRIL 2018 PARIS, FRANCE Wilson disease, alpha-1 AT deficiency), toxic agents (hepatotoxic drugs), chronic autoimmune hepatitis, and of chronic biliary or cholestatic diseases (PBC, PSC, biliary obstruction, biliary atresia, cystic fibrosis). For many years cirrhosis has been a feared diagnosis, since it has been considered to imply an ominous prognosis. However, during the past decades it has become clear that cirrhosis may be for many years totally asymptomatic, a poor prognosis being only associated after development of serious complications. Yet, the anatomical diagnosis of cirrhosis does not correlate well with prognosis. Moreover, liver biopsy is invasive and thus cannot be repeated every 1-2 years to verify how histology is evolving; in addition, it carries a >20% risk of missing the diagnosis, has significant interobserver variability, and not even pathologists like to use the term cirrhosis nowadays. On the other hand, the clinical diagnosis of cirrhosis is inaccurate, and even with the newer non-invasive tools many cases may wrongly classified, dependent on how strict are the criteria for ruling-in or ruling-out cirrhosis. On top of that, the term cirrhosis is polluted by the stigmata of being a self-inflicted disease caused by chronic alcoholism, which as stated is very frequently not true. Finally, the pathophysiology of the complications of cirrhosis changes from early to advanced phases, which has also implications in terms of therapeutic targets and strategies. Because of these caveats, at the past Baveno VI consensus conference on portal hypertension it was proposed to substitute the term cirrhosis by the term advanced chronic liver disease or ACLD. The evolution of ACLD follows several stages. The first stage is compensated ACLD, where the disease is frequently asymptomatic and has an excellent prognosis. Within this phase we can distinguish two substages according to the presence or not of clinically significant portal hypertension (a hepatic vein pressure gradient, HVPG, of 10 mmhg or above) or of varices at endoscopy (or of collaterals on abdominal imaging). The substage without CSPH has an excellent prognosis (1-year mortality of 1.5%) and is potentially reversible by correcting the cause of the ACLD and by adopting a safe life-style. At this stage the patients have not yet developed a hyperkinetic circulation and agents such as non-selective beta-blockers (NSBB) are useless. A rational target for non etiology-specific therapy would be acting on liver fibrosis and on hepatic microvascular endothelial dysfunction. The substage with CSPH still has a good prognosis (1-year mortality of 2%), but carries a 20-40% 2-year risk of transitioning to the stage of decompensated cirrhosis. Treatments are being developed to prevent transitioning to decompensation. In addition to strategies used when there is no CSPH, here NSBB may be effective in decreasing the risk of decompensation. SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 113

116 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME The stage of decompensated cirrhosis starts with the development of severe clinical complications related to portal hypertension and advanced liver failure: ascites (and related complications), variceal bleeding, overt hepatic encephalopathy or jaundice. Prognosis is much worse than in compensated ACLD, and goes from a 10% risk of death at 1-year after experiencing variceal bleeding alone, to about 20% in patients with nonbleeding complications, and 30% when both bleeding and nonbleeding manifestations of decompensation have arisen. After decompensation the reversibility of the ACLD is doubtful or very unlikely and the only curative treatment is liver transplantation, although there are effective medical treatments to delay the evolution to death or transplantation, including endoscopic therapy, NSBB, statins and TIPS. Other novel drugs are being tested. Development of hepatocellular carcinoma may occur at any stage in ACLD, although it is much more frequent after developing CSPH. The clinical stage of ACLD also influences the choice of treatment for liver cancer. SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Nurses and Associates Forum: Involvement of nurses and associates in liver disease management West 3 Chairs: Michelle CLAYTON, United Kingdom Alejandro FORNER, Spain 10:00-10:15 NASH case study introduction Fabienne SCHUMACHER, Germany 10:15-10:30 What is the role of the liver nurse? Lynda GREENSLADE, United Kingdom 10:30-10:45 Optimising nutrition and lifestyle changes Cecile SCHWAB, Switzerland 10:45-11:00 Utilising the diabetes nurse specialist Paula MAYO, United Kingdom 11:00-11:15 NASH case study conclusion Fabienne SCHUMACHER, Germany 11:15-11:30 Questions 114 EASL THE HOME OF HEPATOLOGY

117 11-15 APRIL 2018 PARIS, FRANCE Oral eposters 11:00-11:30 Novel treatments for chronic liver failure and portal hypertension Chair: Christian LANGE, Germany Poster pod 1 11:00-11:30 Immunology, except viral hepatitis Chair: Tobias BÖTTLER, Germany Poster pod 2 11:00-11:30 DILI Chair: John DILLON, United Kingdom Poster pod 3 11:00-11:30 Infections and antimicrobial therapy in cirrhosis Chair: Salvatore PIANO, Italy Poster pod 4 Poster tours 11:00-11:30 Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology Guide: Michael HENEGHAN, United Kingdom Meeting point 1 11:00-11:30 Acute liver failure and drug induced liver injury Guide: Guruprasad AITHAL, United Kingdom Meeting point 2 SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-11:30 Viral hepatitis B/D: Clinical aspects except therapy Guide: Ulrike PROTZER, Germany Meeting point 3 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 115

118 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Grand rounds: Hepatocellular carcinoma in non-cirrhotic liver Main Plenary Chairs: Jean-François DUFOUR, Switzerland Bruno SANGRO, Spain 11:30-12:30 Case Presenter Philippe KOLLY, Switzerland Grand rounds: Cirrhosis complications North 1 Chairs: Manuela MERLI, Italy Rajiv JALAN, United Kingdom 11:30-12:30 Case Presenter Barbara LATTANZI, Italy SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Grand rounds: Fatty liver in a lean patient South 2 Chairs: Claus NIEDERAU, Germany Vlad RATZIU, France 11:30-12:30 Case Presenter Thomas KADEN, Germany Grand rounds: Severe alcoholic hepatitis South 1 Chairs: Mark THURSZ, United Kingdom Dominique THABUT, France 11:30-12:30 Case Presenter Nikhil VERGIS, United Kingdom 116 EASL THE HOME OF HEPATOLOGY

119 11-15 APRIL 2018 PARIS, FRANCE Grand rounds: Primary biliary cholangitis South 3 Chairs: Olivier CHAZOUILLERES, France Frederik NEVENS, Belgium 11:30-11:50 Case Presenter Sara LEMOINNE, France Hot topics in liver transplantation South 4 Part I: Waiting list patient Chairs: Christophe DUVOUX, France Catherine PAUGAM, France 11:30-11:50 Nutrition of patients on the transplant list Rachel WESTBROOK, United Kingdom 11:50-12:10 Portal vein thrombosis anticoagulation management pre- and post-transplant Marco SENZOLO, Italy 12:10-12:30 HCC downstaging and bridging for liver transplantation Christian TOSO, Switzerland 12:30-12:50 Strategies to increase organ donation in Europe Patrizia BURRA, Italy 12:50-13:00 Discussion 13:00-14:00 Lunch break Part II: Liver transplantation for non-hcc malignancy Chairs: Wojciech POLAK, Netherlands Frank TACKE, Germany SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-14:20 Intrahepatic cholangiocarcinoma Sarwa Darwish MURAD, Netherlands 14:20-14:40 Colorectal cancer metastases René ADAM, France THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 117

120 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 14:40-15:00 Endocrine tumors Vincenzo MAZZAFERRO, Italy 15:00-15:20 Vascular tumors Jan LERUT, Belgium 15:20-15:30 Discussion 15:30-16:00 Coffee break Part III: Common complications after liver transplantation Chairs: Patrizia BURRA, Italy Fuat SANER, Germany 16:00-16:20 Immune mediated disorders: clinical and histopathological features Michael A HENEGHAN, United Kingdom SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :20-16:40 Managing of metabolic syndrome and cardiovascular risks post-transplant Emmanuel TSOCHATZIS, United Kingdom 16:40-17:00 The recipient with a DCD-liver challenges in hemodynamic and coagulation Anabel BLASI, Spain 17:00-17:20 Impact of new strategies (machine perfusion, normothermic regional perfusion) on biliary complications after liver transplantation Costantino FONDEVILA, Spain 17:20-17:40 HCV positive donor organs in solid organ transplant recipients- chances and challenges in the era of interferon-free HCV treatment Kerstin HERZER, Germany 17:40-18:00 Infectious complications Pierluigi VIALE, Italy 18:00-18:10 Discussion 18:10-18:15 Summary and closing remarks 118 EASL THE HOME OF HEPATOLOGY

121 11-15 APRIL 2018 PARIS, FRANCE Basic science highlights: Immune checkpoints in liver tumours and beyond West 1 Chairs: Marco MARZIONI, Italy Gisa TIEGS, Germany 11:30-11:50 General principles of checkpoints inhibition Pablo SAROBE, Spain 11:50-12:10 Immune mechanisms in the tumour microenvironment of HCC and CCA 12:10-12:30 Principles and prospects of HCC and CCA immunotherapy Tim GRETEN, United States Young investigators seminar: Palliative care in hepatology: an unmet need West 3 11:30-11:35 11:35-11:50 11:50-12:05 12:05-12:20 Chairs: Annalisa BERZIGOTTI, Switzerland Rodrigo LIBERAL, United Kingdom A clinical case Joana CARVALHO, Portugal Palliative care beyond pain management Aileen MARSHALL, United Kingdom Nursing in end of life scenarios Lynda GREENSLADE, United Kingdom Uncertainty management and psychological support to the patient and the caregiver Barbara KIMBELL, United Kingdom SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :20-12:30 Case discussion and questions from the audience THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 119

122 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME How to succeed in European research grant applications? East 3 Chairs: Emma ANDERSSON, Sweden Philip NEWSOME, United Kingdom 11:30-11:45 11:45-12:00 12:00-12:10 12:10-12:30 Introduction: Overview of EU- level research funding opportunities and support tools Grigorij KOGAN, Belgium Individual grants: ERC Starting Grant and consolidator grant: How I did it Tom LÜDDE, Germany Collaborative grants: Horizon 2020: How I did it Pere GINÈS, Spain Open discussion (Q&A) SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Meet the Experts: Difficult cases of HCV therapy: Is there any? West 4 11:30-12:20 Xavier FORNS, Spain Jean-Michel PAWLOTSKY, France EASL General Assembly West 2 12:30-14:00 EASL Members General Assembly IMPORTANT: Access restricted to active EASL members 120 EASL THE HOME OF HEPATOLOGY

123 11-15 APRIL 2018 PARIS, FRANCE Poster tours 12:30-13:00 12:30-13:00 12:30-13:00 NAFLD: Diagnostics and non-invasive assessment Guide: Vincent WONG, Hong Kong Meeting point 1 Viral hepatitis B/D: Therapy Guide: George PAPATHEODORIDIS, Greece Meeting point 2 Fibrosis Guide: Krista ROMBOUTS, United Kingdom Meeting point 3 13:00-13:30 13:00-13:30 13:00-13:30 Liver development, physiology and regeneration Guide: Ralf WEISKIRCHEN, Germany Meeting point 1 Liver transplantation and hepatobiliary Clinical aspects Guide: Christian TOSO, Switzerland Meeting point 2 Liver tumours: Clinical aspects except therapy Guide: Pierre NAHON, France Meeting point 3 Nurses and Associates Forum: Quality care for people with liver disease West 3 SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Chairs: Michelle CLAYTON, United Kingdom Nathalie GOUTTE, France 13:30-13:50 Value of the nurse within the MDT in managing people with viral hepatitis Colina M, Canada 13:50-14:10 The role of liver transplant coordinator in ensuring quality care Lara ELSHOVE, Netherlands THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 121

124 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 14:10-14:30 Mindfulness based relapse prevention: beyond fighting against craving Laure GITZHOFFEN, France 14:30-15:00 End of life care planning in people with chronic liver disease Elsebeth ELMSTRØM HOLST JENSEN, Denmark 15:00-15:15 Introducing the EASL Nurses CAG Michelle CLAYTON, United Kingdom EASL clinical practice guidelines: Decompensated cirrhosis & Nutrition Main Plenary Chairs: Shiv Kumar SARIN, India Roger WILLIAMS, United Kingdom SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-15:00 Management of patients with decompensated cirrhosis Paolo ANGELI, Italy 15:00-15:30 Nutrition in chronic liver disease Manuela MERLI, Italy Symposium: NAFLD management in 2018 North 1 Chair: Sven FRANCQUE, Belgium 14:00-14:20 Case finding and screening in populations at risk: Where do we stand? Manal ABDELMALEK, United States 14:20-14:40 Non-invasive techniques: Current role in diagnosis and follow-up Jerome BOURSIER, France 14:40-15:00 Life style intervention: What are the needs? Kate HALLSWORTH, United Kingdom 15:00-15:20 Pharmacological therapy: What to expect in the near future? Sven FRANCQUE, Belgium 15:20-15:30 Discussion 122 EASL THE HOME OF HEPATOLOGY

125 11-15 APRIL 2018 PARIS, FRANCE Symposium: DAA failure and post SVR complications South 2 Chair: Alessio AGHEMO, Italy 14:00-14:30 Management of DAA Failures Christoph SARRAZIN, Germany 14:30-15:00 Post SVR follow-up in chronic HCV: When is it necessary? Stefan ZEUZEM, Germany 15:00-15:30 Clinical impact of SVR in patients with Hepatitis C Sabela LENS, Spain Fusion hepatology around the world: HCC South 1 Chairs: Zhongping DUAN, China Tom Hemming KARLSEN, Norway Masatoshi KUDO, Japan Changing patterns in the epidemiology of risk factors for HCC 14:00-14:15 Risk factors for HCC in Europe what is the role of NAFLD? Helen Louise REEVES, United Kingdom 14:15-14:30 Changing pattern of HCC incidence in Eastern countries Junqi NIU, China 14:30-14:40 Discussion SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Diagnosis management of HCC: Are there differences between West and East? 14:40-14:55 Diagnostic algorithm of HCC in Japan Ryosuke TATEISHI, Japan 14:55-15:10 How can the non-invasive diagnosis of HCC be further improved? Hero HUSSAIN, Lebanon 15:10-15:20 Discussion THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 123

126 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Local therapy in HCC: Same disease but different approach? 15:20-15:35 15:35-15:50 15:50-16:00 Role of surgery in non-early HCC patients Tanto CHEUNG, Hong Kong Radioembolization in HCC: Still waiting for positive RCTs? Sherrie BHOORI, Italy Discussion Alcoholic liver disease: are we moving in the right direction to reduce the more frequent and preventable liver disease? South 3 Chairs: Helena CORTEZ-PINTO, Portugal Nick SHERON, United Kingdom SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-14:20 ALD and alcohol related harm in Europe findings from the HEPAHEALTH survey Fiona GODFREY, Switzerland Laura PIMPIN, United Kingdom Nick SHERON, United Kingdom 14:20-14:40 The Scottish experience: MUP and treatment pathways: A public health response to a national health challenge Eric CARLIN, United Kingdom 14:40-15:00 Alcohol policy at EU level: Where we are and where we need to go Aleksandra KACZMAREK, Belgium 15:00-15:30 Discussion: What should be the EASL policy on alcohol in Europe? Eric CARLIN, United Kingdom Helena CORTEZ-PINTO, Portugal Aleksandra KACZMAREK, Belgium Philippe MATHURIN, France Marsha MORGAN, United Kingdom Frank MURRAY, Ireland Nick SHERON, United Kingdom 124 EASL THE HOME OF HEPATOLOGY

127 11-15 APRIL 2018 PARIS, FRANCE Symposium: Extracellular vesicles and signal transmission West 1 Chair: Miroslaw KORNEK, Germany 14:00-14:20 14:20-14:40 14:40-15:00 15:00-15:20 15:20-15:30 Extracellular vesicles in NASH Ariel FELDSTEIN, United States Extracellular vesicles in cholangiopathy Jesus BANALES, Spain Exosomes in alcoholic liver disease Gyongyi SZABO, United States Microvesicles as novel diagnostic tools for HCC and CCA Miroslaw KORNEK, Germany Disucssion Meet the Experts: Prevention of decompensation in cirrhosis West 4 14:00-14:50 Jaime BOSCH, Spain Emmanuel TSOCHATZIS, United Kingdom Oral eposters 15:30-16:00 Viral hepatitis: Immunology Chair: Christoph NEUMANN-HAEFELIN, Germany Poster pod 1 15:30-16:00 Acute-on-chronic liver failure Chair: Jonel TREBICKA, Germany Poster pod 2 SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :30-16:00 Rare liver disease Chair: Philip BUFLER, Germany Poster pod 3 15:30-16:00 Liver tumour clinical Chair: Christian TRAUTWEIN, Germany Poster pod 4 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 125

128 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Poster tours 15:30-16:00 Cirrhosis and its complications: Experimental and pathophysiology Guide: Lindsey DEVISSCHER, Belgium Meeting point 1 15:30-16:00 NAFLD: Therapy Guide: Rohit LOOMBA, United States Meeting point 2 15:30-16:00 Viral Hepatitis C: Post SVR and long term follow up Guide: Peter FERENCI, Austria Meeting point 3 SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Parallel session: NAFLD: Clinical and therapy 16:00-16:15 PS :15-16:30 PS-106 Chairs: Philip NEWSOME, United Kingdom Jörn SCHATTENBERG, Germany Main Plenary Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-coa carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH Eric LAWITZ, United States Non-alcoholic fatty liver disease and relative risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma events in four European primary care databases William ALAZAWI, United Kingdom 16:30-16:45 PS-107 Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study Elena BUZZETTI, Italy 126 EASL THE HOME OF HEPATOLOGY

129 11-15 APRIL 2018 PARIS, FRANCE 16:45-17:00 PS :00-17:15 PS :15-17:30 PS-110 The effect of intragastric balloon therapy on the intestinal microbiome in obese patients with nonalcoholic fatty liver disease, and correlations with anthropometric indices, nutritional factors, and serum immunological markers Vi NGUYEN, United Kingdom Usage of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease Katharina SCHWARZKOPF, Germany Steroidal and non-steroidal FXR agonists elicit clinically-relevant lipoprotein profiles in mice with chimeric humanized livers Romeo PAPAZYAN, United States 17:30-17:45 PS :45-18:00 PS-112 Preclinical and first-in human development of SGM- 1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH) G. Steven DODSON, United States Web-based counseling for NAFLD: Final results Giulio MARCHESINI, Italy Parallel session: Cirrhosis: ACLF and critical illness North 1 16:00-16:15 PS-073 Chairs: Pere GINÈS, Spain Vanessa STADLBAUER, Austria Albumin decreases the incidence of paracentesis induced circulatory dysfunction with less than 5 litres of ascitic tap in acute on chronic liver failure (ACLF) patients: Randomized controlled trial (NCT ) Vinod ARORA, India SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :15-16:30 PS-074 Secondary prophylaxis of hepatic encephalopathy in cirrhosis: A double blind randomized controlled trial of L-ornithine L-aspartate versus placebo Shivakumar VARAKANAHALLI, India THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 127

130 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 16:30-16:45 PS :45-17:00 PS :00-17:15 PS :15-17:30 PS-078 Mucosal invariant T (MAIT) cells are depleted from blood in advanced cirrhosis and accumulate in the peritoneal cavity during bacterial peritonitis Oluwatomi AKINHANMI, Germany Long-term administration of human albumin reduces hospitalization and improves survival in patients with cirrhosis and refractory ascites Marco DI PASCOLI, Italy Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study Michele BARTOLETTI, Italy Therapeutic Plasma-Exchange Improves Systemic Inflammation and Survival in Patients with Acute on Chronic Liver Failure Rakhi MAIWALL, India SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :30-17:45 PS :45-18:00 PS-080 The relationship between burn-associated cholangiopathy and outcome of critically ill burn adults Christian DE TYMOWSKI, France Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections: Results from the ICA global study Salvatore PIANO, Italy Parallel session: HCV: Striving towards elimination South 2 Chairs: Massimo COLOMBO, Italy Philippa EASTERBROOK, Switzerland 16:00-16:15 PS-089 Decentralized care is effective in the management of patients with hepatitis C in a public health care setting: The Punjab model Radha Krishan DHIMAN, India 128 EASL THE HOME OF HEPATOLOGY

131 11-15 APRIL 2018 PARIS, FRANCE 16:15-16:30 PS :30-16:45 PS :45-17:00 PS-092 Direct-acting antiviral treatment in sub-saharan Africa: A prospective trial of Ledipasvir/Sofosbuvir for chronic hepatitis C infection in Rwanda (The SHARED study) Neil GUPTA, United States HCV testing and linkage to care: Expanding access to HCV care through electronic health engagement Zohha ALAM, United States Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study Elana ROSENTHAL, United States 17:00-17:15 PS :15-17:30 PS :30-17:45 PS :45-18:00 PS-096 HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients Stuart FLANAGAN, United Kingdom Risk of liver fibrosis progression in patients with undiagnosed hepatitis C virus infection Dalia Elena MORALES ARRAEZ, Spain Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs (PWID) during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland Valgerdur RUNARSDOTTIR, Iceland Hepatitis C care cascade in the country of Georgia after 2 years of starting national hepatitis C elimination program Tengiz TSERTSVADZE, Georgia SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Parallel session: Alcoholic liver disease South 1 Chairs: Karoline LACKNER, Austria Philippe MATHURIN, France THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 129

132 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 16:00-16:15 PS :15-16:30 PS :30-16:45 PS :45-17:00 PS :00-17:15 PS-069 Alcohol relapse after liver transplantation: impact of a novel risk assessment scoring system Nekisa ZAKERI, United Kingdom Alcohol disrupts a meta-organismal endocrine axis in murine models and patients with AH Laura NAGY, United States Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. Beatriz AGUILAR-BRAVO, Spain Bile acids and intestinal dysbiosis in alcoholic hepatitis Dragos CIOCAN, France Chronic plus binge alcohol consumption leads to Il-6 mediated inflammatory response in a new mouse model of acute-on-chronic liver injury Ersin KARATAYLI, Germany SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :15-17:30 PS :30-17:45 PS :45-18:00 PS-072 Collagen proportionate area is an independent predictor of short and long-term survival in patients with alcoholic hepatitis Marta GUERRERO MISAS, United Kingdom Caspase-cleaved cytokeratin-18 (M30) and ActiTest predict hepatic inflammation in asymptomatic patients with alcoholic liver disease Katrine Holtz THORHAUGE, Denmark Impact of baclofen treatment in 212 alcoholdependent patients of the French OBADE-ANGH series Camille BARRAULT, France Parallel session: Liver regeneration and tissue engineering South 3 Chairs: Fotios SAMPAZIOTIS, United Kingdom Etienne SOKAL, Belgium 16:00-16:15 PS-097 Spatial sorting of hepatocytes reveals broad zonation of liver proteome Shani BEN-MOSHE, Israel 130 EASL THE HOME OF HEPATOLOGY

133 11-15 APRIL 2018 PARIS, FRANCE 16:15-16:30 PS :30-16:45 PS :45-17:00 PS :00-17:15 PS-101 Novel tools for dissecting the functions of Kupffer cells in homeostasis and disease reveal a role for the transcription factors Zeb2 and LXRa in maintaining Kupffer cell identity Charlotte SCOTT, Belgium NAA25 and Tropomyosin regulate liver metabolic zonation, hepatocyte polarity and ploidy Rafael ALDABE, Spain A novel differentiation system to produce hepatocytes for disease modelling and drug screening Rute TOMAZ, United Kingdom 3D bio-printing ofhuman hepatic tissue using human liver extracellular matrix as tissue-specificbioink Luca FRENGUELLI, United Kingdom 17:15-17:30 PS :30-17:45 PS :45-18:00 PS-104 Development of self-renewing 3D organoid culture from human fetal biliary tree stem cells (hbtscs) as a potential system for regenerative medicine and disease modelling. Samira SAFARIKIA, Italy Development and Characterization of a novel microtissue-based 3D human liver fibrosis model for anti-fibrotic drug discovery Radina KOSTADINOVA, Switzerland Hepatic differentiationof human induced pluripotent stem cells (ipsc) using 3D human liverextracellular matrix hydrogel Luca FRENGUELLI, United Kingdom SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 Parallel session: Viral hepatitis: Basic science West 1 Chairs: Thomas BAUMERT, France Mala MAINI, United Kingdom 16:00-16:15 PS-113 Characterization of host and viral proteins involved in the chromatinization of the hepatitis B virus mini chromosome Maëlle LOCATELLI, France THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 131

134 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 16:15-16:30 PS :30-16:45 PS :45-17:00 PS :00-17:15 PS-117 Exhaustion of virus-specific and total B cellpopulations by HBV infection Loghman SALIMZADEH, Singapore Rescuing hepatitis-b-specific T cell responses by modulating cholesterol metabolism Nathalie SCHMIDT, United Kingdom Hepatitis E virus triggers mitochondrial fusion to promote viral replication Yijin WANG, China A microrna screen uncovers O-Linked N-Acetylglucosamine transferase as a host factor involved in hepatitis C virus morphogenesis Katharina HERZOG, France SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :15-17:30 PS :30-17:45 PS :45-18:00 PS-120 The capacity of persistent HCV infection to regulate alloreactive T cells responses is reversed following viral eradication Marc MARTINEZ-LLORDELLA, United Kingdom DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment Yevgeniy GINDIN, United States Hepatitis C virus leaves epigenetic signature post cure by direct-acting antivirals that is linked to distinct mutation signature Meital GAL-TANAMY, Israel Parallel session: Experimental hepatology West 3 Chairs: Matías AVILA, Spain Verena KEITEL, Germany 16:00-16:15 PS-081 Hepatocyte-specific deletion of RuvBL1 leads to chronic liver damage and regeneration, enhancing HCC development Tommaso MELLO, Italy 132 EASL THE HOME OF HEPATOLOGY

135 11-15 APRIL 2018 PARIS, FRANCE 16:15-16:30 PS :30-16:45 PS :45-17:00 PS :00-17:15 PS-085 Beta-catenin-dependent erythropoiesis in adult mice deficient in hepatic ARID1A chromatin remodeler Rozenn RIOU, France Protection from Gao-binge induced liver injury in Mif-/- Mice is associated with decreased ER stress Kyle POULSEN, United States Sigma 1 receptor: a potential actor in hepatocellular adenomas Laure VILLEMAIN, France CCAAT-enhancer-binding protein homologous protein promotes liver ischemia and reperfusion injury by inhibiting Beclin-1-mediated autophagy in hepatocytes Haoming ZHOU, China 17:15-17:30 PS :30-17:45 PS :45-18:00 PS-088 Faecalibacterium improves pathogenesis of nonalcoholic steatohepatitis via controlling Treg induced gut-permeability Takaomi KESSOKU, Japan What drives development of HCC in non-cirrhotic NAFLD? Marco ZAKI, United Kingdom Hepatocyte-specific overexpression of FoxM1 transcription factor leads to spontaneous liver inflammation, fibrosis, and tumorigenesis in mice Tomohide KURAHASHI, Japan Critical reflection on landmark papers 2017 West 2 Chair: Jean-François DUFOUR, Switzerland SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-16:30 NorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis Lead author: Michael TRAUNER, Austria Challenger: Ulrich BEUERS, Netherlands THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 133

136 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 16:30-17:00 Alfapump system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study Lead author: Rajiv JALAN, United Kingdom Challenger: Juan-Carlos GARCIA-PAGAN, Spain 17:00-17:30 Polyphenic trait promotes liver cancer in a model of epigenetic instability in mice Lead author: Marco CASSANO, Switzerland Challenger: Jean-Charles NAULT, France 17:30-18:00 Direct-acting antivirals for chronic hepatitis C Lead author: Janus JAKOBSEN, Denmark Challenger: Jean-Michel PAWLOTSKY, France Meet the Experts: Portal vein thrombosis West 4 SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :00-16:50 Andrea DE GOTTARDI, Switzerland Sarwa Darwish MURAD, Netherlands Meet the Experts: Alpha-1-Antitrypsin deficiency West 4 17:00-17:50 Ronald SOKOL, United States Pavel STRNAD, Germany Skills in hepatology: Non-invasive diagnostics methods: Elastography-I West 5 Chair: Robert DE KNEGT, Netherlands 18:30-19:15 Tutors Sarwa Darwish MURAD, Netherlands Pavel TAIMR, Netherlands Christoph TERKAMP, Germany Dave SPRENGERS, Netherlands Jeoffrey SCHOUTEN, Belgium 134 EASL THE HOME OF HEPATOLOGY

137 11-15 APRIL 2018 PARIS, FRANCE Skills in hepatology: Non-invasive diagnostics methods: Ultrasound and contrast enhanced ultrasound I West 5 Chair: Fabio PISCAGLIA, Italy 18:30-19:15 Tutors Thomas KARLAS, Germany Roxana SIRLI, Romania Horia STEFANESCU, Romania Skills in hepatology: Non-invasive diagnostics methods: Elastography II West 5 Chair: Robert DE KNEGT, Netherlands 19:15-20:00 Tutors Sarwa Darwish MURAD, Netherlands Pavel TAIMR, Netherlands Christoph TERKAMP, Germany Jeoffrey SCHOUTEN, Belgium Dave SPRENGERS, Netherlands Skills in hepatology: Non-invasive diagnostics methods: Ultrasound and contrast enhanced ultrasound II West 5 Chair: Fabio PISCAGLIA, Italy 19:15-20:00 Tutors Thomas KARLAS, Germany Roxana SIRLI, Romania Horia STEFANESCU, Romania SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 135

138 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Skills in hepatology: Invasive methods: Evaluation and procedures Endoscopy West 6 Chair: Andres CARDENAS, Spain 18:30-20:00 Tutors Arnulf FERLITSCH, Austria Carlos NOROHNA, Portugal Skills in hepatology: Invasive methods: Evaluation and procedures Hepatic hemodynamics West 6 Chair: Pierre-Emmanuel RAUTOU, France SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL :30-20:00 Tutors Laure ELKRIEF, Switzerland Thomas REIBERGER, Austria Skills in hepatology: Invasive methods: Evaluation and procedures TIPS West 6 Chair: Fanny TURON, Spain 18:30-20:00 Tutors Ernest BELMONTE, Spain Bogdan PROCOPET, Romania 136 EASL THE HOME OF HEPATOLOGY

139 11-15 APRIL 2018 PARIS, FRANCE Skills in hepatology: Invasive methods: Evaluation and procedures Thermal ablation of focal liver lesions West 6 Chair: Christiane KUHL, Germany 18:30-20:00 Tutors Peter ISFORT, Germany Frederico PEDERSOLI, Germany Industry Symposia 18:30-20:00 Please refer to the industry section for more details, page 348. Industry Mini-workshops 18:30-19:30 Please refer to the industry section for more details, page 356. SCIENTIFIC PROGRAMME / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 137

140 MEETINGS 2018 GUT-LIVER AXIS June 2018 Leuven, Belgium ABDOMINAL SONOGRAPHY, A CLINICAL COURSE NAFLD SUMMIT September 2018 Rotterdam, Netherlands September 2018 Geneva, Switzerland DIAGNOSIS AND MANAGEMENT OF VASCULAR LIVER DISEASES, A CLINICAL COURSE AASLD- EASL MASTERCLASS November 2018 Bern, Switzerland 29 November - 01 December 2018 Washington, United States

141 11-15 APRIL 2018 PARIS, FRANCE SCIENTIFIC PROGRAMME SATURDAY 14 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

142 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SCIENTIFIC PROGRAMME SATURDAY 14 APRIL 2018 Parallel session: Clinical impact of HCV cure Main Plenary Chairs: Xavier FORNS, Spain Karine LACOMBE, France 08:00-08:15 PS :15-08:30 PS-150 Disease outcomes after DAA-induced SVR: data from the resist-hcv cohort Vincenza CALVARUSO, Italy Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension Sabela LENS, Spain SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :30-08:45 PS :45-09:00 PS :00-09:15 PS :15-09:30 PS-154 Survival benefits of direct-acting antiviral therapy in patients with decompensated hepatitis C cirrhosis W. Ray KIM, United States IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy Angelo SANGIOVANNI, Italy HCC recurrence under all-oral DAAs-based antiviral therapy in HCV-infected patients: data from Navigatore web platform Martina GAMBATO, Italy SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study Ana LLEO, Italy 09:30-09:45 PS-155 Risk of total non-hepatic cancer following treatment for HCV infection with direct-acting antiviral (DAA) agents Anand CHOKKALINGAM, United States 140 EASL THE HOME OF HEPATOLOGY

143 11-15 APRIL 2018 PARIS, FRANCE Parallel session: Cirrhosis: Portal hypertension and complication North 1 Chairs: Mattias MANDORFER, Austria Dominique THABUT, France 08:00-08:15 PS :15-08:30 PS-136 A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond Federico RAVAIOLI, Italy Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound: the CLEVER study. Annalisa BERZIGOTTI, Switzerland 08:30-08:45 PS :45-09:00 PS :00-09:15 PS :15-09:30 PS :30-09:45 PS-141 Effect of B-blockers on the systemic hemodynamics of decompensated cirrhosis and survival Edilmar ALVARADO, Spain The global prevalence of Wilson disease from nextgeneration sequencing data Jiali GAO, United Kingdom Contemporary practice patterns and outcomes after transjugular intrahepatic portosystemic shunt placement: A multicenter U.S. experience of 1,146 patients Justin BOIKE, United States Early-TIPS improves survival in cirrhotic patients with high-risk varical bleeding: Results of a China multicenter observational study Guohong HAN, China Resistance training improves muscle size and muscle strength in liver cirrhosis -a randomized controlled trial Luise AAMANN, Denmark SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 141

144 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Parallel session: NAFLD: Diagnostics and non-invasive assessment South 2 Chairs: Quentin ANSTEE, United Kingdom Laurent CASTERA, France 08:00-08:15 PS :15-08:30 PS-178 Noninvasvie prediction of oesophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study Salvatore PETTA, Italy Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response Arun SANYAL, United States SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :30-08:45 PS :45-09:00 PS :00-09:15 PS :15-09:30 PS-182 Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice Javier AMPUERO, Spain Performance of controlled attenuation parameter to assess steatosis in a large prospective multicentre UK study of patients with non-alcoholic fatty liver disease Philip NEWSOME, United Kingdom Identification of serum protein biomarkers for noninvasive discrimination between NASH and simple steatosis using SOMAscan Towia LIBERMANN, United States The development of the diabetes liver fibrosis score: A new prediction model to detect advanced fibrosis in diabetics with nonalcoholic fatty liver disease Amandeep SINGH, United States 09:30-09:45 PS-183 Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease Thierry POYNARD, France 142 EASL THE HOME OF HEPATOLOGY

145 11-15 APRIL 2018 PARIS, FRANCE Parallel session: HBV and HDV: Current and emerging treatments South 4 Chairs: Markus CORNBERG, Germany Grazia NIRO, Italy 08:00-08:15 PS :15-08:30 PS-157 Safety and efficacy at 1 year after switching from tenofovir disoproxil fumurate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use Edward GANE, New Zealand Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: 96 weeks results of phase 3 trial Won KIM, Rep. of South Korea 08:30-08:45 PS :45-09:00 PS :00-09:15 PS :15-09:30 PS-161 Increased incidence of HBsAg seroclearance in HBeAg negative chronic hepatitis B patients discontinued Nuc therapy comparing to natural course--a propensity score matched study Rachel Wen-Juei JENG, Taiwan Rates and predictors of HBsAg loss after discontinuation of effective long-term entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study Margarita PAPATHEODORIDI, Greece Effects of SB9200 (Inarigivir) therapy on immune responses in patients with chronic hepatitis B Renae WALSH, Australia Subanalysis of the LOWR HDV-2 study reveals high response rates to lonafarnib in patients with low baseline viral loads Cihan YURDAYDIN, Turkey SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 143

146 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 09:30-09:45 PS-162 Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial Lena ALLWEISS, Germany Parallel session: Autoimmune and cholestasis 2 South 1 Chairs: Annika M BERGQUIST, Sweden Olivier CHAZOUILLERES, France 08:00-08:15 PS-128 Statins are associated with reduced mortality and morbidity in primary sclerosing cholangitis Knut STOKKELAND, Sweden SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :15-08:30 PS :30-08:45 PS :45-09:00 PS :00-09:15 PS-132 Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma Rocio MACIAS, Spain Fra-2 transgenic mice develop a phenotype of spontaneous primary sclerosing cholangitis Florian STEINBACH, Germany A novel model of acute and specific biliary cell injury reveals a crucial role of circulating monocytes in promoting ductular reaction and cholestasis Adrien GUILLOT, United States Characterization of mir deregulation in cholangiocarcinoma: Consequences in tumour heterogeneity and drug resistance Patricia MUNOZ-GARRIDO, Denmark 09:15-09:30 PS :30-09:45 PS-134 Novel role of amphiregulin in bile acids metabolism and protection from cholestatic liver injury Carmen BERASAIN, Spain International experience of vedolizumab in primary sclerosis cholangitis and inflammatory bowel disease Kate WILLIAMSON, United Kingdom 144 EASL THE HOME OF HEPATOLOGY

147 11-15 APRIL 2018 PARIS, FRANCE Parallel session: Liver tumours: Experimental South 3 Chairs: Jean-Charles NAULT, France Lars ZENDER, Germany 08:00-08:15 PS :15-08:30 PS :30-08:45 PS-172 Therapeutic targeting of LGR5 tumour initiating cells in liver cancer Wanlu CAO, Netherlands Endoplasmic reticulum stress in hepatic stellate cells contributes to the progression of hepatocellular carcinoma Natasa PAVLOVIC, Sweden Genetic inactivation of Nrf2 prevents clonal expansion of carcinogen-initiated cells in a nutritional model of rat hepatocarcinogenesis Claudia ORRÚ, Italy 08:45-09:00 PS :00-09:15 PS :15-09:30 PS :30-09:45 PS-176 Primary liver cancers display divergent epimutator phenotypes in localized and metastatic disease Colm O ROURKE, Denmark Upregulation of the imprinted DLK1/DIO3 locus in response to beta-catenin activation: a promising target for HCC treatment Angélique GOUGELET, France Axin1 deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation Abitbol SHIRLEY, France Cytokine-induced killer cells recruit myeloid derived suppressor cells in HCC, which can be targeted by a PDE5 inhibitor Su Jong YU, Rep. of South Korea SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 145

148 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Parallel session: Acute liver failure and liver transplantation West 1 Chairs: William BERNAL, United Kingdom Ali CANBAY, Germany 08:00-08:15 PS :15-08:30 PS :30-08:45 PS-123 Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study Audrey COILLY, France Platelet aggregation contributing to reperfusion injury can be prevented by normothermic ex vivo liver perfusion prior to liver transplantation Dagmar KOLLMANN, Canada The main determinant of circulating exosomal mirna profile across a spectrum of patients with liver injury is the degree of liver failure Sotiris MASTORIDIS, United Kingdom SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :45-09:00 PS :00-09:15 PS :15-09:30 PS :30-09:45 PS-127 Early and Late Liver-Related Mortality following Drug Induced Liver Injury from Amoxicillin- Clavulanate Hans TILLMANN, United States Orthotopic liver transplantation of xenogeneic livers repopulated with autologous hepatocytes: proof of normal function and consistent survival Stéphanie LACOTTE, Switzerland Following clinical liver transplantation, the majority of circulating cells exhibiting donor MHC are crossdressed not passenger leukocytes Sotiris MASTORIDIS, United Kingdom Intestinal microbiota modulates susceptibility to acetaminophen induced acute liver injury Carsten ELFERS, Germany Parallel session: Inflammation and fibrosis West 2 Chairs: Gianluca SVEGLIATI-BARONI, Italy Michael TRAUNER, Austria 146 EASL THE HOME OF HEPATOLOGY

149 11-15 APRIL 2018 PARIS, FRANCE 08:00-08:15 PS :15-08:30 PS :30-08:45 PS-165 The I148M PNPLA3 impairs LXR signaling and cholesterol metabolism in human hepatic stellate cells Francesca BRUSCHI, Austria Induced pluripotent stem cell derived liver model for the study of PNPLA3-induced non-alcoholic fatty liver disease Samantha TILSON, United Kingdom Interfering with local fibrotic platelet activation significantly inhibits fibrosis in multiple animal models: Suggestions of the importance of the platelet-wound healing axis for fibrosis Kate STUART, United States 08:45-09:00 PS :00-09:15 PS :15-09:30 PS :30-09:45 PS-169 Anti-inflammatory and anti-fibrogenic effects of monoacylglycerol lipase inhibitors in the liver involve macrophage autophagy Dina CHOKR, France IL-33 regulates immune-mediated hepatitis by induction of Areg+ ILC2, M2 macrophages and ST2+ Tregs Aaron OCHEL, Germany TGR5-mediated signalling in the regulation of biliary epithlium permeability Nicolas KAHALE, France Ductular reaction cells promote angiogenesis via SLIT2/ROBO1 pathway in chronic liver disease Mar COLL, Spain Parallel session: Clinical developments in metabolic and rare disease West 3 SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 Chairs: Emma ANDERSSON, Sweden Joost DRENTH, Netherlands THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 147

150 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 08:00-08:15 PS :15-08:30 PS :30-08:45 PS :45-09:00 PS-145 Liver fibrosis and metabolic alterations in adults with homozygous alpha1-antitrypsin deficiency (PiZZ genotype) Vivien WODITSCH, Germany EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria with recurrent attacks Laurent GOUYA, France Effect of sebelipase alfa on liver parameters over 96 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency Florian ABEL, United States Autologous cell/gene therapy approach of hemophilia B using patient specific induced pluripotent stem cells Eleanor LUCE, France SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :00-09:15 PS :15-09:30 PS :30-09:45 PS-148 Low density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial Hypercholesterolemia modelling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection Jérôme CARON, France ARO-AAT, a subcutaneous RNAi-based therapeutic for alpha-1 antitrypsin-related liver disease, demonstrates liver exposure-response and efficacy in preclinical studies Christine WOODDELL, United States Gene therapy optimization for Wilson s disease Oihana MURILLO-SAUCA, Spain Meet the Experts: Hepatitis B: Should we treat immunotolerant patients? West 4 08:00-08:50 Patrick KENNEDY, United Kingdom Anna LOK, United States 148 EASL THE HOME OF HEPATOLOGY

151 11-15 APRIL 2018 PARIS, FRANCE Meet the Experts: Hepatitis B: When to stop NUC therapy? West 4 09: Maria BUTI, Spain George PAPATHEODORIDIS, Greece General session III and award ceremony II Main Plenary Chairs: Mauro BERNARDI, Italy Jessica ZUCMAN-ROSSI, France 10:00-10:15 GS-013 Real-life effectiveness and safety of Glecaprevir/ Pibrentasvir among 723 Italian patients with chronic hepatitis c: the Navigator-II study Roberta D AMBROSIO, Italy 10:15-10:30 GS :30-10:45 GS-015 NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsyconfirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks Stephen HARRISON, United States Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis Jasmohan S BAJAJ, United States 10:45-11:15 Award ceremony 2 11:15-11:30 GS-016 A phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria Eliane SARDH, Sweden SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :30-11:45 GS-017 Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis Sharon HUTCHINSON, United Kingdom THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 149

152 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 11:45-12:00 GS-018 Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with Sofosbuvir-based regimens Alessandra MANGIA, Italy Karl Wilhelm von Kupffer basic state-of-the-art: Beyond albumin and IgG the unexpected prospects of the neonatal Fc receptor Main Plenary 12:00-12:30 Richard Blumberg, United States Brigham & Women s Hospital, Harvard Medical School, United States SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 Dr. Blumberg is Professor of Medicine, Harvard Medical School, Chief of Gastroenterology, Brigham and Women s Hospital, co-director of the Harvard Digestive Diseases Center and past-director of the Brigham Research Institute. He has directed a National Institutes of Health funded laboratory since 1989 which has a particular emphasis on the immunologic functions of the intestinal epithelium; a field that his laboratory has pioneered through the study of non classical MHC class I molecules, such as CD1d and more recently the unfolded protein response and Paneth cell function. He is also a leading authority on carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) and the neonatal crystallizable fragment receptor (FcRn) function. Dr. Blumberg has been the recipient of the an NIH Method to Extend Research in Time (M.E.R.I.T) Award (2005), the William Beaumont Prize (2009), the CCFA Scientific Achievement Award in Inflammatory Bowel Disease Basic Research (2012), a Lifetime Scientific Achievement Award from the Society for Mucosal Immunology (2015), the Lloyd Mayer Award in Mucosal Immunology and is an elected member of the Norwegian Academy of Sciences Lecture summary: The neonatal Fc receptor has emerged as an important clinical target in adult life that is currently under evaluation in a number of clinical scenarios. This talk will provide an introduction to the functions of FcRn in regulating IgG and albumin, its two main ligands, and the clinical opportunities that emerge from this understanding. 150 EASL THE HOME OF HEPATOLOGY

153 11-15 APRIL 2018 PARIS, FRANCE Industry Symposia 12:30-14:00 Please refer to the industry section for more details, page 348. Meet the Experts: Cirrhosis after HCV cure West 4 12:30-13:20 Roberta D AMBROSIO, Italy Stefan ZEUZEM, Germany Poster tours 12:30-13:00 Viral hepatitis A/E: Clinical aspect Guide: Rakesh AGGARWAL, India Meeting point 1 12:30-13:00 12:30-13:00 Oral eposters 12:30-13:00 12:30-13:00 Liver transplantation and hepatobiliary surgery: Experimental Guide: Wojciech POLAK, Netherlands Meeting point 2 Gut microbiota and liver disease Guide: Jasmohan BAJAJ, United States Meeting point 3 HCV Public Health Chair: Jason GREBELY, Australia Poster pod 1 Liver fibrosis, nanomedicine and new technologies Chair: Krista ROMBOUTS, United Kingdom Poster pod 2 SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :30-13:00 Hepatitis B: Natural course Chair: Grace WONG, Hong Kong Poster pod 3 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 151

154 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 12:30-13:00 NAFLD: Clinical Chair: Manuel ROMERO GOMEZ, Spain Poster pod 4 Poster tours 13:00-13:30 13:00-13:30 13:00-13:30 Cirrhosis, portal hypertension and complication Guide: François DURAND, France Meeting point 1 Viral Hepatitis A, B, C, D, E: Virology Guide: Stephan URBAN, Germany Meeting point 2 Immunology except viral hepatitis Guide: Nasser SEMMO, Switzerland Meeting point 3 SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :30-14:00 13:30-14:00 13:30-14:00 Non-invasive assessment of liver disease except NAFLD Guide: Mirella FRAQUELLI, Italy Meeting point 1 Alcoholic liver disease Guide: Laurent SPAHR, Switzerland Meeting point 2 Rare liver diseases (including paediatric and genetic) Guide: Giorgina MIELI-VERGANI, United Kingdom Meeting point 3 Symposium: Current management and emerging treatment in HBV Main Plenary Chair: Jörg PETERSEN, Germany 14:00-14:10 Introduction: Aims and open questions in HBV management Jörg PETERSEN, Germany 152 EASL THE HOME OF HEPATOLOGY

155 11-15 APRIL 2018 PARIS, FRANCE 14:10-14:30 Fighting HBV with limited resources: The global perspective Maud LEMOINE, United Kingdom 14:30-14:50 Stopping NUC therapy before HBsAg loss a good idea? Florian VAN BOEMMEL, Germany The road ahead will novel HBV treatments enter clinics soon? 14:50-15:05 Immunological therapies Mala MAINI, United Kingdom 15:05-15:20 Antiviral therapies Man-Fung YUEN, Hong Kong 15:20-15:30 Discussion Symposium: Advances in local and systemic therapies for HCC South 4 Chair: Jordi BRUIX, Spain 14:00-14:10 Short review of unmet needs in HCC treatment Jordi BRUIX, Spain 14:10-14:35 Ablation and transarterial approaches. Efficacy vs benefit Jens RICKE, Germany 14:35-15:00 Systemic therapy: Current status and lessons learned from success and failure Maria REIG, Spain SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :00-15:25 Immunotherapy and emerging targets in phase 3 Sandrine FAIVRE, France 15:25-15:30 Discussion THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 153

156 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME EASL-EASD Symposium: Testing strategies and pathways in NAFLD South 1 Chairs: Laurent CASTERA, France Michael RODEN, Germany 14:00-14:18 The Hepatologist perspective Lawrence SERFATY, France 14:18-14:36 The Diabetologist perspective Michael RODEN, Germany 14:36-14:54 The General Practicionner perspective Rachel Pryke, United Kingdom 14:54-15:12 The Cardiologist perspective Christopher BYRNE, United Kingdom 15:12-15:30 Panel discussion SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 EASL-WHO symposium: Meeting the 2030 elimination goals of the WHO viral hepatitis strategy South 3 Chairs: Gottfried HIRNSCHALL, Switzerland Tom Hemming KARLSEN, Norway 14:00-14:15 Monitoring progress towards the elimination of viral hepatitis Yvan HUTIN, Switzerland 14:15-14:30 WHO country profiles report Sharon HUTCHINSON, United Kingdom 14:30-14:45 Clinicians as key partners in meeting the 2030 elimination goals Rakesh AGGARWAL, India 14:45-15:00 Revised 2018 WHO Guidelines for the care and treatment of persons with chronic HCV Marc BULTERYS, Switzerland Saeed Sadiq HAMID, Pakistan 154 EASL THE HOME OF HEPATOLOGY

157 11-15 APRIL 2018 PARIS, FRANCE 15:00-15:15 Civil society perspective on the revised 2018 WHO Guidelines and access to treatment Giten KHWAIRAKPAM, France 15:15-15:30 General discussion Symposium: Defining the second line therapy in cholestatic and autoimmune liver disease West 1 Chair: Ulrich BEUERS, Netherlands 14:00-14:20 Second line therapy in PBC: Fibrates? Christophe CORPECHOT, France 14:20-14:40 Second Line therapy in PBC: FXR agonists? Annarosa FLOREANI, Italy 14:40-15:05 When corticosteroids + azathioprine fail in AIH Michael P. MANNS, Germany 15:05-15:30 Future medical treatment of PSC Michael TRAUNER, Austria EASL-APASL Symposium: ACLF and critical care in hepatology West 2 Chairs: Mauro BERNARDI, Italy Shiv Kumar SARIN, India 14:00-14:20 Coagulation disorders as predictors of sepsis and outcome in ACLF Rakhi MAIWALL, India SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :20-14:40 Extracorporeal liver support in ACLF Rafael BAÑARES, Spain 14:40-15:00 Liver regeneration in ACLF-Growth factors and beyond Yu CHEN, China THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 155

158 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 15:00-15:20 High-volume plasma exchange in ACLF lessons from ALF Fin STOLTZE LARSEN, Denmark 15:20-15:50 Discussion Symposium: Systems medicine of metabolic liver disease West 3 Chairs: Peter JANSEN, Netherlands Damjana ROZMAN, Slovenia 14:00-14:20 From experimental models towards systems understanding of metabolic liver disease Damjana ROZMAN, Slovenia SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :20-14:40 Genomescale metabolic models: a personalized approach to analyse metabolic perturbations in NAFLD and NASH Albert GROEN, Netherlands 14:40-15:00 Systems medicine success stories in hepatology Jochen HAMPE, Germany 15:00-15:20 Parameterization of liver metabolism Dirk DRASDO, France 15:20-15:30 Discussion Fusion: Career opportunities in hepatology: an emerging generation of NAFLD researchers East 3 Chairs: Gyongyi SZABO, United States Frank TACKE, Germany 14:00-14:20 Genetics of liver fibrosis Marcin KRAWCZYK, Germany 14:20-14:40 Micro-RNA and long non-coding RNA as biomarkers in NASH and fibrosis Yuanwen CHEN, China 14:40-15:00 Autophagy as a mechanism of fibrosis Hayato HIKITA, Japan 156 EASL THE HOME OF HEPATOLOGY

159 11-15 APRIL 2018 PARIS, FRANCE 15:00-15:20 Microbiota changes in obesity and liver disease Phillipp HARTMANN, United States 15:20-15:30 Concluding remarks: Is NAFLD research a safe career choice for s? Massimo PINZANI, United Kingdom Meet the Experts: Management of patients with chronic hepatitis E West 4 14:00-14:50 Harry DALTON, United Kingdom Darius MORADPOUR, Switzerland Oral eposters 15:30-16:00 15:30-16:00 End stage liver disease: Pathophysiology Chair: Alexander ZIPPRICH, Germany Poster pod 1 Autoimmune and cholestatic diseases: Experimental Chair: María Jesús PERUGORRIA, Spain Poster pod 2 15:30-16:00 HDV Chair: Jörg TIMM, Germany Poster pod 3 15:30-16:00 Non-invasive assessment of liver disease Chair: Naga CHALASANI, United States Poster pod 4 SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 Poster tours 15:30-16:00 Liver tumours: Experimental and pathophysiology Guide: Christian LIEDTKE, Germany Meeting point 1 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 157

160 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 15:30-16:00 NAFLD: Clinical aspects except therapy Guide: Bart STAELS, Belgium Meeting point 2 15:30-16:00 Viral Hepatitis A, B, C, D, E: Immunology Guide: Gabriele MISSALE, Italy Meeting point 3 Late- breaker session Main Plenary Chairs: Vlad RATZIU, France Giorgina VERGANI, United Kingdom SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :00-16:15 LBO :15-16:30 LBO :30-16:45 LBO :45-17:00 LBO-004 A multicenter, randomized, double-blind, PLBcontrolled trial of Galectin-3 inhibitor (GR- MD-02) in patients with NASH cirrhosis and portal hypertension Naga CHALASANI, United States NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial Gideon HIRSCHFIELD, United Kingdom RO , a core protein allosteric modulator, demonstrates robust anti-hbv activity in chronic hepatitis B patients and is safe and well tolerated Edward GANE, New Zealand Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ (JNJ-6379) in treatment-naive chronic hepatitis B (CHB) patients without cirrhosis Fabien ZOULIM, France 17:00-17:15 LBO-005 The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort Jens RICKE, Germany 158 EASL THE HOME OF HEPATOLOGY

161 11-15 APRIL 2018 PARIS, FRANCE 17:15-17:30 LBO :30-17:45 LBO :45-18:00 LBO-008 JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study Manal ABDELMALEK, United States Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing Phase 2 study Christoph SCHRAMM, Germany A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/- ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy Anna LOK, United States EASL recommendations on treatment of hepatitis C 2018 Main Plenary Chairs: Francesco NEGRO, Switzerland Jean-Michel PAWLOTSKY, France 18:30-19:00 Presentation Jean-Michel PAWLOTSKY, France 19:00-19:30 Panel Alessio AGHEMO, Italy Marina BERENGUER HAYM, Spain Olav DALGARD, Norway Geoffrey DUSHEIKO, United Kingdom Fiona MARRA, United Kingdom Massimo PUOTI, Italy Heiner WEDEMEYER, Germany SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 159

162 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Skills in hepatology: Non-invasive diagnostics methods: Elastography I West 5 Chair: Robert DE KNEGT, Netherlands 18:30-19:15 Tutors Sarwa Darwish MURAD, Netherlands Pavel TAIMR, Netherlands Christoph TERKAMP, Germany Dave SPRENGERS, Netherlands Skills in hepatology: Non-invasive diagnostics methods: Ultrasound and contrast enhanced ultrasound I West 5 Chair: Fabio PISCAGLIA, Italy SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL :30-19:15 Tutors Alessandro GRANITO, Italy Horia STEFANESCU, Romania Skills in hepatology: Non-invasive diagnostics methods: Elastography II West 5 Chair: Robert DE KNEGT, Netherlands 19:15-20:00 Tutor Sarwa Darwish MURAD, Netherlands Pavel TAIMR, Netherlands Christoph TERKAMP, Germany Dave SPRENGERS, Netherlands 160 EASL THE HOME OF HEPATOLOGY

163 11-15 APRIL 2018 PARIS, FRANCE Skills in hepatology: Non-invasive diagnostics methods: Ultrasound and contrast enhanced ultrasound II West 5 Chair: Fabio PISCAGLIA, Italy 19:15-20:00 Tutors Alessandro GRANITO, Italy Horia STEFANESCU, Romania Skills in hepatology: Emerging therapies Alfapump West 6 Chair: Andrea DE GOTTARDI, Switzerland 18:30-18:40 Introduction and presentation of the Alfapump Andrea DE GOTTARDI, Switzerland 18:40-18:50 Indications and selection of patients Thomas BERG, Germany 18:40-18:50 Results of the RCT Rajiv JALAN, United Kingdom 19:00-19:10 Real life results Guido STIRNIMANN, Switzerland 19:10-19:30 Complications and their solutions Cornelius ENGELMANN, Germany 19:30-20:00 Discussion and final remarks Skills in hepatology: Emerging therapies SX-ELLA Danis Stent West 6 SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL 2018 Chair: Angels ESCORSELL, Spain THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 161

164 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Skills in hepatology: Emerging therapies Extracorporeal liver assist devices West 6 Chair: Rajiv JALAN, United Kingdom 18:30-20:00 Tutors Carrie BREEN, United Kingdom Nathan DAVIES, United Kingdom Fin STOLTZE LARSEN, Denmark Steffen MITZNER, Germany Jan STANGE, Germany SCIENTIFIC PROGRAMME / SATURDAY 14 APRIL EASL THE HOME OF HEPATOLOGY

165 11-15 APRIL 2018 PARIS, FRANCE SCIENTIFIC PROGRAMME SUNDAY 15 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

166 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SCIENTIFIC PROGRAMME SUNDAY 15 APRIL 2018 Breakfast morning rounds: The difficult to treat patient with chronic hepatitis C South 1 Chair: Kosh AGARWAL, United Kingdoml 07:30-08:20 Case presentation Tsai OW, United Kingdom Experts Alessio AGHEMO, Italy Sabela LENS, Spain Massimo PUOTI, Italy Johannes VERMEHREN, Germany SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL 2018 Breakfast morning rounds: Drug-induced liver injury How to diagnose, how to treat? West 1 07:30-08:20 Chair: Michael MERZ, Switzerland Case presentation Michael MERZ, Switzerland Experts Raul ANDRADE, Spain Ann K DALY, United Kingdom Michael TRAUNER, Austria Breakfast morning rounds: Strictures of the bile duct West 2 Chair: Ulrich BEUERS, Netherlands 07:30-08:20 Case presentation Elsemieke DE VRIES, Netherlands 164 EASL THE HOME OF HEPATOLOGY

167 11-15 APRIL 2018 PARIS, FRANCE Experts Lars AABAKKEN, Norway Annika M BERGQUIST, Sweden Christian TOSO, Switzerland Breakfast morning rounds: Cirrhotic patient with a single nodule Diagnostic work-up and best treatment option? West 3 Chair: Bruno SANGRO, Spain 07:30-08:20 Case presentation Carlota JORDAN, Spain 07:30-08:20 Experts Vincenzo MAZZAFERRO, Italy Jens RICKE, Germany Peter SCHIRMACHER, Germany Best poster summary South 4 Chairs: Mario Umberto MONDELLI, Italy Diana PAYAWAL, Philippines 08:30-08:50 Viral hepatitis Christophe HEZODE, France 08:50-09:10 Metabolic and cholestasis Lawrence SERFATY, France 09:10-09:30 Hepatocellular carcinoma Jens MARQUARDT, Germany SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL :30-09:50 General hepatology (including liver transplantation) Agustin ALBILLOS, Spain THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 165

168 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis and the community: Dynamics of the viral hepatitis epidemic South 3 Chairs: Andrew AMATO-GAUCI, Sweden Marieta SIMONOVA, Bulgaria 08:30-08:35 Introduction, agenda, setting the goals Francesco NEGRO, Switzerland 08:35-08:50 Monitoring viral hepatitis elimination across EU/ EEA Erika DUFFELL, Sweden 08:50-09:05 The Georgia experience: lessons for viral hepatitis elimination John WARD, United States SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL :05-09:20 Elements for an effective response to viral hepatitis in PWID (EU28) Thomas SEYLER, Portugal 09:20-09:35 HCV epidemic EE and Central Asia: current situation Olga GOLUBOVSKAYA, Ukraine 09:35-09:45 Panel discussion Meet the Experts: Wilson s Disease West 4 08:30-09:20 Peter FERENCI, Austria Francisco HEVIA, Costa Rica Viral hepatitis and the community: Addressing the continuum of care South 3 Chairs: Jerzy JAROSZEWICZ, Poland Ludmila MAISTAT, Switzerland 10:00-10:15 Access to care in precarious populations (awareness, stigma, self-stigma) Nicola PERRY, United Kingdom 166 EASL THE HOME OF HEPATOLOGY

169 11-15 APRIL 2018 PARIS, FRANCE 10:15-10:30 Streamlining diagnostics Francesco MARINUCCI, Switzerland 10:30-10:45 Linkage to care Philip BRUGGMANN, Switzerland 10:45-11:00 Models for access to medicines Ludmila MAISTAT, Switzerland 11:00-11:30 Panel discussion EASL-ESMO Symposium: Collaboration between medical oncologists and hepatologists to boost therapeutic advances in liver cancer North 1 Chairs: Peter GALLE, Germany Jean-Luc RAOUL, France The multidisciplinary team in HCC treatment paths 10:30-10:45 The role of the medical oncologist Lorenza RIMASSA, Italy 10:45-11:00 The role of the hepatologist Bruno SANGRO, Spain 11:00-11:10 Panel discussion 11:10-11:30 Perspectives of personalized medicine in primary liver cancer Eric RAYMOND, France EASL clinical practice guidelines: Hepatitis E & DILI South 2 SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL 2018 Chairs: Karoline LACKNER, Austria Oren SHIBOLET, Israel 10:30-10:50 Hepatitis E virus infection Harry DALTON, United Kingdom 10:50-11:10 WHO HEV Guidelines presentation Philippa EASTERBROOK, Switzerland THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 167

170 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 11:10-11:30 Drug-induced liver injury Raul J. ANDRADE, Spain EASL-ALEH Symposium: Diagnostic dilemmas in metabolic liver disease South 4 Chairs: Francisco HEVIA, Costa Rica Philip NEWSOME, United Kingdom 10:30-10:35 Case presentation 1: Fatty liver with elevated ferritin and PiMZ phenotype Francisco HEVIA, Costa Rica 10:35-10:55 Discussion 1: Causes and relevance of hyperferritinaemia and alpha-1-anti-trypsin MZ in NAFLD Pavel STRNAD, Germany SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL :55-11:00 General discussion 11:00-11:05 Case presentation 2: Fatty liver without the metabolic syndrome other causes? Philip NEWSOME, United Kingdom 11:05-11:15 Discussion of investigation and management of possible Wilson s Francisco HEVIA, Costa Rica 11:15-11:25 Discussion of investigation and management of possible LAL-deficiency Marcelo SILVA, Argentina 11:25-11:30 General discussion Symposium: Impaired renal function in advanced cirrhosis: diagnosis and management West 1 Chairs: François DURAND, France Mitra NADIM, United States 168 EASL THE HOME OF HEPATOLOGY

171 11-15 APRIL 2018 PARIS, FRANCE 10:30-10:45 Prevalence and prognostic implications of impaired renal function in cirrhosis: beyond definitions and classifications Guadalupe GARCIA-TSAO, United States 10:45-11:00 New insights in the mechanisms: interactions between kidney circulatory changes, systemic circulatory changes, systemic inflammation and parenchymal kidney changes Paolo ANGELI, Italy 11:00-11:15 Predicting renal recovery versus non recovery after liver transplantation: the role of kidney biomarkers Claire FRANCOZ, France 11:15-11:30 Management of AKI in cirrhosis: place of terlipressin, hemofiltration and combined liver and kidney transplantation Mitra NADIM, United States Symposium: Multidisciplinary management of alcoholic liver disease West 2 Chair: Marsha MORGAN, United Kingdom 10:30-10:45 New EASL Clinical Practice Guidelines on ALD Mark THURSZ, United Kingdom 10:45-11:00 Managing obesity and other comorbidities in alcohol-related liver disease Arun SANYAL, United States 11:00-11:15 Management of alcohol dependence and other codependencies Lorenzo LEGGIO, United States SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL :15-11:30 Liver transplantation in patients with alcoholrelated liver disease Alexandre LOUVET, France THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 169

172 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Symposium: The gut-liver axis: from concepts to data West 3 Chair: Sophie LOTERSZTAJN, France 10:30-10:50 Pathogenicity of disturbances in the gut-liver axis Bernd SCHNABL, United States 10:50-11:10 From gut to the liver: inflammatory signaling Robert SCHWABE, United States 11:10-11:30 Targeting the gut-liver axis for liver diseases Herbert TILG, Austria Meet the Expert: Hepatitis Delta: Wait for new drugs or treat now with interferon alfa? West 4 SCIENTIFIC PROGRAMME / SUNDAY 15 APRIL :30-11:20 Grazia NIRO, Italy Cihan YURDAYDIN, Turkey Sheila Sherlock 100 th year anniversary ILC 2018 wrap up session North 1 Chairs: Francesco NEGRO, Switzerland Massimo PINZANI, United Kingdom 11:30-11:52 Viral hepatitis Maria BUTI, Spain 11:52-12:14 Metabolic and cholestatic diseases Herbert TILG, Austria 12:14-12:36 Hepatocellular carcinoma Fabio PISCAGLIA, Italy 12:36-12:58 Complications of cirrhosis and liver transplantation Dominique THABUT, France 170 EASL THE HOME OF HEPATOLOGY

173 11-15 APRIL 2018 PARIS, FRANCE LATE-BREAKER POSTERS CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

174 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME LATE-BREAKER POSTERS LATE-BREAKER POSTERS LBP-001 LBP-002 LBP-003 LBP-004 LBP-005 LBP-006 LBP-007 LBP-008 Long-term efficacy and safety of WTX101 in Wilson disease: Data from an ongoing extension of a phase 2 study (WTX ) Karl Heinz WEISS, Germany Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study Gideon HIRSCHFIELD, United Kingdom Scheduled endoscopic dilatation of dominant strictures improves survival in patients with primary sclerosing cholangitsi Christian RUPP, Germany Long term outcomes of treatment with Trientine in Wilson Disease: Final results from a multicentre study in patients withdrawn from d-penicillamine therapy Karl Heinz WEISS, Germany Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial) Vishal PATEL, United Kingdom PBI-4050, a potential anti-fibrotic drug, improves liver fibrosis in Alström Syndrome, an ultra-rare disease Shanat BAIG, United Kingdom Phase 1/2a trial of a bioartificial liver support system for acute liver failure patients Sanghoon LEE, Korea, Rep. of South Addition of pegylated interferon alfa-2a to an ongoing nucleos(t)ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study Martin SPRINZL, Germany 172 EASL THE HOME OF HEPATOLOGY

175 11-15 APRIL 2018 PARIS, FRANCE LBP-009 LBP-010 LBP-011 LBP-012 LBP-013 LBP-014 LBP-015 LBP-016 LBP-017 Long term real life follow-up of patients with chronic hepatitis C virus and decompensated cirrhosis after direct acting antivirals - what is the clinical benefit of antiviral treatment? Michelle CHEUNG, United Kingdom High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non severe fibrosis HCV GT1B-infected patients: Interim results of the STREAGER study Armand ABERGEL, France A pilot study of empagliflozin for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus Wah-Kheong CHAN, Malaysia Interim safety, tolerability pharmacokinetics, and antiviral activity of abi-h0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B Man-Fung YUEN, Hong Kong Comparisons the durability of 6 months and 12 months prolonged treatment duration after cessation chemotherapy in chronic hepatitis B patients with prophylaxis antiviral therapy: A open level randomized clinical trial Tsung-Hui HU, Taiwan Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of Fibrosis/Cirrhosis in patients with Primary Biliary Cholangitis (PBC) Christopher BOWLUS, United States Safety, tolerability, and pharmacokinetics of BMS / ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 sirna, in healthy participants: A randomised, placebocontrolled, double-blind, phase 1 study Benjamin SOULE, United States Autologouos peripheral blood stem cell transplantation improves long term survival of patients with cirrhosis without increasing risk of hepatocellular carcinoma Xinmin ZHOU, China Plasma msept9: A novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma Abderrahim OUSSALAH, France LATE-BREAKER POSTERS THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 173

176 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME LATE-BREAKER POSTERS LBP-018 LBP-019 LBP-020 LBP-021 LBP-022 LBP-023 LBP-024 LBP-025 LBP-026 A human in vitro three-dimensional bioprinted tissue system can be used to model nutritional damage and protective effects of MSDC-0602K, a novel modulator of the mitochondrial pyruvate carrier Jerry COLCA, United States 13C-Methacetin Breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH Jaume BOSCH, Switzerland Validation of NIS4 algorithm for detection of NASH at risk of cirrhosis in 467 NAFLD patients prospectively screened for inclusion in the RESOLVE-IT trial Remy HANF, France The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European Liver Transplant Registry Giovanni PERRICONE, Italy Mas-related G-protein coupled receptor type D (MrgD) antagonism produces splanchnic vasculature-specific effects, leading to a large reduction in portal pressure in cirrhotic animals Lakmie GUNARATHNE, Australia HCV treatment with DAA in patients listed for liver transplant does not result in an increased risk of HCC recurrence postliver transplant Chiara MAZZARELLI, Italy Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals Maria REIG, Spain Prophylaxis with CMV-hyperimmunglobulin reduces immunologic graft damage in critically ill liver transplant patients Arno KORNBERG, Germany A structurally engineered fatty acid, icosabutate, displays optimised absorption, distribution and metabolism properties for targeting hepatic inflammation and normalises elevated liver enzymes in dyslipidemic patients David A. FRASER, Netherlands 174 EASL THE HOME OF HEPATOLOGY

177 11-15 APRIL 2018 PARIS, FRANCE LBP-027 LBP-028 LBP-029 LBP-030 LBP-031 LBP-032 Rifaximin reduces the incidence of sepsis and all cause admissions whilst on the liver transplant waiting list Debbie SHAWCROSS, United Kingdom The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality Joan CLÀRIA, Spain Viral integration profiles in the plasma cell-free DNA from patients with HBV infection well represent tumor clone compositions during HCC development Dake ZHANG, China 8 weeks of ledipasvir-sofosbuvir for non-cirrhotic patients with HCV genotype 4: A single-arm multicenter phase 3b study (HepNed-001) Anne BOEREKAMPS, Netherlands A deep-learning approach for pattern recognition allows rapid and reproducible quantification of histological NASH parameters: integration into the QuPath platform John BROZEK, France Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in non-cirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: the STORM-C-1 phase II/III trial Isabelle ANDRIEUX-MEYER, France LATE-BREAKER POSTERS THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 175

178

179 11-15 APRIL 2018 PARIS, FRANCE POSTERS THURSDAY 12 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

180 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME : the presenting author is a young investigator Top 10% : Abstract is in the top 10% posters Molecular and cellular biology POSTERS / THURSDAY 12 APRIL 2018 THU-001 Top 10% THU-002 THU-003 THU-004 THU-005 THU-006 THU-007 THU-008 THU-009 Internalization of canalicular transporters in estradiol 17ß-Dglucuronide-induced cholestasis involves shift from raft to non-raft membrane domains and clathrin-mediated endocytosis Gisel S. MISZCZUK, Argentina Different micro-environtmental factors induce proliferation, epithelial-mesenchymal transition (EMT) and senescence of primary cultures of human biliary tree stem/progenitor cells (hbtscs), recapitulating the pathological features typical of human cholangiopathies Daniele COSTANTINI, Italy Transcriptional repressors Zeb1 and Zeb2 regulate collagen production in drug-induced hepatic stellate cell activation in mice Inge MANNAERTS, Belgium Dechipering the role of Axin2/Lgr5+ pericentral hepatocytes Lara PLANAS-PAZ, Switzerland A combined laser microdissection and proteomic analysis method for identification of liver tumors signatures Anne-Aurélie RAYMOND, France Identificiation of compounds targeting CD133-positive hepatogellular carcinoma while minimizing the damage on hepatocytes by phenotypic high-content screening Yeonhwa SONG, Korea, Rep. of South Negative allosteric modulators of metabotropic glutamate receptor subtype 5 protect against hepatic ischemia/reperfusion injury Clarissa BERARDO, Italy Rapid generation of somatic liver knockouts using multiplex CRISPR/Cas9 editing Karl-Dimiter BISSIG, United States Common immunological and cellular pathways of human alcoholic hepatitis and murine models of alcohol consumption Alyx VOGLE, United States 178 EASL THE HOME OF HEPATOLOGY

181 11-15 APRIL 2018 PARIS, FRANCE THU-010 THU-011 THU-012 THU-013 THU-014 THU-015 THU-016 THU-017 THU-018 THU-019 THU-020 THU-021 Demethylation increases the expression of type 3 inositol 1,4,5-trisphosphate receptor in hepatocytes Rodrigo MACHADO FLORENTINO, Brazil Correction of ATP7B restores its sub-cellular localisation in hepatocytes from Wilson s disease induced pluripotent stem cells Jiayin YANG, China Alternative splicing regulation during the course of liver disease Hualin WANG, United States Improving the efficacy of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator Charlotte LEE, United Kingdom Rab35 drives hepatocellular carcinoma development via action of Erk1/2 pathway Xueyan WANG, China hascs-derived exosomes rescuing rats with acute liver failure by releasing IncRNA H19 Yinpeng JIN, China A novel Akt activatorsc79 prevents lethal hepatic failure induced by Fas-mediated apoptosis of hepatocytes Wannan CHEN, China New insights in Transforming Growth Factor Beta signalling pathway on tumor suppression and metastatic potential in primary liver cancer Sharon PEREIRA, Germany Amiodarone-induced adipose tissue endoplasmic reticulum stress and lipolysis may contribute to hepatic lipid accumulation Inbal HOURI, Israel Effect of melatonin on the circadian clock pathway in liver fibrosis and progression to hepatocarcinoma Bárbara GONZÁLEZ FERNÁNDEZ, Spain Unravelling the role of the Hedgehog siganlling pathway in the hepato-ovarian axis Christiane RENNERT, Germany WDHD1 is a candidate driver gene in Hepatocellular Carcinoma Jun CAI, China POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 179

182 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Molecular and cellular biology (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-022 THU-023 THU-025 THU-026 THU-027 THU-028 THU-029 THU-030 THU-031 THU-032 THU-033 Investigating the effect of adrenomedullin on hepatic NF-kB activation by 2D and 3D hepatic cell cultures Krista ROMBOUTS, United Kingdom Dna methylation profiling of hepatitis C virus patients treated with direct acting antivirals identifies consistent methylation changes in livers and blood Aparna VASANTHAKUMAR, United States Involvement of sphingosine-1p receptor 2 (S1PR2) in taurolithocholate-induced impairment of multidrug resistenceassociated protein 2 (Mrp2) in rat Romina ANDERMATTEN, Argentina The analysis of delta40p53, one of p53 splicing isoforms, in hepatocellular carcinoma cells Haruhisa NAKAO, Japan CCNT1 mediates mtor inhibitor related antiviral effects in HCV genotype 2a Alexandra FREY, Germany Cerium oxide nanoparticles protect against oxidant mediated injury and recover kinase activity of multiple pathways in human-derived hepatocellular carcinoma cells Meritxell PERRAMON COROMINAS, Spain Interaction between hepatic sinusoidalendothelial cells and monocytes modulates IL33 driven Th2 dependent liver fibrogenesis Johanna REISSING, Germany Stereochemistry enhances pharmacological properties of APOC3 antisense oligonucleotides Luciano APPONI, United States Hypoxia strongly modulates hepcidin mrna expression via macrophage-hepatocyte crosstalk Ines SILVA, Germany Hypoxia enhances H2O2-mediated upreguation of hepcidin: potential role of oxidases in iron regulation Ines SILVA, Germany Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mtor expressions and was correlated with their impaired function Johnny AMER, Israel 180 EASL THE HOME OF HEPATOLOGY

183 11-15 APRIL 2018 PARIS, FRANCE THU-034 THU-035 THU-036 THU-037 THU-038 THU-039 THU-040 THU-041 Constructing a cell-type resolved human liver proteome atlas Lili NIU, Denmark Metabolic rewiring and de novo lipogenesis induced by Glucokinase expression in hepatocarcinoma cell line Vincent LOTTEAU, France Role ofseptin 9 in interferon gsignalling and the development of cholangiocarcinoma Yifan DING, France Molecular and histological characterization of the pathological events in a model of cirrhosis and hepatocarcinoma María Paulette CASTRO-GIL, Mexico The emerging realm of morphogens in the adult liver of mice and human a deep insight into distribution, interaction and regulation Erik SCHRÖDER, Germany Direct and indirect hepatoprotective mechanism of CBLB502 a TLR5 agonist Nicolas MELIN, Switzerland Towards understanding the mechanisms of chlorpromazineinduced hepatic toxicity using a human HepaRG- based model Joanna BRZESZCZYNSKA, United Kingdom Uncovering the liver Notch code using high-throughput reporter imaging on micropatterns Jan MAŠEK, Sweden POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 181

184 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Public Health THU-047 Top 10% Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia Josephine WALKER, United Kingdom POSTERS / THURSDAY 12 APRIL 2018 THU-048 THU-049 THU-050 THU-051 THU-052 THU-053 THU-054 THU-055 Protective effect of cannabis and coffee consumption on HCVrelated mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort) Maria Patrizia CARRIERI, France Treatment of Hepatitis C in dedicated homeless GP practice by a multidisciplinary team Katherine DAVIDSON, United Kingdom Comorbid disease burden in patients with primary liver pathologies- data from a comprehensive analysis of serial transient elastography and other liver disease evaluations at the Toronto liver centre (CASTLE-TLC) Kerstina BOCTOR, Canada Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017 Jeffrey LAZARUS, Spain Heterogeneity in hepatitis C virus treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access Nick SCOTT, Australia Moderate and severe renal impairment in European CHB patients treated with TDF or ETV: a 7-year retrospective cohort study in 490 patients (on behalf of the ReCoRd investigators group) Heribert RAMROTH, United Kingdom The time trend of proportion and mortality rate of admissions associated with acute respiratory illness in cirrhotic patients with diverse ethnicity and socioeconomic status: an analysis on the U.S. National Inpatient Sample Donghak JEONG, United States The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs Zoe WARD, United Kingdom 182 EASL THE HOME OF HEPATOLOGY

185 11-15 APRIL 2018 PARIS, FRANCE THU-056 THU-057 THU-058 THU-059 THU-060 THU-061 THU-062 THU-063 THU-064 THU-065 THU-066 Population health and economic impact of reaching the WHO 2030 targets in chronic hepatitis B diagnosis and treatment in the United States Mehlika TOY, United States Quantifying the impact of achieving the World Health Organization global health sector strategy goals for hepatitis C in the EURO region Sarah ROBBINS, United States Quantifying the impact of achieving the World Health Organization global health sector strategy goals for hepatitis C in the African Region Sarah ROBBINS, United States Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the underwater portion of the iceberg matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? Sarah ROBBINS, United States Outcomes of delaying hepatitis C treatment in persons who inject drugs: Dynamic modeling of C-EDGE CO-STAR trial cohort Jagpreet CHHATWAL, United States Improved health outcomes from hepatitis C treatment scale-up in Spain s prisons: A cost-effectiveness study Jagpreet CHHATWAL, United States Poor awareness of liver disease shortly before cirrhosis death: findings from a large community cohort in the UK Hamish INNES, United Kingdom Eradicate hepatitis C: A pilot of treatment as prevention in active drug users Jasmine SCHULKIND, United Kingdom HIV co-infection is associated with increased liver complications and reduced mental health among patients with chronic hepatitis B Mei LU, United States Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake Jisoo Amy KWON, Australia Hepcare Europe: HepCheck; reaching vulnerable populations Jack LAMBERT, Ireland POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 183

186 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Public Health (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-067 THU-068 THU-069 THU-070 THU-071 THU-072 THU-073 THU-074 THU-075 THU-076 Achieving World Health Organization targets for hepatitis B by 2030: Results from 17 WHO AFRO Countries Helen NDE, United States Achieving World Health Organization targets for hepatitis B in infants and 5-year olds by 2030: Results from 17 WHO AFRO countries Helen NDE, United States Impact of the hepatitis B vaccine birth-dose on perinatal incidence between : Results from 17 WHO AFRO Countries Helen NDE, United States The 10-year chronic liver disease spectrum evolution in China: experience from the largest tartiary special hospital with liver biopsy cases Dong JI, China The ENABLE projects: Consistent high prevalence of undiagnosed active blood borne virus infection [HBV, HCV, HIV] across four urban emergency departments in England. Data for action? Mark HOPKINS, United Kingdom Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population Jelle KOOPSEN, Netherlands Transient elastography for screening of liver fibrosis in the population: A cost-effectiveness analysis using prospective databases from 6 countries in Europe and Asia Miquel SERRA, Spain Scale-up of the national HCV screening and treatment program in Indonesia: data from Jakarta, West Java and Central Java Atiek ANARTATI, Indonesia Hepatitis C screening within the national elimination program in the country of Georgia Ana ASLANIKASHVILI, Georgia Inferring the migration routes of hepatitis C virus subtype 1a lineages identifies a need for pan-european prevention strategies Lize CUYPERS, Belgium 184 EASL THE HOME OF HEPATOLOGY

187 11-15 APRIL 2018 PARIS, FRANCE THU-077 THU-078 THU-079 THU-080 THU-081 THU-082 THU-083 THU-084 THU-085 THU-086 THU-087 Outcomes of hepatitis C testing, linkage to care, and treatment in a community based program in high versus low prevalence sites Lora MAGALDI, United States Testing and linkage to care outcomes in baby boomers versus young adults tested in the community and linked to care at a Federally Qualified Health Center in the US Lora MAGALDI, United States The impact of EMR modification and a multi-disciplinary care team on the hepatitis C care cascade of a US Federally Qualified Health Center Lora MAGALDI, United States Identifying patients with cirrhosis at high risk of readmission: a population-based data-linkage Australian study Patricia VALERY, Australia The role of a template-based assessment letter in the continuing education of general practitioners: a qualitative exploration of NAFLD educatioin Patricia VALERY, Australia The first large scale registry for non alcoholic fatty liver disease in Israel Inbal GOLDSHTEIN, Israel Hospitality discharge for alcohol related problems in north east Italy in a sixteen-years period: Influence of new population at risk ERIK ROSA-RIZZOTTO, Italy Is macro-elimination of HCV infection the right approach for Canada? Julie HOLEKSA, Canada Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada Mia BIONDI, Canada Scale up of hepatitis C virus treatment in the era of all-oral direct-acting antivirals: a 9-year Greek cohort study Vasilios PAPASTERGIOU, Greece Design and cost effectiveness of a hepatitis C virus elimination strategy based on an updated epidemiological study (ETHON cohort) Antonio CUADRADO, POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 185

188 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Public Health (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-088 THU-089 THU-090 THU-091 THU-092 THU-093 THU-094 THU-095 THU-096 THU-097 Hepatitis C infection in the Pan American Health Organization Region: The current burden of disease and a road map for achieving the WHO Global Health Sector Strategy Goals Jonathan SCHMELZER, United States The current and future disease burden of hepatitis B in the general population and among five year olds in the Eastern Mediterranean Region Jonathan SCHMELZER, United States The covert C : prevalence: Risk factors and management of hepatitis C in psychiatric in-patients Jeyamani RAMACHANDRAN, Australia Modelling the impact and efficiency of screening and treatment scale-up for hepatitis C virus in Pakistan: Working towards elimination Aaron G. LIM, United Kingdom Characteristics and outcomes of patients with late presentation of hepatitis B among newly-diagnosed hepatocellular carcinoma : A national cohort study Dong Hyun SINN, Korea, Rep. of South Evaluation of the Xpert fingerstick HCV viral load assay François LAMOURY, Australia Sero-prevalence of Hepatitis B surface antigen among 5-7 years old children and their mothers in Cambodia by nationwide multi-stage stratified random sampling strategy Junko TANAKA, Japan Burden of comorbidity in patients with advanced NASH a retrospective analysis using a large US insurance claims database Tzuyung Douglas KOU, United States Khat chewing increases the risk for developing chronic liver disease: a hospital-based case-control study Stian ORLIEN, Norway The global prevalence of HBsAg by age in 2016 and the case for universal treatment in low and middle income countries Devin RAZAVI-SHEARER, United States 186 EASL THE HOME OF HEPATOLOGY

189 11-15 APRIL 2018 PARIS, FRANCE THU-098 THU-099 THU-100 THU-101 THU-102 THU-103 THU-104 THU-105 THU-106 THU-107 THU-108 Influence of geographical origin on access to therapy and therapy outcomes in hepatitis C virus-infected persons: the Swiss Hepatitis C Cohort Study Matteo BREZZI, Switzerland Lowering the upper limit of serum alanine aminotransferase levels may detect significant liver disease in the elderly Hemda SCHMILOVITZ-WEISS, Israel Hepatitis C patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients Stuart C GORDON, United States Progress toward hepatitis C virus elimination through provision of care and treatment services, Georgia, David SERGEENKO, Georgia High prevalence of hepatitis delta virus in specimens from Cameroon Mary RODGERS, United States Achieving the World Hepatitis Organization global health sector strategies goals for hepatitis in the WHO Western Pacific Region: A modeling study Samantha BRANDON, United States The first result from the general population hepatitis screening in Mongolia: 38% of year olds screened and anti-hcv prevence of 15.6% among year olds Bekhbold DASHTSEREN, Mongolia Diagnosis of hepatitis C virus infection in Spain. On the correct side of the road? Federico GARCIA GARCIA, Spain HepCARE: A tool enabling the identification, assessment and management of viral hepatitis. An integrated approach to the patient journey Benjamin ANTHONY, United Kingdom A tool to measure the impact of inaction towards elimination of hepatitis C virus: A case study in Germany Markus CORNBERG, Germany Linkage to HCV care and reincarceration following release from New York City jails Matthew AKIYAMA, United States POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 187

190 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Public Health (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-109 THU-110 THU-111 THU-112 THU-113 THU-114 THU-115 THU-116 THU-117 THU-118 Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis Issifou YAYA, France High agreement with HCV RNA in screening and DAA treatment monitoring indicates that cost-effective HCV core Ag test can also be enlisted in the fight to eliminate hepatitis C Nazibrola CHITADZE, Georgia Elimination of hepatitis C in two different Swiss regions A model-based microelimination scenario Urs RUSCH, Switzerland Role of physician specialties to close gaps in the care cascade of hepatitis C: Evidence from paid claims in the United States from 2010 to 2016 Yuri SANCHEZ, United States Effectiveness of hepatitis C virus screening laws in United States: Evidence from paid claims data from 2010 to 2016 Yuri SANCHEZ, United States Development of a clinical prediction score for targeted hepatitis C screening in a low-risk HIV cohort in Cambodia Anja DE WEGGHELEIRE, Belgium The hepatitis C continuum of care among HIV infected individuals in the Icona study network Antonella D ARMINIO MONFORTE, Italy One-step diagnostic strategy of viremic hepatitis C virus infection from dried-blood spots: feasibility and usefulness in people who inject drugs Verónica SALUDES, Spain The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study Adam TRICKEY, United Kingdom Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study Adam TRICKEY, United Kingdom 188 EASL THE HOME OF HEPATOLOGY

191 11-15 APRIL 2018 PARIS, FRANCE THU-119 THU-120 THU-121 THU-122 THU-123 THU-124 THU-125 THU-126 THU-127 THU-128 THU-129 THU-130 Factors associated with self-reported HCV infection among people who inject opioids: the role of incarceration Perrine ROUX, France Mass screening for hepatitis B and C in South Upper Egypt: lessons learned from a real life experience Mahmoud ELZALABANY, Egypt Track, Trace & Treat: Results from a retrieval strategy to identify lost to follow-up chronic hepatitis C patients Isabelle MUNSTERMAN, Netherlands Community interventions and peer support for active case finding and treatment support for underserved populations with hepatitis C in the UK, Ireland, Romania and Spain as part of the HEPCARE programme Julian SUREY, United Kingdom Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men Sergio RODRÍGUEZ-TAJES, Spain Anemia in chronic liver disease Sang Jun SUH, Korea, Rep. of South Increasing access to treatment for hepatitis C by vulnerable, high risk patients through community pharmacy: The SuperDOT-C study in Scotland Andrew RADLEY, United Kingdom Drug utilization in patients with liver cirrhosis in ambulatory care Sander BORGSTEEDE, Netherlands Long-term effectiveness of Sofosbuvir-based hepatitis C regimens in Central and West Africa (ANRS 12342) Maël BAUDOIN, France Cost-effectiveness of Sofosbuvir-based hepatitis C regimens in Central and West Africa (ANRS 12342) Sylvie BOYER, France HCV screening in the adult general population of a basic health area in the Valencian Region (Spain) Antonio GARCIA HEROLA, Spain The nature and impact of stigma in patients with chronic hepatitis B: a systematic literature review Kristien BONROY, Belgium POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 189

192 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Public Health (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-131 THU-132 THU-133 THU-134 THU-135 THU-136 THU-137 THU-138 THU-139 THU-140 THU-141 Cost-effectiveness of scaling up Hepatitis C virus prevention, testing and treatment interventions among people who inject drugs in the US Hannah FRASER, United Kingdom HEV positivity in domesticated pigs and a relative risk of HEV zoonosis among occupationally exposed individuals in Vietnam Xuan Hoan NGHIEM, Germany Is HCV elimination among HIV-infected people who inject drugs possible through HCV treatment targeting HIV/HCV coinfection? A modeling analysis for Andalusia, Spain Britt SKAATHUN, United States Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study Behzad HAJARIZADEH, Australia The French donor risk index for liver transplantation: Development, internal and external validation Cyrill FARAY, France Looking for the best matching between donor and recipient in liver transplantation: a sequential stratification approach Cyrill FARAY, France One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montréal, Canada Emmanuel FORTIER, Canada Cost-effectiveness of elbasvir/grazoprevir + sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina Emiliano BISSIO, Argentina Molecular epidemiology of hepatitis B and D in the Pacific Islands of Kiribati Kathy JACKSON, Australia Screening and treatment of hepatitis C virus infection of adult general population in Spain is cost-effective Maria BUTI, Spain Efficacy of a program based on on -site dried blood spot testing for hepatitis C to improve linkage to care and treatment uptake for people who injected drugs Dalia MORALES ARRAEZ, Spain 190 EASL THE HOME OF HEPATOLOGY

193 11-15 APRIL 2018 PARIS, FRANCE THU-142 THU-143 THU-144 THU-145 THU-146 THU-147 Hepatitis B changes in epidemiological and molecular features of Afro-Brazilian communities, Central Brazil Ana Rita MOTTA-CASTRO, Brazil Screening for hepatitis C in Ontario, Canada: Exploring antibody positivity in the federal and provincial correctional systems Kinsey BECK, Canada Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates Patrick INGILIZ, Germany Hepatitis C elimination by 2030 is feasible in Brazil: a mathematical modelling aproach Maria Cassia MENDES CORREA, Brazil Micro-elemination of hepatitis C among patients with congenital bleeding disorders in Slovenia Mojca MATICIC, Slovenia Hepatitis E in pigs in Israel: seroprevalence, molecular characterization and potential impact on humans Orna MOR, Israel POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 191

194 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Therapy POSTERS / THURSDAY 12 APRIL 2018 THU-151 THU-152 THU-153 THU-154 THU-155 THU-156 THU-157 THU-158 THU-159 THU-160 Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients Jean-Frédéric BLANC, France Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib Alvaro DIAZ-GONZALEZ, Spain Comparison of the prognosis between non-viral HCC and viral HCC Kenta TAKAURA, Japan Risk-stratified management of advanced hepatocellular carcinoma (HCC) David James PINATO, United Kingdom A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, Ras mutation and immunoscore Pamela BALDIN, Belgium Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism Maria REIG, Spain A statistical model for survival risk prediction in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment Sarah BERHANE, United Kingdom The ALBI and p-albi grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE) Claudia CAMPANI, Italy Verification of staging systems and treatment algorithms for hepatocellular carcinoma: perspectives from a Japanese field practice Sadahisa OGASAWARA, Japan Temporal changes in recurrent incidences after curative therapies in early stage hepatocellular carcinoma Akane KUROSUGI, Japan 192 EASL THE HOME OF HEPATOLOGY

195 11-15 APRIL 2018 PARIS, FRANCE THU-161 THU-162 THU-163 THU-164 THU-165 THU-166 THU-167 THU-168 THU-169 THU-170 The predictive role of procalcitonin for guiding use of antibiotics in HCC patients with post TACE/RFA fever Sung Bum CHO, Korea, Rep. of South Combined therapy of transarterial chemoembolizatoin and stereotactic body radiotherapy versus transaterial chemoembolizatoin for < 5m hepatocellular carcinoma: A propensity score matching analysis Baek Gyu JUN, Korea, Rep. of South Out of Milan criteria and worse intetion to treat results at large liver transplant center Julia HERRERAS LÓPEZ, Spain Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS Markus PECK-RADOSAVLJEVIC, Austria Comparision of long-term outcome for single small hepatocellular carcinoma between different treatment modalities by size and tumor marker Dong Hyun SINN, Korea, Rep. of South Multimodal and sequential treatmente for hepatocellular carcinoma: how real-life complies with international recommendations Michela TRIOLO, Italy Surgical resection is considered in resectable solitary hepatocellular carcinoma with portal vein tumor thrombosis of patients with Child A Jong Man KIM, Korea, Rep. of South Performance of ALBI-PD Model and PALBI Grade in Sorafenib-failed Hepatocellular Carcinoma Pei-Chang LEE, Taiwan Feasibility of dynamic risk assessment for patients with repeated tras-arterial chemoembolization for hepatocellular carcinoma Mi Young JEON, Korea, Rep. of South Surgical resection vs radiofrequency ablation for hepatocellular carcinoma: a propensity score matching analysis Grazisa SCIALANDRONE, Italy POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 193

196 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Therapy (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-171 THU-172 THU-173 THU-174 THU-175 THU-176 THU-177 THU-178 THU-179 THU-180 Impact of the alpha-fetoprotein model for patient selection for Liver Transplantation for Hepatocellular Carcinoma, a French experience Bleuenn BRUSSET, France Transarterial-chemoembolization and hepatocellular carcinoma. A regular interval approach avoids the 10% of the procedures and an optimal survival with the transition to systemic therapy in 80% of the patients Marco SANDUZZI ZAMPARELLI, Spain Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients Marco SANDUZZI ZAMPARELLI, Spain Combined photodynamic therapy with systemic chemotherapy improves survival of patients with irresectable cholangiocarcinoma Maria Angeles GONZALEZ-CARMONA, Germany Outcomes of single or sequential dual modality loco-regional therapies in Hepatocellular carcinoma Vinay Kumar BALACHANDRAKUMAR, United Kingdom Clinical features and prognosis of advanced stage hepatocellular carcinoma; verification of diverse progression processes Masayuki YOKOYAMA, Japan Soluble urokinase plasminogen activator receptor (supar) represents a novel serum biomarker for patients undergoing resection of colorectal liver metastases Sven LOOSEN, Germany Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib Giulio ANTONELLI, Italy The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment Jee-Fu HUANG, Taiwan Analyses of intermediate stage hepatocellular carcinoma patients from the point of view of designing clinical trials comparing transarterial chemoembolization and systemic therapies Keisuke KOROKI, Japan 194 EASL THE HOME OF HEPATOLOGY

197 11-15 APRIL 2018 PARIS, FRANCE THU-181 THU-182 THU-183 THU-184 THU-185 THU-186 THU-187 THU-188 THU-189 THU-190 Impact of BCLC treatment stage migration in the survival of patients with hepatocellular carcinoma Silvia ACOSTA-LÓPEZ, Spain ALBI is an independent predictor ofsurvival in resected patients with HCC Philippe KOLLY, Switzerland Portal vein tumor thrombosis has a direct impact on liver function Roman KLÖCKNER, Germany A novel model for the outcome prediction of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma with or without impaired hepatic function Hwi Young KIM, Korea, Rep. of South Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver Sherief ABD-ELSALAM, Egypt Comparison of efficacy between sorafenib monotherapy vs. transarterial chemoembolization sorafenib sequential therapy in hepatocellular carcinoma patients with extrahepatic metastatis An interim analysis of randomized controlled trial Hyung Joon M, Korea, Rep. of South A comparison of surgical resection and transarterial chemoembolization for solitary hepatocellular carcinoma larger than 10cm: A propensity score matching analysis Hsiao-Sheng LU, Taiwan Phase II trial using combination of TACE and SBRT for unresectable single large HCC: preliminary report Michael BUCKSTEIN, United States Real life experience with selective internal radiation therapy (SIRT) as part of multimodality treatment of advanced hepatocellular carcinoma (HCC) Florian VAN BOEMMEL, Germany Ubr Ubiquitin ligases as modulators of inflammation in hepatocellular carcinoma Dominique LEBOEUF, Russian Federation POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 195

198 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Autoimmune and chronic cholestatic liver disease: Clinical aspects POSTERS / THURSDAY 12 APRIL 2018 THU-191 Top 10% THU-192 THU-193 THU-194 THU-195 THU-196 THU-197 THU-198 THU-199 THU-200 THU-201 Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and their relatives: a Danish nationwide family cohort study Lisbet GRØNBÆK, Denmark Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls Lisbet GRØNBÆK, Denmark Autoantibodies against Huntingtin-interacting protein 1-related protein are superior to conventional autoantibodies in diagnosing autoimmune hepatitis in children Richard TAUBERT, Germany Time trendsin liver transplantation for primary biliary cholangitis in Europe over thepast three decades Maren HARMS, Netherlands The antidepressantmirtazapine improves survival in patients with primary biliary cholangitis Abdel-Aziz SHAHEEN, Canada Impact of access to specialized health care on the primary biliary cholangitis (PBC) patient outcomes: a Canadian experience Abdel-Aziz SHAHEEN, Canada Biliary IL8 is a marker for disease progression and risk for biliary neoplasia in primary sclerosing cholangitis Martti FÄRKKILÄ, Finland Pruritus strongly reduces quality of life in PBC patients real life data from a large national survey Andreas E KREMER, Germany Functional connectivity reveals altered activation of distinct brain areas in pruritus of cholestasis Andreas E KREMER, Germany A stepwise algorithm for biliary brush cytology shows high diagnostic performance in primary sclerosing cholangitis Erik VON SETH, Sweden VCAM-1 and soluble CD-163 as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis a prospective study Maciej JANIK, Poland 196 EASL THE HOME OF HEPATOLOGY

199 11-15 APRIL 2018 PARIS, FRANCE THU-202 THU-203 THU-204 THU-205 THU-206 THU-208 Top 10% THU-209 THU-210 THU-211 THU-212 Rituximab treatment experience in patients with complicated type 1 autoimmune hepatitis in Europe and North America Nwe Ni THAN, United Kingdom Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years Anna REIG, Spain Histologic stageis a stronger predictor of transplant free survival than APRI and FIB-4 inpatients with primary biliary cholangitis Aliya GULAMHUSEIN, Canada Morning bright light treatment for sleep-wake disturbances in Primary Biliary Cholangitis Matteo TURCO, Italy Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis in patients with ulcerative colitis Jesus M BANALES, Spain A nationwide population-based evaluation of mortality and cancer-risk in patients with ulcerative colitis/primary sclerosing cholangitis young age at diagnosis and the unmet need to reduce mortality Palak TRIVEDI, United Kingdom Differentiation of acute icteric autoimmune hepatitis from idiosyncratic drug-induced liver injury by histological and biochemical criteria Marcial SEBODE, Germany Patients with primary biliary cholangitis exhibit reduced hippocampal volume and MRI evidence of neuroinflammation Victoria MOSHER, Canada Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis Carla Fiorella MURILLO PEREZ, Canada Risk factors for hepatocellular carcinoma in a large cohort of patients affected by primary sclerosing cholangitis Francesca SAFFIOTI, United Kingdom POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 197

200 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-213 THU-214 THU-215 Optimal institution of azathioprine maintenance therapy in autoimmune hepatitis: a multicenter cohort study Simon PAPE, Netherlands The risk predictive values of UK-PBC and GLOBE scoring system and performance of biochemical response criteria in Chinese patients with primary biliary cholangitis (PBC) on ursodeoeycholic acid Ang HUANG, China Biochemical response to ursodeoxycholic acid predicts histologic primary biliary cholangitis progression Tadashi NAMISAKI, Japan THU-216 Durable response in the markers of cholestasis through 36 months of open-label extension study of obeticholic acid in primary biliary cholangitis Michael TRAUNER, Austria THU-217 THU-218 THU-219 THU-220 THU-221 THU-222 Quantification of biliary phosphatidylcholine by non-invasive 31P magnetic resonance spectroscopy imaging suggests differences in cholangiopathies: A pilot study Emina HALILBASIC, Austria Pre-treatment risk stratification in primary biliary cholangitis: a predictive model to guide first-line combination therapy Marco CARBONE, Italy Sustained biochemical response to oral antibiotics in pediatric PSC and ASC are correlated to changes in gut microbiota during therapy Pauline SAMBON, Belgium Primary biliary cholangitis specific T cell receptors on N-Ras high CD4+ T cells Ryo NAKAGAWA, Japan Validation of various prognostic models in primary biliary cholangitis in Korean patients Jeong-Ju YOO, Korea, Rep. of South Imaging features of macro regenerative nodules (MRN) in primary sclerosing cholangitis: MRimaging characteristics Andres MORGADO, United States 198 EASL THE HOME OF HEPATOLOGY

201 11-15 APRIL 2018 PARIS, FRANCE THU-223 THU-224 THU-225 THU-226 THU-227 THU-228 THU-229 THU-230 THU-231 THU-232 THU-233 Effect of nalfurafine hydrochloride for refractory pruritus in patients with primary biliary cholangitis: a multicenter, postmarketing, single-arm, prospective study Minami YAGI, Japan Primary biliary cholangitis in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC Cynthia LEVY, United States Primary biliary cholangitis in the U.S.: clinical characteristics of patients enrolled in TARGET-PBC Cynthia LEVY, United States Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis the Global PBC Study Group Willem J LAMMERS, Netherlands A dose-responserelationship in the association between ursodeoxycholic acid treatment andprolonged transplant-free survival in primary biliary cholangitis Adriaan VAN DER MEER, Netherlands Incidence of autoimmune hepatitis is increasing, while primary biliary cholangitis and primary sclerosing cholangitis have remain unchanged: a population-based study Mehul LAMBA, New Zealand Autoantibody-negative autoimmune hepatitis presents more commonly with advanced fibrosis or cirrhosis Mehul LAMBA, New Zealand Prognosis in patients with primary biliary cholangitis based on histological stage at diagnosis. A nationwide population-based study Lars BOSSEN, Denmark Change in bilirubin with obeticholic acid treatment in primary biliary cholangitis patients with high baseline bilirubin: a retrospective analysis of POISE, 201, and 202 Gideon HIRSCHFIELD, United Kingdom Chloroquine in monotherapy is safe and effective for induction of remission in anti-sla/lp positive patients with autoimmune hepatitis Débora TERRABUIO, Brazil Health-Related Quality of Life in patients with autoimmune hepatitis Atsushi TAKAHASHI, Japan POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 199

202 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-234 THU-235 THU-236 THU-237 THU-238 THU-239 Pregnancy and autoimmune hepatitis: presentation and outcomes Laura Patricia LLOVET, Spain Efficacy and safety of calcineurin inhibitors as salvage therapy in patients with autoimmune hepatitis Simone STRASSER, Australia Risk stratification using transient elastography and the new scoring systems for patients with primary biliary cholangitis Lisa PERINI, Italy Independent predictors of primary biliary cholangitis (PBC) at high risk for progressive course in the United States: data from a large- real world database Zobair YOUNOSSI, United States Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitis Pol BOUDES, United States Seladelpar s mechanism of action as a potential treatment for primary biliary cholangitis and non-alcoholic steato-hepatitis Pol BOUDES, United States 200 EASL THE HOME OF HEPATOLOGY

203 11-15 APRIL 2018 PARIS, FRANCE Cirrhosis: ACLF and Critical illness THU-245 THU-246 THU-247 THU-248 THU-249 THU-250 THU-251 THU-252 THU-253 Class III (morbid) obesity is an independent risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis Vinay SUNDARAM, United States Regional variations in the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis and bacterial infections Florence WONG, Canada Number of organ failures is a better predictor of waitlist mortality in those who die within 30 days of listing for liver transplantation Paul J. THULUVATH, United States Impact of receptor interacting protein kinase 3 levels on acute on chronic liver failure progression Takayuki KONDO, United Kingdom NASH/NAFLD patients with end stage liver disease experienced high inpatient hospitalization costs and substantial disease progression: Results of a French national database on hospital care analysis Jerome BOURSIER, France Combinations of inflammatory markers, soluble (s)cd163, mannose receptor (smr) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-onchronic liver failure Henning GRØNBÆK, Denmark The outcome of acute-on-chronic liver failure in the intensive care is similar to a propensity matched ICU population without liver disease Schalk VAN DER MERWE, Belgium Early management of critically ill cirrhotic patients admitted in ICU for gastrointestinal bleeding: wait day 3 to avoid taking a bad decision Lucy MEUNIER, France Dynamic assessment is superior to baseline assessment in prognostication of patients with acute on chronic liver failure Sahaj RATHI, India POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 201

204 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis: ACLF and Critical illness (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-254 THU-255 THU-256 THU-257 THU-258 THU-259 THU-260 THU-261 THU-262 Acute onchronic liver failure-comparison of patients identified by the Europeanassociation for the study of the liver and the North American consortium forstudy of end-stage liver diseases Zita GALVIN, Canada Liver transplantation in patients admitted to intensive care with acute-on-chronic liver failure Eleni THEOCHARIDOU, United Kingdom Impact of the non-hepatic surgery on the survival of patients with viral cirrhosis: prospective study from the CirVir cohort Cécile ZYLBERFAJN, France Clinical Phase 1b Study Results for Safety, Pharmacokinetics and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 sirna for the Treatment of Japanese Patients with Advanced Liver Fibrosis Naoya SAKAMOTO, Japan Acute kidney injury in patients with hepatitis B virus related acute-on-chronic liver failure is different from in decompensated cirrhosis Meifang HAN, China Invasive fungal infections in Acute on chronic liver failure An Asia Pacific experience from the AARC consortium Sunil TANEJA, India Albumin function in acute-on-chronic liver failure (ACLF): Effect of plasma exchange with albumin 5% (PE-A5%) Mireia TORRES, Spain Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute on chronic liver failure (ACLF) Andres CARDENAS, Spain Impact of organ failure in patients with acute on chronic liver failure (ACLF) and the newly defined AARC liver failure score in predicting 90 days survival-results from APASAL-ACLF research consortium (AARC) Apurva PANDE, India 202 EASL THE HOME OF HEPATOLOGY

205 11-15 APRIL 2018 PARIS, FRANCE THU-263 THU-264 THU-265 THU-266 THU-267 THU-268 THU-269 THU-270 THU-271 THU-272 Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC) Juned AHMAD, India Serum caspase-1 level as a diagnostic and prognostic biomarker for HBV-related acute-on-chronic liver failure Xiangying ZHANG, China Outcome of bacterial infections complicated or not by acuteon-chronic liver failure in patients with cirrhosis admitted to hospital for acutedecompensation Michele BARTOLETTI, Italy Typing acute-on-chronic liver failure according to World Gastroenterology Organization working party definition in HBV-related patients Xiaoting TANG, China Analyzing the Duration between Acute Insult and ACLF in a Chinese 14 centers, prospective study for natural course of ACLF Gu WEN, China Relative adrenal insufficiency in acute-on chronic liver failure a new futility marker? Anca TRIFAN, Romania The combination of acute-on-chronic liver failure (ACLF) as defined by EASL-CLIF consortium definition and MELD can predict post-transplant survival in patients with ACLF Uchenna AGBIM, United States Hemophagocytic Lymphohistiocytosis (HLH) in patients of acute on chronic liver failure -Results of multination study from APASL-ACLF research consortium (AARC) Harsh Vardhan TEVETHIA, India Human beta-defensin-1 is a highly predictive marker of mortality in patients with acute-on-chronic liver failure Ilianna MANI, Greece Thromboelastography parameters in acute on chronic liver failure Sandeep GOYAL, India POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 203

206 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis: ACLF and Critical illness (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-273 THU-274 THU-275 THU-276 THU-277 Features of levels of neurospecific proteins in patients with hepatic encephalopathy Nataliia DYNNYK, Ukraine Non inferiority of combination of slow continuous albumin,furosemide with low dose Terlipressin with Noradrenaaline infusion in ACLF patients in comparison to slow continuous albumin, furosemide and Terlipressin Gaurav PANDEY, India Impact of response guided aggressive pharmacological therapy with slow continuous albumin, furosemide and terlipressin infusion in chronic liver failure consortium acute on chronic liver failure score Gaurav PANDEY, India Impact of Clostridium difficile 027 ribotype in decompensated cirrhotic patients Ainhoa FERNANDEZ, Spain Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-sbp infections Javier FERNANDEZ, Spain 204 EASL THE HOME OF HEPATOLOGY

207 11-15 APRIL 2018 PARIS, FRANCE Viral hepatitis C: Therapy and resistance THU-281 THU-282 THU-283 THU-284 THU-285 THU-286 Top 10% THU-287 Top 10% THU-288 THU-289 THU-290 Emergence and long-term persistence of NS3, NS5A, and NS5B resistance associated substitutions after treatment with directacting antivirals David WYLES, United States Behavioral and clinical factors and Direct Acting Antiviral effectiveness in HCV/HIV co-infection; clinical experience from the TRIO network Gregory HUHN, United States HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy Vincenza CALVARUSO, Italy Therapy with DAAs in patients with chronic hepatitis C and advanced chronic kidney disease: Real-world experience from the German Hepatitis C-Registry (DHC-R) Johannes WIEGAND, Germany Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes Alison BOYLE, United Kingdom Direct Antiviral Agents are safe and efficacious in paediatric patients with chronic hepatitis C; Real world data from the public health perspective Madhumita PREMKUMAR, India Treatment of chronic hepatitis C with direct acting antivirals and its effect on body mass index and hepatic steatosis as measured by controlled attenuation parameter Hend SHOUSHA, Egypt Factors associated with nonresponse in a cohort of chronic hepatitis C patients treated with direct acting antivirals Hend SHOUSHA, Egypt Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3-year study Elisabetta DEGASPERI, Italy Diagnosis and treatment of hepatitis C virus in a Spanish jail Juan José URQUIJO, Spain POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 205

208 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Therapy and resistance (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-291 THU-292 THU-293 THU-294 THU-295 THU-296 THU-297 THU-298 THU-299 THU-300 Sofosbuvir + Glecaprevir/Pibrentasvir in patients with difficult to treat HCV infection. Final results of the French compassionate use Victor DE LEDINGHEN, France Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis Fanpu JI, China Management of patients with chronic kidney disease in the setting of interferon-free treatment for chronic HCV hepatitis Elena Laura ILIESCU, Romania Untreated HCV in HIV/HCV co-infection: Data from the TRIO network Dushyantha JAYAWEERA, Changing landscape of HCV treatment in Germany: Data from a large real-world cohort Jörg PETERSEN, Germany Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis Fred POORDAD, United States Comparison of resistance profiles among DAA-naive and DAAexperienced patients infected with HCV non-1 genotype in Italy Velia Chiara DI MAIO, Italy Impact of direct acting antiviral treatment in hospital admission rates in patients with cirrhosis and hepatitis C virus infection Álvaro HIDALGO ROMERO, Spain A national study of risk for non-liver cancer in people with hepatitis C treated with direct acting antivirals or an interferon-based regimen Charlotte LYBECK, Sweden Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvirbased regimens are suboptimal in genotype 2 patients: real-life experience Christophe HEZODE, France 206 EASL THE HOME OF HEPATOLOGY

209 11-15 APRIL 2018 PARIS, FRANCE THU-301 THU-302 THU-303 THU-304 THU-305 THU-306 THU-307 THU-308 THU-309 THU-310 Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy Christophe HEZODE, France Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Realworld outcomes from the state of South Australia James HARIDY, Australia Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: a single-center experience Roberta D AMBROSIO, Italy Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Chen-Hua LIU, Taiwan How do you feel about your diagnosis of Hepatitis C today? : The emotional benefits of direct-acting antiviral therapy Sarah MONTAGUE, United Kingdom Rapid virological response, as a predictor of sustained virological response of Sofosbuvir and Ribavirin in Korean patients with genotype 2 chronic hepatitis C virus infection Hyun Young WOO, Korea, Rep. of South Ledipasvir 90mg/sofosbuvir 400mg for treatment of children with CHC genotype 4: Single Centre experience Gamal SHEHA, Egypt Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: a single center 3-year study from Italy Federica INVERNIZZI, Italy Efficacy and safety of IFN-free DAA therapy in HIV/HCV coinfected patients: Results from a pan-european study Lars PETERS, Denmark Emergence of hepatitis C virus resistance associated variants in patients failing direct acting antivirals by ultra-deep sequencing Thuy NGUYEN, France POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 207

210 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Therapy and resistance (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-311 THU-312 THU-313 THU-314 THU-315 THU-316 THU-318 THU-319 THU-320 THU-321 HCV clearance and pro-thrombotic shift in advanced liver disease Elisa BILIOTTI, Italy Identification of novel resistance associated substitutions for sofosbuvir in HCV genotype 3a David SMITH, United Kingdom Utilization and outcomes of elbasvir/grazoprevir in genotype 1B chronic hepatitis C: updated retrospective data analyses from the Trio network Naoky TSAI, United States Effectiveness and utilization of Grazoprevir and Elbasvir in HCV genotype 1 and 4 infection in the veterans affairs healthcare system in the US Amy PUENPATOM, United States Efficacy, safety and clinical outcomes of Paritaprevir/ Ombitasvir/r + Dasabuvir 8 weeks: results from a spanish real world cohort (Hepa-C) Marc PUIGVEHÍ, Spain Multidisciplinary Support Program for patients with addictions and suspected chronic hepatitis C (MSP ADIC-C) to improve their evaluation and access to antiviral treatment Marc PUIGVEHÍ, Spain Direct acting antiviral treatment improves hepatitis C-related neurocognitive impaiment Joaquin CABEZAS GONZALEZ, Spain Effectiveness of 8 vs. 12 week ledipasvir-sofosbuvir (LDV/SOF) in black, treatment naïve patients with non-cirrhotic, genotype 1 HCV and baseline viral load Michael CURRY, United States Effectiveness of elbasvir/grazoprevir in patients with cirrhotic genotype 1 or 4 chronic hepatitis C: updated retrospective data analyses from the Trio network Michael CURRY, United States Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R) Vanessa WITTE, Germany 208 EASL THE HOME OF HEPATOLOGY

211 11-15 APRIL 2018 PARIS, FRANCE THU-322 THU-323 THU-324 THU-325 THU-326 THU-327 THU-328 THU-329 THU-330 THU-331 High efficacy of IFN-free DAA therapy for acute HCV infection in HIV patients David CHROMY, Austria High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV) Alessandra MANGIA, Italy The evolution of treatment for HCV Genotype 3 (GT3) infected patients with advanced fibrosis/cirrhosis over time Alessandra MANGIA, Italy Impact of acid-reducing agents on effectiveness of Elbasvir/ Grazoprevir in treating US veterans affairs population with hepatitis C virus Jennifer KRAMER, United States HCV treatment responses among people who use drugs: an evaluation of patients on and off opiate agonist therapy in a real-life setting Julie HOLEKSA, Canada VIEKIRA PAK (ritonavir-boosted paritavir/ombitasvir and dasabuvir) associated drug-induced interstitial lung disease: Case series with systematic review Yu Jun WONG, Singapore HCV genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with Glecaprevir and Pibrentasvir Gretja SCHNELL, United States Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience Mahmoud ELZALABANY, Egypt Real-life experience of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin for treatment of HCV-GT4 in Egyptian patients with severe renal impairment Heba OMAR, Egypt The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors Ewa JANCZEWSKA, Poland POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 209

212 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Therapy and resistance (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-332 THU-333 THU-334 THU-335 THU-336 THU-337 THU-338 THU-339 THU-340 THU-341 Characteristics and retreatment of HCV DAA failure patients: Real-life experience Isaac RUIZ, France Concomitant drug use in patients with chronic hepatitis C and change over time: A nationwide population-based register study from 2005 to 2013 Jonas SÖDERHOLM, Sweden Unexpected findings from a large Asian HCV real live study Seng Gee LIM, Singapore A comparison of elbasvir/grazoprevir, ledispasvir/sofosbuvir and velpatisvir/sofosbuvir therapy among people who use drugs (PWUD): real world experience Arshia ALIMOHAMMADI, Canada Real world experience of retreatment of chronic hepatitis C patients who failed IFN-free DAA therapy Karin KOZBIAL, Austria Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina Ezequiel RIDRUEJO, Argentina Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders David BACK, United Kingdom Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia Tengiz TSERTSVADZE, Georgia Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program Tengiz TSERTSVADZE, Georgia AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitisc Xiao-Jian ZHOU, United States 210 EASL THE HOME OF HEPATOLOGY

213 11-15 APRIL 2018 PARIS, FRANCE THU-342 THU-343 THU-344 THU-345 THU-346 THU-347 THU-348 THU-349 Impact of treatment with Elbasvir and Grazoprevir (EBR/GZR) on chronic hepatitis C virus disease specific health related quality of life outcomes in HCV/HIV coinfected patients Chizoba NWANKWO, United States C-EDGE treatment experienced: Effect of 12 week oral regimens of Elbasvir and Grazoprevir on health related quality of life in prior treatment experienced patients with chronic hepatitis C infection infection Chizoba NWANKWO, United States Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in HIV-negative cancer patients with chronic hepatitis C Haley PRITCHARD, United States The real-world safety and efficacy of sofosbuvir plus ribavirin for eldery patients over 75 years of age Hideyuki TAMAI, Japan Sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/ Sofosbuvir or Sofosbuvir/Velpatasvir Sam TRINH, United States Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/ velpatasvir/voxilaprevir: results from the Frankfurt Resistance Database Johannes VERMEHREN, Germany Are patients treated with direct antiviral agents for HCV infection at greater risk for extrahepatic malignancies? Tarek SAADI, Israel Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy Elisabetta TETI, Italy THU-350 Efficacy and safety of direct-acting antivirals for 1,961 Japanese chronic hepatitis C patients Real Word Data from a multicenter cohort Norihiro FURUSYO, Japan THU-351 Adverse reactions of direct-acting antiviral agents in HCV patients: Our experience Diana PADOVANI, Italy POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 211

214 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Therapy and resistance (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-352 THU-353 THU-354 THU-355 THU-356 THU-357 THU-358 THU-359 THU-360 THU-361 A comparison of renal function before and after treatment in chronic hepatitis C patients who achieved sustained viral response with direct acting antivirals Paul FITZMORRIS, United States Fast-track HCV check-up enhances possibility of sustained virologicalresponse in HCV infected patients Teresa ANTONINI, France Grazoprevir/elbasvir dosing according to viral load and NS5A resistance: real world confirmation of the efficacy of EASL guidance Fiona MARRA, United Kingdom Impact of HCV viral load on elbasvir/grazoprevir effectiveness in chronic hepatitis C: Updated retrospective data analyses from the Trio network Steven FLAMM, United States Therapeutic drug monitoring of DAAs overcomes contraindications against anti-epileptics in HCV treatment (HepNed003) Minou VAN SEYEN, Netherlands What impact do the new direct acting antiviral drugs have on the patients quality of life? Marta GENTILI, Italy Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy are all HCV subpopulations treated similarly? Results from the German hepatitis C Cohort Stefan CHRISTENSEN, Germany National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing Valeria CENTO, Italy Genetic diversity of genotype 6 HCV infections in France: epidemiology and consequences for treatment strategy Charlotte PRONIER, France Hepatitis C direct-acting antiviral failures: clinical characteristics and resistance testing from a real-world setting Alnoor RAMJI, Canada 212 EASL THE HOME OF HEPATOLOGY

215 11-15 APRIL 2018 PARIS, FRANCE THU-362 THU-363 THU-364 THU-365 THU-366 THU-367 THU-368 THU-369 THU-370 THU-371 Prevalence of baseline NS5A resistance associated substitutions in treatment naive patients with Genotype 1a or 3 Alnoor RAMJI, Canada Efficacy and safety of glecaprevir/pibrentasvir in renallyimpaired patients with chronic hepatitis C virus genotype 1-6 infection Marcello PERSICO, Italy Multicenter study on outcome of HCV elimination using LDV/ SOF combination in Mongolians Lkhaasuren NEMEKHBAATAR, Mongolia Salvage Treatment of HCV patients by Sofosbuvir, Daclatasvir, Simeprevir and Ribavirin after repeated treatment failures is associated with SVR and reduced risk of hepatocellular carcinoma Amr HANAFY, Egypt Sofosbuvir/Ledipasvir: Efficacy and tolerance in HCV positive patients naïve or pre-treated in Cameroun Serge TCHAMGOUE, Cameroon Hepatitis B virus reactivation during direct-acting antiviral therapy in hepatitis B/C co-infected patients on hemodialysis Chunhua HU, China High efficacy of resistance guided retreatment of Genotype 3 in real life Federico GARCIA GARCIA, Spain Z-PROFILE: Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada Brian CONWAY, Canada Efficacy of Elbasvir-Grazoprevir/Sofosbuvir and Ribavirin in direct acting antiviral therapy failures in pre and post liver transplant patients: A single center experience Hany ELBESHBESHY, Saudi Arabia Real world experience with twelve weeks of therapy without ribavirin in genotype 1 HCV infected compensated cirrhotics Dorota ZAR BSKA-MICHALUK, Poland THU-372 Sofosbuvir-based treatment of viral hepatitis C genotype 3 infection a Polish real-world study Dorota ZAR BSKA-MICHALUK, Poland POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 213

216 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Therapy and resistance (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-373 THU-374 THU-375 THU-376 THU-377 THU-378 THU-379 THU-380 THU-381 Naturally occurring drug resitance substitutions in the NS5A and NS5B regions in Hepatitis C virus genotype 2 and response to sofosbuvir plus ribavirin therapy Kazuhiko HAYASHI, Japan Effectiveness and safety of direct-acting antiviral therapies in chronic hepatitis C infections patients with cirrhosis in Turkey Fehmi TABAK, Prevalence of baseline NS5A resistance associated substitutions in a real world cohort of veterans with chronic genotype 1 HCV infection Sara LEVY, United States Efficacy and safety of sofosbuvir-containing regimen for Korean patients with chronic hepatitis C virus infection: A retrospective, nationwide, real-world study Sook-Hyang JEONG, Korea, Rep. of South Real-life efficacy and safety of daclatasvir and asunaprevir therapy for genotype 1b chronic hepatitis C patients without NS5A resistance-associated substitution: A nationwide study in South Korea Sook-Hyang JEONG, Korea, Rep. of South Genotype 3 Infection in HIV/HCV co-infected subjects in the DAA era: Real life data from the ICONA/HepaICONA Foundation cohorts Roberto ROSSOTTI, Italy Safety and efficacy of Daclatasvir at doses other than 60mg daily in HIV/HCV co-infected subjects: data from the ICONA/ HepaICONA Foundation cohorts Roberto ROSSOTTI, Italy Cost-effectiveness analysis of baseline testing for resistanceassociated polymorphisms to optimise treatment duration in genotype 1 non-cirrhotic treatment-naive patients with chronic hepatitis C virus Christopher FAWSITT, United Kingdom Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multi-center early access program Ramazan IDILMAN, Turkey 214 EASL THE HOME OF HEPATOLOGY

217 11-15 APRIL 2018 PARIS, FRANCE THU-382 THU-383 THU-384 THU-385 THU-386 THU-387 Resistance analysis of hepatitis C virus NS5A gene in Brazilian patients infected with genotypes 1 and 3 treated with Daclatasvir Elisabeth LAMPE, Brazil Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R) Stefan MAUSS, Germany Time to viral suppression does not impact SVR in patients treated with Glecaprevir/Pibrentasvir for 8 weeks Christoph SARRAZIN, Germany Identification, by Cold-PCR, of treatment-resistant HCV mutations in baseline samples of patients treated with DAAs Antonio MADEJÓN, Spain Persistence and risk of transmission of the hepatitis C virus NS5B S282T substitution in a HIV-positive man who has sex with men Astrid NEWSUM, Netherlands On treatment HCV-RNA evaluation in real-life: still a role in the era of direct acting antiviral agents? Francesca CECCHERINI SILBERSTEIN, Italy POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 215

218 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Clinical aspects except therapy THU-389 THU-390 THU-391 Top 10% THU-392 Top 10% Ethnic differences in HCV-related HCC outcomes: Report from the Real-world Evidence by the Asia Pacific Rim Liver Consortium for HCC (REAL-HCC) Debi PRASAD, Changes in the characteristics of hospital admissions due to complications of cirrhosis in the era of direct-acting antivirals against HCV Miguel FRAILE, Spain Validation of a clinical scoring system to predict risk of hepatocellular carcinoma in an ethnically diverse cohort of patients with chronic hepatitis C virus infection Mike Tzuhen WEI, United States Minimal monitoring of direct-acting antiviral therapy within a real world, urban population Sarah KATTAKUZHY, United States POSTERS / THURSDAY 12 APRIL 2018 THU-393 THU-394 THU-395 THU-396 THU-397 THU-398 Improving detection and management of HCV infection in prisons William ROSENBERG, United Kingdom Full analysis of comorbidities in chronic hepatitis C patients compared with matched comparators: A nationwide population-basedregister study from 2001 to 2013 Jonas SÖDERHOLM, Sweden Lower risk of multiple sclerosis in patients with chronic hepatitis C: A nationwide population-based register study Jonas SÖDERHOLM, Sweden A universal offer of blood borne virus testing substantially increases diagnosis and treatment of hepatitis C in prisons Stuart MCPHERSON, United Kingdom Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort Loreta KONDILI, Italy DNA methylation and immune cell markers demonstrate associations of accelerated aging with chronic HCV/HIV coinfection and liver fibrosis Shyamasundaran KOTTILIL, United States 216 EASL THE HOME OF HEPATOLOGY

219 11-15 APRIL 2018 PARIS, FRANCE THU-399 THU-400 THU-401 THU-402 THU-403 THU-404 THU-405 THU-407 THU-408 THU-409 THU-410 Incidence and prevalence of extrahepatic manifestations of HCV Hashem EL-SERAG, United States Changes in hepatic steatosis measured by CAP-fibroscan in patients with chronic hepatitis C treated with direct action antivirals Pedro LINARES, Spain Influence of statines in the modifications of lipid and hydrocarboned metabolism in patients with chronic hepatitis C treated with direct-acting antivirals Pedro LINARES, Spain Changes in serum neurotransmitters are associated with changes in patient reported outcomes and neurocognitive performance in patients with hepatitis C virus-genotype 1 who achieved sustained virologic response Zobair YOUNOSSI, United States Patient-reported outcomes in chronic hepatitis C: The impact of placebo, active treatment, and sustained viral eradication Zobair YOUNOSSI, United States Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia Marianne MARTINELLO, Australia The Rapid-EC study A feasibility study of point-of-care testing in community clinics targeted to people who inject drugs in Melbourne, Australia Bridget WILLIAMS, Australia Evaluation of APRI index to identify cirrhosis prior to directacting antiviral HCV treatment Joseph DOYLE, Australia Hepatitis C treatment success in primary and tertiary care among people with HCV/HIV coinfection Joseph DOYLE, Australia REtrieval and Cure of Hepatitis C patients in the Utrecht province in the Netherlands: REACH Patricia KRACHT, Netherlands Preliminary analysis of the Prime Study; a randomized controlled trial comparing the hepatitis C care cascade in primary care vs. tertiary care Amanda WADE, Australia POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 217

220 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Clinical aspects except therapy (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-411 THU-412 THU-413 THU-414 THU-415 THU-416 THU-417 THU-418 THU-419 Strategic elimination: Efficacy of hepatitis C treatment in people who inject drugs in an urban, underserved clinic in the United States Christian RAMERS, United States Among birth cohort patients with at least one additional hepatitis C virus risk factor, one in eight were positive for HCV antibody: An underserved safety-net population experience Grishma HIRODE, United States Among patients being treated in addiction center, alcohol consumption increases the risk of hepatitis C seroconversion and the severity of hepatic fibrosis in those seropositive for hepatitis C virus Michel DOFFOËL, France Prevalence and clinical characteristics of portal vein thrombosis in HCV related cirrhosis: a cohort of Egyptian patients Omar ELSHAARAWY, Germany Outcomes of an opt-out strategy for Hepatitis C testing in the East Midlands prison estate Kathryn JACK, United Kingdom Evaluation of a hepatitis C virus core antigen assay in driedblood spots: a cohort study Tanya APPLEGATE, Australia Antiviral treatment of hepatitis C improve glucose metabolism along the entire spectrum from normal glucose tolerance to diabetes Sara BIANCO, Italy Lymphomas incidence in HIV/HCV coinfected versus HIV monoinfected patients over twenty-one years of follow up ( ) Álvaro MENA DE CEA, Spain Using hepatitis C viral load distribution data from a global database to derive the optimal limit of detection for a point-ofcare diagnostic test Benjamin LINAS, United States 218 EASL THE HOME OF HEPATOLOGY

221 11-15 APRIL 2018 PARIS, FRANCE THU-420 THU-421 THU-422 THU-423 THU-424 THU-425 THU-426 THU-427 THU-428 THU-429 Early HCV viral kinetics in the setting of transplantation of kidneys from HCV-infected deceased donors into HCV-negative recipients David GOLDBERG, United States Screening for neurocognitive dysfunction in non-cirrhotic chronic hepatitis C infection in an Irish academic unit Damien FERGUSON, Ireland Decrease in blood borne viral infections, liver fibrosis and drug use in a Danish prison population Peer Brehm CHRISTENSEN, Denmark Strong correlation of hepatitis B virus prevalence among Mongolian adults 40 to 65 years old of age with HCC mortality rate: A result from the national general hepatitis screening program Uurtsaikh BAATARSUREN, Mongolia Identification of the fast progression and spontaneous regression liver fibrosis phenotypes by a serological collagen turnover profile Sara Toftegaard HJULER, Denmark Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia Sokchea YANN, Cambodia Screening for hepatitis C at the emergency department: babyboomers should also be screened in Belgium Rob BIELEN, Belgium Factors related to differential HCV therapy success or failure based on clinic location within a single health system: A possible role for increasing access to co-located support services? Jacqueline SHERBUK, United States Use of medications with clinically important drug-drug interactions with direct-acting antivirals for the treatment of chronic hepatitis C infection:focus on ethinyl estradiol and HMG CoA reductase inhibitors Shelby CORMAN, United States Strong increase of acute HCV infections in HIV-negative men having sex with men Laurent COTTE, France POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 219

222 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis C: Clinical aspects except therapy (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-430 THU-431 THU-432 THU-433 THU-434 THU-435 Top 10% THU-436 THU-437 Implementation of a unique hepatitis C care continuum model in a resource limited setting Poonam MATHUR, United States The IL6-174 C/C genotype is associated with high quality of life scores in patients with chronic hepatitis C Luciana DINIZ SILVA, Brazil Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany? Stefan MAUSS, Germany Cost-effectiveness of one-time screening for hepatitis C virus infection in Korean general population Kyung-ah KIM, Korea, Rep. of South Case finding can successfully re-engage persons lost to followup and increase treatment rates in hepatitis C virus services Lynsey CORLESS, United Kingdom Direct acting anti-viral therapy rescues neutrophil dysfunction in hepatitis C infection by reduction of heamolysis Bettina LEBER, Austria Treatment of adolescents genotype 4 chronic HCV infected patients with Ledipasvir/Sofosbuvir combination: a real world experience Dina ATTIA, Egypt Impact of a hepatitis C virus electronic medical record screening alert for baby boomers Robyn TEPLY, United States 220 EASL THE HOME OF HEPATOLOGY

223 11-15 APRIL 2018 PARIS, FRANCE NAFLD: Experimental and pathophysiology THU-441 THU-442 THU-443 Top 10% Stk25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and NAFLD in mice Margit MAHLAPUU, Sweden Decreased circulating peripheral blood mucosal associated invariant T cells is correlated with insulin resistance in patients with nonalcoholic fatty liver disease Johnny AMER, Palestine Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis Sander LEFERE, Belgium THU-444 Top 10% THU-445 Top 10% THU-446 THU-447 THU-448 THU-449 Lipid-induced ASK1 activation in hepatocytes and Kupffer cells mediates the increased vulnerability of fatty liver to Ischemia/ Reperfusion injury in mice Chiara IMARISIO, Italy Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease Serena PELUSI, Italy Neurocognitive dysfunction in NAFLD occurs early and is associated with hyperammonemia, neurotransmitter defects, astroglial and microglial activation Karen Louise THOMSEN, Denmark Metabolomic patterns associated with known genetic variants for hepatic steatosis and non-alcoholic steatohepatitisidentify biomarkers that may be of utility in predicting adverse liver outcomes Jake MANN, United Kingdom Gut barrier dysfunction contributes to the pathological progression of nonalcoholic fatty liver disease induced by high fat diet in mice Jinghua PENG, China Inhibition of IL-1 signaling in hepatocytes retains insulin sensitivity and protects from hepatocellular injury in nonalcoholic fatty liver disease Nadine GEHRKE, Germany POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 221

224 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Experimental and pathophysiology (Cont.) THU-450 Top 10% THU-451 Top 10% Mechanism for hypertriglyceridemia and effect of fibrate coadministration during acetyl-coa carboxylase inhibitor treatment Leigh GOEDEKE, United States Effect of exercise on gut microbiota and metabolic status modulation in an in vivo model of early obesity and NAFLD Sara CARBAJO-PESCADOR, Spain POSTERS / THURSDAY 12 APRIL 2018 THU-452 THU-453 THU-454 THU-455 THU-456 THU-457 THU-458 THU-459 The paracrine effect of viscerala dipose tissue obtained at bariatric surgery on primary human hepatic stellate cells grown in human 3D healthy liver scaffolds Krista ROMBOUTS, United Kingdom Integrative analysis of NGS data highlight a genetic variant in ATG7 gene as a novel risk factor for nonalcoholic fatty liver disease progression Guido Alessandro BASELLI, Italy Effect of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on liver fibrosis Naotaka SHIMOZATO, Japan Efficacy of statins for the treatment of non-alcoholic steatohepatitis with mild portal hypertension Miren BRAVO, Spain Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis Patrick R. SHEA, United States Nicotine enhances lipid accumulation and lipotoxicity in hepatocytes via suppression of autophagy Shunhei YAMASHINA, Japan Involvement of the CREB-E2F2-PPAR axis in nonalcoholic fatty liver disease development and progression to hepatocarcinoma Patricia ASPICHUETA, Spain Akkermansia spp. mediates protection from obesity-associated NAFLD development in germ free mice following intestinal microbiota transplantation from high fat diet and quercetin treated donors David PORRAS, Spain 222 EASL THE HOME OF HEPATOLOGY

225 11-15 APRIL 2018 PARIS, FRANCE THU-460 THU-461 THU-462 THU-463 THU-464 THU-465 THU-466 THU-467 THU-468 THU-469 THU-470 Bile acid composition modulate insulin resistance in nondiabetic patients with NAFLD Chiara ROSSO, Italy Pharmacological inhibition of the medium chain fatty acid receptor GPR84 reduces myeloid cell in filtration into injured liver and ameliorates steatohepatitis and fibrosis Tobias PUENGEL, Germany Non-alcoholic steatohepatitis impairs Kupffercell-mediated immune tolerance in the mouse liver Stéphanie LACOTTE, Switzerland BCAA and ER stress activate SREBP-1c cleavage and hepatic lipogenesis through mtor Franck PHAN, France The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease Olivier GOVAERE, United Kingdom BAFF neutralization ameliorates the evolution of experimental NASH Salvatore SUTTI, Italy The multifactorial pathogenesis of nonalcoholic fatty liver disease: connecting inflammation and oxidation Fedra LUCIANO-MATEO, Spain Expression of the chemokine CCL24 and its receptor in the sera and livers of patients with non-alcoholic fatty liver disease Yaakov MAOR, Israel LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis Bryan LAFFITTE, United States EDP-305 modulates lipoprotein metabolism via distinct chromatin and microrna regulatory mechanisms Lijuan JIANG, United States CXCL16 promotes hepatocyte steatosis and fibrosis in nonalcoholic fatty liver disease via hepatocyte-stellate cell crosstalk Lina JIANG, China POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 223

226 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Experimental and pathophysiology (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-471 THU-472 THU-473 THU-474 THU-475 THU-477 THU-478 THU-479 THU-480 THU-481 THU-482 Inhibition of IL6 trans-signaling leads to NAFLD, matureonset obesity and metabolic syndrome Tali LANTON, Israel Genetic and functional analysis of FGF21 in NAFLD/NASH Rocío GALLEGO-DURÁN, Spain Divergent effects of RIP3 and MLKL inhibition on HF diet induced steatosis Waqar SAEED, Korea, Rep. of South Micro RNA 199a-3p attenuates hepatic lipogenesis through regulating specific protein 1 Yang CHENG, China RIPK1 depletion exacerbates progression of liver fibrosis in high fat diet induced non-alcoholic steatohepatitis (NASH) in mice Jacques LE SEYEC, Clinical-grade human liver mesenchymal stem cells reduce NAS score and fibrosis progression in advanced stage NASH pre-clinical model through immunomodulation Maria Mercedes BINDA, Belgium Ablation of Interleukin-4 Receptor alpha in macrophages ameliorated steatohepatitis and fibrosis in murine model of non alcoholic steatohepatitis (NASH) Muhammad ASHFAQ-KHAN, Germany Combined administration of obeticholic acid (OCA) and GFT- 505: additive histological improvements in mice with dietinduced and biopsy-confirmed non-alcoholic steatohepatitis (NASH) Jonathan ROTH, United States Evaluation of the rodent Octodon degus as a pre-clinical model of liver fibrosis Sarah BROCKBANK, Germany Impact of proprotein convertase subtilisin/kexin type 7 genetic variation in patients with non-alcoholic fatty liver disease Paola DONGIOVANNI, Italy Expression profiling of 728 mirnas in a NASH model identifies excellent correlations of hepatic and circulation mir-34a levels with histological lesions in rats and men Remy HANF, France 224 EASL THE HOME OF HEPATOLOGY

227 11-15 APRIL 2018 PARIS, FRANCE THU-483 THU-484 THU-485 THU-486 THU-487 THU-488 THU-489 THU-490 THU-491 THU-492 THU-493 Discovery of inhibitors of NLRP3 inflammasome assembly for the treatment of NASH and liver fibrosis Davide POVERO, United States Four-and-a-half LIM-domain protein affects diet induced (hepatic) steatosis and lipid droplet formation Judith SOMMER, Germany Hepatic effects of NS-0200 (Leucine-Metformin-Sildenafil) in an obese mouse model of diet-induced and biopsy-confirmed NASH Michael ZEMEL, United States Comorbidity-specific augmented hepatic injury in a murine model of obesity-induced NAFLD and peritoneal sepsis Paul HORN, Germany The anti-inflammatory and anto-fibrogenic effects of namodenoson in NAFLD/NASH animal models Shira COHEN, Israel Histopathologic assessment of fatty liver progression in a rodent model of chronic intake of high-fat diet, ethanol or both Carolina GUZMAN, Mexico Nicotinamide, not N1 methylnicotinamide, ameliorates hepatic steatosis via NAD-depended sirtuin activation Shusuke MORIZONO, Japan Elafibranor and obeticholic acid differentially alter NASH and lipid metabolism in diet-induced NASH mouse and hamster models Francois BRIAND, France Characterization of ASK1 signaling in human NASH liver and human hepatic stellate cells Grant BUDAS, United States CD4+ RORgt+ T cells, CD4+ T-bet+ T cells, CD4+ CD25+ Foxp3+ T cells and CD8+ T cells are differentially altered in liver and adipose tissue of mice fed a high-fat high-fructose diet in a time-dependent manner Mikhail VAN HERCK, Belgium Treatment with the Adra2a antagonist, Yohimbine, reduces fibrosis progression and liver inflammation in a NASH fibrosis rat Helen JONES, United Kingdom POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 225

228 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Experimental and pathophysiology (Cont.) POSTERS / THURSDAY 12 APRIL 2018 THU-494 THU-495 THU-496 THU-497 THU-498 THU-499 THU-500 THU-501 THU-502 THU-503 THU-504 THU-505 Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model Robert WALCZAK, France LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse model Claus KREMOSER, Germany Maternal obesity programs offspring s liver immune cells intra-uterine Jude A. OBEN, United Kingdom Elafibranor restores lipogenic gene expression in a human skin stem cell-derived non-alcoholic fatty liver disease (NAFLD) model Joost BOECKMANS, Belgium The interplay between liver and muscle begins much earlier than cirrhosis. A diet-induced animal model Francesca Maria TROVATO, Italy Hyperreactivity to vasoconstrictors in a rat model of nonalcoholic fatty liver disease Denise VAN DER GRAAFF, Belgium Role of mitofusin-2 in NAFLD and targeting by mirnas André SIMÃO, Portugal Diseased human 3D microtissues as building blocks for complex metabolic in-vitro systems Radina KOSTADINOVA, Switzerland A novel microtissue-based 3D human liver NASH model for drug discovery Radina KOSTADINOVA, Switzerland Modeling NAFLD using 3D bioprinted human liver tissue Dwayne CARTER, United States The changing profile of extracellular vesicles in non-alcoholic fatty liver disease progression and their role in signalling to hepatocytes Linda BAN, Australia RIP3-dependent signalling contributes to non-alcoholic fatty liver disease-related hepatocarcinogenesis Marta B. AFONSO, Portugal 226 EASL THE HOME OF HEPATOLOGY

229 11-15 APRIL 2018 PARIS, FRANCE THU-506 THU-507 THU-508 THU-509 THU-510 THU-511 THU-512 THU-513 THU-514 THU-515 THU-516 THU-517 NAFLD in HIV mono-infection is a consequence of insulin resistance but not bacterial translocation James MAURICE, United Kingdom Hepatic steatosis potentiates irinotecan-induced hepatocellular injury via dysregulation of irinotecan-metabolizing enzymes Abdo MAHLI, Germany Glutaminase 1 targeting in non-alcoholic steatohepatitis Jorge SIMÓN, Spain Epigenetic modification ofurea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches Francesco DE CHIARA, United Kingdom Ammonia: A novel target for the prevention of NAFLD progression in NASH Francesco DE CHIARA, United Kingdom During aging osteopontin deficiency increases vulnerability to non-alcoholic fatty liver disease progression and the associated extrahepatic metabolic complications Beatriz GÓMEZ SANTOS, Spain Discovery and validation of new modulators of necroptosis using phenotypic high throughput screening of a large compound library Hugo Miguel de Sousa BRITO, Portugal Pharmacological inhibition of myeloperoxidase attenuates nonalcoholic steatohepatitis-induced liver fibrosis in mice Anja KOOP, Germany Angiopoietin-like protein 8 is a novel vitamin D receptortargeted lipogenic gene associated with non-alcoholic fatty liver Carmelo GARCÍA-MONZÓN, The liver-specific deletion of the respiratory chain inhibitor MCJ attenuates NAFLD progression by enhancing hepatic betaoxidation María Luz MARTÍNEZ-CHANTAR, Spain Targeting the NAFLD metabolome and the shaping of precision medicine for patients with NASH Marta IRUARRIZAGA-LEJARRETA, Spain The pathophysiological significance of nerve growth factor in non-alcoholic fatty liver disease via FXR upregulation Ming-Shian TSAI, Taiwan POSTERS / THURSDAY 12 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 227

230 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Experimental and pathophysiology (Cont.) THU-518 THU-519 THU-520 THU-521 Modulation of the NLRP3 inflammasome pathway mediates the anti-inflammatory action of indoleamine dioxygenase in experimental NASH Benedetta PIOMBANTI, Italy The role of dendritic cells in different stages of non-alcoholic fatty liver disease Nahúm MÉNDEZ, Mexico Evolving alterations of hepatic macrophage population in the disease progression of non-alcoholic ateatohepatitis in a mouse model Xiaotang ZHOU, China Partial hepatectomy and hemodynamics: insights from numerical modeling on vascular response Irene VIGNON-CLEMENTEL, France POSTERS / THURSDAY 12 APRIL EASL THE HOME OF HEPATOLOGY

231 11-15 APRIL 2018 PARIS, FRANCE POSTERS FRIDAY 13 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

232 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Nurses research in Hepatology POSTERS / FRIDAY 13 APRIL 2018 FRI-001 FRI-002 FRI-003 FRI-004 FRI-005 FRI-006 FRI-007 FRI-008 FRI-009 A six month follow-up study to determine the clinical utility and patient acceptability of fibroelastography in detection and treatment of alcohol-related liver disease Lynn OWENS, United Kingdom Pilot study: evaluation of the role of the coordinating nurse in the management of patients with hepatocellular carcinoma and treated with chemoembolization Julie DEVICTOR, France Patient education results in better sustained virological response to anti-viral therapy in a high number of patients with chronic hepatitis C than conventional care François HABERSETZER, France Reliability and validity study of the Turkish version of the chronic liver disease questionnaire Ferya CELIK, Turkey Using healthcare professionals views to update and improve the Royal College of Nursing Caring for people with liver disease: a competence framework to deliver quality person centred care Lynda GREENSLADE, United Kingdom Hepatitis C treatment in prisons through a nurse-led program with telemedicine Annika OLSSON, Sweden Comparison of different models of nursing care delivery in the management of hepatitis C treatment among people who inject drugs Giovanna RUDEL, Switzerland Is the presence of fat and fibrosis a higher mortality risk factor versus cardiovascular disease? Anna Marie HEFNER, United States Nurse-led clinic for liver cirrhotic patients: Effects on healthrelated quality of life Maria HJORTH, Sweden 230 EASL THE HOME OF HEPATOLOGY

233 11-15 APRIL 2018 PARIS, FRANCE Liver transplantation and hepatobiliary surgery: Clinical aspects FRI-016 FRI-017 FRI-018 Top 10% FRI-019 FRI-020 FRI-021 FRI-022 FRI-023 FRI-024 FRI-025 Outcomes of liver transplantation in patients with nonalcoholic steatohepatitis: high recurrence rate in ultrasound and transientelastography Ahad ESHRAGHIAN, Iran Can liver transplantation or hepatic resection achieve cure for hepatocellular carcinoma? Carlo SPOSITO, Italy Alcoholic liver disease surpasses hepatitis C virus in 2016 to become the leading indication for liver transplantation among adults without hepatocellular carcinoma in the United States Jennifer WANG, United States Among adults with hepatocellular carcinoma awaiting liver transplantation, Asians, Hispanics, and patients with nonalcoholic steatohepatitis have disproportionately lower likelihood of receiving liver transplantation Jennifer WANG, United States Risk factors for dropout from the liver transplant waiting list under locoregional treatment Han Ah LEE, Korea, Rep. of South Outcome of liver grafts procured from hepatitis C-positive donors in the era of direct-acting antiviral drugs: a preliminary single centre experience Silvia MARTINI, Italy Preemptive direct-acting antiviral therapy in naive or NS5Arelapser liver transplant recipients: a single centre experience Silvia MARTINI, Italy Donor-specific anti-hla antibodies are not associated with non-anastomotic biliary strictures, but both are independent risk factors for graft loss after liver transplantation Bart VAN HOEK, Netherlands Short-term suvival after liver transplantation depends on the matching of graft and recipient caracteristics Cyrille FERAY, France Rescue allocationin the french nationwide liver graft cohort Cyrille FERAY, France POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 231

234 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-026 FRI-027 FRI-028 FRI-029 Role of interventional radiology in the scenario of liver transplantation Michael Bernhard PITTON, Germany Incidence of waitlist removal and transplantation rates are similar in NASH, cryptogenic and autoimmune hepatitis cirrhosis Paul J. THULUVATH, United States Liver transplant waitlist mortality, transplantation rates and post-liver transplant outcomes in Hispanics Paul J. THULUVATH, United States Pretransplant Karnofsky Performance Status is an independent predictor of post-liver transplant survival Paul J. THULUVATH, United States FRI-030 Survival benefit of liver transplantation in Catalonia: A FRI-031 FRI-032 FRI-033 FRI-034 FRI-035 analysis Julissa LOMBARDO, Spain The survival benefit of hepatic resection in advanced cases for intrahepatic cholangio carcinoma: a surveillance, epidemiology and end results (SEER) analysis Mohamed MOUSTAFA, Italy A nomogram with sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant patients: a competing risk analysis in a national cohort Jeroen VAN VUGT, Netherlands Tacrolimus cumulative exposure after liver transplantation is associated with a progressive derangement of renal function despite routine dose adjustments Manuel RODRÍGUEZ-PERÁLVAREZ, Spain Evolution and impact of obesity in patients on the liver transplant waiting list Guillaume LASSAILLY, France A beneficial weekend effect? Weekend liver transplantation isassociated with reduced graft and transplant failure Neil HALLIDAY, United Kingdom 232 EASL THE HOME OF HEPATOLOGY

235 11-15 APRIL 2018 PARIS, FRANCE FRI-036 FRI-037 FRI-038 FRI-039 FRI-040 FRI-041 FRI-042 FRI-043 FRI-044 FRI-045 FRI-046 Long-term post-transplant liver biopsies of children: Central perivenulitis is associated with circulating donor-specific antibodies and tissue C4d deposition Lara NEVES SOUZA, United Kingdom DAA therapy improves early post-liver transplant survival and induces significant changes in wait-list composition Gonzalo CRESPO, Spain Long-term subclinical inflammatory lessions in liver transplant recipients Maria-Carlota LONDOÑO, Spain Utility of FDG-PET/CT in pre-transplantation workup of the potential liver recipient with hepatocellular carcinoma Sang Young, Korea, Rep. of South Long-term outcome of donor biliary complications following living donor liver transplantation Hyun Young WOO, Korea, Rep. of South Impact of surgical margin according to AFP ratebefore hepatectomy for hepatocellular carcinoma Eric VIBERT, France Upper limb lean mass by Dual Energy Xray Absorptiometry is associated with increased mortality in men with advanced cirrhosis Marie SINCLAIR, Australia MELD dynamics predicts waitlist outcomes in patients awaiting liver transplantation Bo Hyun KIM, Korea, Rep. of South Effects of liver transplantation (LTx) on health-related quality of life (HRQoL) in patients with PBC Marcin KRAWCZYK, Germany Filamin aexpression predicts early recurrence of hepatocellular carcinoma Ana LLEO, Italy Patients with 18F-FDG PET-positive hepatocellular carcinoma and elevated values of alpha-fetoprotein and C-reactive protein have an extraordinary high risk of tumor recurrence following liver transplantation Arno KORNBERG, Germany POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 233

236 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-047 FRI-048 FRI-049 FRI-050 FRI-051 FRI-052 FRI-053 FRI-054 FRI-055 FRI-056 FRI-057 FRI-058 Multi-frequency bioelectrical impedance output correlates to liver disease severity, nutritional status and functional capacity Jane FOO, United Kingdom Pregnancy outcomes and reproductive health after liver transplantation Christina LINDENMEYER, United States Is a telehealth-to-home group lifestyle intervention a feasible and safe option for specialist liver clinics? Ingrid HICKMAN, Australia Pre-liver transplant visceral adipose tissue predicts the early development of metabolic syndrome post transplant Aidan WOODWARD, Australia Follow-up of non-hla and anti-hla antibodies: importance in graft failure after liver transplantation Speranta IACOB, Romania CXCL9 and CXCL10 gene polymorphisms are associated with earlier onset of acute cellular rejection after liver transplantation Ana OSTOJIC, Croatia Post-transplantation outcomes in cirrhosis secondary to granulomatous liver diseases Avesh THULUVATH, United States The effect of immunosuppression on coagulation in patients after liver transplantation Sotiria BEDRELI, Germany 99mTechnetium-MebrofeninHepatobiliary Scintigraphy predicts portal hypertension in Child-Pugh Acirrhosis Thiery CHAPELLE, Belgium Chronic rejectionin children: risk factors, diagnosis and outcome Tamir MILOH, United States Hyperglycemia-triggered S1P-S1PR3 signaling worsens liver ischemia/reperfusion injury by regulating M1/M2 polarization Jianhua RAO, China Stabilization of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival Peter HUEBENER, Germany 234 EASL THE HOME OF HEPATOLOGY

237 11-15 APRIL 2018 PARIS, FRANCE FRI-059 FRI-060 FRI-061 FRI-062 High mortality after liver transplantation for cirrhotic patients with previous spontaneous peritonitis occurring within one year prior to transplantation Mayada ELNEGOULY, Germany Sofosbuvir-based antiviral therapy in patients with HCV recurrent infection after liver transplant had a high rate of SVR but can be a trigger to a graft rejection Mario Reis ÁLVARES-DA-SILVA, Brazil Donor liver small droplet macrovesicular steatosis is associated with reduced graft survival after liver transplantation Flaminia FERRI, Italy Liver transplantation in HIV patients: a descriptive cohort study Sara CASTELO BRANCO, Portugal POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 235

238 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Fibrosis FRI-063 FRI-064 FRI-065 FRI-066 FRI-067 Top 10% Functional relevance and pro-fibrogenic properties of Mucosal- Associated invariant T cells(mait) during chronic liver diseases Pushpa HEGDE, France Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of nonalcoholic steatohepatitis Bradley ZINKER, United States Cholesterol-mediated expression of ganglioside GD3 acetylation contributes to liver fibrogenesis M. Carmen GARCIA-RUIZ, Spain Inducible ablation of TGFß receptor type 2 limited to hepatic stellate cells potently inhibits liver fibrosis and attenuates inflamation Olena MOLOKANOVA, Germany Caspase-8 is a gender-specific modulator of chronic cholestatic liver disease in female Mdr2 knockout mice Julia JUNG, Germany POSTERS / FRIDAY 13 APRIL 2018 FRI-068 FRI-069 Top 10% FRI-070 FRI-071 FRI-072 Novel pro-fibrotic properties of macrophage migration inhibitory factor in non-alcoholic steatohepatitis is associated with a shift in natural killer T cell populations Daniel HEINRICHS, Germany High density lipoproteins production induced by selective intestinal LXR activation protects against the progression of liver injury by shifting M1 to M2 Kupffer cell phenotype Irene PIERANTONELLI, Italy Increased expression of pregnancy-associated plasma protein-a in activated hepatic stellate cells is a potential therapeutic target and serum marker of hepatic fibrosis Kim FREESE, Germany Oncostatin M regulates the role of macrophage during progression and resolution of hepatic fibrosis Michitaka MATSUDA, Japan Selective NDRP1 E3 ubiquitin ligase overexpression in inflammatory macrophages using functionalized carbon nanoparticles promotes fibrosis regression in cirrhotic mice Pedro MELGAR-LESMES, Spain 236 EASL THE HOME OF HEPATOLOGY

239 11-15 APRIL 2018 PARIS, FRANCE FRI-073 FRI-074 FRI-075 FRI-076 FRI-077 FRI-078 FRI-079 FRI-080 FRI-081 FRI-082 FRI-083 Platelet c-type lectin-like receptor reduces cholestatic liver injury in mice Suguru MARUYAMA, Japan AXL increase in NASH patients and anti-fibrotic efficacy of AXL inhibition in experimental NASH Anna TUTUSAUS, Spain Platelet-derived growth factor receptor alpha deprived hepatocytes attenuate thioacetamide induced liver fibrosis in mice Jung IL LEE, Korea, Rep. of South Platelet deactivationattenuates CCL4 induced liver fibrosis progression in mice Adil BHAT, India Combination of an FXR agonist and an ACC inhibitor increases anti-fibrotic efficacy in rodent models of NASH Jamie BATES, United States Non-invasive phenotypingof hepatic fibrosis using unsupervised machine learning Yuta NAKANO, France BMS , a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and Pro-C3 in a mouse model of non-alcoholic steatohepatitis Yi LUO, United States Human amnion epithelial cells reduce liver fibrosis via effects on macrophages phenotype and liver progenitor cells in murine liver injury Majid ALHOMRANI, Australia Stimulation of soluble guanylate cyclase inhibited fibrosis and inflammation in human liver microtissues and in an animal model of liver disease Katherine HALL, United States Zoledronic Acid suppresses tumour associated macrophages andmyeloid derived suppressor cells in murine HCC Misbah ASLAM, Germany Rapamycin and Zoledronic acid exert a potent antifibrotic effect in murine biliary fibrosis Misbah ASLAM, Germany POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 237

240 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Fibrosis (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-084 FRI-085 FRI-086 FRI-087 FRI-088 FRI-089 FRI-090 FRI-091 FRI-092 FRI-093 EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo Lijuan JIANG, United States Fibrosis involves increased fibroblast and hepatocyte collagen species, reflecting the interstitial and basement membrane matrix: Restoration of the local tissue milieu with FXR agonism Jonathan ROTH, United States Possible liver regeneration and anti-fibrogenic effect of NOTCH1 selective inhibitor in the diseased liver model Mitsuteru KITADE, Japan ACC inhibitor demonstrates potent anti-fibrotic activity in vitro and in vivo Jamie BATES, United States During the progression of liver fibrosis, myofibroblasts develop endoplasmic reticulum stress that both decreases their proliferation and increases their pro-angiogenic activity Axelle CADORET, France The antiretroviral rilpivirine induces hepatic regeneration in liver fibrosis and cirrhosis by modulating the STAT3/STAT1 balance Alberto MARTÍ-RODRIGO, Spain Performance of quantitative collagen parameters for assessing longitudinal non-advanced liver fibrosis Yan WANG, China RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease Divya RAMNATH, Australia Interference of PTTG1 mrna dramatically reduces portal hypertension and liver fibrosis in fibrotic rats Silvia CARVAJAL RESTOY, Spain Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C Chiara MAZZARELLI, Italy 238 EASL THE HOME OF HEPATOLOGY

241 11-15 APRIL 2018 PARIS, FRANCE FRI-094 FRI-095 FRI-096 FRI-097 FRI-098 FRI-099 FRI-100 FRI-101 FRI-102 FRI-103 FRI-104 SWAVE: Steady State Shear Wave Elastography for Fibrosis Evaluation in Liver Disease Caitlin SCHNEIDER, Canada A PEGylated fibroblast growth factor 21 variant improves hepatic steatosis in a mouse model of non-alcoholic steatohepatitis, as determined by magnetic resonance imagingderived hepatic fat-fraction Haiying TANG, United States AGAP2, a new player in TGF-beta signalling Amaia NAVARRO-CORCUERA, United Kingdom Role of the interleukin 15/macrophage axis in the immune response of liver fibrosis Maiju MYLLYS, Germany Establishment of an ex vivo model of human fibrotic liver slices culture: characterization of intrahepatic immune cells and TH17 cytokines Daria KARTASHEVA, France Endocannabinoid system contributes to activation of neutrophils in mouse chronic liver injury Liying LI, China Exosomes secreted by the hepatocytes can inhibit and reverse hepatic stellate cells stimulation Michal SAFRAN, Israel The anti-fibrotic effect of Aramchol on rat liver fibrosis induced by TAA and in vitro on primary hepatic stellate cells Shimon REIF, Israel 25(OH) D3 alleviate liver NK cytotoxicity in early but not in late fibrosis model of Balb/c mice due to modulations in vitamin D receptor Johnny AMER, Israel Role of the protein tyrosine kinase Mer (MerTK) in the crosstalk between macrophages and hepatic stellate cells Mirella PASTORE, Italy PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model François SARRA-BOURNET, Canada POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 239

242 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Fibrosis (Cont.) FRI-105 FRI-106 FRI-107 FRI-108 The wrong or right effects of HCV on cardiac function in patients with low-mild liver fibrosis: a case-control study Andrea DALBENI, Italy BMS , a PEGylated fibroblast growth factor 21 analogue for the treatment of non-alcoholic steatohepatitis: A population pharmacokinetics and exposure-response analysis Giridhar TIRUCHERAI, United States Primary human HSC cell phenotype is differently regulated by pro-fibrogenic and pro-inflammatory stimuli in cirrhotic andhealthy human liver 3D ECM scaffolds Krista ROMBOUTS, United Kingdom Integrin αvβ6-targeted near-infrared/positron emission tomography contrast agent for liver fibrosis imaging Yong Ook KIM, Germany POSTERS / FRIDAY 13 APRIL EASL THE HOME OF HEPATOLOGY

243 11-15 APRIL 2018 PARIS, FRANCE Liver development, physiology and regeneration FRI-111 FRI-112 Top 10% Glycosyltransferase GLT25D2 acts as a negative regulator of autophagy to promote acetaminophen-induced hepatotoxicity Feng REN, China Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases Stefaan VERHULST, Belgium FRI-113 FRI-114 FRI-115 FRI-116 FRI-117 FRI-118 FRI-119 FRI-120 FRI-121 FRI-122 Osteopontin might be a central regulator of inflammation during postoperative liver regeneration in humans David PEREYRA, Austria Obeticholic acid improves fetal hypercholanaemia during cholestatic gestation Vanessa PATAIA, United Kingdom In vivo functional genetics for liver regeneration and disease Viktoriia IAKOVLEVA, Singapore Differentiation of human pluripotent stem cells into hepatocytes is more efficient in spheroids than in 2D culture Messina ANTONIETTA, France Hepatic autophagy potentiates ureagenesis and its enhancement protects against acute and chronic hyperammonemia Leandro SORIA, Italy lkb1 inhibits the hepatic gluconeogenis by impeding the availability of amino acids Sara CHARAWI, France Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells Diego CALABRESE, Switzerland Mechanisms of action of cortisol in steatotic and non-steatotic livers subjected to partial hepatectomy with vascular occlusion Esther BUJALDON, Spain Double resin casting micro computed tomography (DUCT) of biliary and vascular system Simona HANKEOVA, Sweden Human skin-derived precusor cells: a potential source for cellular therapy of the liver Joery DE KOCK, Belgium POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 241

244 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver development, physiology and regeneration (Cont.) FRI-123 FRI-124 PRMT5 deficiency results in liver abnormalities and impairs liver regenerationfollowing partial hepatectomy Ying Xim TAN, Singapore Bile duct organogenesis using ECM micropatterning Mazari-Arrighi ELSA, France POSTERS / FRIDAY 13 APRIL EASL THE HOME OF HEPATOLOGY

245 11-15 APRIL 2018 PARIS, FRANCE Liver tumours: Clinical aspects except therapy FRI-127 FRI-128 FRI-129 Top 10% FRI-130 FRI-131 Top 10% FRI-132 FRI-133 FRI-134 FRI-135 While hepatocellular carcinoma (HCC) has become the leading indication for liver transplantation in the United States, the probability of receiving liver transplantation among adults with HCC has rapidly declined Jennifer WANG, United States Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer Thierry POYNARD, France Contrast-enhanced ultrasound for non-invasive diagnosis of hepatocellular carcinoma: a comparison between CEUS LI- RADS and ESCULAP criteria in a large high-risk cohort of patients Antonio SAVIANO, France Tumour progression and recurrence after direct acting antiviral therapy for hepatitis C in patients with previously treated or active hepatocellular carcinoma Simone STRASSER, Australia Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using 18F-FDGPET and CYFRA 21-1 Takayuki KAWAI, Japan Hepatocellular carcinoma (HCC) after direct-acting antivirals (DAA) does not show differences at diagnosis compared with HCC after IFN-based treatments. Results of a national HCC registry in Spain Carlos RODRÍGUEZ DE LOPE, Spain Regression of fibrosis stage after treatment in patients with HFE haemochromatosis and severe fibrosis at diagnosis: relevance to hepatocellular carcinoma Edouard BARDOU-JACQUET, France Nonalcoholic fatty liver disease is the most common cause of hepatocellular carcinoma (HCC) in individuals without cirrhosis: A United States multicenter study Andrew DELEMOS, United States Clinical effectiveness of enhanced surveillance in super-high risk cirrhotics as evaluated in the ITA.LI.CA. Study Group Filippo PELIZZARO, Italy POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 243

246 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Clinical aspects except therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-136 FRI-137 FRI-138 FRI-139 FRI-140 FRI-141 FRI-142 FRI-143 FRI-144 FRI-145 FRI-146 Patterns of glutamine synthetase expression as marker of beta catenin activation in hepatocellular adenomas Christine SEMPOUX, Switzerland Usefulness of newly proposed albumin-bilirubin grade and its modification -Japan nationwide survey Atsushi HIRAOKA, Japan Serological diagnosis of early HCC in NASH: A German multicenter study Jan BEST, Germany Deviations of the immune cell lanscape between healthy liver and hepatocellular carcinoma Nataliya ROHR-UDILOVA, Austria Subcutaneous adipose tissue is a predictor of survival in patients with hepatocellular carcinoma Leona VON KOECKRITZ, Switzerland Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance Julien CALDERARO, France Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20 year experience from a national programme Ibrahim HASSAN, New Zealand Prospective evaluation of gadoxetic-acid MR for the noninvasive diagnosis of hepatocellular carcinoma in newly detected nodules <=2 cm in cirrhotic patients Alejandro FORNER, Spain Risk of early de-novo hepatocellular carcinoma (HCC) in patients with genotype-1b HCV compensated cirrhosis treated with 3 direct-acting antivirals (DAAs) a real life, multicenter study Cristina-Maria MUZICA, Romania Incidence of HCC in TIPS bearing cirrhotic patients José Manuel GARCIA-ORTIZ, Spain Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection Ana LLEO, Italy 244 EASL THE HOME OF HEPATOLOGY

247 11-15 APRIL 2018 PARIS, FRANCE FRI-147 FRI-148 FRI-149 FRI-150 FRI-151 FRI-152 FRI-153 FRI-154 FRI-155 FRI-156 FRI-157 Clinical correlates of the genetic variability of the CD274 gene (Programmed Cell Death-Ligand 1) among patients with hepatocellular carcinoma Federico DAFFARA, Italy Gp38+ hepatic progenitor cell-derived large extracellular vesicles in biliary cancers a novel liquid biopsy marker? Sabine URBAN, Germany Recommendations for the management of women with suspected hepatocellular adenoma and childbearing potential Marcia GASPERSZ, Netherlands Preoperative van Willebrand factor is a predictor for early recurrence and overall survival in patients undergoing liver resection for oncological entities Patrick STARLINGER, Austria Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2007 Soon Sun KIM, Korea, Rep. of South The validity of serum midkine, dickkopf-1 and alpha-lfucosidase as surrogate biomarkers for the diagnosis of hepatocellular carcinoma Mariam ZAGHLOUL, Egypt The impact of platelets on patients with hepatocellular carcinoma Bernhard SCHEINER, Austria Proton pump inhibitors and risk of hepatocellular carcinoma: a population-based study Wei-Yu KAO, Taiwan Virologic control increased overall survival after radiofrequency ablation of hepatocellular carcinoma developed on hepatitis related cirrhosis Manon ALLAIRE, France Clinical and biological features according to fibrosis of HBV related HCC in a Western country Manon ALLAIRE, France HIV infection adversely influences the natural history of untreated hepatocellular carcinoma (HCC) David James PINATO, United Kingdom POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 245

248 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Clinical aspects except therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-158 FRI-159 FRI-160 FRI-161 FRI-162 FRI-163 FRI-164 FRI-165 FRI-166 FRI-167 Factors implicated in the risk of developing hepatocellular carcinoma in patients with cirrhosis due to HCV. Implications of Sustained Virological Response Andres CASTAÑO, Spain Increased intestinal permeability and inflammation are associated with hepatocellular carcinoma in patients with NAFLD-related liver cirrhosis Francesca PONZIANI, Italy Towards elucidating a universal panel of diagnostic biomarkers for early hepatocellular carcinoma Abellona U, United Kingdom Presence of steatosis does not increase the risk of Hepatocellular Carcinoma in patients with Chronic Hepatitis B over long follow-up CHONG TEIK LIM, Singapore Sarcopenia is not a predictor of survival or sorafenib toxicity in advanced hepatocellular carcinoma: A Dutch multicenter study Tim LABEUR, Netherlands The direct comparison between 7th AJCC staging system and 8th AJCC staging system for prediction of survival with Korean multicenter HCC patients Young-Sun LEE, Korea, Rep. of South Serum and urine extracellular vesicles contain mrna biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA) Ander ARBELAIZ, Spain Age and not comorbidity determines access to liver transplantation of patient with hepatocellular carcinoma Alberto LUÉ, Spain Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in single patients with cirrhosis undergoing surveillance for hepatocellular carcinoma Gabriele RICCO, Italy Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a validation study of the HAP and SAP scores Francesco TOVOLI, Italy 246 EASL THE HOME OF HEPATOLOGY

249 11-15 APRIL 2018 PARIS, FRANCE FRI-168 FRI-169 FRI-170 FRI-171 FRI-172 FRI-173 FRI-174 FRI-175 FRI-176 FRI-177 CD44 rs gene polymorphism in cirrhotic hepatitis C patients with hepatocellular carcinoma Nermeen ABDEEN, Egypt Hepatocellular carcinoma as second primary malignancy: exposing an overlooked presentation of liver cancer Harrys TORRES, United States Adherence to enhanced post-treatment surveillance is associated with increased detection of early stage recurrence after radiofrequency ablation but not surgical management of hepatocellular carcinoma Yin CHAN, Canada Hepatocellular carcinoma: pretreatment computed tomography texture analysis as an independent predictor of survival after surgical resection Lucie BRENET DEFOUR, France Particularities of hepatocellular carcinoma on chronic hepatitis C in the era of all- oral antiviral treatment Elena Laura ILIESCU, Romania Short-term evaluation of hepatocellular carcinoma after locoregional treatment: usefulness of contrast-enhanced ultrasonography Giulia GIBIINO, Italy Performance of Wisteria floribunda agglutinin-positive Mac2- binding protein as an HCC biomarker in an ethnically diverse cohort of patients with chronic HBV and HCV Tomi JUN, United States A functional ATG16L1 (T300A) gene variant is associated with increased risk for hepatocellular carcinoma in cirrhosis Philipp REUKEN, Germany Serial changesin alpha-fetoprotein, lectin-bound alphafetoprotein and Des-r-Carboxy prothrombinin prospectively collected serum samples before the diagnosis of hepatocellular carcinoma Jonggi CHOI, Korea, Rep. of South Sphingolipids: a further step into the detection of early and intermediate hepatocellular carcinoma Iuliana NENU, Romania POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 247

250 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Clinical aspects except therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-178 FRI-180 FRI-181 FRI-182 FRI-183 FRI-184 FRI-185 FRI-186 FRI-187 FRI-188 A high alpha-fetoprotein slope prior to therapy correlates with poor prognosis of patients with hepatocellular carcinomas Carolin CZAUDERNA, Germany In Moldova, social situation is a primary modulator of survival in a hepatocellular carcinoma Adela TURCANU, Moldova Clinical presentation and survival of Asian and non-asian patients with HBV-related hepatocellular carcinoma (HBV- HCC): Results of 767 United States patients with long-term follow-up Joseph HOANG, United States Dynamic [18F]FLT-PET is sensitive in detecting hepatocellular carcinoma Rohini SHARMA, United Kingdom Monofocal HCC: Milan Criteria or BCLC staging system? An analysis of the ITA.LI.CA. database Giulia PESERICO, Italy Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma Sebastian SCHOTTEN, Germany Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis receiving biologics: a 10-year population-based propensity-score matched cohort study Ching-Sheng HSU, Taiwan Risk assessment of hepatocellular carcinoma in chronic liver disease patients with a combination of liver stiffness measurement and controlled attenuation parameter by FibroScan Kenichi MORIKAWA, Japan Single-cell mrna sequencing to characterize circulating tumor cells in hepatocellular carcinoma Delia D AVOLA, Spain Validation of the MESH, HKLC and BCLC classification in a large German cohort of hepatocellular carcinoma patients Sophia FRANCK, Germany 248 EASL THE HOME OF HEPATOLOGY

251 11-15 APRIL 2018 PARIS, FRANCE Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology FRI-191 FRI-192 FRI-193 Top 10% Obeticholic acid response in primary biliary cholangitis associated with differential expression of antigen presentation, Wnt signalling and mrna splicing Andrew L. MASON, Canada TGR5 modulates gallbladder function and bile acid pool composition : potential hepatoprotective impact in mice Bidault Jourdainne VALESKA, France NLRP3 deletion leads to decreased inflammation and prevents fibrosis formation in mice after chronic bile duct ligation Mick FRISSEN, Germany FRI-194 FRI-195 FRI-196 Top 10% FRI-197 FRI-198 Top 10% Activation of pyruvate kinase isoform M2 (PKM2) in myeloid cells protects from Concanavalin A-mediated liver injury Andrea HORST, Germany Ceacam1 controls IL-2-dependent regulatory Tcell induction in immune-mediated hepatitis Andrea HORST, Germany The suppressive effect of Interleukin-17-expression in antigen specific CD8+ T cells in acute experimental cholangitis in mice Stephanie STEIN, Germany Batf3-dependent CD103+CD11b-dendriticcells are crucial for the development of primary biliary cholangitis Debby REUVENI, Israel FXR Agonist Obeticholic Acid Increases Gallbladder FGF19 in Gallstone Patients Samer AL-DURY, Sweden POSTERS / FRIDAY 13 APRIL 2018 FRI-199 FRI-200 Loss of BSEP protects MDR2/ABCB4 KO mice from cholestatic liver injury by altering bile acid profile and signaling Claudia FUCHS, Austria The faecal microbiome of patients with primary sclerosing cholangitis has a characteristic signature across different geographic regions Timur LIWINSKI, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 249

252 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology (Cont.) FRI-201 FRI-202 Top 10% FRI-203 FRI-204 FRI-205 Top 10% The faecal microbiome of patients with autoimmune hepatitis is characterised by reduced diversity and is different from healthy subjects and patients with ulcerative colitis Timur LIWINSKI, Germany Different bile acids display distinct ability to trigger Nlrp3 inflammasome activation in a cell-dependent manner contributing to cholestatic liver injury and fibrosis Maria INZAUGARAT, Germany Decreased ratio of Tregs to Th17 cells exacerbates disease progression of autoimmune hepatitis Weiming YAN, China A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis Adi MOR, Israel Generation of a novel mouse model for the study of autoimmune liver disease overlap syndrome Sina FUCHS, Germany POSTERS / FRIDAY 13 APRIL 2018 FRI-206 Top 10% FRI-207 FRI-208 FRI-209 FRI-210 Anticholestatic mechanisms of ursodeoxycholic acid in inflammatory cholestasis induced by lipopolysacharide María Valeria RAZORI, Argentina Fine tuning of SIRT1 expression is essential to protect the liver from cholestasis Naiara BERAZA, United Kingdom Leukemia inhibitory factor induces cholangiocyte proliferation and corrects the impaired bile duct proliferation in sortilindeficient mice following cholestatic injury Isabel ZVIBEL, Israel Relapse of autoimmune hepatitis is associated with a low intrahepatic ratio of regulatory T cells to cytotoxic T cells prior to immunosuppression withdrawal Finn DERBEN, Germany Experimental autoimmune hepatitis in mice is associated with formation of ectopic lymphoid tissue in the liver Max PRETI, Germany 250 EASL THE HOME OF HEPATOLOGY

253 11-15 APRIL 2018 PARIS, FRANCE FRI-211 FRI-212 FRI-213 FRI-214 FRI-215 FRI-216 FRI-217 FRI-218 FRI-219 FRI-220 FRI-221 Cell therapy of Acute liver injury- in vivo efficacy of mesenchymal stromal cells in toxic and immune-mediated murine hepatitis Mohammed ALFAIFI, United Kingdom Cu isotope ratio shifts in common bile duct ligated mice and correlates with the degree of cholestatic-induced liver disease Sanne VAN CAMPENHOUT, Belgium Sarcopenia induction in a mouse model of chronic cholestatic liver disease: Role of the ubiquitin-proteasome system and oxidative stress Daniel CABRERA, Chile The atypical antidepressant mirtazapine is hepatoprotective in a mouse model of immune-mediated hepatitis Wagdi ALMISHRI, Canada Fine-mapping and colocalisation analysis of GWAS risk loci in Primary Sclerosing Cholangitis suggests role for protooncogene ETS2 in disease pathogenesis Elizabeth GOODE, United Kingdom Hypersensitivity and constitutive activation of the IL-12/STAT4 pathway in NK cells in Primary Biliary Cholangitis: a novel mechanism Theresa HYDES, United Kingdom Deletion of tumor necrosis factor alpha receptor 1 leads to an increased Th17 cell response in the chronically inflamed liver Laura BERKHOUT, Germany Lysophosphatidic acid activates peripheral glia cells via LPA receptor 1 Katharina WOLF, Germany Intrahepatic type II natural killer T cells switch to a proinflammatory cytokine profile in patients with autoimmune hepatitis Marcial SEBODE, Germany Human chorionic-plate-derived mesenchymal stem cells restore hepatic lipid metabolism in a rat model of bile duct ligation Yun Bin LEE, Korea, Rep. of South In vitro rescue of ABCB11 nonsense mutations : induction of a readthrough of premature stop codons Rachida AMZAL, France POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 251

254 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME FRI-222 FRI-223 FRI-224 FRI-225 FRI-226 FRI-227 The anti-inflammatory receptor TREM2 protects the liver from cholestatic injury in mice Ibone LABIANO, Spain Elevated plasma levels of FGF19 isassociated with repression of bile salt synthesis in patients with obstructivecholestasis KIran KOELFAT, Netherlands Low-dose interleukin-2expands the number of circulating regulatory T cells in patients with treatment-refractory autoimmune hepatitis Tiong Yeng LIM, United Kingdom Intrahepatic recuriment of cytotoxic NK cells contributes to autoimmune hepatitis progression Fang XIAO, China Deep immunophenotyping of liver infiltrating lymphocytes reveals distinct differences in the T cellcompartment of patients with primary sclerosing cholangitis Tobias POCH, Germany Cross-species molecular imaging of bile salts and lipids: Identification of hydroxyl-sulfatides as marker of bile ducts Frank SCHAAP, Netherlands POSTERS / FRIDAY 13 APRIL EASL THE HOME OF HEPATOLOGY

255 11-15 APRIL 2018 PARIS, FRANCE Cirrhosis and its complications: Experimental and pathophysiology FRI-228 FRI-229 FRI-230 Top 10% FRI-231 Top 10% Necroptosis signalling pathway in hepatic fibrosis; role of receptor-interacting serine-threonine kinase 3 and mixed lineage kinase domain-like in cirrhosis Waqar SAEED, Korea, Rep. of South Role of Toll-like receptor 4 (TLR4) in regulating severity of hyperammonemia and gene expression of urea cycle enzymes Annarein KERBERT, Netherlands Regulatory T cells modulate the concentration of short chain fatty acids and the Th function in response to induced bacterial traslocation episodes, and improve the integrity of the gut barrier in an experimental cirrhosis model Oriol JUANOLA, Spain Characterization ofthe protective effects of yaq-001on organ injury in cirrhosis Francesco DE CHIARA, United Kingdom FRI-232 Top 10% FRI-233 FRI-234 FRI-235 FRI-236 Systemic inflammation and portal vein thrombosis in gastroesophageal varices Xiaoquan HUANG, China Pharmacokinetics study of 2 investigational rifaximin soluble solid dispersion formulations (immediate release and sustained extended release) in healthy volunteers Jason VITTITOW, United States Simvastatin-loaded polymeric micelles are a new, safe and effective drug delivery system targeting liver sinusoidal endothelial cells Diana HIDE, Spain Transcriptome analysis of human and murine cirrhotic livers identifies shared molecular pathways as potential targets to enhance cirrhosis regression Erica LAFOZ, Spain In cirrhotic rats, mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis by modulating oxidative stress and mitophagy Saadet TURKSEVEN, Italy POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 253

256 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis and its complications: Experimental and pathophysiology (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-237 FRI-238 FRI-239 FRI-240 FRI-241 FRI-242 FRI-243 FRI-244 FRI-245 FRI-246 FRI-247 Ascites NK cells are phenotypically distinct from blood and liver NK cells in patients with liver cirrhosis and become activated by bacterial stimulation in-vitro and during spontaneous bacterial peritonitis Philipp LUTZ, Germany Protective role of VEGF-A165b in liver cirrhosis with portal hypertension Robert SCHIERWAGEN, Germany Real world experience of lusutrombopag for thrombocytopenia in patients with liver cirrhosis Hitomi TAKADA, Japan Chronic liver damage causes a reduction in the number and a dysfunction of the activity of liver resident macrophages Elisa POSE, Spain An immuno-metabolic phenotype of acute-on-chronic liver failure predicts early mortality Rabiya ZIA, United Kingdom Etiology-specific hemostatic profiles in cirrhosis Sarah BOS, Netherlands Prediction of blood ammonia levels in modeled human liver dysfunction and application to gut-restricted ammonia lowering therapeutics Christine BREW, United States Polymorphisms in toll-like receptors identify a defective oxidative response and a reduction in the regulatory T cell population in patients with cirrhosis and non-infected ascites Paula PIÑERO, Spain Bacterial translocation during experimental cirrhosis coincidences with the infiltration of inflammatory monocytes in the gut Lore MEELBERGHS, Belgium Effectiveness of a practical nutritional intervention in advanced liver disease: A prospective study Dalila COSTA, Portugal Udenafil decreases portal pressure and improves erectile dysfunction in liver cirrhosis Frank Erhard USCHNER, Germany 254 EASL THE HOME OF HEPATOLOGY

257 11-15 APRIL 2018 PARIS, FRANCE FRI-248 FRI-249 FRI-250 FRI-251 FRI-252 The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH Philipp SCHWABL, Austria Genetic factorsof hepatic encephalopathy on patients with cirrhosis: candidate gene study Antonio GIL-GOMEZ, Spain LSECtin and CD206 participate in the regulation of the hepatic inflammatory response to E coli in a model of cirrhosis Esther CAPARRÓS, Spain Changes of bile acids profile in different etiologies of liver cirrhosis and its association with neutrophil response Irina KOMAROVA, Austria Assessment of conjugated, primary and secondary bile acids in the portal venous system across the spectrum of chronic HCV associated liver disease; link to inflammation and microbial products Rabab ALI, United States POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 255

258 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis B/D: Clinical aspects except therapy POSTERS / FRIDAY 13 APRIL 2018 FRI-254 FRI-255 FRI-256 FRI-257 FRI-258 FRI-259 FRI-260 FRI-261 FRI-262 Occult hepatitis B infection in hepatocellular carcinoma patients with negative HBsAg Danny WONG, Hong Kong Non-linear association between serum hepatitis B virus DNA levels and hepatocellular carcinoma risk in treatment-naive, non-cirrhotic chronic hepatitis B patients Gi-Ae KIM, Korea, Rep. of South Hepatitis B splice variants are strongly associated with and are indeed predictive of hepatocellular carcinoma Peter REVILL, Australia Lower baseline quantitative HBcAb may help predict response to sequential combination therapy with IFN, rhil-2 and HBV therapeutic vaccine in entecavir-suppressed CHB patients Weiming YAN, China Antiviral therapy can be avoided in most HBeAg-negative Caucasian patients in the Gray Zone Martin BONACCI, Spain Basal values and on treatment decline of hepatitis B corerelated antigen are predictive of response to interferon therapy in chronic hepatitis D Antonella OLIVERO, Italy Soluble cytotoxic T-lymphocyte-associated antigen-4 and soluble programmed cell death protein-1are predictive immune checkpoint seromarkers for spontaneous functional cure of chronic hepatitis B with opposite effects Hwai-I YANG, Taiwan The levels of middle surface HBV antigen increase in patients with HBV-driven liver cancer despite prolonged virological suppression: implications for a novel marker of HBV-driven hepatocarcinogenesis Valentina SVICHER, Italy Identifying epigenetic markers for characterization of host response to hepatitis B virus infection during the development of hepatocellular carcinoma Wan-Jung WU, Taiwan 256 EASL THE HOME OF HEPATOLOGY

259 11-15 APRIL 2018 PARIS, FRANCE FRI-263 FRI-264 FRI-265 FRI-266 FRI-267 FRI-268 FRI-269 FRI-270 FRI-271 FRI-272 External validation of clinical scoring system for the prediction of hepatocellular carcinoma in chronic hepatitis B treated by nucleotide/nucleoside analogue Masayuki KUROSAKI, Japan Monitoring patients with a resolved hepatitis B virus infection for HBV reactivation Akihiro TAMORI, Japan Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10- year longitudinal study Wai Pan TO, Hong Kong Real-world rates of hepatitis B surface antigen seroclearance in patients with chronic hepatitis B: a systematic review, conventional aggregated data meta-analysis and individual patient data meta-analysis Donghak JEONG, United States Association of common polymorphism in the Interleukin 1 beta gene with Hepatitis B virus-related hepatocellular carcinoma in Caucasians Janett FISCHER, Germany Effective hepatitis B vaccination by serologic results in the United States: A population-based study from Michael Huan LE, United States Suboptimal rates of effective hepatitis B vaccination in adults at high risk of infection in the United States from Michael Huan LE, United States Droplet digital PCR quantitation of HBV cccdna pool and transcriptional activity in long-term nucleos(t)ide analogue treated patients Aurore INCHAUSPÉ, France Estimated the number of undiagnosed patients and antiviral treatment rate of chronic hepatitis B in the U.S. based on the Truven Health MarketScan Database Eiichi OGAWA, Japan Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B Romina SALPINI, Italy POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 257

260 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis B/D: Clinical aspects except therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-273 FRI-274 FRI-275 FRI-276 FRI-277 FRI-278 FRI-279 FRI-280 FRI-282 FRI-283 Comparison of the risks of hepatocellular carcinoma in patients with chronic hepatitis B virus infection: Estimation of direct carcinogenic effect of hepatitis B virus Young CHANG, Korea, Rep. of South Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy Minjong LEE, Korea, Rep. of South Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection Gian Paolo CAVIGLIA, Italy Pan-genotypic loop-mediated isothermal amplification assay for HBV: A simple, rapid and affordable point-of-care test to semi-quantify HBV DNA Yusuke SHIMAKAWA, France Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccdna transcriptional activity in HBeAg negative chronic hepatitis B infection Luna COLAGROSSI, Italy Impact of gender, menopause status and age at menarche on severity of liver fibrosis among patients with chronic hepatitis B Ming XIONG, China Early on-treatment alanine aminotransferase normalization reduces risk of hepatic events in patients with chronic hepatitis B Lai-Hung, Grace WONG, Hong Kong Occult Hepatitis B infection is frequent and a risk factor of advanced liver disease in The Gambia, West Africa Gibril NDOW, United Kingdom Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel predictive scores for HCC and HBsAg seroclearance Yan Yue James FUNG, China Serum WFA+-M2BP level as a diagnostic marker of HBVrelated HCC: A case-control study Natthaya CHUAYPEN, Thailand 258 EASL THE HOME OF HEPATOLOGY

261 11-15 APRIL 2018 PARIS, FRANCE FRI-284 FRI-285 FRI-286 FRI-287 FRI-288 FRI-289 FRI-290 FRI-291 FRI-292 FRI-293 FRI-294 FRI-295 The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden Ann-Sofi DUBERG, Sweden The efficacy of a computer alert programme for increasing hepatitis B screening rates before starting immunosuppressive therapy Aydin KOKSAL, Turkey First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001 Henk REESINK, Netherlands Quantification of hepatitis B virus covalently closed circular DNA by a peptide nucleic acid-clamping PCR method Chau-Ting YEH, Taiwan Long-term outcome of hepatitis delta compared to HBV monoinfection Anika WRANKE, Germany The WHO guidelines for chronic hepatitis B fails to detect half of the patients in need of treatment Hanna ABERRA, Ethiopia A new utility of HBcrAg a pan-genotypic predictor of mother to child HBV transmission Ivana CAREY, United Kingdom Virological heterogenity of hepatitis delta among Vietnamese populations Thanh Binh MAI, Germany Comorbidities in chronic hepatitis B patients currently treated with nucleos(t)ide analogues Spyridon (Spyros) SIAKAVELLAS, Greece Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection Arianna BATTISTI, Italy Patients with genotype 5 hepatitis delta infection have a favourable outcome of disease and better treatment response to pegylated interferon therapy compared to genotype 1 patients Michelle SPAAN, Netherlands Prevalence and clinical outcome of hepatitis Delta infection in patients with HIV/HBV coinfection Giovanni Battista GAETA, Italy POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 259

262 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis B/D: Clinical aspects except therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-296 FRI-297 FRI-298 FRI-299 FRI-300 FRI-301 FRI-302 FRI-303 FRI-304 FRI-305 FRI-306 Clinical features of HDV infection in Mongolian patients Anir ENKHBAT, Mongolia Monitoring of subjects with previous hepatitis B exposure on Rituximab for hepatitis B reactivation and on demand treatment for hepatitis B reactivation is safe and reduces cost Victoria EKSTROM, Singapore Prevalence and impact of hepatitis E virus infection in the Hepatitis B Research Network cohort David MCGIVERN, United States Red blood cell distribution width to albumin ratio is a potential index for predicting long-term prognosis for hepatitis B virusrelated liver cirrhosis Chao WU, China Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years followup of a prospective longitudinal study (ALBATROS study) Viola KNOP, Germany Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection Lung-Yi MAK, Hong Kong Changes in serum levels of the novel mac-2 binding protein glycosylation isomer and risk of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleos(t)ide analogues Yao-Chun HSU, Taiwan A risk score combining quantitative hepatitis B surface antigen and core-related antigen levels to predict off-therapy relapse after cessation of nucleos(t)ide analogues in patients with chronic hepatitis B Yao-Chun HSU, Taiwan Acute hepatitis B in adulthood: not such a benign disease Mar RIVEIRO-BARCIELA, Spain The first results of genotyping of virus hepatitis D and virus hepatitis B in Kazakhstan Bibigul ILYASSOVA, Kazakhstan The levels of cytokines in progression of chronic hepatitis D Bibigul ILYASSOVA, Kazakhstan 260 EASL THE HOME OF HEPATOLOGY

263 11-15 APRIL 2018 PARIS, FRANCE FRI-307 Assessment of hospitalizations and comorbidities in 2138 hepatitis B patients followed in diverse specialist care clinics based on administrative data analysis: The Canadian hepatitis B network Carla COFFIN, Canada FRI-308 FRI-309 FRI-310 FRI-311 FRI-312 FRI-313 FRI-314 FRI-315 FRI-316 Can pre-core region mutations distinguish between HBeAg negative genotype A1 and A2 patients with similar HBV DNA viral load levels? Natalie BOLTON, United Kingdom Switching immunoglobulin base therapy to nucleoside/ nucleotide analogues monotherapy is safe and effective as preventive therapy of reccurent HBV in liver transplanted patients- single centre experience Orly SNEH, Israel Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy Calvin PAN, United States HLA-G 3 UTR polymorphism are associated with different patterns of tissue expression and severity of liver injury in chronic hepatitis B infection Ana DE LOURDES CANDOLO MARTINELLI, Brazil Prophylactic antiviral therapy for the prevention of motherto-child transmission of hepatitis B virus can be stopped at delivery Qing-Lei ZENG, China Validation of AASLD treatment guideline eligibility based on disease outcomes of large community and clinical cohorts of chronic hepatitis B patients Dong Hyun LEE, United States Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B Yun Bin LEE, Korea, Rep. of South Quantitative Hepatitis B surface antigen in different phases of Vietnamese chronic HBV infected patients Huong NGUYEN, Viet Nam HBeAg negative chronic hepatitis B patients with HBV- DNA levels between 2,000-20,000IU/ml and normal aminotransferases are really inactive? Bilal ERGÜL, Turkey POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 261

264 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis B/D: Clinical aspects except therapy (Cont.) FRI-317 FRI-318 Which pregnancy biomarkers predict post-delivery ALT flares in mothers with chronic hepatitis B? Salome IMBERT, United Kingdom Adherence to AASLD treatment guidelines on treatment initiation among treatment-eligible patients with chronic hepatitis B: Experiences from primary care and referral practices Vy Hoang NGUYEN, United States POSTERS / FRIDAY 13 APRIL EASL THE HOME OF HEPATOLOGY

265 11-15 APRIL 2018 PARIS, FRANCE Viral hepatitis B/D: Therapy FRI-319 FRI-320 FRI-321 Top 10% FRI-322 FRI-323 FRI-324 FRI-325 FRI-326 FRI-327 Durability of HBsAg loss during or after antiviral treatment in a predominantly middle European collective Gerlinde TEUBER, Germany The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment Lei YAN, China A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study Anika WRANKE, Germany Novel markers predict HBs-antigen seroclearance in chronic hepatitis B patients from the SWAP clinical trial Wah Wah PHYO, Singapore Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study Harel DAHARI, United States Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection Harel DAHARI, United States Efficacy and safety of combination therapy with interferon and immunomodulators in entecavir-suppressed chronic hepatitis B patients (the endeavor study) Di WU, China Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV / HDV coinfection: 18 month follow-up results from the REP 301-LTF study Andrew VAILLANT, Canada Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial Man-Fung YUEN, Hong Kong POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 263

266 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis B/D: Therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-328 FRI-329 FRI-330 FRI-331 FRI-332 FRI-333 FRI-334 FRI-335 FRI-336 FRI-337 Every-two-week ropegienterferon alfa-2b is safe with higher hepatitis B e antigen seroconversion rate in interferon naive patients with chronic hepatitis B infection: A phase 2, open label, randomized, active control, dose finding study Yi-Wen HUANG, Taiwan HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B Mina FARAG, Canada Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis Shuhei HIGE, Japan Treatment of chronic hepatitis B and renal impairment in patients with and without cirrhosis Sam TRINH, United States Is renal impairment associated with chronic hepatitis B a propensity score matched study of healthy non-hepatitis B patients compared to patients with untreated chronic hepatitis B Sam TRINH, United States Comparison of fibrosis-adjusted long-term clinical outcomes in patients with minimally active chronic hepatitis B who did not undergo antiviral therapy vs. those with complete virological response by antiviral therapy Hye Won LEE, Korea, Rep. of South CD56 bright natural killer cell induces HBsAg clearance via cytolysis and non-cytolysis: Analysis of the OSST patient dataset Tao CHEN, China Loss of HbsAg is enough to discontinue long-term therapy with Nucleos(T)ide analogues in HbeAg negative CHB patients in real clinical practice? Andreas KAPATAIS, Greece Evaluation of renal and bone safety in post liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis Edward GANE, New Zealand RO , a novel prodrug of a toll-like receptor 7 agonist, is safe, well tolerated and activates TLR signaling in healthy volunteers Edward GANE, New Zealand 264 EASL THE HOME OF HEPATOLOGY

267 11-15 APRIL 2018 PARIS, FRANCE FRI-338 FRI-339 FRI-340 FRI-341 FRI-342 FRI-343 FRI-344 FRI-345 FRI-346 Top 10% FRI-347 Ledipasvir/Sofosbuvir for 12 weeks is safe and effective in adolescents with chronic hepatitis C virus infection and hematological malignancies undergoing chemotherapy Manal Hamdy EL-SAYED, Egypt Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitits B Sabela LENS, Spain Five years follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac Aguilar JULIO, Cuba Association of metabolic adipokines with persistence of fibrosis in chronic hepatitis B during long-term nucleoside analogue therapy Ka-Shing CHEUNG, Hong Kong Tenofovir Disoproxil Fumarate use during pregnancy and infant bone health and growth: the Tenofovir in pregnancy study Athena KOURTIS, United States Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a Andrew VAILLANT, Canada A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240 Jing-Hang XU, China Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B Seng LIEM, Canada Low serum HBsAg and HBV DNA predict response of peginterferon addition to entecavir in HBeAg positive chronic hepatitis B Seng LIEM, Canada Renal outcomes in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or entecavir: a propensity score matched study Sam TRINH, United States POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 265

268 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral hepatitis B/D: Therapy (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-348 FRI-349 FRI-350 FRI-351 FRI-352 FRI-353 FRI-354 FRI-355 FRI-356 FRI-357 Peginterferon is superior to nucleos(t)ide analogues for reduction ofchronic hepatitis B-related hepatocellular carcinoma in patients with high-riskscore Peipei REN, China Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting Alessandro LOGLIO, Italy The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compesated caucasian HBV cirrhotics treated with Tenofovir or Entecavir Alessandro LOGLIO, Italy Clinical and genetic predictors of HCC occuring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years Alessandro LOGLIO, Italy Pharmacokinetic-pharmacodynamic modeling of Tenofovir Exalidex in HBV subjects Robert FOSTER, United States Bile acid monitoring to support safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection Mathias HAAG, Germany HeberNasvac: Novel therapeutic vaccine against chronic hepatitis B Gerardo GUILLEN, Cuba At least 90% long-term adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir Young-Suk LIM, Korea, Rep. of South Predictors of HBeAg loss and seroconversion by baseline clinical features and viral deep sequencing after 144 weeks of treatment with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate Young-Suk LIM, Korea, Rep. of South Serum hepatitis B virus DNA and pregenomic RNA levels and kinetics in nucleos(t)ide analogue treated and untreated subjects Emily BUTLER, United States 266 EASL THE HOME OF HEPATOLOGY

269 11-15 APRIL 2018 PARIS, FRANCE FRI-358 FRI-359 FRI-360 FRI-361 FRI-362 On-treatmant serum wisteria fioribunda agglutinin-positive Mac-2 binding protein level and risk of hepatocellular carcinoma development in patients with chronic hepatitis B during nucleot(s)ide analog therapy Ayato MURATA, Japan Hepatitis B surface antigen reduction by switching from longterm preceding nucleoside/nucleotide analog administration to pegylated interferon or tenofovir Tamaki NOBUHARU, Japan Clinical predictors for relapse after cessation of nucleoside analogues by stopping rule in chronic hepatitis B patients Do Seon SONG, Korea, Rep. of South Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG- IFN Lucio BOGLIONE, Italy RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV Man-Fung YUEN, Hong Kong POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 267

270 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis C: Post SVR and long term follow up FRI-363 Top 10% Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity Lisette KRASSENBURG, Canada POSTERS / FRIDAY 13 APRIL 2018 FRI-364 FRI-365 FRI-366 FRI-367 FRI-368 Top 10% FRI-369 FRI-370 FRI-371 FRI-372 The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy Lisette KRASSENBURG, Canada TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFNfree DAA-based regimens Pietro LAMPERTICO, Italy Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: Results from the Gilead SVR registry Stefan ZEUZEM, Germany Serum immune signatures predict HCC development in DAAtreated HCV patients Jose DEBES, United States Long-term immunological and clinical impact of HCV eradication with direct acting antivirals in patients with HCVassociated cryoglobulinemia vasculitis Martin BONACCI, Spain Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a sinlge-center prospective 3 year study Roberta D AMBROSIO, Italy The impact of HCV eradication by IFN-free regimens on the transition of precancerous hepatic nodules to HCC: a prospective observational study Hidenori TOYODA, Japan Impact of curative HCC history on the development of HCC after the eradication of HCV by DAA therapy in patients with HCV infection Hidenori TOYODA, Japan Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection Hidenori TOYODA, Japan 268 EASL THE HOME OF HEPATOLOGY

271 11-15 APRIL 2018 PARIS, FRANCE FRI-373 FRI-374 FRI-375 FRI-376 FRI-377 FRI-378 FRI-379 FRI-380 FRI-381 FRI-382 Sustainable improvement of patient-reported outcomes in cirrhotic patients with hepatitis C who achieved sustained virologic response Zobair YOUNOSSI, United States The impact of sustained virologic response on severe fatigue in patients with chronic hepatitis C: The role of HCV viremia and co-morbidities Zobair YOUNOSSI, United States De novo hepatocellular carcinoma in patients with cirrhosis due hepatitis C virus infection after treatment with direct antiviral agents Pablo RUIZ, Spain Resolution of clinically significant portal hypertension after sustained virologic response to interferon-free regimens prevents hepatic decompensation Mattias MANDORFER, Austria Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals Veronika PIETSCH, Germany Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma in SVR achieved hepatitis C patients with interferon-free treatment Yutaka YASUI, Japan Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis Chiara MASETTI, Italy The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance Vincenza CALVARUSO, Italy Sustained and continued improvement in hepatic fibrosis beyond the first year following hepatitis C virus treatment Robert WONG, United States The role of Hepatitis C virus eradication with DAA on insulin resistence regulation Ilaria BORTOLUZZI, Italy POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 269

272 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis C: Post SVR and long term follow up (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-383 FRI-384 FRI-385 FRI-386 FRI-387 FRI-388 FRI-389 FRI-390 FRI-391 FRI-392 Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis SHALIMAR, India Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C Itaru OZEKI, Japan In hepatitis C patients with cirrhosis who achieve SVR with treatment, reduction in transient elastography measures does not translate to reduced risk of hepatocellular carcinoma: A prospective cohort study Jessica HOWELL, Australia Risk of de novo hepatocellular carcinoma after DAA treatment within two years following treatment with Ombitasvir/ Paritaprevir/ritonavir±Dasabuvir±Ribavirin in the AMBER real world experience study Robert FLISIAK, Poland Antiviral therapy can prevent in HCV infected patients relapse of diffuse large B cell lymphoma Adriano PELLICELLI, Italy Prospective follow up of 80 patients with addictive behaviors and advanced fibrosis after treatment of chronic HCV infection with DAA : a suboptimal management Camille BARRAULT, France Predictors of clinical improvement among HCV patients with advanced liver disease treated with DAA: a single center experience Chiara MAZZARELLI, Italy Sustained virologic response leading to improved long-term metabolic outcomes Benjamin EMMANUEL, United States High virological cure rate and low rate of reinfection in a project to eradicate HCV in people who inject drugs at risk for non-adherence to direct-acting antivirals in Vienna Michael GSCHWANTLER, Austria Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment Alberto ZANETTO, Italy 270 EASL THE HOME OF HEPATOLOGY

273 11-15 APRIL 2018 PARIS, FRANCE FRI-393 FRI-394 FRI-395 FRI-396 FRI-397 FRI-398 FRI-399 FRI-400 FRI-401 FRI-402 FRI-403 A cost-effectiveness analysis of shortened direct-acting antiviral treatment for mild chronic hepatitis C virus Christopher FAWSITT, United Kingdom HCV testing and linkage to care: Expanding access to HCV care through electronic health engagement and linkage to C care program in the PWID population Zohha ALAM, United States Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? Margaret BASSENDINE, United Kingdom Treatment of HCV infection with DAAs is associated with lower HCC recurrence and improved survival after liver transplant Katharina WILLUWEIT, Germany Effect of hepatitis C sustained virological response on the endothelial dysfunction and the cardiovascular risk. HepCAR study Rocio MUNOZ HERNANDEZ, Spain The impact of direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related chronic hepatitis C Blaise KUTALA, France Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients Tea Lund LAURSEN, Denmark Involvement of angiotensin II/angiotensin-(1-7) fibrinolytic pathway in improvement of liver fibrosis in chronic hepatitis C patients who had sustained virological response by directacting antiviral therapy: a prospective trial Nicha TEERATORN, Thailand The lack of improvement in liver stiffness after SVR in HCV compensated advanced chronic liver disease is associated with the risk of presenting liver related events Monica PONS DELGADO, Spain Health utilities in Spanish chronic hepatitis C patients treated with direct acting antivirals in real life conditions Regina JUANBELTZ, Spain Hepatitis C virus infection a new reversible cardiovascular risk factor in cirrhotic patients after viral eradication? Tudor CUCIUREANU, Romania POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 271

274 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis C: Post SVR and long term follow up (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-404 FRI-405 FRI-406 FRI-407 FRI-408 FRI-409 FRI-410 FRI-411 FRI-412 FRI-413 Controlled attenuation parameter values of Fibroscan compatible with steatosis in patients with chronic hepatitis C and changes after sustained virological response Teresa BROQUETAS, Spain Recurrent viremia after successful hepatitis C virus therapy with direct-acting antivirals in a cohort of people who use drugs Arshia ALIMOHAMMADI, Canada Changes in liver steatosis and lipid metabolism accompanied by successful interferon-free DAAs therapy in HCV infected patients; a comprehensive analysis Naoki KAWAGISHI, Japan Impact of direct acting antiviral drugs on HCV- related decompensated liver cirrhosis El-Sayed THARWA, Egypt No evidence of fibrosis regression in HCV/HIV co-infected and HCV monoinfected participants up to 3 years after achieving SVR with DAA treatment: interim results for the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) Marion PETERS, United States Direct acting anti-viral treatment for hepatitis C results in a rapid reduction in MRI measures of hepatic microstructure Robert SCOTT, United Kingdom Clinical consequences of occult HCV infection in a post-liver transplant population Jeffrey KAHN, United States Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: a multicenter prospective cohort study from Latin America Federico PIÑERO, Argentina Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities Elena GONZÁLEZ-COLOMINAS, Spain Noninvasive diagnosis of fibrosis in the patients with hepatitis C virus infection treated with direct-acting antivirals Hiroshi NUMAO, Japan 272 EASL THE HOME OF HEPATOLOGY

275 11-15 APRIL 2018 PARIS, FRANCE FRI-414 FRI-415 FRI-416 FRI-417 FRI-418 Impact of SVR to IFN-free DAA therapy on steatosis in HIV/ HCV coinfected patients David CHROMY, Austria Sustained virological response predicts fibrosis regression in chronic hepatitis C patients treated with direct acting antivirals-a single tertiary care centre experience Rajendra Sudamrao GUNJAL, India Long-term evolution of thrombocytopenia in patients with chronic hepatitis C and advanced fibrosis after sustained virological response with direct antiviral agents Judith GÓMEZ- CAMARERO, Spain Treatment of patients with decompensated cirrhosis with DAAs improves clinical symptoms without affecting their MELD score John ROMANO, United States Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort Eiichi OGAWA, Japan POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 273

276 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Diagnostics and non-invasive assessment POSTERS / FRIDAY 13 APRIL 2018 FRI-421 FRI-422 FRI-423 FRI-424 FRI-425 FRI-426 FRI-427 FRI-428 FRI-429 FRI-430 Top 10% Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI Stephen HARRISON, United Kingdom Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis Arun SANYAL, United States Non-invasive liver tests in electronic health records of patients with non-alcoholic fatty liver disease: combined analysis from four European countries William ALAZAWI, United Kingdom Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver diseasedevelopment in a large prospective multicenter UK study Philip NEWSOME, United Kingdom Noninvasive mapping of fibrosis and inflammation in nonalcoholic fatty liver disease: isolating fibrogenesis in the Space of Disse with MRI R2 multicomponent relaxometry Hilton LEAO FILHO, Brazil The EPoS staging system is a reproducible 7-tierfibrosis score for NAFLD adapted both to glass slides and digitized images(eslides) Pierre BEDOSSA, France An algorythm for screening for liver fibrosis in primary care using population-based data Isabel GRAUPERA, Spain Comparison of ElastPQ Shear-wave Elastography (ElastPQ- SWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD Davide ROCCARINA, United Kingdom Establishing reliability criteria forliver ElastPQ Shear-wave Elastography (ElastPQ-SWE): comparison between 3, 5 and 10 measurements Davide ROCCARINA, United Kingdom Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study Louise ALFERINK, Netherlands 274 EASL THE HOME OF HEPATOLOGY

277 11-15 APRIL 2018 PARIS, FRANCE FRI-431 FRI-432 FRI-433 Top 10% New diagnostic method for hepatic steatosis using attenuation measurement by B mode ultrasound: Comparison with controlled attenuation parameter Yohei KOIZUMI, Japan Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH Michelle LAI, United States Electronic-nose breath print distinguishes non-alcoholic fatty liver disease from healthy lean control: a pilot study Rohit SINHA, United Kingdom FRI-434 FRI-435 FRI-436 FRI-437 Top 10% FRI-438 FRI-439 FRI-440 A study of breath metabolome in Non-alcoholic fatty liver disease Rohit SINHA, United Kingdom Appropriateness of inclusion criteria according to transaminases ALT in studies assessing performances of noninvasive tests in type-2 diabetes patients (T2D) Thierry POYNARD, France Performance and reliability of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity Andreas DROLZ, Germany Controlled attenuation parameter is useful in the diagnosis of fatty liver disease and allows to identify patients with high vascular risk as well as those with advanced liver disease Marta GONZÁLEZ, Spain Effects of bariatric surgery on Non-alcoholic fatty liver disease: The role of macrophage-mediated the systemic inflammation Noemí CABRÉ, Spain Magnetic Resonance Elastography versus Transient Elastography in detection of fibrosis in nonalcoholic fatty liver disease: A systematic review and meta-analysis of individual participant date Cynthia HSU, United States Gut-liver interactions in celiac disease: FGF-19 and GLP-1 link disease activity to hepatic steatosis and liver injury Svenja SYDOR, Germany POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 275

278 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Diagnostics and non-invasive assessment (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-441 FRI-442 FRI-443 FRI-444 FRI-445 FRI-446 FRI-447 FRI-448 FRI-449 FRI-450 Utility and limitation of non-invasive fibrosis markers for predicting the prognosis in biopsy-proven Japanese NAFLD patients Takanori ITO, Japan FibroScan stiffness and CAP in the evaluation of cardiovascular risk assessment in patients with NAFLD Rosa LOMBARDI, Italy Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver Henry WILMAN, United Kingdom The Community based management of NAFLD Study (COMMANDS): Improved diagnosis and referral using a novel integrated care pathway Lynsey CORLESS, United Kingdom Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) Rudolf E. STAUBER, Austria Genetic variations of three important anti-oxidative enzymes: SOD2, CAT and CPX1 in non-alcoholic steatohepatitis Yi-Shin HUANG, Taiwan Comparison of conventional ultrasound signs to current stateof-the-art MRI method for detection of hepatic steatosis Mi Mi KIM, Korea, Rep. of South Responsiveness of controlled attenuation parameter and its correlation with magnetic resonance imaging-proton density fat fraction in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis Mazen NOUREDDIN, United States A non-invasive biomarker of hepatic inflammation based on magnetic resonance imaging Tim ST PIERRE, Australia Temporal assessment of the non-invasive fibrosis scores FIB-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) in a retrospective cohort study among patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Carolina MUÑOZ CODOCEO, Spain 276 EASL THE HOME OF HEPATOLOGY

279 11-15 APRIL 2018 PARIS, FRANCE FRI-451 FRI-452 FRI-453 FRI-454 FRI-455 FRI-456 FRI-457 FRI-458 FRI-459 FRI-460 Top 10% In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease Amalia GASTALDELLI, Italy Excess weight has a major impact on hepatic fibrosis by users of psychoactive substance Michel DOFFOËL, France Hepatic microrna and phosphoproteomic analysis provide insights about hepatic collagen deposition and stage of fibrosis in non-alcoholic steatohepatitis Zobair YOUNOSSI, United States Serum metabolomics analysis to identify boilermakers for advanced fibrosis in NASH patients Yi LUO, United States Liver and pancreatic steatosis in children are both assosiated with metabolic syndrome but have different influence on insulin sensitivity and glucose metabolism Olha LUKIANENKO, Ukraine Prospective evaluation of serum gamma-glutamyl transferase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis Cynthia LEVY, United States Metabolomics in the progression of fatty liver disease Jacopo TROISI, Italy Comparison of HepaFat-Scan and controlled attenuation parameter for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease using histology as the reference standard Wah-Kheong CHAN, Malaysia Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis Maria Magdalena BALP, Switzerland Spatial systems lipidomics reveals nonalcoholic fatty liver disease heterogeneity Klara SCUPAKOVA, Netherlands POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 277

280 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Diagnostics and non-invasive assessment (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-461 FRI-462 FRI-463 FRI-464 FRI-465 FRI-466 FRI-467 FRI-468 FRI-469 FRI-470 Validation of a quantitative imaging assessment biomarker metric for MRI-estimated proton density fat fraction in a large multi-center clinical trial Michael MIDDLETON, United States FIBROSpect NASH serum test identifies advanced liver fibrosis in patients with non-alcoholic steatohepatitis: Results of a validation study Rohit LOOMBA, United States The association of circulating micrornas (mirs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH Michael CHARLTON, United States ELF test in NAFLD: Poor concordance with liver stiffness values Laura IOGNA PRAT, United Kingdom Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: Lessons from a cohort with available liver biopsies Laura IOGNA PRAT, United Kingdom Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach Jeanne C. LATOURELLE, United States A new score to predict presence of advanced fibrosis in NAFLD and comparison with established scoring systems Hannes HAGSTRÖM, Sweden Evaluation of severity of hepatic fibrosis and steatosis in biopsy-proven NAFLD patients using MR imaging, transient elastography, and serum biomarker Young-Sun LEE, Korea, Rep. of South Monocyte subpopulations for non-invasive diagnosis of NAFLD and NASH in a bariatric patient collective Katharina STAUFER, Austria Comparing of noninvasive tests in predicting diagnosis of Nonalcoholic Steatohepatitis Carmen FIERBINTEANU BRATICEVICI, Romania 278 EASL THE HOME OF HEPATOLOGY

281 11-15 APRIL 2018 PARIS, FRANCE FRI-471 FRI-472 FRI-473 FRI-474 FRI-475 FRI-476 FRI-477 Machine learning approaches for non-invasive ultrasound. based quantitative assessment of liver steatosis Maurizia BRUNETTO, Italy Positive predictive value of a physician diagnosis of nonalcoholic steatohepatitis is low and risks high rates of unnecessary liver biopsy Anna ROSKILLY, United Kingdom Screening for liver fibrosis using transient elastography by fibroscan and fibrotest in type 2 diabetic patient Julia SANDLER, Russian Federation Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan M probe. When should we evaluate steatosis with the XL probe? Teresa BROQUETAS, Spain The easy Liver Fibrosis Test ( elift) avoids unnecessary specialized evaluations of liver fibrosis in NAFLD and ALD patients Thomas BROUSSIER, France Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children Andrea SCOTT, United States Optimal cutoff value of assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting Bo-Kyeong KANG, Korea, Rep. of South POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 279

282 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Therapy POSTERS / FRIDAY 13 APRIL 2018 FRI-478 FRI-479 FRI-480 Top 10% FRI-481 Top 10% FRI-482 FRI-483 FRI-484 FRI-485 FRI-486 Saroglitazar treatment prevents NASH, eliminates hepatocyte ballooning, and significantly improves serum LFTS, lipids and and insulin resistance in DIAMOND mice compared to pioglitazone benchmark Rebecca CAFFREY, United States Mitochondrial uncoupler HU6 successfully treats NASH in DIAMOND mouse model Rebecca CAFFREY, United States Fibrosis stage improvement in nonalcoholic steatohepatitis: A systematic review of placebo treated participants in randomized controlled trials Anna ROSKILLY, United Kingdom Persistent improvement of liver function tests and healthrelated quality of life from an individualized exercise program in patients with histological confirmed NAFLD the HELP study Yvonne HUBER, Germany Treatment with obeticholic acid in patients with NASH does not show increased markers of liver toxicity based on evaluation of Drug-Induced Serious Hepatotoxicity (edish) Arun SANYAL, United States The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: data from a randomised Phase 2 trial Philip NEWSOME, United Kingdom Effet of bariatric surgery in biopsy-proven NASH patients after 5 years Guillaume LASSAILLY, France Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a liver targeting ACC inhibitor (PF ) following single and multiple oral doses Arthur BERGMAN, United States Regular aspirin use is not protective against advanced fibrosis in type-2 diabetics with biopsy-proven nonalcoholic fatty liver disease Amandeep SINGH, United States 280 EASL THE HOME OF HEPATOLOGY

283 11-15 APRIL 2018 PARIS, FRANCE FRI-487 FRI-488 FRI-489 FRI-490 FRI-491 FRI-492 FRI-493 FRI-494 FRI-495 FRI-496 Preliminary efficacy and safety of acetyl-coa carboxylase (ACC) inhibitor GS-0976 in patients with compensated cirrhosis due to NASH Stephen HARRISON, United States Characterization of changes in lipoprotein profiles of patients with nonalcoholic steatohepatitis treated with the acetyl-coa carboxylase (ACC) inhibitor GS-0976 Parvez MANTRY, United States Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects Nathalie ADDA, United States An integrated safety analysis of phase 2 studies of BMS , a PEGylated fibroblast growth factor 21 analogue for the treatment of non-alcoholic steatohepatitis Dina HALEGOUA-DEMARZIO, United States Improvement of liver steatosis achieved byprobiotics in patients with nonalcoholic fatty liver disease Ionel COPACI, Romania Endoscopic sleeve gastroplasty improves liver enzymes and hepatic steatosis index Sonal KUMAR, United States Effects of rosuvastatin and pioglitazone long therapy on NASH and coronary heart disease courses Nataliya VIRSTYUK, Ukraine Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients Tatiana ERMOLOVA, Russian Federation The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4 weeks of treatment, an interim analysis of ongoing clinical trial, MN-001-NATG-201 Kazuko MATSUDA, United States Lifestyle intervention is effective in treating non-alcoholic fatty liver disease in morbidly obese patients Simon HOHENESTER, Germany POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 281

284 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Acute liver failure and drug induced liver injury FRI-498 Top 10% Tauroursodeoxycholic acid protects against valproic acidinduced sensitization to acetaminophen hepatotoxicity Sandra TORRES, Spain POSTERS / FRIDAY 13 APRIL 2018 FRI-499 FRI-500 FRI-501 FRI-502 FRI-503 FRI-504 Top 10% FRI-505 Top 10% s-ademetionine effectively prevents drug-induced liver injury in overweight patients with acute leukemia Igor SKRYPNYK, Ukraine Drug exposure and risk of Acute Liver Failure leading to registration for liver Transplantation (ALFT): Results of the SALT III study in adults in France Dominique LARREY, France Long-term liver safety of lomitapide in patients with homozygous familial hypercholesterolemia: Three-Year Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) Dominique LARREY, France Proof-of-concept of full-length genome sequencing as diagnostic tool of acute viral hepatitis Isaac RUIZ, France MH cells in combination with proteomics identify a potential biomarker for Drug-induced Liver Injury by Diclofenac Andreas BENESIC, Germany Health care utilisation in spontaneous survivors of acute liver failure Mhairi DONNELLY, United Kingdom Amatoxin poisoning in Germany important clues for clinical practice Bernhard SCHLEVOGT, Germany FRI-506 FRI-507 Opal, but not MARS improves patients albumin binding function measured by Electron Spin Resonance (ESR) in a prospective multicenter trial Jan STANGE, Germany Etiology and clinical features of patients with drug-induced liver injury diagnosed by liver biopsy Guofeng CHEN, China 282 EASL THE HOME OF HEPATOLOGY

285 11-15 APRIL 2018 PARIS, FRANCE FRI-508 FRI-509 FRI-510 FRI-511 FRI-512 FRI-513 FRI-514 FRI-515 FRI-516 FRI-517 FRI-518 Acute Liver Failure-Organ Failure (ALF-OF) score is better than King s College Hospital criteria in predicting mortality in patients with non-paracetamol-related acute liver failure (ALF). Francesco FIGORILLI, Italy Drug Induced Liver Injury A study on the factors affecting severity and prognosis with special emphasis on metabolic syndrome Sandeep NARAYANAN, India Serum CXCL10, CXCL11, CXCL12 and CXCL14 chemokine patterns in patients with acute liver injury Arnaud CHALIN, France The proportion of patients waitlisted for transplantation for HDS induced liver injury is increasing and differs by race Joseph ODIN, United States Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: a retrospective monocentric cohort study Lucia PARLATI, France Impact of early corticosteroid treatment in patients with indeterminate acute severe hepatitis Elisabeth MOHR, Germany Evaluation of the hepatoprotective effects of Polygonum Multiflorum Thunb in acetaminophen induced liver injury Amarzaya CHAGNAADORJ, Mongolia Prophylactic use of entecavir for lymphoma patients with past HBV infection: a randomized controlled trial Wei Ping LIU, China Inhibition of pyruvate dehydrogenase complex and lactate dehydrogenase for therapy of acute liver failure Rosa FERRIERO, Italy Pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: clinical characteristics, imaging signs and pathological findings Yuhu SONG, China Low Serum hepcidin and high transferrin saturation are associated with a poor short-term survival in adults with acute liver failure Igor SPIVAK, Germany POSTERS / FRIDAY 13 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 283

286 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Acute liver failure and drug induced liver injury (Cont.) POSTERS / FRIDAY 13 APRIL 2018 FRI-519 FRI-520 FRI-521 FRI-522 FRI-523 FRI-524 FRI candidate SNPs were not found to be associated with drug induced liver injury Lili PANG, China CC10 protein attenuates hepatic injury in MHV-3 induced fulminant hepatitis by inhibiting fgl2 expression on macrophages Haijing YU, China Role and regulation of mitophagy by ROS in hepatic stellate cells during acute liver failure Zhen TIAN, China DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome Raul J. ANDRADE, Spain Independent cohort validation of hepatic metabolism, daily dose and comorbidities as features associated with delayed symptom onset in drug-induced liver injury Raul J. ANDRADE, Spain Prediction of early mortality despite liver transplantation in acute liver failure Mariana CARDOSO, Portugal Should age be an absolute contraindication to liver transplantation in acute liver failure? Mariana CARDOSO, Portugal 284 EASL THE HOME OF HEPATOLOGY

287 11-15 APRIL 2018 PARIS, FRANCE POSTERS SATURDAY 14 APRIL 2018 CHECK OUT THE ILC 2018 APP FOR THE LATEST PROGRAMME UPDATES EASL THE HOME OF HEPATOLOGY

288 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Gut microbiota and liver disease SAT-001 Top 10% mir-21 contributes to the onset and progression of liver disease through the deregulation of small intestine permeability André A. SANTOS, Portugal POSTERS / SATURDAY 14 APRIL 2018 SAT-002 Top 10% SAT-003 Top 10% SAT-004 SAT-005 SAT-006 SAT-007 SAT-008 SAT-009 SAT-010 Depletion of Paneth cells is associated with decreased portal hypertension and angiogenesis after partial portal vein ligation in mice Mohsin HASSAN, Switzerland A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy Vincenza DI GREGORIO, Italy Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement Rohit LOOMBA, United States Iron reduction by venesection alters the gut microbiome in Haemochromatosis patients John RYAN, United Kingdom Does the bile acid receptor TGR5 play a role in Kupffer cell response during Alcoholic Liver Disease? Madeleine SPATZ, France Does the gut play a pivotal role in the protective effect of coffee on liver damage? Antonella ROSSI, Italy Intestinal microbiota significantly alters hepatic expression of energy metabolism genes in mice with acute cholestasis Sheida MOGHADAMRAD, Switzerland Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition Michal SAFRAN, Israel Gut microbes mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with hepatitis B virus Masaya SUGIYAMA, Japan 286 EASL THE HOME OF HEPATOLOGY

289 11-15 APRIL 2018 PARIS, FRANCE SAT-011 SAT-012 SAT-013 Prebiotic treatment prevents alcohol-induced liver lesions in mice with indigenous microbiota and mice with human microbiota Laura WRZOSEK, France Comprehensive analysis of alcohol treatment in mouse model of acute-on-chronic liver injury Shinji FURUYA, Japan The Impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients Freya WELLHÖNER, Germany POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 287

290 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Immunology except viral hepatitis POSTERS / SATURDAY 14 APRIL 2018 SAT-014 SAT-015 SAT-016 SAT-017 SAT-018 SAT-019 SAT-020 SAT-021 SAT-022 SAT-023 SAT-024 Paradoxically functioning onco-mir-155 and the tumor suppressor mir-194 consensus on PD-L1 immune checkpoint upregulation via MALAT-1 and XIST in hepatocellular carcinoma Sara ATWA, Egypt Circulating NK cells in cirrhosis are hypofunctional, with an expanded inhibitory liver-homing CD56dimCD16+/- NK cell population Naveenta KUMAR, United Kingdom Liver sinusoidal endothelial cells are involved in the aggravation of liver injury induced by the activated NKT cells in aged mice Hiroyuki NAKASHIMA, Japan M2 macrophage specfifc gene silencing in the liver using third generations mannose coated, sirna-loaded nanohydrogel particles Leonard KAPS, Germany The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa William ALAZAWI, United Kingdom AXL-expressing monocytes indicate immuneparesis and disease severity in patients with cirrhosis Robert BRENIG, Switzerland Paired-Cell sequencing reveals global transcriptional zonation of liver non-parencymal cells Keren BAHAR HALPERN, Israel Secreted ectodomain of SIGLEC-9 and MCP-1 ameliorate acute liver failure in rats by altering bone marrow macrophage polarity Takanori ITO, Japan Elevated programmed death ligand 2 (PDL2) in macrophages of BALB/c mice model of liver fibrosis associated with decreased CD80 and IL12 expressions Johnny AMER, Palestine WISP1: a novel key protein in acute liver damage Daniela GONZÁLEZ, Germany Ethanol dampens IL-37 expression in liver tissue Felix GRABHERR, Austria 288 EASL THE HOME OF HEPATOLOGY

291 11-15 APRIL 2018 PARIS, FRANCE SAT-025 SAT-026 Serum CXCL14 chemokine as a biomarker during murine acute and chronic hepatitis Christelle DEVISME, France Autophagy-related liver enzymes in chronic liver disease Demetrious SAMONAKIS, Greece POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 289

292 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Rare liver diseases (including paediatric and genetic) SAT-027 SAT-028 Top 10% SAT-029 Top 10% SAT-031 SAT-032 Top 10% Precision medicine targeting disrupted IGF signaling in hepatoblastoma Olga KUCHUK, United States Clinical presentation, natural history and treatment of hepatic sarcoidosis: a case-series of 39 patients with histologically proven hepatic sarcoidosis Malte WEHMEYER, Germany Upregulation of mir-34c driven by JNK and FOXO3 in livers expressing mutant Z alpha1-antitrypsin Pasquale PICCOLO, Italy Refinement of diagnostic criteria and frequency estimation of LPAC syndrome: a French multicenter study Dong CATHERINE, France Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease Vítor PEREIRA, Portugal POSTERS / SATURDAY 14 APRIL 2018 SAT-033 Top 10% SAT-034 SAT-035 SAT-036 Top 10% Genetic ablation of CHOP decreases hepatic accumulation of mutant Z alpha1-antitrypsin Sergio ATTANASIO, Italy Etiology of splanchnic vein thrombosis in 812 chinese patients from a single center Guohong HAN, China Step-wise strategy for Chinese Budd-Chiari syndrome patients: Long-term outcome of a large scaleprospective observational cohort Guohong HAN, China Hepatic outcomes from childhood intestinal failure: A metaanalysis of 8223 patients Aureliane PIERRET, United Kingdom SAT-037 Characteristics and outcomes of cystic fibrosis paediatric patients admitted with cirrhosis in the United States Abdel-Aziz SHAHEEN, Canada 290 EASL THE HOME OF HEPATOLOGY

293 11-15 APRIL 2018 PARIS, FRANCE SAT-038 Top 10% SAT-039 Top 10% SAT-040 SAT-041 SAT-042 Top 10% Comparison between room-temperature susceptometry and MRI with respect to the cell-specific detection of liver iron Johannes MUELLER, Germany Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patientes with severe alpha1-antitrypsin-deficiency Carolin Victoria HEIMES, Germany Impact of acute hepatic porphyrias on quality of life and work loss: An analysis of EXPLORE natural history study Sonalee AGARWAL, United States Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria Sonalee AGARWAL, United States Prevalence and predictive factors of hepatic nodules in patients with fontan surgery: the VALDIG fonliver study Enrique RODRÍGUEZ-SANTIAGO, Spain SAT-043 Top 10% SAT-044 Top 10% SAT-045 SAT-046 SAT-047 The effect of re-exposure to somatostatin analogues in patients with polycystic liver disease René VAN AERTS, Netherlands The PR interval in the fetal electrocardiogram is significantly prolonged in severe intrahepatic cholestasis of pregnancy and potentially normalised by UDCA therapy Tharni VASAVAN, United Kingdom Differential diagnostics of congenital cholestatic diseases in children of early age Galina VOLYNETS, Russian Federation Quantitative and qualitative lymphocyte alterations in patients with autoimmune hepatitis: what is the clinical relevance? Amédée RENAND, France High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage Claudia EINER, Germany POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 291

294 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Rare liver diseases (including paediatric and genetic) (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-048 SAT-049 SAT-050 SAT-051 SAT-052 SAT-053 SAT-054 SAT-055 SAT-056 SAT-057 The natural course of FIC1 deficiency and BSEP deficiency: Initial results from the NAPPED-consortium (NAtural course and Prognosis of PFIC and Effect of biliary Diversion) Daan VAN WESSEL, Netherlands Mild iron overload in homozygous carriers of the alpha1- antitrypsin PiZ variant is not a major driver of liver fibrogenesis Nurdan GULDIKEN, Germany Compound library screening for the identification of a new treatment for polycystic liver disease Liyanne VAN DE LAARSCHOT, Netherlands Splenic iron deficiency is characteristic for HFE-associated hemochromatosis André VIVEIROS, Austria Transcatheter recanalization with angioplasty and/or stenting: a novel, minimally-invasive treatment option for children with chronic portal vein thrombosis with cavernous transformation Henri JUSTINO, United States Clinical response after laparoscopic fenestration of large simple hepatic cysts: a systematic review L.H.P. BERNTS, Netherlands Pertinence of liver stiffness measurement inpatients with Wilson s disease for assessment of initial fibrosis and treatmentfollow-up Rodolphe SOBESKY, France Clinical presentation and outcome of Wilson s disease patients in a monocentric cohort ofliver reference center Rodolphe SOBESKY, France Abnormalities in left ventricular geometry are associated with mortality and morbidity in children with biliary atresia and end stage liver disease Noelle GORGIS, United States Disease severity, obeticholic acid disposition and dose selection in patients with biliary atresia Jeffrey EDWARDS, United States 292 EASL THE HOME OF HEPATOLOGY

295 11-15 APRIL 2018 PARIS, FRANCE SAT-058 SAT-059 SAT-060 SAT-061 SAT-062 SAT-063 The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease Thomas Damgaard SANDAHL, Denmark The global prevalence of lysosomal acid lipase deficiency estimated by meta-analysis of pathogenic mutations and functional variants from next-generation sequencing data Anna CARTER, United Kingdom Correlation of autotaxin levels, serum bile acids, and pruritus in a multiple-dose, open-label, multinational study of the ileal bile acid transport inhibitor A4250 Emmanuel GONZALES, France Liver disease in a cohort of patients with Gaucher disease from Southern Brazil: a cross-sectional study Rodrigo STAROSTA, Brazil Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis Teresa DIAS, Portugal Evaluation of the new criteria in the diagnosis of cystic fibrosis liver disease Ilianna MANI, Greece POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 293

296 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Non-invasive assessment of liver disease except NAFLD POSTERS / SATURDAY 14 APRIL 2018 SAT-065 SAT-066 SAT-067 SAT-068 SAT-069 SAT-070 SAT-071 SAT-072 SAT-074 SAT-075 SAT-076 Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort Elba LLOP, Spain Prognostic value of 2D-shear wave elastography for staging cirrhosis in chronic liver diseases in two severity classes according to liver-related complications Priscila POLLO-FLORES, Brazil Reliability criteria for liver stiffness measurement with ARFI Jerome BOURSIER, France The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients Maja THIELE, Denmark Serum hyaluronic acid is an independent predictor of mortality in patients with chronic liver disease Nikolas PLEVRIS, United Kingdom Liver stiffness measurement predicts short-term liver relatedmorbidity of allogeneic hematopoietic stem cell transplantation Thomas KARLAS, Germany Liver stiffness measurement by 2D SWE from General Electric is similar with Transient Elastography in clinical significant portal hypertension diagnosis Rusu CORINA, Romania Controlled attenuation parameter reflects intrahepatic fat content in patients with compensated advanced chronic liver disease Rosangela PICCINNI, Switzerland Usefulness of liver stiffness measurement by transient elastography for predicting complications in patients with alcoholic liver disease Ana GOMEZ, Spain Evaluation of multiparametric MRI in comparison with MR elastography in patients evaluated for chronic liver disease Stephen BRAVO, United Kingdom Glomerular filtration rate evaluation in patients with cirrhosis, which equation shall be used in clinical daily practice? Sofia MONTEIRO, Portugal 294 EASL THE HOME OF HEPATOLOGY

297 11-15 APRIL 2018 PARIS, FRANCE SAT-077 SAT-078 SAT-079 SAT-080 SAT-081 SAT-082 SAT-083 SAT-084 SAT-085 SAT-086 SAT-087 Predictions from a very hard liver: The role of liver stiffness in alcoholic hepatitis Fischer PETRA, Romania Soluble serum vascular adhesion protein (svap)-1: A new biomarker in primary sclerosing cholangitis? Francesca SAFFIOTI, United Kingdom Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection Shu Yein HO, Taiwan Enhanced liver fibrosis test predicts liver-related outcomes in postmenopausal women with risk factors in the community Paul TREMBLING, United Kingdom Correlation between controlled attenuation parameter assessed with Fibroscan and steatosis percent objectively quantified from the entire liver biopsy specimen using a computer analysis tool: Preliminary results Monica LUPSOR-PLATON, Romania Performance of shear-wave elastography to detect high-risk esophageal varices in cirrhosis is improved by spleen stiffness estimation Seong Hee KANG, Korea, Rep. of South Non-invasive estimation of hepatic fibrosis and steatosis: Comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter Valentin BLANK, Germany CT-driven model for end-stage liver disease: Comparison of survival prediction with MELD score Ji Eun LEE, Korea, Rep. of South Non invasive assessment of liver fibrosis by three different Shear Wave Techniques: Head-to-Head Performance Sebastiana ATZORI, United Kingdom The gamma-glutamyl transpeptidase to platelet ratio: a novel index for predicting significant liver inflammation in chronic hepatitis B Rui HUANG, China Comparison of T2* and signal intensity ratio methods for MRI assessment of hepatic iron overload Christopher KAGAY, United States POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 295

298 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Non-invasive assessment of liver disease except NAFLD (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-088 SAT-089 SAT-090 SAT-091 SAT-092 SAT-093 SAT-094 SAT-095 SAT-096 SAT-097 Serum biomarker use in decentralized care sites to overcome liver assessment barriers in patientswith chronic hepatitis C and HIV co-infection Anne LOAREC, France Normal liver elasticity values in a healthy population, by age and gender, for two novel elastography systems Anesa MULABECIROVIC, Norway Detection of hereditary haemochromatosis in the clinic and community using standard haematological tests: a comparison with iron studies Nancy WHALEN, Australia Evolving diagnostic pathways in liver disease: using quantitative magnetic resonance imaging to distinguish parenchymal and biliary disease Katherine ARNDTZ, United Kingdom Non invasive diagnostic approach for screening and grading of portal hypertension in patients with advanced liver disease Sergii KOZLOV, Ukraine Circulating micro-arns as biomarkers of alcohol liver disease and hepatocellular carcinoma Charles-Antoine PAPILLON, France Liver function assessment using magnetic resonance imaging with gadoxetic acid administration Christina LEVICK, United Kingdom Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity Christina LEVICK, United Kingdom Overestimation and underestimation of liver fibrosis stage classification assessed by transient elastography and twodimensional shear wave ultrasound Sang Gyune KIM, Korea, Rep. of South Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis Tomi JUN, United States 296 EASL THE HOME OF HEPATOLOGY

299 11-15 APRIL 2018 PARIS, FRANCE SAT-098 SAT-099 SAT-100 SAT-101 SAT-102 SAT-104 SAT-105 SAT-106 Top 10% Assessing liver function: Diagnostic efficacy of parenchymal enhancement and liver volume ratio during hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid enhanced-magnetic resonance imaging studies Anna PECORELLI, Italy Distribution and changes of FIB-4 index in normal health checkup examinees Shuhei HIGE, Japan Which is the chance for type 2 diabetes patients to develop severe liver disease? Ioan SPOREA, Romania Intelligent liver function diagnostic pathway Relevance of alanine transaminase normal values Emma ROBINSON, United Kingdom The impact of inflammation grade of liver histology on the improvement of liver stiffness assessed by transient elastography Jeong-Ju YOO, Korea, Rep. of South Phenotypic characteristics and improvement of liver stiffness measurement during follow-up in patients with Wilson s disease Razvan IACOB, Romania Is food-intake a confusing factor for liver stiffness evaluation by 2D-SWE in normal subjects? Alina POPESCU, Romania Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic- HCV patients Elton DAJTI, Italy POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 297

300 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver transplantation and hepatobiliary surgery: Experimental POSTERS / SATURDAY 14 APRIL 2018 SAT-109 SAT-110 Top 10% SAT-111 SAT-112 SAT-113 SAT-114 SAT-115 SAT-116 SAT-117 SAT-118 Rictor/mTORC2 signaling protects ischemic liver injury by targeting both liver parenchymal and non-parenchymal cells Haoming ZHOU, China Hyperglycemia-triggered ATF6-CHOP pathway exacerbates liver ischemia/reperfusion injury: immnomodulation by betacatenin signaling Jianhua RAO, China An effective defatting cocktail to reduce liver graft steatosis before transplantation Lynda AOUDJEHANE, France A merged protocol of hypothermic oxygenated machine perfusion and normothermic machine perfusion optimises the reconditioning of marginal donor livers Yuri BOTEON, United Kingdom The effectiveness of a pharmacological intervention for defatting of primary human hepatocytes and its effect on other cell types ofthe liver: a precursor in-vitro study to the defatting of steatotic humanlivers using normothermic machine perfusion Yuri BOTEON, United Kingdom The postoperative serumcourse of the liver regenerationassociated signaling molecules bile salts and FGF19 in cholestatic patients undergoing liver resection Kiran KOELFAT, Netherlands Establishing a porcine model of small for size syndrome following liver resection Mohammad GOLRIZ, Germany Induction of beta-catenin in embryonic stem cell-derived dendritic cells alleviates liver damage in mouse liver inflammatory injury Bibo KE, United States Sealant pathology Omid GHAMAR NEJAD, Germany Preoperative biliary drainage reverses cholestasis-associated inflammatory and fibrotic gene signatures in patients with perihilar cholangiocarcinoma Rowan VAN GOLEN, Netherlands 298 EASL THE HOME OF HEPATOLOGY

301 11-15 APRIL 2018 PARIS, FRANCE Liver tumours: Experimental and pathophysiology SAT-122 SAT-123 SAT-124 SAT-125 SAT-126 SAT-127 SAT-128 SAT-129 Top 10% SAT-130 Top 10% SAT-131 Top 10% Distinct functions of phosphorylated and un-phosphorylated STAT1 in hepatocellular carcinoma Buyun MA, Netherlands High fat diet induces a tumor like metabolism in the liver Joao DUARTE, Belgium Nrf2 pathway plays an important role in the development of hepatocellular carcinoma: the gene expression signature of Nrf2 observed in a rat hepatocarcinogenesis model Carlos David LÓPEZ, Mexico ADAR-mediated A-to-I RNA editing in human hepatocellular carcinoma Guangqi SONG, China Sulfatase 2 Antagonizes Starvation-Induced Autophagy in Hepatocellular Carcinoma Paola ROMECIN, United States In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle sirna carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma François H.T. DUONG, France CeO2NPs aresimilarly effective as sorafenib in increasing survival in rats with HCC Guillermo FERNÁNDEZ VARO, Spain Hepatocyte c-jun N-terminal kinases determine cell fate and carcinogenesis in NEMO-deficient mice Mohamed Ramadan MOHAMED, Germany Chemokine receptor CXCR3 modulates polarization of tumor associated macrophages limiting tumor growth and angiogenesis in murine hepatocellular carcinoma Elisa Fabiana BRANDT, Germany Hepatocyte-derived Osteopontin drives the development of hepatocellular carcinoma Romain DESERT, United States POSTERS / SATURDAY 14 APRIL 2018 SAT-132 AAV2 viral infection in liver and tumor development Tiziana LA BELLA, France THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 299

302 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Experimental and pathophysiology (Cont.) SAT-133 SAT-134 Top 10% SAT-135 Top 10% Sorafenib increases the percentage and cytotoxicity of circulating NK cells in hepatocellular carcinoma patients Guohong HAN, China Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity Muhammad ASHFAQ-KHAN, Germany Inflammation driven hepatocarcinogenesis is associated with a progenitor-like phenotype and Trp53 dependent differentiation Michael SVINARENKO, Germany POSTERS / SATURDAY 14 APRIL 2018 SAT-136 SAT-137 SAT-138 SAT-139 SAT-140 SAT-141 SAT-142 Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma Eva BENABOU, France Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma Barbara OLIVIERO, Italy Difference of gene mutational profile among viral- and nonviral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration Fukiko KAWAI-KITAHATA, Japan Therapeutics of cell-specific MAPK modulation in chronic liver disease using (sijnk2) nanodelivery Marius WOITOK, Germany Deletion of MyD88 in non-parenchymal cells, but not in parenchymal cells attenuates the progression of hepatocellular carcinoma Antje MOHS, Germany Interventional gene targeting of cell cycle regulators identifies Cyclin E1 as a suitable target for attenuating hepatocellular carcinoma progression Roland SONNTAG, Germany Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: the Blueprint-HCC study David James PINATO, United Kingdom 300 EASL THE HOME OF HEPATOLOGY

303 11-15 APRIL 2018 PARIS, FRANCE SAT-143 SAT-144 SAT-145 SAT-146 SAT-147 SAT-148 SAT-149 SAT-150 SAT-151 SAT-152 SAT-153 Mixed HCC-ICC liver cancer derives from hepatic progenitor cells- A lineage tracing investigation in mouse liver inflammation models Nofar ROSENBERG, Israel Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma Yu Rim LEE, Korea, Rep. of South Fgl2 contributes to hepatocellular carcinoma via suppressing the inflammatory phenotypes and functions of dentritic cells and cytotoxic lymphocytes in tumor microenvironment Muyang YANG, China Molecular characterization of autophagic and apoptotic signaling induced by Sorafenib in liver cancer cells: In vitro and in vivo studies Jordi MUNTANÉ, Spain In-vivo validation of cancer genes using liver organoids Anna SABOROWSKI, Germany Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment Natasa PAVLOVIC, Sweden Polyploidy and chromosomal instability correlates with proliferative traits and lack of immune-related gene signatures in hepatocellular carcinoma Laia BASSAGANYAS, Spain Tumor-stroma crosstalk enhances Reg3A expressions that drives the progression of hepatocellular carcinoma Yuri CHO, Korea, Rep. of South Inhibition of YAP activation induces cell senescence and autophagy while blocking cell proliferation in cholangiocarcinoma (CCA) Massimiliano CADAMURO, Italy Dietary cholesterol and StARD1 overexpression aggravate chemically induced hepatocarcinogenesis in vivo Laura CONDE DE LA ROSA, Spain Peribiliary glands and biliary tree stem cells are involved in the pathogenesis of cholangiocarcinoma arising in patients affected by primary sclerosing cholangitis Diletta OVERI, Italy POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 301

304 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Experimental and pathophysiology (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-154 SAT-155 SAT-156 SAT-157 SAT-158 SAT-159 SAT-160 SAT-161 SAT-162 SAT-163 Transforming growth factor-βeta and AXL collaborate to induce CXCL5 and neutrophil infiltration in hepatocellular carcinoma Wolfgang MIKULITS, Austria Mitochondrial VDAC1 based peptide as a new therapeutic agent for hepatocellular carcinoma Srinivas PITTALA, Israel The role of Lysyl oxidase in tumor microenvironment of primary liver cancer Monika LEWINSKA, Denmark The anti-inflammatory receptor TREM2 halts the generation of HCC in mice through the inhibition of liver inflammation and hepatocyte proliferative responses María Jesús PERUGORRIA, Spain Functional genomics identified actin cytoskeleton remodeling required for the hypoxia-mediated EMT: A mechanistic link of tumor size to metastasis Sen-Yung HSIEH, Taiwan The HDAC inhibitor belinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors ina murine hepatocellular carcinoma model Pablo SAROBE, Spain Blocking the CDK1/PDK1/B-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment with targeting cancer stem cell in preclinical model of hepatocellular carcinoma Chuanxing WU, Hong Kong Obeticholic acid, a FXR agonist, inhibits the cancerogenic potential of primary human cholangio carcinoma (CCA) cells cultures Sabina DI MATTEO, Italy Sensitization of cholangiocarcinoma to chemotherapy by SOX17-induced down-regulation of drug export pumps ABCC3 and AGCG2 Jose MARIN, Spain Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells Stefania MANTOVANI, Italy 302 EASL THE HOME OF HEPATOLOGY

305 11-15 APRIL 2018 PARIS, FRANCE SAT-164 SAT-165 SAT-166 SAT-167 SAT-168 SAT-169 SAT-170 SAT-171 SAT-172 SAT-174 SAT-175 Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening Charlotte NG, Switzerland Lack of Osteopontin promotes non-alcoholic steatohepatitis (NASH) and fibrosis, but protects against hepatocellular carcinoma (HCC) progression and mortality in a NASH-HCC mouse model Alexander Daniel NARDO, Austria Canonical inhibition of Transforming Growth Factor β Receptor 1 triggers proliferation of hepatocellular carcinoma andis associated with Toll like Receptor 7 upregulation Fatma MOHAMED, Germany S100a11 is part of a whole network of tumor suppressors and oncogenes deregulatedearly with hepatic steatosis and contributing to hepatocellular carcinoma development Cyril SOBOLEWSKI, Switzerland Low density neutrophils, as immunosuppressant, increased in HCC patients, highly correlated with advanced stage, predicted stage I HCC recurrence and all patients survival Chien-Hao HUANG, Taiwan Chemosensitizing effects of beta-caryophyllene oxide in liver cancer Silvia DI GIACOMO, Italy Application of patient-derived liver cancer cells for personalized treatment approach: from phenotypic characterization to therapeutic target identification Darko CASTVEN, Germany Depletion of the HDC/histamine axis ablates tumor formation, angiogenesis, EMT and inflammation in Mdr2 knockout mice Lindsey KENNEDY, High mir-224 expression in cholangiocarcinoma may predict survival Tímea SZEKERCZÉS, Hungary Do extracellular vesicles secreted from senescent hepatic stellate cells promote or suppress cancer development? Yuri MIYAZOE, Japan The role of IL-6 signaling pathway in cholangiocarcinoma Thi Mai Ly NGUYEN, Germany POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 303

306 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Liver tumours: Experimental and pathophysiology (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-176 SAT-177 SAT-178 SAT-179 SAT-180 SAT-181 SAT-182 Exosome derived from mir-199*-modified adipose tissuederived MSCs increase chemosensitivity of hepatocellular carcinoma Guohua LOU, China A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma Riccardo PATTI, Italy Disrupted cholesterol synthesis leads to female prevalent hepatocellular carcinoma in transgenic mice Kaja BLAGOTINŠEK COKAN, Slovenia Impact of Trp53 on tumor heterogeneity in the background of liver fibrosis Umesh THAREHALLI MATHADA, Germany Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile Anna TUTUSAUS, Spain Maldi imaging of hepatocholangiocarcinomas: A clue to tackle tumor heterogeneity preliminary results Elia GIGANTE, France HBx / DLEU2 / EZH2 co-regulation of host genes expression in HCC Massimo LEVRERO, France SAT-183 Aspecific ECM composition regulates Smad dependent TGFbeta1 induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds Krista ROMBOUTS, United Kingdom SAT-184 SAT-185 SAT-186 Analysis of HBV DNA integration in tumor and non-tumor liver tissues by a high-through put viral integration detection method Deborah D ALIBERTI, Italy New targets for hepatocellular carcinoma therapy: the Myc/ PRMT5/RNAP II circuit Cristiana PORCU, Italy Novel microrna-based drug CD5-2 reduces liver cancer development in multi-drug-resistance gene-2 knockout mice Ken LIU, Australia 304 EASL THE HOME OF HEPATOLOGY

307 11-15 APRIL 2018 PARIS, FRANCE SAT-187 SAT-188 SAT-189 SAT-190 KRAS-dependent AKT signaling drives hepatocyte proliferation to promote tumor development in a genetic model of liver cancer Thomas RÖSNER, Germany The impact of the epigenetic writer LSD1in the cell cycle control in liver fibrosis and hepatocellular carcinoma Lingyu WANG, Germany Sofosbuvir directly promotes the clonogenic capability of human hepatocellular cancer cells Jiaye LIU, Netherlands Gene signature of HDV-associated hepatocellular carcinoma (HCC): Differences with HCC associated with other hepatitis viruses Patrizia FARCI, United States POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 305

308 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication SAT-191 Top 10% SAT-192 SAT-193 SAT-194 Top 10% SAT-195 Top 10% Protective effect of statins in cirrhosis might be dependent on common genetic risk variants Matthias REICHERT, Germany Determinants of clinical efficacy of empirical antibiotic treatment in patients with cirrhosis and bacterial infections: Results from the ICA Global study Rakhi MAIWALL, India The mechanism of irreversibility of late stage cirrhosis Ian WANLESS, Canada Acellular growth retardation ability (AGRA), a novel biomarker for humoral immune function, predicts the occurrence of severe bacterial infections in cirrhosis Angela HORVATH, Austria Assessing Baveno VI criteria with a new point-shear wave elastography technique: the BAVElastPQ study Giulia GIBIINO, Italy POSTERS / SATURDAY 14 APRIL 2018 SAT-196 SAT-197 SAT-198 SAT-199 Top 10% SAT-200 Top 10% The efficacy and clinical outcome of transjugular intrahepatic portosystemic shunts (TIPS) in the management of ectopic variceal bleeding: a multicenter retrospective study Rosalie OEY, Netherlands Outcomes of pregnancy in women with cirrhosis a national, population-based cohort study Hannes HAGSTRÖM, Sweden Prevalence and resistance rates of infections with enterococci in patients with cirrhosis Theresa BUCSICS, Austria Effectiveness of early TIPS implantation vs late TIPS vs standard endoscopic treatment for acute variceal bleeding in patients with liver cirrhosis Theresa BUCSICS, Austria Cholemic nephropathy is frequently observed in jaundiced patients and associated with increased mortality Ingmar MEDERACKE, Germany 306 EASL THE HOME OF HEPATOLOGY

309 11-15 APRIL 2018 PARIS, FRANCE SAT-201 SAT-202 Top 10% SAT-203 SAT-204 Top 10% The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large monocentric study Cornelius ENGELMANN, United Kingdom TLR9-mediated immune sensing of bacterial DNA in decompensated cirrhosis is stage-dependent Eihab AL-HERWI, Germany Longitudinal outcomes of the application of non-selective betablockers in portal hypertension: Are low-dose non-selective beta-blockers effective? Seong Hee KANG, Korea, Rep. of South Sub maximally dilated Viatorr CX improves one year survival compared to conventional covered TIPS: a case-control study Michael PRAKTIKNJO, Germany SAT-205 SAT-206 SAT-207 SAT-208 SAT-209 SAT-210 Top 10% Prognosis after abdominal surgery in patients with idiopathic non-cirrhotic portal hypertension: a multicenter retrospective study Laure ELKRIEF, Switzerland Addition of simvastatin to standard treatment is safe, effective and improves quality of life in patients with decompensated cirrhosis Alberto MUÑOZ, Argentina Characterization of systemic inflammatory response in hepatorenal syndrome in cirrhosis. A major role for il-6, TNFalpha, and VCAM Cristina SOLE, Spain Skeletal Muscle Index indicates mortality risk more accurately than Psoas Muscle Index in patients with cirrhosis. From the FLEXIT consortium Aldo J MONTANO-LOZA, Canada Loss of subcutaneous adipose tissue associates with higher mortality risk in patients with cirrhosis Aldo J MONTANO-LOZA, Canada Assessment of biventricular function in patients with decompensated cirrhosis and hepatopulmonary syndrome Stergios SOULAIDOPOULOS, Greece POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 307

310 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-211 Top 10% SAT-212 SAT-213 SAT-214 SAT-215 SAT-216 SAT-217 SAT-218 SAT-219 SAT-220 SAT-221 Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome Florian RAINER, Austria The amelioration of muscle wasting leads to the improvement of cognitive impairment after transjugular intrahepatic portosystemic shunt: A proof of concept that sarcopenia and hepatic encephalopathy are causally related Stefania GIOIA, Italy Non cirrhotic portal hypertension secondary to oxaliplatin therapy: Incidence and presentation Stefania GIOIA, Italy The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in italy, spain and germany Paolo CARACENI, Italy The role of HbA1c as a risk factor for the development of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis Tammo TERGAST, Germany Antibiotic-associated disruption of microbial composition and functionality is restored after fecal transplant in cirrhosis Jasmohan S BAJAJ, United States Beta-Blocker use in cirrhosis is independently associated with minimal hepatic encephalopathy Jasmohan S BAJAJ, United States Validation of the baveno criteria for endoscopic surveillance of varices in cholestasic diseases Stephanie TASAYCO, Spain High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis Laura TURCO, Italy Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States Pauline NGUYEN, United States Sepsis in HBV associated decompensated cirrhosis: A comparison between SIRS (Sepsis-1) and qsofa (Sepsis-3) based criteria Zhujun CAO, China 308 EASL THE HOME OF HEPATOLOGY

311 11-15 APRIL 2018 PARIS, FRANCE SAT-222 SAT-223 SAT-224 SAT-225 SAT-226 SAT-227 SAT-228 SAT-229 SAT-230 SAT-231 Assessment of portal hypertension evolution in HCV cirrhosis patients with baseline large oesophageal varices after sustained virological response Antonio OLVEIRA MARTIN, Spain The impact of hepatic steatosis on portal hypertension Bernhard SCHEINER, Austria Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease Bernhard SCHEINER, Austria Thromboelastography guided blood product transfusion in cirrhosis patients with acute variceal bleeding: a randomized controlled trial Gyanranjan ROUT, India Chronic kidney disease in patients with cirrhosis surviving an episode of acute kidney injury. Frequency and impact on patient s outcome Octavi BASSEGODA, Spain Non-selective beta-blockers increase liver mortality when MELD is >12 in a prospective 5 year follow-up cohort of alcoholic cirrhosis Paul CALES, France Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort Apurva YELURU, United States Prior or on-treatment infection does not affect response to treatment or survival in patients with Hepatorenal Syndrome Type 1(HRS-1) Florence WONG, Canada Anticoagulant treatment for atrial fibrillation and decompensation rate in patients with liver cirrhosis Irina GIRLEANU, Romania Decreased Model for End-Stage Liver Disease score after antiviral treatment predicts reduced risk of mortality and hepatic events in chronic hepatitis B related cirrhosis A study of 1,729 subjects Lai-Hung, Grace WONG, Hong Kong POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 309

312 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-232 SAT-233 SAT-234 SAT-235 SAT-236 SAT-237 SAT-238 SAT-239 SAT-240 SAT-241 SAT-242 Propranolol treatment associated with better survival and reduced sepsis in cirrhotic patients with hepatic encephalopathy Pei-Chang LEE, Taiwan Six-minute walk test and sarcopenia in predicting mortality in patients with cirrhosis ThucNhi DANG, Canada The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma Hsiao-Sheng LU, Taiwan Characteristics of bone marrow drived mesenchymal stem cells in patients with liver cirrhosis Ki TAE SUK, Korea, Rep. of South Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: a systematic review and metaanalysis of randomized controlled trials Roger F. BUTTERWORTH, Canada Deleterious effect of proton pump inhibitors on the disease course of cirrhosis Zsuzsanna VITÁLIS, Hungary The impact of pulmonary arterial hypertension therapy in patients with portopulmonary hypertension: a single tertiary center cohort analysis Frederik NEVENS, Belgium Non-selective beta-blockers reduce cardiac systolic function and impair renal function in patients with refractory ascites Luis TÉLLEZ, Spain High risk of esophageal varices in patients with fontan surgery: The valdig fonliver study Luis TÉLLEZ, Spain Distinct MELD Trajectories in Liver Transplant Candidates with Hepatitis C and NASH Allison KWONG, United States Natural history of patients with compensated cirrhosis and a Hepatic Venous Pressure Gradient >20 mmhg: A prospective Longitudinal Cohort Study Ankit BHARDWAJ, India 310 EASL THE HOME OF HEPATOLOGY

313 11-15 APRIL 2018 PARIS, FRANCE SAT-243 SAT-244 SAT-245 SAT-248 SAT-249 SAT-250 SAT-251 SAT-252 SAT-253 SAT-254 Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebocontrolled trial Rafael PATERNOSTRO, Austria Varices on CT is the surrogate of clinically significant portal hypertension and can predict survival in patients with cirrhosis Dong Ho LEE, Korea, Rep. of South Predictors of endoscopic high risk esophageal varices in compensated cirrhosis: can we avoid fibroscan? Julian HERCUN, Canada Uncontrolled diabetes increases all causes of mortality and particularly cardiovascular death in patients with cirrhosis Fatima HIGUERA-DE LA TIJERA, Mexico TIPS placement improves sarcopenia and modifies fat distribution: a monocentric retrospective study Florent ARTRU, France Increasing burden of hepatic encephalopathy among hospitalized adults, with significantly higher risk of in-hospital mortality in african americans: An analysis of the nationwide inpatient sample Grishma HIRODE, United States Health care costs are double for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC) who progress to endstage liver disease (ESLD) Rohit LOOMBA, United States High real-world healthcare costs in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) compensated cirrhosis (CC)patients with and without type-2 diabetes mellitus (DM): A large German database study Ali CANBAY, Germany Functional polymorphisms of innate immunity receptors are not risk factors for non-sbp type bacterial infections in cirrhosis Tamas TORNAI, Hungary The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis Ji Jade KING, United Kingdom POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 311

314 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-255 SAT-256 SAT-257 SAT-258 SAT-259 SAT-260 SAT-261 SAT-262 SAT-263 SAT-264 MELD-score underestimates mortality in patients with nosocomial spontaneous bacterial peritonitis Markus KIMMANN, Germany The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: A systematic review and meta-analysis Nelson VALENTIN, United States Reduced serum ceruloplasmin concentration is common in patients with cirrhosis and a NaMELD independent predictor of transplantation or death Benedikt SCHAEFER, Austria Development and predictive validity of the Cirrhosis-associated Ascites Symptom Scale: A cohort study of 103 patients Agnete RIEDEL, Denmark Clinical, paraclinical and MR-spectroscopy profile in cirrhotic and non-cirrhotic portal hypertension patients with minimal hepatic encephalopathy Bertrand HERMANN, France Multimodal approach including MR-spectroscopy for the diagnosis of minimal hepatic encephalopathy Bertrand HERMANN, France Kinetics of polymorphonuclear count in ascitic fluid. Persistent spontaneous bacterial peritonitis Alberto AMADOR, Spain Impact of an antimicrobial stewardship policy on the reduction of empirical antibiotic treatment failure and the spread of multidrug-resistant organisms in hospitalized cirrhotic patients Simone INCICCO, Italy Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant Brooke CHAPMAN, Australia Dynamic visual processing in patients with decompensated cirrhosis Katherine WONG, United States 312 EASL THE HOME OF HEPATOLOGY

315 11-15 APRIL 2018 PARIS, FRANCE SAT-265 SAT-266 SAT-267 SAT-268 SAT-269 SAT-270 SAT-271 SAT-272 SAT-273 SAT-274 SAT-275 The physical component of the SF-36 Quality of Life tool is an independent predictor of mortality in patients with severe ascites Stewart MACDONALD, United Kingdom Clinical frailty scale as a novel tool predicts unplanned hospitalisation and/or death in outpatients with cirrhosis Singh ANIRUDDHA PRATAP HARIPAL, India Relationship between visceral fat and portal vein thrombosis in patients with liver cirrhosis Marta HERNÁNDEZ CONDE, Spain Terlipressin for variceal bleeding induces severe plasma sodium disturbances in non-cirrhotic portal hypertension Peter LYKKE ERIKSEN, Denmark Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience Nikolaus PFISTERER, Austria The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites Nikolaus PFISTERER, Austria The post-living donor liver transplantation survival-defining factor high tricuspid regurgitation pressure gradient in liver cirrhosis correlates with the diastolic heart failure and a high oxidative stress status Akinobu TAKAKI, Japan Hemodynamic disturbances across different stages of decompensated cirrhosis and influencie on outcomes Marta GARCÍA GUIX, Spain Prevalence and clinic impact of rectal colonization by multidrug-resistant bacteria in descompensated cirrhosis Maria HERNANDEZ-TEJERO, Spain Improving assessment of hepatic encephalopathy in outpatient clinics Floranne HANSA, Australia Proton pump inhibitors increase the risk of minimal and overt hepatic encephalopathy and they are associated with high mortality in cirrhotic patients Silvia NARDELLI, Italy POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 313

316 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-276 SAT-277 SAT-278 SAT-279 SAT-280 SAT-281 SAT-282 SAT-283 SAT-284 SAT-285 The time trend of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: an analysis on the National Inpatient Sample Donghak JEONG, United States Validation and modification of Baveno criteria to rule out highrisk varices in patients with compensated cirrhosis Varun RAVINDRA TADKALKAR, India Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: A systematic review and meta-analysis Susana RODRIGUES, Switzerland Clinically significant portal hypertension in chronic liver disease: Always cirrhosis? Susana RODRIGUES, Switzerland Screening of esophagogastric varices: performance of the Expanded Baveno VI criteria and the platelet 150/MELD 6 strategy in all etiology compensated advanced chronic liver disease Giulia TOSETTI, Italy Combined elastin and collagen proportionate area subclassifies cirrhosis and predicts clinical outcomes Avik MAJUMDAR, Australia Transjugular intrahepatic portosystemic Shunt is highly effective in patients with a MELD score <20 and does not require routine Doppler ultrasound follow-up Koos DE WIT, Netherlands Efficacy of liver stiffness measurement and platelet count in screening for high grade varies in patients with cirrhosis Ashish AGARWAL, India Correlation and prognostic accuracy between noninvasive liver reserve markers and portal pressure in cirrhosis: Role of ALBI score Yun-Cheng HSIEH, Taiwan Tolerability and kinetics of SYNB1020 in a Phase 1, first-in- Human, healthy adult volunteer study Marja PUURUNEN, United States 314 EASL THE HOME OF HEPATOLOGY

317 11-15 APRIL 2018 PARIS, FRANCE SAT-286 SAT-287 SAT-288 SAT-289 SAT-290 SAT-291 SAT-292 SAT-293 SAT-294 SAT-295 SAT-296 Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy? Signe WIESE, Denmark The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis Signe WIESE, Denmark Hepatopulmonary syndrome: A spontaneously reversible condition? Variability in prevalence in a prospective follow-up study of cirrhotic patients Aurelia CHIRICUTA, Romania Is obesity an additional negative factor in sarcopenic cirrhotic patients? Daria D AMBROSIO, Italy Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets Lasse LANGHOLM, Denmark The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices Salvador MACHLAB, Spain Association between hospital type and transplant-free survival in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunts (TIPS): A population-based study Jeffrey MAH, Canada A simple patient-reported instrument can predict development of overt hepatic encephalopathy Mette Munk LAURIDSEN, Denmark The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multimodal intervention Mette Munk LAURIDSEN, Denmark Transjugular intrahepatic portosystemic shunt versus beta-blocker and/or endotherapy for prevention of variceal rebleeding in adults with EHPVO Guohong HAN, China Slow continuous albumin Infusion with furosemide with or without terlipressin in cirrhotic patients with refractory ascites Vivek SARASWAT, India POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 315

318 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-297 SAT-298 SAT-299 SAT-300 SAT-301 SAT-302 SAT-303 SAT-304 SAT-305 SAT-306 SAT-307 A prospective evaluation of symptom burden, opioid risk in cirrhosis patients Mina NIAZI, Canada Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures Javier AMPUERO, Spain Four years outcomes of Baveno VI low risk cirrhotic patients Priscila POLLO-FLORES, Brazil A novel sonographic parameter for the quantification of muscle mass in cirrhosis Kazufumi KOBAYASHI, Japan Repeated episodes of acute kidney injury on the transplant waiting list: Impact on post-liver transplantation renal and patient outcomes Shuetfong NEONG, Canada Eradication of hepatitis C virus in patients with decompensated cirrhosis does not improve the management of ascites after one year of follow-up Adria JUANOLA, Spain Gender differences regarding sarcopenia development in chronic liver disease Atsushi HIRAOKA, Japan Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI Ioan-Cristian LUPESCU, Romania Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrugresistant bacteria Marcus MÜCKE, Germany The Indication, dosage and duration of proton pump inhibitors in liver cirrhosis Marianne DE ROZA, Singapore the effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients Vincenza DI GREGORIO, Italy 316 EASL THE HOME OF HEPATOLOGY

319 11-15 APRIL 2018 PARIS, FRANCE SAT-308 SAT-309 SAT-310 SAT-311 SAT-312 SAT-313 SAT-314 SAT-315 SAT-316 SAT-317 SAT-318 Presepsin, C reactive protein and procalcitonin have similar accuracy for bacterial infection and sepsis in decompensated cirrhosis Fischer PETRA, Romania Predictive factors of esophageal varices recurrence after prophylactic endoscopic band ligation Jaime RODRIGUES, Portugal A study evaluating outcomes of cirrhotic patients managed in a dedicated liver cirrhosis clinic and factors influencing survival David KOCKERLING, United Kingdom Frialty is an independent predictive factor of hospital admissions and falls in patients with cirrhosis Eva ROMAN, Spain Cardiac assessment in children with chronic liver disease: cholestatic and non-cholestatic Tawhida Yassin ABDEL GHAFFAR, Egypt Non-invasive predictors of varices in non-cirrhotic portal hypertension Morven CUNNINGHAM, Canada Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis Graziella PRIVITERA, Italy Drug-induced encephalopathy in cirrhotic patients with neurological symptoms: A metabolomic study Nicolas WEISS, France Endoscopic radiofrequency ablation for the treatment of gastric antral vascular ectasia in cirrhotic patients: A bi-centric clinical and economical cost-effective analysis Marco SENZOLO, Italy Avatrombopag decreases need for platelet transfusion in patients chronic liver disease and thrombocytopenia undergoing medical procedures with low to high associated bleeding risks Kavita AGGARWAL, United States Efficacy ofavatrombopag compared with placebo across various mean baseline platelet countsubgroups- pooled data from 2 Phase 3 studies Kavita AGGARWAL, United States POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 317

320 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cirrhosis, portal hypertension, and complication (Cont.) SAT-319 SAT-320 SAT-321 Consistent efficacy of avatrombopag compared to placebo in patients with thrombocytopenia and chronic liver disease undergoing procedures across various disease severities and etiologies Kavita AGGARWAL, United States Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity Hiroaki TAKAYA, Japan Sustained long-term improvement in clinical and cognitive outcomes after fecal microbiota transplantation in cirrhosis Jasmohan S BAJAJ, United States POSTERS / SATURDAY 14 APRIL EASL THE HOME OF HEPATOLOGY

321 11-15 APRIL 2018 PARIS, FRANCE Viral hepatitis A/E: Clinical aspects SAT-325 SAT-326 SAT-327 SAT-328 SAT-329 Top 10% High mortality rate in HBV-related cirrhosis patients with HEV superinfection Tai-Chung TSENG, Taiwan Clinical features and outcomes of hepatitis E in patients with underlying chronic liver disease: a respective case-control study Yijin WANG, China Risk factors of hepatitis E related liver failure: a restrospective case-control study Yijin WANG, China The role of hepatitis E in acute non-traumatic neuropathy in China: a prospective case-control study Yijin WANG, China Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe Johannes HARTL, Germany SAT-330 SAT-331 Top 10% SAT-332 SAT-333 SAT-334 SAT-335 SAT-336 Dynamics of HBsAg clearance in a UK cohort of chronic HBV infection Philippa MATTHEWS, United Kingdom Blood products as source of HEV transmission? 1-year experience with routine HEV screening at a tertiary center Thomas HORVATITS, Germany Poor outcome of acute hepatitis E in liver cirrhosis and transplant recipients Mar RIVEIRO BARCIELA, Spain Preceding hepatitis E virus infection in patients with myasthenia gravis Lin WANG, China Hepatitis A affecting men having sex with men: ongoing outbreak in Israel, December September 2017 Orna MOR, Israel Incidence of hepatitis E infection in renal transplant patients in The Netherlands Robin ERKEN, Netherlands Hepatitis E Virus adapts to cell culture, but shows limited mutagenesis in immune compromised hosts Thomas VANWOLLEGHEM, Netherlands POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 319

322 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis A, B, C, D, E: Virology POSTERS / SATURDAY 14 APRIL 2018 SAT-339 SAT-340 SAT-341 SAT-342 SAT-343 SAT-344 SAT-345 SAT-346 SAT-347 SAT-348 SAT-349 Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A Slim FOURATI, France Efficient, reproducible, and long-term hepatitis B virus infection in cryopreserved primary human hepatocytes Guofeng CHENG, United States NLRX1 and the p.arg707cys variant in NLRX1 affect host susceptibility of hepatitis B virus infection in Huh7-NTCP cells Liang PENG, China The stapled peptides derived from hepatitis B virus core protein hijack viral replication Jinchao HAN, China DEAD-box helicases DDX5 and DDX17 areinvolved in the fine tuning of hepatitis B virus minichromosome transcriptional regulation Fleur CHAPUS, France Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes Philippa MATTHEWS, United Kingdom LTPprodrug technology offers new generation nucleotide antiviral agents Lin ZHI, United States Conservation and variation of the hepatitis E virus open reading frame 2 proteome Shaoshi ZHANG, Netherlands Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture Sandra CIESEK, Germany Expanding the donor pool- decontamination of HCV RNA positive kidneys with methylene blue Sandra CIESEK, Germany Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort Daniel FELMLEE, United Kingdom 320 EASL THE HOME OF HEPATOLOGY

323 11-15 APRIL 2018 PARIS, FRANCE SAT-350 SAT-351 SAT-352 SAT-353 SAT-354 SAT-355 SAT-356 SAT-357 SAT-358 SAT-359 A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro Lorenzo PIERMATTEO, Italy Palmitoylation determines the subcellular localization of the hepatitis E virus ORF3 protein Jérôme GOUTTENOIRE, Switzerland Identification of hepatitis B virus core protein nuclear interacting factors points to RNA binding proteins as major regulators of HBV replication Hélène CHABROLLES, France Potential contribution of more sensitive hepatitis B surface antigen assays to detect and monitor hepatitis B infection Charlotte PRONIER, France Compare HBsAg retention in the endoplasmic reticulum and the ER stress between the cells transfected or infected by the wild type and pre-s HBV mutants using in vitro transfection and in vivo infection of FRG mice Jenny Yuh-Jin LIANG, Taiwan HBV peptide array demonstrates candidate mechanisms of CRV431 anti-hbv activity Robert FOSTER, United States Assessing the in vitro anti-hbv activity of combinations including CRV431, TXL, and prototype capsid assembly modulators Robert FOSTER, United States Establishment of a method to compare antiviral effect of drug products by human hepatitis B virus infected humanized chimeric mice Hatsune ENOMOTO, Japan Identification of HBV genotypes and mutations associated to antiviral resistance and vaccine escape in serum and oral fluid samples from chronic hepatitis B patients Moyra MACHADO PORTILHO, Brazil Identification of a stable HBV inter-genotype (A/G) recombinant strain in a guinean patient in grey zone of treatment Ana Isabel GIL, Spain POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 321

324 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis A, B, C, D, E: Virology (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-360 SAT-361 SAT-362 SAT-363 SAT-364 SAT-365 SAT-366 SAT-367 SAT-368 In vitro and in vivo antiviral characterization of RO , a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B Lu GAO, China HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell derived hepatic cells Yasuhiro ASAHINA, Japan Post transcriptional regulation of Hepatitis B virus in a prospective cohort of chronically infected patients Aurélie SCHNURIGER, France Statin inhibits HDV assembly, secretion, and large hepatitis delta antigen-smad3-twist mediated epithelial-mesenchymal transition Jaw-Ching WU, Taiwan Murine hepatocytes with humanized sodium taurocholat polypeptide (NTCP) limit HDV infection in vivo independent of adaptive immune responses Marc LUETGEHMANN, Germany Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models Julie LUCIFORA, France Inhibition of hepatitis B virus X protein in HBV-infected primary human hepatocytes leads to the reappearance of the Smc5/6 complex Rudolf BERAN, United States FXR is a proviral factor whose binding to HBV genome is modulated by FXR agonist and correlates with presence of the activated chromatin mark H3K4me3 in an HBx dependant manner Benoît LACOMBE, France Developing a new world monkey model of chronic HBV infection in the post-chimpanzee era Christian VOITENLEITNER, United States 322 EASL THE HOME OF HEPATOLOGY

325 11-15 APRIL 2018 PARIS, FRANCE SAT-369 SAT-370 SAT-371 SAT-372 SAT-373 Top 10% SAT-374 SAT-375 Top 10% SAT-376 SAT-377 SAT-378 SAT-379 Reduction of serum infectivity of Hepatitis Delta virusinfected patients treated with Myrcludex B: An in vitro assay to determine infectious units Katrin SCHÖNEWEIS, Germany The protein complex structural maintenance of chromosomes reappears after interferon alpha treatment in hepatitis B virus infected humanized mice but its presence does not hinder viral rebound Maura DANDRI, Germany Hepatitis B virus escapes non-canonical CTL effector function Dirk WOHLLEBER, Germany HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients Kai-Henrik PEIFFER, Germany Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation Florian LEMPP, Germany Proteomic analysis of hepatitis B virus cccdna-specific associated proteins identifies crucial regulators of viral transcription and RNA processing Barbara TESTONI, France Biogenesis and function of intracellular hepatitis B e antigen Bidisha MITRA, United States EFTUD2 restricts hepatitis B virus infection by regulating RIG-I expression Chuanlong ZHU, China Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate virus replication Wenshi WANG, Netherlands Pro-fibrogenic mediator osteopontin is intimately involved in chronic hepatitis B and promotes cccdna production Sandra PHILLIPS, United Kingdom Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients Ondrej PODLAHA, United States POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 323

326 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis A, B, C, D, E: Virology (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-380 SAT-381 SAT-382 SAT-383 SAT-384 SAT-385 SAT-386 SAT-387 SAT-388 SAT-389 Control of glycokinase activity by the HCV protein NS5A increases lipogenesis Olivier DIAZ, France Evolution and persistence of resistance-associated substitutions of hepatitis c virus after daclatasvir plus asunaprevir treatment failures Yechan JEONG, Korea, Rep. of South FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with raav2/8- HBV Patrice ANDRE, France Cellular retinoic acid-binding proteins regulation of hepatitis C virus infection Takeshi SAITO, United States GalXC technology enables potent and durable RNAi-mediated inhibition of hepatitis B virus in preclinical models Martin KOSER, United States Sodium taurocholate cotransporting popypeptide variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B Olympia ANASTASIOU, Germany Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein Laurence COCQUEREL, France Serum HBcrAg levels as a predictor of slow HBV DNA suppression following initiation of nucleoside therapy in HBV/ HIV co-infected individuals Ruth BYRNE, United Kingdom Statins suppress hepatitis B virus replication and reduce hepatoma cell viability by interfering with Rho-GTPases Maarten VAN DE KLUNDERT, Germany Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized upa/scid mice using an agent-based modeling approach Harel DAHARI, United States 324 EASL THE HOME OF HEPATOLOGY

327 11-15 APRIL 2018 PARIS, FRANCE SAT-390 SAT-391 SAT-392 SAT-393 SAT-394 SAT-395 SAT-396 SAT-397 SAT-398 SAT-399 SAT-400 Understanding HDV and HBV dynamics during acute coinfection in humanized upa/scid chimeric mice using an agent-based modeling appraoch Harel DAHARI, United States Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years Athenaïs GERBER, France Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains Athenaïs GERBER, France Deep sequencing analysis highlights variations associated with HBeAg seroconversion in adolescents with chronic hepatitis B Christophe COMBET, France Prevalence, pathogenesis and cross-species transmission of a novel hepatitis E virus from bactrian camels Lin WANG, China Mitochondrial electron transport chain complex III: a promising antiviral target for hepatitis E virus Changbo QU, Netherlands HCV induced-mir-21 activation triggers lipid accumulation and promotes viral replication Sophie CLÉMENT-LEBOUBE, Switzerland Hepatitis E virus replication and interferonresponse in human placental-derived cells Patrick BEHRENDT, Germany Are there different profiles in microrna expression in HBV/ HDV co-infected patients reflecting plasma HBsAg and HBcrAg concentrations? Ivana CAREY, United Kingdom Dimerization: A structural feature for the protection of Hepatitis E virus capsid protein against trypsinization Wenjuan WEI, China The correlations between HBV markers in sera and HBVcccDNA for genotypes Matsui TAKESHI, Japan POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 325

328 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis A, B, C, D, E: Virology (Cont.) SAT-401 Top 10% SAT-402 Estrogen receptor R1 and CAD are host factors for HDV replication and antiviral targets Eloi VERRIER, France Defining hos DNA repair factors in the formation of the hepatitis B virus covalentrly close circular DNA persistence reservoir Eloi VERRIER, France POSTERS / SATURDAY 14 APRIL EASL THE HOME OF HEPATOLOGY

329 11-15 APRIL 2018 PARIS, FRANCE Viral Hepatitis A, B, C, D, E: Immunology SAT-405 SAT-406 SAT-407 SAT-408 SAT-409 Top 10% MicroRNA-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes/macrophages during chronic hepatitis C virus infeciton Ying ZHANG, China Depletion of RIPK1 in hepatocytes exacerbates PolyI:C and Murine Hepatitis Virus induced liver damage Michel SAMSON, France A novel chimpanzee adenoviral vectored HBV vaccine, encoding multiple HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy Senthil Kumar CHINNAKANNAN, United Kingdom Modeling HBV infections and immune responses in humanized mouse models Helene STRICK-MARCHAND, France Highly immunogenic virally vectored T cell vaccine against HCV are able to induce specific CD4+ T cell helper responses Ilaria ESPOSITO, United Kingdom SAT-410 SAT-411 SAT-412 Top 10% SAT-413 Top 10% Induction of liver sinusoidal endothelial cells immune activation by HBeAg during HBV infection Jia LIU, China Regulation of antiviral CD8 T cell response by MMP mediated soluble CD100 releasing in HBV infection Jia LIU, China Transcriptomic profiling of intrahepatic B cells suggests a B-cell impairment in the immune active phase of chronic hepatitis B Stijn VAN HEES, Belgium Dysfunctional surface antigen-specific memory B cells accumulate in chronic hepatitis B infection Alice BURTON, United Kingdom POSTERS / SATURDAY 14 APRIL 2018 SAT-414 Hepatitis B virus entry in primary human hepatocytes initiates toll-like receptor 2-dependent immune signaling Ruth BROERING, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 327

330 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Viral Hepatitis A, B, C, D, E: Immunology (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-415 SAT-416 SAT-417 SAT-418 SAT-419 SAT-420 SAT-421 SAT-422 SAT-423 SAT-424 SAT-425 Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes Upkar S. GILL, United Kingdom HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load Upkar S. GILL, United Kingdom Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes Katrin MANSKE, Germany The RNA genome of hepatitis E virus robustly triggers antiviral interferon response Wenshi WANG, Netherlands The impact of HBsAg on general and HBV-specific immunity Nina LE BERT, Singapore Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection Elena PERPIÑAN, Spain Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver Shingo NAKAMOTO, Japan PTEN-mediated beta-catenin/pd-l1 signaling in hepatocytes modulates hepatitis B virus immune evasion from T cell responses Changyong LI, China Nuclear DNA sensor protein IFI16 recognizes hepatitis B virus covalently closed circular DNA and regluates the antiviral innate immunity Xiao-ben PAN, China Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort Kris BENNETT, United Kingdom MicroRNA-181C potentially relieved fulminant viral heaptitis by targeting TNF-a in mice Dong XI, China 328 EASL THE HOME OF HEPATOLOGY

331 11-15 APRIL 2018 PARIS, FRANCE SAT-426 SAT-427 SAT-428 SAT-429 SAT-430 SAT-431 SAT-432 SAT-433 SAT-434 SAT-435 SAT-436 HLA-A2 restricted CD8+ T cell immune hierarchy towards full length hepatitis E virus for T cell-based therapy in chronic HEV Chaifen SOON, Germany Development and characterization of unique hepatitis C virus neutralizing antibodies associated with infection outcome Shiri ELMEDVI BARAN, Israel EP2 associated with the inflammatory storm in HBV related acute-on-chronic liver failure Yunyun WANG, China Cytokine-dependent activation of MAIT cells by the TLR8 agonist GS-9688 but not the TLR7 agonist GS-9620 Hassan JAVANBAKHT, United States Characterization of thehev-specific CD8+ T-cell response in acute and chronic Hepatitis E virus infection Janine KEMMING, Germany A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes Timothy DONNISON, United Kingdom Performance of recomwell HEV and Wantai HEV in acute Hepatitis E and German blood donors Friedhelm STRUCK, Germany Ex vivo characterization of co-inhibitory molecules on MHC class II tetramer positive HCV-specific CD4+ T cells in HCV infection Christin ACKERMANN, Germany Association of PD1 and TIM3 polymorphisms with HBV susceptibility Chunhong HUANG, China Preclinical mechanistic and efficacy evaluation of a novel small molecule TLR7 agonist RO for the treatment of chronic hepatitis B Lu GAO, China A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication Qin WANG, China POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 329

332 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Alcoholic liver disease SAT-441 Top 10% Alcoholic liver disease replaces HCV infection as the leading indication for liver transplantation in the United States George CHOLANKERIL, United States POSTERS / SATURDAY 14 APRIL 2018 SAT-442 SAT-443 SAT-444 SAT-445 SAT-446 SAT-447 SAT-448 SAT-449 SAT-450 SAT-451 Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis Marot ASTRID, Belgium Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis Marot ASTRID, Belgium Heparin like effect increases risk of mortality and bleeding tendency in patients with severe alcoholic hepatitis during systemic Inflammatory Response (SIRS) and sepsis Madhumita PREMKUMAR, India Prevalence of alcoholic steatosis in the general adult Portuguese population Jorge Antonio M.CARVALHO PRATAS LEITAO, Portugal Making sense of liver function tests: Is the Intelligent Liver Function Test (ilft) cost-effective? Kathleen BOYD, United Kingdom Combination of the Lille model with baseline scores is useful to predict mortality in severe alcoholic hepatitis: a confirmation study in a large database of patients Alexandre LOUVET, France Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis Brian LEE, United States Bayesian sparse regression modelling more accurately predicts mortality risk than commonly used prognostic scoring systems in patients with severe alcoholic hepatitis Stephen ATKINSON, United Kingdom Insufficient diagnostic accuracy of general practitioners and routine liver function tests lead to high risk of under-referrals of patients with alcohol induced advanced liver fibrosis Thor Lars HANSEN, Denmark Delineating complement activation molecular patterns in patients with alcoholic hepatitis Rebecca MCCULLOUGH, United States 330 EASL THE HOME OF HEPATOLOGY

333 11-15 APRIL 2018 PARIS, FRANCE SAT-452 SAT-453 SAT-454 SAT-455 SAT-456 SAT-457 SAT-458 SAT-459 SAT-460 SAT-461 SAT-462 SAT-463 Presence of IgA isotype F-actin is frequent in patients with cirrhosis and consitutes the risk of progressive disease course Boglárka BALOGH, Hungary The TIM3-Gal9 immune checkpoint axis is inter-linked with severity of Alcoholic Liver Disease Antonio RIVA, United Kingdom Interleukin-22 binding protein in alcoholic hepatitis Sidsel STØY, Denmark The bile acid biome and its relationship to the development and severity of alcoholic hepatitis Puneet PURI, United States Collagen proportionate área is an independent predictor of long term outcome in patients with alcoholic liver disease Marta GUERRERO MISAS, United Kingdom Hepatoprotective biomarkers, amphiregulin and soluble Fas, increase during ELAD treatment inalcoholic hepatitis subjects Jason LAPETODA, United States The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death Ulrich BANG, Denmark mirna regulation of macrophage M1/M2 polarization of Kupffer cells and PBMCs in alcoholic liver disease Adam KIM, United States The correlation of obesity with morbidity and mortality in alcoholic hepatitis Yasir YASIRALAZZAWI, United States Serum metabolic profiling for the identification of patients with severe alcoholic hepatitis Adelina HORHAT, Romania Persistence of decompensation despite long-term abstinence in alcoholic cirrhosis is associated with poor outcomes and lower survival Ana CLEMENTE, Spain Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis Ashwin DHANDA, United Kingdom POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 331

334 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Alcoholic liver disease (Cont.) SAT-464 SAT-465 SAT-466 Morphometrical quantification of fibrosis correlates with clinical cirrhosis stage and predicts long-term survival in patients with alcoholic liver disease Karoline LACKNER, Austria Masked hemolysis as novel factor contributing to hepatic iron overload in ALD Vanessa RAUSCH, Germany Use of rifaximin in alcoholic hepatitis: Pilot study Cesar JIMENEZ, Spain POSTERS / SATURDAY 14 APRIL EASL THE HOME OF HEPATOLOGY

335 11-15 APRIL 2018 PARIS, FRANCE NAFLD: Clinical aspects except therapy SAT-471 SAT-472 Top 10% SAT-473 SAT-475 SAT-476 SAT-477 Top 10% SAT-478 SAT-479 SAT-480 Top 10% Maternal dietary patterns and the risk of large-for-gestational age births Satomi MINATO, Japan Impact of short term weight loss (very low calorie diet vs bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile Chiara BARBIERI, Italy Substantial healthcare utilization and costs among nonalcoholic steatohepatitis patients with comorbid diabetes mellitus: Real-world analysis of US Medicare data Stuart C GORDON, United States Prediction of decompensation events in NASH cirrhosis patients Roberta FORLANO, United Kingdom A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease Roberta FORLANO, United Kingdom Lipofuscin is detected in early stages of the disease in liver biopsies of patients with Non-Alcoholic Fatty Liver Disease Roberta FORLANO, United Kingdom Stage-specific benefitsof treatment associated fibrosis regression in patients with NASK: A Markovmodeling approach Jagpreet CHHATWAL, United States NAFLD/NASH patients with compensated cirrhosis had a high prevalence of comorbidities, substantial liver disease progression, and increased annual number of hospitalizations and associated costs in France: a PMSI database analysis Jerome BOURSIER, France Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD Alexandra FELDMAN, Austria POSTERS / SATURDAY 14 APRIL 2018 SAT-481 SAT-482 Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort Naim ALKHOURI, United States Increased gut permeability is associated with oxidative stress in patients with NAFLD Francesco BARATTA, Italy THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 333

336 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Clinical aspects except therapy (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-483 SAT-484 SAT-485 SAT-486 SAT-487 SAT-488 SAT-489 SAT-490 SAT-491 Top 10% SAT-492 SAT-493 Increasing trend for Hepatocellular Carcinoma linked to Nonalcoholic Fatty Liver Disease in the United States Ethan MILLER, United States Non-alcoholic fatty liver disease in non-obese young adults Yaakov MAOR, Israel Risk factors for development of severe liver disease in more than patients with type 2 diabetes: A population-based cohort study Karl BJÖRKSTRÖM, Sweden Multidisciplinary intervention on lifestyle improves the management of patients with nonalcoholic fatty liver disease Sara POLICARPO, Portugal Long-term associations between non-high density Lipoprotein Cholesterol and Apolipoprotein B in young adulthood and subclinical atherosclerosis in persons with nonalcoholic fatty liver disease in middle age: The CARDIA study Lisa VANWAGNER, United States Association of nonalcoholic fatty liver disease with changes in left ventricular structure and function: The coronary artery risk development in young adults (CARDIA) study Lisa VANWAGNER, United States Investigating the relationship between rare genetic variants and advanced fibrosis in pediatric nonalcoholic fatty liver disease Julia WATTACHERIL, United States Hepatic steatosis in an adult population: stronger correlation with the presence of obesity and insulin resistence than with the dietary pattern. Results from a cross-sectional study Jorge Antonio M.CARVALHO PRATAS LEITAO, Portugal Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH) Elena BUZZETTI, Italy NAFLD has a negligible role for survival in old subjects Giampaolo BIANCHI, Italy Do patients with abnormal liver tests and nonalcoholic fatty liver disease get statins even when indicated? Sonal KUMAR, United States 334 EASL THE HOME OF HEPATOLOGY

337 11-15 APRIL 2018 PARIS, FRANCE SAT-494 SAT-495 SAT-496 SAT-497 SAT-498 SAT-499 SAT-500 SAT-501 SAT-502 SAT-503 SAT-504 SAT-505 The effect of microvascular complications of diabetes on advanced fibrosis in nonalcoholic fatty liver disease Sonal KUMAR, United States Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the United States Karn WIJARNPREECHA, United States The platelet count is declining in American adults in parallel with an increase in risk factors for nonalcoholic fatty liver disease Amandeep SINGH, United States Real world evidence showing high rates of cardiovascular events in NAFLD patients regardless of liver disease Arun SANYAL, United States The relationship between NAFLD and breast cancer: High prevalence and poor prognosis Young-Sun LEE, Korea, Rep. of South Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease Thomas KARLAS, Germany Nonalcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes: A prospective cohort study Won KIM, Korea, Rep. of South Plasma cells in non-alcoholic steatohepatitis correlates with disease activity Mehul LAMBA, New Zealand Cardiovascular risk factors and fibrosisseverity in NAFLD: is there a link? Davide ROCCARINA, United Kingdom Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD the German CONSTANS STUDY Jörn SCHATTENBERG, Germany Analyze of ballooning biomarker in patients with non-alcoholic steatohepatitis: A multicenter study Yuji OGAWA, Japan Health-related quality of life correlates with histological severity in non-alcoholic fatty liver disease Yvonne HUBER, Germany POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 335

338 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NAFLD: Clinical aspects except therapy (Cont.) POSTERS / SATURDAY 14 APRIL 2018 SAT-506 SAT-507 SAT-508 SAT-509 SAT-510 SAT-511 SAT-512 SAT-513 SAT-514 SAT-515 Influence of non-alcoholic fatty liver disease on cardiovascular risk in patients with stable coronary heart disease Iryna VAKALYUK, Ukraine Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity Javier AMPUERO, Spain Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry Javier AMPUERO, Spain Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosisin patients with advanced fibrosis/compensated cirrhosis Salvatore PETTA, Italy A Comprehensive Assessment of Serial Transient elastography in various Liver disease Etiologies at the Toronto Liver Centre (CASTLE-TLC) Kerstina BOCTOR, Canada Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients Amalia GASTALDELLI, Italy The triglycerides and glucose (TyG) index : A new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients? Stephanie FAURE, France Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars Panu LUUKKONEN, Finland Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/ Study of Latinos (HCHS/SOL) Aynur UNALP-ARIDA, United States Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD a pilot study Veeral AJMERA, United States 336 EASL THE HOME OF HEPATOLOGY

339 11-15 APRIL 2018 PARIS, FRANCE SAT-516 SAT-517 SAT-518 SAT-519 SAT-520 SAT-521 SAT-522 SAT-523 SAT-524 SAT-525 SAT-526 Role of nutritional intake on clinical presentation of lean and overweight NAFLD Rosa LOMBARDI, Italy Non-alcoholic fatty liver disease is omega-6 fatty acids diet dipendent in a group of obese children Anna MANTOVANI, Italy Sarcopenia is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease Min Kyu KANG, Korea, Rep. of South Change of microbiota in patients with improved fatty liver and obesity Sang Bong AHN, Korea, Rep. of South Role of L-carnitine in pathogenesis of the atherogenic dyslipidemia in ischemic heart disease with concominent nonalcoholic steatohepatitis Igor SKRYPNYK, Ukraine Assessment of baseline Hepatitis B Virus (HBV) immunity and HBV vaccine responses in prospectively vaccinated adults with Non Alcoholic Fatty Liver Disease Carla COFFIN, Canada Clinical characteristics and epidemiology of patients with nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in a large community-based healthcare delivery system in the U.S. Heather PATTON, United States Sex hormone binding globulin levels are increased in HIVinfected men and are independently associated with lower odds of nonalcoholic fatty liver disease regardless of HIV serostatus Jennifer PRICE, United States The conundrum of cryptogenic liver disease with advanced fibrosis: poor clinical outcomes without treatment options Zobair YOUNOSSI, United States The worldwide prevalence of Non-alcoholic Steatohepatitis (NASH) in patients with Type 2 Diabetes Mellitus (DM) Zobair YOUNOSSI, United States Moderate alcohol consumption protects against fatty liver in males Takemi AKAHANE, Japan POSTERS / SATURDAY 14 APRIL 2018 THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 337

340 HEPAHEALTH Project Report To be launched at The International Liver Congress

341 11-15 APRIL 2018 PARIS, FRANCE ACKNOWLEDGEMENTS EASL THE HOME OF HEPATOLOGY

342 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME ABSTRACT REVIEWERS Abraldes Juan G., Canada Aithal Guru, United Kingdom Alazawi Wiliam United Kingdom Albillos Agustín, Spain Alemann Soo, Sweden Altamirano Jose, Spain Ampuero Javier, Spain Anstee Quentin, United Kingdom Avila Mathias, Spain Banales Jesus, Spain Bechman Lars, Germany Berasain Carmen, Spain Bertoletti Antonio, Singapore Bhoori Sherrie, Italy Björkström Niklas, Sweden Coco Barbara, Italy Colle Isabelle, Belgium Crespo Javier, Spain Cucchetti Alessandro, Italy De Gottardi Andrea, Switzerland Del Pulgar Sofia, Spain Demir Münevver, Germany Deterding Katja, Germany Feray Cyrille, France Fernandez Javier, Spain Francque Sven, Belgium Giannini Edoardo, Italy Gissen Paul, United Kingdom Goutte Nathalie, France Heinzow Hauke, Germany ACKNOWLEDGEMENTS Bourlière Marc, France Boursier Jerome, France Bruno Raffaele, Italy Bruns Tony, Germany Bugianesi Elisabetta, Italy Burra Patrizia, Italy Cantz Tobias, Germany Ceccherini Silberstein Francesca, Italy Henderson Neil, United Kingdom Hirschfield Gideon, United Kingdom Hov Johannes, Norway Invernizzi Pietro, Italy Jaeckel Elmar, Germany Jaroszewicz Jerzy, Poland Jepsen Peter, Denmark Karlas Thomas, Germany Chazouillères Olivier, France Cheung Michelle, United Kingdom Clavien Pierre, Switzerland Clayton Michelle, United Kingdom Keitel Verena, Germany Kennedy Patrick, United Kingdom Knolle Percy, Germany Koek Ger, Netherlands 340 EASL THE HOME OF HEPATOLOGY

343 11-15 APRIL 2018 PARIS, FRANCE Krag Aleksander, Denmark Kremer Andreas, Germany Kroy Daniela, Germany La Mura Vincenzo, Italy Larrey Dominique, France Lazarus Jeffrey, Denmark Leclercq Isabelle, Belgium Lens Sabela, Spain Lesurtel Mickaël, Switzerland Leth Hjort Kristine, Denmark Liaskou Evaggelia, United Kingdom Llarch Neus, Spain Lucena Maria Isabel, Spain Lucifora Julie, France Luis Calleja José, Spain Maasoumy Benjamin, Germany Mueller Sebastian, Germany Mülhaupt Beat, Switzerland Nahon Pierre, France Nault Jean-Charles, France Neumann-Haeflin Christoph, Germany Nobili Valerio, Italy Parola Maurizio, Italy Peck Markus, Austria Perugorria Maria Jesus, Spain Pietrangelo Antonello, Italy Piscaglia Fabio, Italy Pischke Sven, Germany Pollicino Teresa, Italy Reig Maria, Spain Ripoll Cristina, Germany Maini Mala, United Kingdom Makara Michael, Hungary Mallet Vincent, France Mandorfer Mattias, Austria Mathurin Philippe, France Mazza Giuseppe, United Kingdom Melum Espen, Norway Mertens Joachim, Switzerland Meulemann Philipp, Belgium Meyer Tim, United Kingdom Miele Luca, Italy Romagnoli Renato, Italy Rombouts Krista, United Kingdom Samuel Didier, France Sanchez-Fueyo Alberto, United Kingdom Sancho-Bru Pau, Spain Schurich Anna, Germany Schwabe Robert, United States Schwabl Philipp, Austria Sheron Nick, United Kingdom Simonova Marietta, Bulgaria ACKNOWLEDGEMENTS Missale Gabriele, Italy Moeller Soeren, Denmark Soubrane Olivier, France Stäl Per, Sweden THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 341

344 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Strassburg Christian, Germany Strnad Pavel, Germany Svegliati Baroni Gianluca, Italy Thiele Maja, Denmark Thompson Alexander, Australia Tiegs Gisa, Germany Trauner Michael, Austria Trautwein Christian, Germany Tsochatzis Emmanuel, United Kingdom Urban Stephan, Germany Valenti Luca, Italy Van der Meer Adriaan, Netherlands Vanwolleghem Thomas, Netherlands Varela Calvo Maria, Spain Vermehren Johannes, Germany Villa Erica, Italy Villanueva Augusto, United States Vitale Alessandro, Italy Vogel Arndt, Germany Vom Dahl Stephan, Germany Welzel Tania, Germany Wiest Reiner, Switzerland Wörns Marcus, Germany Yurdaydin Cihan, Turkey Zelber-Sagi Shira, Israel Zender Lars, Germany Zoller Heinz, Austria Zoulim Fabien, France ACKNOWLEDGEMENTS 342 EASL THE HOME OF HEPATOLOGY

345 11-15 APRIL 2018 PARIS, FRANCE SPONSORS PLATINUM SPONSORS GOLD SPONSORS SILVER SPONSORS OTHER SPONSORS ACKNOWLEDGEMENTS Pharmaceuticals THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 343

346 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SPONSORS OF THE SKILLS LEARNING CENTRE ACKNOWLEDGEMENTS 344 EASL THE HOME OF HEPATOLOGY

347 11-15 APRIL 2018 PARIS, FRANCE BIOTECH VILLAGE VLVbio ACKNOWLEDGEMENTS THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 345

348 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME NATIONAL ASSOCIATIONS VILLAGE EASL BOOTH Hall 2 ACKNOWLEDGEMENTS Country Association Abbreviation Austria Azerbaijan Österreichische Gesellschaft für Gastroenterologie & Hepatologie Azerbaijan Gastroenterology and Hepatology Association ÖGGH Belgium Belgium Association for the Study of the Liver BASL Bulgaria Czech Republic Bulgarian Association for the Study of the Liver Czech Society of Hepatology BgASL CSH France Société Française d Hépatologie AFEF Georgia Georgian Hepatology Association GHA Germany Greece German Association for the Study of the Liver GASL Hellenic Association for the Study of the Liver HASL Israel Israel Association for the Study of the Liver IsASL Italy Associazione Italiana per lo Studio del Fegato AISF Poland Polish Association for the Study of the Liver PASL Romania Romanian Society of Gastroenterology and Hepatology SRGH Russia Russian Scientific Liver Society RSLS Slovakia Slovak Society of Hepatology SHS Spain Spanish Association for the Study of the Liver AEEH Sweden Swedish Society of Gastroenterology SGF Switzerland Swiss Association for the Study of the Liver SASL Turkey Turkish Association of Studies of the Liver TASL United Kingdom British Association for the Study of the Liver Mediterrean Association for Study of Liver BASL MASL 346 EASL THE HOME OF HEPATOLOGY

349 11-15 APRIL 2018 PARIS, FRANCE INDUSTRY EASL THE HOME OF HEPATOLOGY

350 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME SATELLITE SYMPOSIA ABBVIE Wednesday 11 April 2018 Room: Main plenary From Treatment Simplification to HCV Elimination: Effective Multi- Stakeholder Care Chair: Michael Manns, Germany 18:00-18:10 Welcome and introduction Michael Manns, Germany 18:10-18:30 Treatment Simplification: The Pan-genotypic Era Nancy Reau, United States 18:30-18:50 Overcoming barriers within the HCV Care Continuum Victor de Lédinghen, France 18:50-19:10 HCV Elimination: Strategies and Stakeholders Greg Dore, Australia 19:10-19:25 Audience Q&A/Panel Discussion All faculty 19:25-19:30 Summary and Close Michael Manns, Germany INDUSTRY BAYER PHARMACEUTICALS Wednesday 11 April 2018 Room: South 3 Treatment sequencing and maximizing survival uhcc in 2018 Chair: Markus Peck-Radosavljevic, Austria 18:00-18:10 Welcome and introduction Markus Peck-Radosavljevic, Austria 18:10-18:30 Systemic therapy in 2018 using the uhcc sequence Sherrie Bhoori, Italy 348 EASL THE HOME OF HEPATOLOGY

351 11-15 APRIL 2018 PARIS, FRANCE 18:30-18:50 Looking ahead treatment planning in uhcc Fabio Piscaglia, Italy 18:50-19:00 Maximizing survival in practice ask the panel All moderated by the chair Conformément à la charte de la visite médicale et en vertu des dispositions des articles 38 et suivants de la loi informatique et Libertés, nous vous informons que vous disposez d un droit d accès, de modification et d opposition pour des motifs légitimes, aux données à caractère personnel collectées vous concernant. Vous pouvez exercer ce droit en vous adressant au Pharmacien Responsable, Bayer HealthCare, Parc Eurasanté, 220 Avenue de la recherche, LOOS Cedex. Nous vous informons que, conformément à l article L du Code de la Santé Publique et préalablement à sa tenue, nous avons soumis pour avis la pré-sente manifestation au Conseil compétent de l Ordre dont vous dépendez. Pour les médecins, chirurgiens-dentistes, sages-femmes et infirmier(e)s : en vertu de l article L du Code de la Santé Publique, vous devez transmettre la présente invitation à votre Conseil Départemental ou Régional. En application des dispositions de l article L du Code de la Santé Publique, Bayer rendra publiques les informations relatives à la présente convention visées par le décret n du 26 décembre 2016 relatif à la déclaration publique d intérêts prévue à l article L du Code de la Santé Publique et à la transparence des avantages accordés par les entreprises produisant ou commercialisant des produits à finalité sanitaire et cosmétique destinés à l homme. Bayer HealthCare est également soumise aux dispositions du Code de la Transparence des liens (Disclosure code) de l EFPIA et s engage à publier les transferts de valeurs se rapportant à cet évènement de manière anonyme et agrégée. NORGINE Wednesday 11 April 2018 Room: South 2 Driving change to optimise the HE patient journey Chair: Jasmohan Bajaj, United States 18:00-18:02 Welcome and introductions Jasmohan Bajaj, United States 18:02-18:22 Starting the journey at HE diagnosis Dominique Thabut, France 18:22-18:42 Decelerating to slow progression of HE Marcus Schuchmann, Germany INDUSTRY 18:42-19:02 Avoiding roadblocks along the way to prevent HE re-admissions Debbie Shawcross, United Kingdom 19:02-19:22 Reaching our destination together to drive positive change in HE management Jasmohan Bajaj, United States 19:22-19:30 Q&A and panel discussion All THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 349

352 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME CELSION Thursday 12 April 2018 Room: West 1 Emerging Horizons in HCC: From Palliation to Cure Chairs: Ghassan Abou-Alfa, United States Riccardo Lencioni, Italy 07:30-08:00 Rethinking Our Approach to Intermediate-Size HCC Riccardo Lencioni, Italy 08:00-08:30 New Developments in Targeted Therapies for HCC: The Mounting Wave of TKIs and Immuno-Oncology Ghassan Abou-Alfa, United States GILEAD SCIENCES EUROPE LTD Thursday 12 April 2018 Room: South 2 Shaping tomorrow together: advances driven by commitment in HBV care Chair: Fabien Zoulim, France 07:30-07:40 The changing face of hepatitis B: from virological control to elimination Fabien Zoulim, France INDUSTRY 07:40-07:55 Learning from the past to shape the future Henry Chan, Hong Kong 07:55-08:10 Translating clinical research into individualised patient management Pietro Lampertico, Italy 08:10-08:20 What could the future hold for management of hepatitis B? Fabien Zoulim, France 08:20-08:30 Driving the future: faculty perspectives on the future priorities in hepatitis B management Chaired by Fabien Zoulim, France 350 EASL THE HOME OF HEPATOLOGY

353 11-15 APRIL 2018 PARIS, FRANCE BRISTOL-MYERS SQUIBB Thursday 12 April 2018 Room: South 1 Advanced NASH and HCC The New Frontiers Objectives: Describe the pathophysiology and potential complications of advanced NASH and HCC Understand the unmet needs of patients with advanced NASH and HCC Explore novel treatments for HCC Chair: Lawrence Serfaty, France 18:30-18:35 Welcome and Introductions Lawrence Serfaty, France 18:35-18:55 Advanced NASH: how do we take action? Quentin Anstee, United Kingdom 18:55-19:15 Is there a connection between NASH and HCC? Peter Galle, Germany 19:15-19:35 What are the latest innovations in HCC treatments? Bruno Sangro, Spain 19:35-19:55 Roundtable Discussion with Panel All speakers 19:55-20:00 Meeting Close Lawrence Serfaty, France GILEAD SCIENCES EUROPE LTD Thursday 12 April 2018 Room: Main plenary INDUSTRY Shaping tomorrow together: from aspiration to achievement in HCV care Chairs: Victor de Lédinghen, France Stefan Zeuzem, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 351

354 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME 18:30-18:34 Welcome and introduction Victor de Lédinghen, France 18:34-18:42 From aspiration to achievement in HCV care Stefan Zeuzem, Germany 18:42-18:57 Shaping tomorrow together through treatment Stefano Fagiuoli, Italy 18:57-19:12 Shaping tomorrow together through screening and linkage to care Victor de Lédinghen, France 19:12-19:22 Shaping tomorrow together for patients Michael Ninburg, United States 19:22-19:37 Shaping tomorrow together through collaboration José-Luis Calleja, Spain 19:37-19:54 Shaping tomorrow together through learning and exchange All Moderator: Stefan Zeuzem, Germany 19:54-20:00 Summary Stefan Zeuzem, Germany INTERCEPT PHARMA EUROPE LTD Thursday 12 April 2018 Room: West 1 INDUSTRY Primary Biliary Cholangitis (PBC): Old Disease, New perspectives Chair: Olivier Chazouillères, France 18:30-18:35 Chair s welcome and introduction Olivier Chazouillères, France 18:35-18:50 PBC: evolving role of patients in disease management Achim Kautz, Germany 18:50-19:05 Enhanced understanding of Farnesoid X receptor(fxr) agonists Michael Trauner, Austria 352 EASL THE HOME OF HEPATOLOGY

355 11-15 APRIL 2018 PARIS, FRANCE 19:05-19:20 Obeticholic Acid: Clinical evidence through long term treatment and real world experience Frederik Nevens, Belgium 19:20-19:45 PBC Case Presentations Gideon Hirschfield, United Kingdom Vincent Leroy, France 19:45-19:55 Panel discussion / Q&A All 19:55-20:00 Summary and meeting close Olivier Chazouillères, France ABBVIE Friday 13 April 2018 Room: Main plenary HCV Unsymposium: Your Meeting, Your Agenda! Chair: Jean-Michel Pawlotsky, France Speakers: Heiner Wedemeyer, Germany and Robert Brown, United States Take the opportunity to create your perfect meeting by voting for the HCV topics you want to hear more about. Global perspectives will be provided by our leading experts accompanied by virtual guest appearances, offering insights into the HCV topics that you care about. Choose from 9 hot topics prior to the meeting, then come and enjoy the fun and interactive agenda you designed! INDUSTRY 18:30-20:00 Panel discussion Robert Brown, United States Jean-Michel Pawlotsky, France Heiner Wedemeyer, Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 353

356 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME GENFIT Friday 13 April 2018 Room: South 1 Game changers in NASH management Chair: Rohit Loomba, United States 18:30-18:40 Introductory remarks Rohit Loomba, United States 18:40-19:05 How close are we to the first NASH drugs? Vlad Ratziu, France 19:05-19:25 Future NASH diagnostics: overcoming the bottleneck Jean-François Dufour, Switzerland 19:25-19:45 Concrete actions to improve disease awareness: The NASH Education Program TM Sven Francque, Belgium 19:45-20:00 Discussion with the speaker panel GILEAD SCIENCES EUROPE LTD Saturday 14 April 2018 Room: South 2 INDUSTRY Shaping tomorrow together addressing the challenges in the management of advanced fibrosis due to non-alcoholic steatohepatitis (NASH) Chair: Lawrence Serfaty, France 12:30-12:35 Welcome and introductions Lawrence Serfaty, France 12:35-12:50 The evolving contribution of NASH to the global liver disease burden Quentin Anstee, United Kingdom 12:50-13:05 Understanding the challenges: focus on disease progression Rohit Loomba, United States 354 EASL THE HOME OF HEPATOLOGY

357 11-15 APRIL 2018 PARIS, FRANCE 13:05-13:25 Debate: are lifestyle modifications and current therapy sufficient for management of advanced fibrosis due to NASH? Kenneth Cusi, United States Rohit Loomba, United States Lawrence Serfaty, France 13:25-13:40 Shaping tomorrow together: diagnostic challenges in NASH Laurent Castera, France 13:40-13:55 Shaping tomorrow together: what does the future hold for the management of NASH with advanced fibrosis Michael Trauner, Austria 13:55-14:00 Summary and panel discussion MSD Saturday 14 April 2018 Room: North 1 A Future Without Hepatitis C: What Will it Take? Chair: Tarik Asselah, France 12:30-12:40 Opening and introductions Tarik Asselah, France 12:40-12:55 HCV Elimination Begins with Awareness and Prevention Jeff Lazarus, Spain 12:55-13:10 From Diagnosis to Cure: Breaking Down the Barriers to HCV Care Ashley Brown, United Kingdom INDUSTRY 13:10-13:25 The Changing Landscape of HCV Treatment and Lessons from the Real World Heiner Wedemeyer, Germany 13:25-13:40 HCV Elimination in Action: First Step Towards a Global Change Brian Conway, Canada 13:40-14:00 Q & A Panel THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 355

358 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME MINI-WORKSHOPS DIAFIR Thursday 12 April 2018 Room: West 2 Mid-infrared metabolic signature: Perspective for non-invasive diagnosis of NASH & liver diseases Chair: Hugues Tariel, France 07:30-07:35 Welcome introduction Hugues Tariel, France 07:35-07:50 NAFLD : which liver lesion to diagnose, only fibrosis? Jerome Boursier, France 07:50-08:05 Mid-infrared technology: A new non-invasive diagnosis approach Olivier Loreal, France 08:05-08:20 Application of the SPIDTM for the screening of NASH Rodolphe Anty, France 08:20-08:30 Q&A and conclusion GALMED PHARMACEUTICALS Thursday 12 April 2018 Room: West 3 INDUSTRY NASH in sub-populations: similarities, differences and clinical development of Aramchol Chair: Vlad Ratziu, France 07:30-07:50 NASH in sub-populations: similarities and differences Arun Sanyal, United States 07:50-08:10 Treating NASH with Aramchol The scientific rationale Scott Friedman, United States 08:10-08:30 Clinical development of Aramchol in NASH subpopulations Rohit Loomba, United States 356 EASL THE HOME OF HEPATOLOGY

359 11-15 APRIL 2018 PARIS, FRANCE ALNYLAM PHARMACEUTICALS Friday 13 April 2018 Room: East 3 Developing Innovative Treatments for Patients with Rare Diseases: Liver-Targeted RNA Interference Therapeutics Chair: Laurent Gouya, France 18:30-18:40 Welcome and Introductions Paolo Ventura, Italy 18:40-18:55 RNA interference: Targeting Liver Expressed Genes to Treat Rare Diseases Amy Simon, United States 18:55-19:10 Natural History Studies: Expanding the Understanding of Rare Diseases Laurent Gouya, France 19:10-19:25 Clinical Development: Path to Patients with an Investigational RNAi Therapeutic to Treat Acute Hepatic Porphyrias Eliane Sardh, Sweden 19:25-19:30 Q&A All INSPHERO Friday 13 April 2018 Room: West 3 Defeating the animal: accelerate drug discovery with screen-able 3D Liver Disease Models INDUSTRY Chair: Andrea Lindemann, Switzerland 18:30-18:40 18:40-19:05 19:05-19:20 Accelerating Drug Discovery with 3D Disease Models Monika Kijanska, Switzerland Efficacy testing in 3D Liver Disease Models: an enabling tool covering single and multi-modal pathways Radina Kostadinova, Switzerland Modeling Metabolic Circuits in NAFLD Burcak Yesildag, Switzerland THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 357

360 EXHIBITION EXHIBITION OPENING HOURS Thursday 12 to Saturday 14 April 09:00 17:00 POSTER AREA 2 Posters POSTER AREA 1 Posters EASL EDUCATION JOURNAL OF HEPATOLOGY EASL APPS eposters POSTER AREA 3 Posters POSTER AREA 4 Posters THU-SAT Access to hall 7.3 THU-SAT Abbvie 510 Intercept EASL COMMUNITY HUB BIOTECH VILLAGE CAREER CENTRE EASL SHARE ZONE Norgine THU-SAT INDUSTRY THU-SAT Abbvie 410 Access to hall 7.3 Gilead Intercept MSD 310 DELEGATE LOUNGE sponsored by Bristol-Myers Squibb Gilead 240 Gilead THU-SAT 358 ENTRANCE TO EXHIBITION Exhibition & meeting rooms help desk Poster help desk & poster tours meeting points

361 11-15 APRIL 2018 PARIS, FRANCE 110 Vital Therapies, Inc 120 Genfit SA 140 W. L. Gore & Associates 210 genedrive plc 220 Delegate Lounge, sponsored by BMS 230 Novo Nordisk A/S 240 Gilead Sciences Europe Ltd 251 Echosens 252 GE Healthcare 261 Cepheid 310 MSD 320 Wilson Therapeutics 321 BTG 322 Fujirebio Europe NV 330 Alexion Pharma GmbH 331 Gilead Sciences Europe Ltd 340 Humedics GmbH 350 The NASH Education Program 360 Novartis Pharma AG 410 AbbVie 421 INHSU-International Network on Hepatitis in Substance Users 422 APASL Asian Pacific Association for the Study of the Liver 423 Liverpool Drug Interactions 424 LiSyM Liver Systems Medicine 425 Global Hepatitis Summit ELPA-European Liver Patients Association 430 Intercept Medical Affairs 453 Gilead Sciences Europe Ltd 510 AbbVie 521 Sirtex Medical Europe GmbH 522 Philips 523 Audentes Therapeutics 524 Fresenius Medical Care Deutschland GmbH 525 ProSciento, Inc. 531 Canon Medical Systems Europe 532 Wisepress 534 Shionogi Limited 541 Cisbio 542 Median Technologies 543 Virology Education 544 Gubra 550 Alfasigma S.p.A. 610 Perspectum Diagnostics Ltd 611 High Point Clinical Trials Center, LLC 612 Alnylam Pharmaceuticals 614 PSC Partners Seeking a Cure 620 Dr. Falk Pharma GmbH 711 SuperSonic Imagine 716 Siemens Healthineers 721 PhoenixBio EFSUMB-European Federation of Societies for Ultrasound in 722 Medicine & Biology 723 ILCA-International Liver Cancer Association 724 UEG-United European Gastroenterology 725 ALEH-Asociación Latinoamericana para el Estudio del Hígado 726 World Gastroenterology Organisation 727 Iran Hepatitis Network 728 The Cochrane Hepato-Biliary Group 810 Intercept 821 BioPredictive 822 International Coalition to Eliminate HBV 823 OraSure Technologies 830 Resoundant 840 Norgine 911 Baxter Healthcare SA 912 Helena Biosciences 914 Nordmark Arzneimittel GmbH & Co. KG 915 Fimmic Oy 920 AASLD American Association for the Study of Liver Diseases Biotech Village Advanced Biological Laboratories (ABL) S.A Biotech Village Albutec GmbH Biotech Village ALIVER Biotech Village Alnylam Pharmaceuticals Biotech Village DIAFIR Biotech Village Organovo Biotech Village ONE WAY LIVER S.L. Biotech Village Sanyal Biotechnology LLC Biotech Village VLVbio EXHIBITOR S LIST COMPANY BOOTH SPACE AASLD American Association for the Study 920 of Liver Diseases AbbVie 410 AbbVie 510 Advanced Biological Laboratories (ABL) S.A Albutec GmbH Biotech Village Biotech Village ALEH-Asociación Latinoamericana para 725 el Estudio del Hígado Alexion Pharma GmbH 330 Alfasigma S.p.A. 550 ALIVER Biotech Village Alnylam Pharmaceuticals Biotech Village Alnylam Pharmaceuticals 612 APASL Asian Pacific Association for the Study 422 of the Liver Audentes Therapeutics 523 Baxter Healthcare SA 911 BioPredictive 821 BTG 321 Canon Medical Systems Europe 531 Cepheid 261 Cisbio 541 Delegate Lounge, sponsored by BMS 220 DIAFIR Biotech Village Dr. Falk Pharma GmbH 620 Echosens 251 EFSUMB-European Federation of Societies for Ultrasound in 722 Medicine & Biology INDUSTRY THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 359

362 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME INDUSTRY COMPANY BOOTH SPACE ELPA-European Liver Patients Association 426 Fimmic Oy 915 Fresenius Medical Care Deutschland GmbH 524 Fujirebio Europe NV 322 GE Healthcare 252 genedrive plc 210 Genfit SA 120 Gilead Sciences Europe Ltd 240 Gilead Sciences Europe Ltd 331 Gilead Sciences Europe Ltd 453 Global Hepatitis Summit Gubra 544 Helena Biosciences 912 High Point Clinical Trials Center, LLC 611 Humedics GmbH 340 International Coalition to Eliminate HBV 822 ILCA-International Liver Cancer Association 723 INHSU-International Network on Hepatitis 421 in Substance Users Intercept 810 Intercept Medical Affairs 430 Iran Hepatitis Network 727 LiSyM Liver Systems Medicine 424 Liverpool Drug Interactions 423 Median Technologies 542 MSD 310 Nordmark Arzneimittel GmbH & Co. KG 914 Norgine 840 COMPANY BOOTH SPACE Novartis Pharma AG 360 Novo Nordisk A/S 230 OraSure Technologies 823 Organovo Biotech Village ONE WAY LIVER S.L. Biotech Village Perspectum Diagnostics Ltd 610 Philips 522 PhoenixBio 721 ProSciento, Inc. 525 PSC Partners Seeking a Cure 614 Resoundant 830 Sanyal Biotechnology LLC Biotech Village Shionogi Limited 534 Siemens Healthineers 716 Sirtex Medical Europe GmbH 521 SuperSonic Imagine 711 The Cochrane Hepato-Biliary Group 728 The NASH Education Program 350 UEG-United European Gastroenterology 724 Virology Education 543 Vital Therapies, Inc 110 VLVbio Biotech Village W. L. Gore & Associates 140 Wilson Therapeutics 320 Wisepress 532 World Gastroenterology Organisation EASL THE HOME OF HEPATOLOGY

363 11-15 APRIL 2018 PARIS, FRANCE MEETING ROOMS HALL b 818 a FLOOR 7.3 & ACCESS 7.4 FLOOR 7.2 INDUSTRY B 741 C 741 A Pavillon 4: Oceanie meeting rooms THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 361

364 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME COMPANY PROFILES AbbVie 410, North Waukegan Road North Chicago United States AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world s most complex and critical conditions. The company s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at abbvie on Twitter, Facebook or LinkedIn. Advanced Biological Laboratories (ABL) S.A. Biotech Village 17 Rue des Jardiniers Luxembourg L-1835 Luxembourg INDUSTRY Advanced Biological Laboratories (ABL) SA is a Medical & Diagnostics company founded in 2000 located in Europe and specialized in Virology. ABL has a comprehensive suite of healthcare management products, which are used for data and patient management, monitoring and personalized reporting applications. ABL s products offer to infectious disease clinicians and virology laboratories, optimal and efficient solutions for sequencing, clinical genotyping and drug resistance analyses, compatible with standard Sanger and highthroughput Next Generation Sequencing technologies and which target different microbiology applications (HIV, HBV, HCV, TB, CMV, etc ). 362 EASL THE HOME OF HEPATOLOGY

365 11-15 APRIL 2018 PARIS, FRANCE Albutec GmbH Biotech Village Schillingallee 68 Rostock Germany Albutec is a research and development company with 6 permanent and 2 parttime employees. The company is based in the Hanseatic city of Rostock at the Biomedical Research Center. Albutec developed the Hepalbin -Adsorbent, which can easily remove unwanted stabilizers from human albumin solutions in order to enhance albumin binding capacity significantly. According to the literature this is associated with a survival benefit for liver patients. The nano structured Hepalbin -Adsorbent can be used for a bed-side removal of contaminations or to prepare large albumin pools for albumin dialysis, e.g. MARS or OPAL The new CE certified infusion device bears the world wide first technology for applying human albumin solutions without caprylate and acetyltryptophanate, which is most important for patients with liver failure. Albutec is DIN EN ISO certified. It has authorisation for wholesale trade in medicinal products in accordance with 52 AMG (German Medicines Act). Alexion Pharma GmbH 330 Giesshübelstrasse 30 Zürich 8045 Switzerland Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion s metabolic franchise includes two highly innovative enzyme replacement therapies Kanuma (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D), and Strensiq (asfotase alfa) for patients with hypophosphatasia (HPP). Alexion also developed and commercializes Soliris (eculizumab), the first and only approved complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (ahus). Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas. INDUSTRY THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 363

366 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Alfasigma S.p.A. 550 Viale Sarca 223 Milan Italy Alfasigma was set-up in 2015 by aggregating Alfa Wassermann and Sigma-tau, 2 Italian leading pharma players who put together their expertise and assets to create a new international key player. Based in Italy (Bologna) with 16 subsidiaries, it employs more than 3,000 people. Through its R&D, manufacturing capabilities and commercial units, Alfasigma markets prescription and OTC drugs and medical foods turnover expected to overcome 1 billion euro; 35% of it is made of 3 internally developed molecules: Sulodexide, L-Carnitin and Rifaximin-α (Normix, Xifaxan and others), an innovative intestine-targeted, non-absorbable antibiotic, now available in most countries worldwide, including the USA. Allergan 5 Giralda Farms Madison, NJ United States INDUSTRY Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women s health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, the Company s R&D model, which defines our approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry. For more information, visit Allergan s website at EASL THE HOME OF HEPATOLOGY

367 11-15 APRIL 2018 PARIS, FRANCE Alnylam Pharmaceuticals 612, Biotech Village Dammstrasse 19 Zug 6300 Switzerland Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Audentes Therapeutics California Street, 17th Floor San Francisco, California United States Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2- CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities. INDUSTRY Baxter Healthcare SA 911 Thurgauerstrasse 130 Glattpark Opfikon CH-8152 Switzerland THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 365

368 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Baxter International Inc. provides a broad portfolio of essential hospital and renal products, including home, acute and in-centre dialysis: sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anaesthetics; and pharmacy automation, software and services. The company s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter s employees worldwide are building upon the company s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care. Bayer HealthCare Pharmaceuticals, Inc. 100 Bayer Boulevard P.O. Box 915 Whippany NJ United States INDUSTRY Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer currently includes four oncology products in eight indications. Several other compounds are in various stages of clinical development, with the focus on potential first-in-class approaches across the areas of novel oncogenic signaling in combination with an effective biomarker strategy, antibody drug conjugates including a thorium platform and immuno-oncology. An Oncology Strategic Business Unit within the Pharmaceuticals Division of Bayer was established in 2017 to support the accelerated development of new treatment options. BioPredictive Boulevard Saint-Germain Paris France BioPredictive offers diagnostic and prognostic blood tests for liver diseases. BioPredictive is dedicated to improve the management of liver diseases. Over 1.5 million tests performed worldwide. BioPredictive s diagnosis and prognosis patented tests (FiboTest-ActiTest, SteatoTest, and just released NewNashTest) are available online via a secured and anonymous Internet connection www. biopredictive.com. 366 EASL THE HOME OF HEPATOLOGY

369 11-15 APRIL 2018 PARIS, FRANCE FibroTest App (free) including ElastoFibroTest and DAAFibroTest is also available on iphone and Android. We invite you to take a look at our online scientific library: biopredictive.com/ Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str. 173 Ingelheim am Rhein Germany Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the Making More Health initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. Bristol-Myers Squibb INDUSTRY 3401 Princeton Pike Lawrenceville NJ United States Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 367

370 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME BTG 321 Biocompatibles UK Ltd, a BTG International group company Lakeview, Riverside Way, Watchmoor Park Camberley, Surrey GU15 3YL United Kingdom At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Healthcare is constantly evolving so BTG never stands still. Inspired by a deep understanding of our customers needs, we re working to meaningfully improve the lives of patients and their healthcare experience. Canon Medical Systems Europe 531 Zilverstraat 1 Zoetermeer 2718RP Netherlands INDUSTRY Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Canon Medical we work hand in hand with our partners our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industryleading solutions that deliver an enriched quality of life. 368 EASL THE HOME OF HEPATOLOGY

371 11-15 APRIL 2018 PARIS, FRANCE Celsion Corporation 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey United States Celsion Corporation is a development-stage company currently recruiting patients in the OPTIMA Study, a phase III trial evaluating ThermoDox (our proprietary formulation of heat-sensitive liposomal Doxorubicin) in combination with RFA for the treatment of Hepatocellular Carcinoma. The company is developing other drug candidates as well as part of a highpotential portfolio of innovative cancer treatments, including Gen-1, a local immuno-oncology drug. With platform technologies in chemotherapy and gene-mediated immunotherapy, Celsion s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. Cepheid 261 Vira Solelh Maurens-Scopont France Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer. INDUSTRY THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 369

372 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Cisbio 541 Parc Marcel Boiteux / BP Codolet France Cisbio Bioassays, a privately held life sciences company committed to improving human healthcare, provides creative technological solutions and partnerships to the global scientific community. The company with more than 30 years of experience in vitro diagnostics (RIA and ELISA assays) and drug discovery is a partner of choice for medical device in ELISA (CgA, P3NP, S100A12 assays) and has facilities in France, the United States, China and Japan, and a network of distributors across the globe. Cook Medical O Halloran Road, National Technology Park Limerick Ireland Since 1963, Cook Medical has worked closely with physicians to develop technologies to eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help world s healthcare systems deliver better outcomes more efficiently. INDUSTRY We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. DIAFIR Biotech Village Parc Lorans 26J, Avenue Chardonnet Rennes France DIAFIR develops, manufactures and markets diagnostic tests trough its proprietary mid-infrared (MIR) metabolic signature technology. The MIR technology, combined with proprietary algorithm, enables to deliver a score 370 EASL THE HOME OF HEPATOLOGY

373 11-15 APRIL 2018 PARIS, FRANCE within 15 minutes from a simple drop of blood serum. The current development is focused on the non-invasive diagnosis of NASH and its complications. The aim is to propose a simple test permitting fast and accurate NASH patient screening and monitoring. Dr. Falk Pharma GmbH 620 Leinenweberstrasse Freiburg Germany Dr. Falk Pharma GmbH is a family-owned enterprise based in Freiburg/ Germany with affiliates in UK and Ireland, the BeNeLux countries, Spain, Portugal and Russia. Dr. Falk Pharma and its over 200 employees are specialised in the development and distribution of pharmaceuticals for hepatological and gastroenterological diseases. These, mainly prescription drugs, are marketed in Germany and more than 60 countries worldwide. The Falk Foundation e.v. is a medical education organisation associated with Dr. Falk Pharma, offering a wide variety of congresses and media to support product independent postgraduate education for doctors on a national and international level. Echosens 251 Echosens is an innovative high-technology company based in France. Since its inception in 2001, Echosens has been recognized as the world s leading provider of non-invasive diagnostic devices for chronic liver diseases. Our innovative non-invasive technologies are recognized for cost effectively diagnosing and monitoring chronic liver diseases with precision, standardization and repeatability over time and users. INDUSTRY The Group develops, manufactures and sells under its own names and trademarks duly registered portfolio of products and solutions to physicians for the diagnosis, assessment and monitoring of various chronic liver diseases. As a major, global and rising public health issue, liver disease represents a main development focus for Echosens. The Group owns three products lines: a range of non-invasive diagnostic devices named FibroScan, a family of diagnostic blood tests named FibroMeter and a suite of data management software solutions named THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 371

374 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME FibroView. These product lines are covered by several families of patents belonging to Echosens. Eisai Europe Ltd About Eisai Co., Ltd. Eisai Co., Ltd. is a leading global research and development based pharmaceutical company headquartered in Japan. We define our corporate mission as giving first thought to patients and their families and to increasing the benefits health care provides, which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology. About Eisai EMEA in Oncology Eisai is committed to the development and delivery of highly beneficial new treatments for people with cancer. The development of therapeutic options in oncology is a major strategic area for Eisai in Europe, the Middle East, Africa, Russia and Oceania (EMEA). Fimmic Oy 915 Tukholmankatu 8 Helsinki Finland INDUSTRY Fimmic s aiforia AI Cloud brings Deep Learning powered Image Analysis to the fingertips of every pathologist or researcher. Our Deep Learning technology enables fast automation of complex image analysis tasks with superior accuracy and sensitivity. Fresenius Medical Care Deutschland GmbH 524 Else-Kroener-Str Bad Homburg Germany EASL THE HOME OF HEPATOLOGY

375 11-15 APRIL 2018 PARIS, FRANCE Fresenius Medical Care is the world s largest integrated provider of products and services for individuals undergoing haemodialysis because of chronic kidney failure. In patients suffering from severe liver failure, elimination of toxins by dialysis is not sufficient because here also albumin-bound toxins have to be removed. With Prometheus, Fresenius Medical Care offers a therapy system that combines an apheresis procedure to remove albumin bound toxins by adsorption and haemodialysis to clear additionally the blood from water soluble substances. Other blood purification therapies like immunoadsorption, lipid apheresis and peritoneal dialysis are also provided by the company. Fujirebio Europe NV 322 Technologiepark 6 Zwijnaarde 9052 Belgium Fujirebio is a global leader within high quality IVD testing. The company counts more than 50 years experience, is a world-wide reference in oncology for routine and novel markers, has solid experience with immunoassay testing solutions and has, under the name Innogenetics (now Fujirebio Europe), been pioneering the field of molecular diagnostics and multiparameter testing. Fujirebio s infectious diseases products are focused on chronic liver disease, providing molecular monitoring tools for HBV (genotyping, drug resistance mutations, basal core/precore mutations). The LUMIPULSE G1200 and G600II offer fully automated screening solutions for specialty infectious diseases (HBcrAg, HBsAg Quant) and markers for HCC (AFP/PIVKA-II). Galmed Pharmaceuticals 16 Tiomkin St Tel-Aviv Israel INDUSTRY Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in 248 subjects with NASH. Galmed also sponsors the ARRIVE Study, a proof- THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 373

376 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME of-concept Phase IIa clinical trial designed to evaluate the safety and efficacy of Aramchol in 50 patients with HIV-associated NAFLD and lipodystrophy. More information about the ARREST Study and the ARRIVE Study may be found on ClinicalTrials.gov identifiers: NCT and NCT , respectively. GE Healthcare 252 Beethovenstrasse 239 Solingen Germany GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. genedrive plc Grafton Street Manchester M13 9XX United Kingdom INDUSTRY and genedrive plc is based in Manchester, UK. We have developed a revolutionary nucleic acid based point of care system that provides near patient results for use in decentralised settings. Genedrive is a rapid, low cost molecular diagnostics platform reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The Genedrive HCV ID Kit is an accurate and cost effective molecular solution for HCV testing, providing results direct from plasma without any requirement for viral RNA extraction, the assay is an ideal solution for low throughput, decentralised laboratories. 374 EASL THE HOME OF HEPATOLOGY

377 11-15 APRIL 2018 PARIS, FRANCE GENFIT SA , Avenue Eugène Avinée Loos France GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions in areas of high unmet medical need. GENFIT s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic disease that affect the liver (such as NASH Nonalcoholic steatohepatitis). GENFIT s lead proprietary compound, elafibranor, is currently being evaluated in the Phase 3 study RESOLVE-IT in NASH and in a Phase 2 study in PBC (Primary Biliary Cholangitis). Gilead Sciences Europe Ltd 240, 331, Roundwood Avenue, Stockley Park Uxbridge UB11 1 AF United Kingdom Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. Gilead s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead has a rapidly expanding product portfolio, a growing pipeline of investigational drugs and 9,700 employees in offices across six continents. Millions of people around the world are living healthier lives because of innovative therapies developed by Gilead. Gubra 544 INDUSTRY Hørsholm Kongevej 11B Hørsholm 2970 Denmark Gubra is a Danish biotech company delivering preclinical contract research services as well as early target and drug discovery programs aimed for partnering. Focus is the metabolic space (obesity, diabetes, NASH and Gastro Intestinal diseases) where we specialize in in vivo pharmacology, histology, RNA sequencing, bioinformatics, imaging and related services. THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 375

378 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Helena Biosciences 912 Queensway South Gateshead NE11 0SD United Kingdom Helena Biosciences are a leading IVD specialist company with over 40 years industry experience in manufacturing innovative diagnostic instruments and reagents for clinicians within the healthcare industry. Proudly manufactured in the North East of England, Helena Biosciences are dedicated to providing quality products to our customers and partners.ð dpioneers in Biochemistry, Immunology and Haematology, Helena Biosciences are excited to expand our portfolio with a new non-invasive chronic liver disease diagnostic, the Glyco Liver Profile. Developed with scientists at the University of Ghent, this glycomicsbased test delivers a full profile of liver disease from a single blood sample. High Point Clinical Trials Center, LLC MendenHall Oaks Parkway, Suite 105 High Point, North Carolina United States INDUSTRY High Point Clinical Trials Center has provided comprehensive (Phase I-III) clinical site services since Our 42,000 ft 2 facility consists of three unique units for the execution of outpatient and inpatient clinical studies. In addition to healthy normal Phase I studies, HPCTC focuses on specialty populations such as Metabolic Diseases, NASH, Renal Respiratory, CNS, Cardiovascular and Nicotine Humedics GmbH 340 Marie-Elisabeth-Lüders-Str.1 Berlin Germany Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This 376 EASL THE HOME OF HEPATOLOGY

379 11-15 APRIL 2018 PARIS, FRANCE easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes. LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally. InSphero AG Wagistrasse Schlieren Switzerland InSphero partners with the pharmaceutical industry to bring better, safer drugs to market faster with our highly physiologically relevant 3D InSight Microtissues and Services. Our Human Liver Fibrosis Model is a powerful, next-generation 3D cell-based model for anti-fibrotic drug discovery, while our gold-standard Human Liver Microtissues serve as a pharma-validated in vitro toxicology model for more predictive and reproducible DILI prediction. Microtissues are delivered to your lab ready to use, removing the burden of production and validation, or are available through contract screening services conducted by our experts with 3D-optimized endpoints. Intercept 810 Intercept Medical Affairs 430 Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada. INDUSTRY Janssen Pharmaceutical Companies of Johnson & Johnson 1125 Trenton-Harbourton Road Titusville United States THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 377

380 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME At Janssen, we have an ambitious goal. We strive to bring forth transformational medical innovations that improve the lives of people affected by hepatitis B and ensure future generations can live without fear of the disease. With a goal like this, there s no time to waste. That is why we partner with organizations around the world, connecting our own expertise with that of others. Because, only together we can Make Hepatitis History. Median Technologies 542 Les 2 Arcs Bât B 1800 route des Crêtes Valbonne France Median Technologies, The Imaging Phenomics Company, is at the heart of innovative imaging solutions and provides insights into novel therapies and treatment strategies. Our unique solutions, ibiopsy for imaging diagnostics, MediScan for patient care, and isee for clinical trials, and, together with our global team of experts, are advancing the development of new drugs and diagnostic tools around the world. ibiopsy is a high-throughput, comprehensive, accurate, end-to-end image retrieval and analysis platform for large scale extraction of imaging biomarkers and phenotypic signatures. ibiopsy will revolutionize the way liver disease is treated by harnessing the power of imaging phenomics. INDUSTRY MSD Galloping Hill Road Kenilworth United States For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world s most challenging diseases. Today, MSD continues be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. 378 EASL THE HOME OF HEPATOLOGY

381 11-15 APRIL 2018 PARIS, FRANCE Nordmark Arzneimittel GmbH & Co. KG 914 Pinnauallee 4 Uetersen Germany Nordmark Biochemicals offers Collagenase NB products for tissue dissociation suitable for the isolation of various cell types for research and clinical applications. We, the German pharmaceutical company Nordmark, are the world-wide largest manufacturer of collagenase. Pharmaceutical manufacturing standard stands for high lot-to-lot consistency and the superior quality guarantees cell viability and high yields. Supporting documentation and access to the drug master file registered with the FDA are available for GMP grade users. Our product portfolio also includes the world s first animalfree GMP grade collagenase, Collagenase AF-1 GMP Grade and Neutral Protease AF GMP Grade. Norgine 840 Norgine House, Moorhall Road Harefield UB9 6NS United Kingdom Norgine is a European specialist pharmaceutical company that has been established for over 110 years. Norgine provides expertise and know how in Europe to develop, manufacture and market products that offer value to healthcare professionals, payers and patients. Norgine specializes in gastroenterology, hepatology, cancer and supportive care. INDUSTRY Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France. Join us for our symposium on Wednesday 11th April at 6:00pm, Title Road trip: Driving change to optimise the HE patient journey For more information, please visit THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 379

382 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Novartis Pharma AG 360 Forum 1, Novartis Campus Basel 4056 Switzerland Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis products are available in more than 180 countries around the world. Novo Nordisk A/S 230 Vandtaarnsvej 114 Soeborg, 2860 Denmark At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. INDUSTRY Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders, obesity, chronic kidney disease, cardiovascular disease and NASH. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. ONE WAY LIVER S.L. Biotech Village Parque Tecnologico de Bizkaia edificio 502, planta 0 Derio Spain OWL is a biotechnology firm focused on hepatology diagnostics and research, with a deep knowledge of metabolomics and liver diseases: 380 EASL THE HOME OF HEPATOLOGY

383 11-15 APRIL 2018 PARIS, FRANCE OWLiver is the first non-invasive test to diagnose steatosis and nonalcoholic steatohepatitis (NASH). OWLiver is used not only to diagnose and monitor patients in standard clinical practice, but also to pre-screen and monitor patients in NASH clinical trials. Additionally, OWL applies its unique expertise in hepatology and metabolomics to offer biomarker discovery services. OWL participates in companion diagnostic projects, uncovers patient randomization/selection issues, identifies best drug responders, monitors drug efficacy and helps better understand drugs mechanism of action or toxicity. OraSure Technologies East 1st Street Bethlehem United States OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. Organovo Biotech Village 6275 Nancy Ridge Drive San Diego, CA United States Organovo develops dynamic, multicellular, 3D bioprinted human tissues that closely model native biology. With the NovoGen Bioprinter Platform, the Company designs tissues for use in applications spanning preclinical safety testing, disease modeling, and therapeutics. Commercially available through its NovoView Preclinical Testing Services, ExVive Human Liver and Kidney Tissues enable mechanistic insights into phenotypes that progress over time and that require multiple cell types in a specific spatial organization, reflecting the true complexity of human biology. INDUSTRY THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 381

384 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Perspectum Diagnostics Ltd Hythe Bridge Street OX1 2ET Oxford United Kingdom Perspectum Diagnostics has developed a novel multiparametric Magnetic Resonance Imaging (MRI) technique to quantitively characterize liver tissue non-invasively using LiverMultiScan. LiverMultiScan provides measures of fat and correlates of iron and fibro-inflammation. There is growing interest in using LiverMultiScan in clinical practice, as well as in clinical trials for screening and efficacy signalling in non-alcoholic fatty liver disease. Research has shown that multiparametric MRI may detect early liver disease and has been deemed to perform best in assessing NASH. Perspectum will also be showcasing its latest product, MRCP+, which allows visualisation and quantification of the biliary tree by enhancing conventional MRCP. Pfizer Inc. 235 East 42nd Street New York United States INDUSTRY At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines and many of the world s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. PHILIPS 522 VB-4 Boschdijk 525 PO Box Eindhoven 5600JJ Netherlands Creating a healthier future, together. 382 EASL THE HOME OF HEPATOLOGY

385 11-15 APRIL 2018 PARIS, FRANCE At Philips, we look beyond technology to the experiences of patients, providers and caregivers across the health continuum from healthy living to prevention, diagnosis, treatment, recovery and home care. We unlock insights leading to meaningful innovations from hospital to home. Our solutions combine clinical breadth and depth of expertise, technology and services, actionable data, consultative new business models and partnerships. Together, with our customers, we take risks and share responsibility so that we can transform how care is delivered and experienced. It s a unique perspective empowering us all to create a healthier future PhoenixBio Broadway Suite New York United States PhoenixBio produces the PXB-Mouse, the world s most widely used humanized liver chimeric mouse model, for drug discovery and development. With 80 to > 95% of the liver replaced with human hepatocytes, the PXB- Mouse provides clinically relevant data in the fields of HBV/HCV, DMPKS/ Safety, oligonucleotide therapeutics and non-viral liver diseases. The translatability of the PXB-Mouse model enables accelerated pre-clinical drug development and reduces the risk of failure at the clinical development stage. The PXB-Mouse is the reliable, cost-effective, next step for your pre-clinical drug development. ProSciento, Inc rd Avenue, Suite Chula Vista, CA United States INDUSTRY ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all relevant metabolic drug and device classes. Through its scalable R&D services model combining deep therapeutic area expertise, strategic planning, and operational execution from preclinical to phase III readiness THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 383

386 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME ProSciento provides highly customized services for its global client base in today s rapidly evolving landscape of metabolic drug and device development. Resoundant st Ave SW STE 204W Rochester, MN United States Resoundant Inc. is the developer of Magnetic Resonance Elastography (MRE), an advanced imaging technique for measuring tissue stiffness and aiding the diagnosis and staging of liver fibrosis. Through strategic partnerships with GE, Philips, and Siemens, MRE is available at over 1000 leading imaging centers and hospitals throughout the world. Developed at the Mayo Clinic, MRE provides physicians with the most comprehensive and accurate picture of liver health available, while recognzed by numerous professional societies as a standard of care for the clinical management of liver disease. Sanyal Biotechnology LLC Biotech Village 3645 Faculty Blvd Virginia Beach United States INDUSTRY Sanyal Biotechnology is a contract research organization specializing in preclinical small animal model screening of drugs. We have developed a proprietary isogenic mouse model, the DIAMONDTM mouse, that develops NAFLD and NASH solely as a result of Western Diet. The progression of the pathology and physiological changes exactly parallel development of human liver disease due to metabolic syndrome. The DIAMONDTM mice develop symptoms of metabolic syndrome including obesity, dyslipidemia, and insulin resistance; additionally, their liver pathology also progresses to cirrhosis and HCC. Our CRO services are performed in an AAALAC-accredited GLP environment. Sequana Medical AG Technoparkstr. 1 Zürich 8005 Switzerland EASL THE HOME OF HEPATOLOGY

387 11-15 APRIL 2018 PARIS, FRANCE Sequana Medical is a commercial stage medical device company and an innovator in the management of liver disease. The alfapump is a fully implantable, programmable, transcutaneouslycharged, battery-powered pump for the management of RA due to liver cirrhosis or malignant ascites with a life expectancy of 6 months or less. It is one of the first real alternatives to LVP for drainage of excess fluid. By moving ascites to the bladder, the alfapump prevents fluid build-up and its possible complications, improving patient quality of life and nutrition, and potentially reducing hospital visits and healthcare costs. The alfapump DirectLink Technology allows clinicians to receive pump performance information and more effectively manage patients treated by the alfapump. The product is CE Marked. The alfapump is currently under evaluation in the US under an IDE study Shionogi Limited , Kingsway London WC2B 6UF United Kingdom Shionogi & Co. Ltd. was founded nearly 130 years ago in Osaka, Japan. Shionogi Europe is a newer venture, launched in 2012 as part of a new global era for the company (more information at Our commitment is to ensure that the real-life challenges patients face are the primary driver behind our R&D. Our research-led organisation is defined by a distinct openness and close partnership approach to discovering and developing medicines. We have an impressive legacy of fostering long-term scientific and industry partnerships built on a mutual ambition to develop innovative medicines that address unmet medical needs. INDUSTRY Siemens Healthineers 716 Karlheinz Kaske Strasse 2 Erlangen DE Germany THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 385

388 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Making healthcare providers successful by offering solutions that improve outcomes and reduce costs. Siemens Healthineers Ultrasound Imaging Systems enhance your diagnosis with improved imaging performance and adaptive technologies. Our portfolio of ultrasound machines and sonography equipment meet your clinical needs with the versatility and functionality you need for patient diagnosis. With unmatched image quality and cutting-edge versatility for the full range of clinical applications, Siemens ultrasound imaging systems enhance confidence in your diagnoses for improved patient outcomes. Partner with us to expand your clinical capabilities and improve care by personalizing the way you care for your patients. Sirtex Medical Europe GmbH 521 Joseph-Schumpeter-Allee Bonn Germany Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients. Our innovative technology, SIR-Spheres Y-90 resin microspheres (microscopic Yttrium-90 resin beads), was approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark. SIR-Spheres Y-90 resin microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma in over 1,090 centres worldwide. To date, more than 80,000 doses have been delivered worldwide. INDUSTRY SuperSonic Imagine rue René Descartes Aix-en-Provence France www. supersonicimagine.com SuperSonic Imagine designs, develops and markets a diagnostic imaging ultrasound system, Aixplorer, that provides a turnkey solution for the noninvasive assessment of liver fibrosis and steatosis. Real-time ShearWave Elastography (SWE ), only available on Aixplorer, enables non-invasive liver stiffness measurements under ultrasound- 386 EASL THE HOME OF HEPATOLOGY

389 11-15 APRIL 2018 PARIS, FRANCE image guidance. The one-probe SWE exam is easy and fast, and delivers a quantitative live color-coded map of liver stiffness. Over 100 publications have already demonstrated the reliability, reproducibility and effectiveness of SWE for the assessment and the monitoring of chronic hepatopathies. The NASH Education Program , Avenue Eugène Avinée Loos France The NASH Education Program TM is a healthcare initiative driven in collaboration with an independent and international scientific committee, aimed at producing and disseminating essential medical knowledge about NASH (Non-Alcoholic Steatohepatitis). The objective is to develop disease awareness activities targeting multiple audiences (physicians, patients and families) and address unmet information needs. Virology Education 543 Biltstraat 106 Utrecht 3572BJ Netherlands Virology Education is the leading provider of top quality educational and scientific programs for healthcare professionals involved in HIV, hepatitis, tuberculosis, emerging viruses, NASH, Liver disease, Pharmacology, and oncology. With over two decades of experience, an expert in-house team and over 30,000 opt-in subscribers, Virology Education is committed to delivering highly acclaimed and accredited programs that reach healthcare professionals worldwide. INDUSTRY The company takes on the role of identifying needs, driving new initiatives, designing tailored programs, developing educational and scientific content, and handling the face-to-face logistical management of programs. THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 387

390 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME Vital Therapies, Inc Avenue of Science, Ste. 200 San Diego, CA United States Vital Therapies, Inc. is developing ELAD, an extracorporeal human hepatic cell-based liver treatment. ELAD is designed to improve survival in patients with liver failure by providing hepatic support continuously for up to five days. VLVbio Biotech Village Hästholmsvägen 32 Nacka Sweden At VLVbio we offer unique assays for accurate and non-invasive detection of liver damage and disease. Our biomarker assays, M30 and M65, measure apoptosis and total cell death respectively, and are used globally by academia, industry and healthcare providers. INDUSTRY Measuring apoptosis and levels of total cell death is of interest in the diagnosis and treatment follow-up of patients suffering from liver diseases such as NASH and ASH, in the development of new drugs and when assessing toxicological effects of pharmaceuticals and other substances. Come and say hi and let us tell you more about our products! W.L.Gore & Associates 140 Europe Gore Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide 388 EASL THE HOME OF HEPATOLOGY

391 11-15 APRIL 2018 PARIS, FRANCE sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.w. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Wilson Therapeutics 320 Kungsgatan 3 SE Stockholm Sweden Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics lead product, WTX101 (bis-choline-tetrathiomolybdate), is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics AB was founded in 2012 and is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Wisepress Medical Bookshop Lyon Road, Merton London SW19 2RL United Kingdom Wisepress.com, Europe s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on INDUSTRY THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 389

392 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME ASSOCIATION PROFILES AASLD-American Association for the Study of Liver Diseases N Fairfax St., 4th floor Alexandria VA United Sates We are AASLD. We are 5,000 professionals dedicated to preventing and curing liver disease. We are clinicians, researchers and educators. We are a global community. We are your professional home. Learn more and become a member at stand 920. ALEH- Asociación Latinoamericana para el Estudio del Hígado 725 Estoril 50, oficina 1005, Las Condes Santiago Chile INDUSTRY A non-profit scientific association founded in 1968, whose main objective is to promote and disseminate the study of Hepatology in Latin America, through training and exchange of scientific knowledge and experiences, to reduce current gaps in the world. Through academic activities, ALEH seeks to establish a solid leadership within the field at an international and Latin American level. ALEH is also a member of GLOBAL LIVER SUMMIT. Member countries are: Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Cuba, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Paraguay, Panama, Peru, Dominican Republic, Uruguay, and Venezuela. 390 EASL THE HOME OF HEPATOLOGY

393 11-15 APRIL 2018 PARIS, FRANCE ALIVER Biotech Village Rue Daubin 7 Geneva 1203 Switzerland ALIVER is a project that has received funding from the European Union s Horizon 2020 research and innovation programme after 25 years of experimental research and data collection on extracorporeal perfusion as a therapy option in liver failure. The ALIVER Consortium has developed and optimised a novel liver dialysis device, DIALIVE. APASL-Asian Pacific Association for the Study of the Liver Shinjuku, Shinjuku-ku Tokyo Japan The Asian Pacific Association for the Study of the Liver (APASL) is a leading association for the investigation and treatment of liver diseases in the world, and the largest scientific body that upholds the standards and profession, research and creates improved treatment methods for millions of liver patients, particularly in the Asia Pacific Region. APASL s main objectives are to promote the latest scientific advances and education of hepatology science, exchange information and develop consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region. INDUSTRY EFSUMB- European Federation of Societies for Ultrasound in Medicine & Biology 722 PO Box London SW19 9HD United Kingdom The Federation s purpose is to promote the exchange of scientific knowledge and development in the medical and biological professions as applied to THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 391

394 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME ultrasound. The Federation proposes standards and gives advice concerning criteria for the optimum apparatus and techniques, and concerning presentation and interpretation of results. This aim is to be served by arrangement of congresses and study and development meetings on an international level, as well as the exchange of information both in and outside Europe by the member organisations. ELPA- European Liver Patients Association 426 Rue de la Loi 235 Brussels 1040 Belgium ELPA emerged from a desire amongst European liver patient groups to share their experiences on very different healthcare approaches which often vary from country to country. ELPA was formally launched in Paris on April 14 th 2005 and now has 34 association members from 27 countries. ELPA s vision is that all liver patients are diagnosed on time, are treated with respect, and have equal access to the best standard of medical care regardless of origin, lifestyle and type of liver disease. Our ultimate goal is a world without liver disease. Global Hepatitis Summit INDUSTRY 18 Keewatin Avenue Toronto M4P 1Z8 Canada In the tradition of the ISVHLD, the Global Hepatitis Summit will bring together top international clinicians and researchers in the field of hepatitis. In addition to delivering the highest quality scientific program, the upcoming summit will add a new dimension: a focus on global public health. The Global Hepatitis Summit will include plenary and parallel public health sessions to complement the high quality basic and clinical scientific presentations. Join us in contributing to driving the next phase of the international agenda on the diagnosis and treatment of viral hepatitis and liver disease June 14-17, 2018 in Toronto, Canada. 392 EASL THE HOME OF HEPATOLOGY

395 11-15 APRIL 2018 PARIS, FRANCE International Coalition to Eliminate HBV 822 C/O University of Melbourne Melbourne 3000 Australia The International Coalition to Eliminate HBV (ICE-HBV) is an international, independent, research-based and patient-centered non-profit forum which aims to coordinate, promote and foster collaborative partnerships working towards a cure for chronic hepatitis B. Our objective is the discovery of a safe, affordable, scalable and effective hepatitis B cure, accessible to all including children. Created in 2016, ICE-HBV is composed of multidisciplinary scientific working groups consisting of more than 50 leaders in HBV virology, immunology, technologies and clinical research from 5 continents and 36 key HBV research stakeholders from 25 countries, including regional and international organizations. To get involved, contact info@ice-hbv.org. ILCA- International Liver Cancer Association 723 Boulevard du Souverain 280 Brussels 1160 Belgium The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively to liver cancer research for experts from all related disciplines. INDUSTRY ILCA aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer. ILCA will do so by promoting novel pathogenic, diagnostic and therapeutic interventions for liver cancer by taking a transversal approach to research and bringing together scientists, physicians and allied professionals from all interrelated fields. THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 393

396 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME INHSU-International Network on Hepatitis in Substance Users 421 C/O ARUD, Konradstrasse 32 Zurich 8005 Switzerland The International Network on Hepatitis in Substance Users (INHSU) is an international organization dedicated to: Supporting and facilitating scientific exchange and dissemination of knowledge Providing education for international health professionals, researchers, community organisations, people who use drugs and policy makers on hepatitis C prevention, screening, linkage to care, and treatment among people who use drugs Collaborating with other societies, government organisations, professional associations, community members, institutions and individuals to advocate for hepatitis C prevention and care among people who use drugs Iran Hepatitis Network 727 No. 178, Cross Shadab, Sepahbod Gharani Street Tehran 14155/3651 (Postal box) Iran INDUSTRY Iran Hepatitis Network (IHN) is an active non-governmental association connecting Iranian and Middle Eastern research centers and researchers active in the field of liver diseases. The following points are activities of IHN: 1. Hepatitis Monthly Journal: with JCR IF 1.67 and more than 50% contribution of international authors. 2. Tehran Hepatitis Conference: Is the biannually international conference of viral hepatitis and liver diseases. 3. National seminars on viral hepatitis and liver diseases. 4. National meetings for compilation of treatment guidelines. 394 EASL THE HOME OF HEPATOLOGY

397 5. Workshops to increase the knowledge of professionals in the field of hepatology. 6. Public awareness activities and campaigns APRIL 2018 PARIS, FRANCE LiSyM Liver Systems Medicine 424 Hermann-Herder-Str 3 Freiburg D Germany LiSyM (Liver Systems Medicine) represents a network of twenty German centers and institutions, brought together by a 20 Million Euro funding program of the German Government, in which mathematicians, modelers, pharmacologists, molecular biologists and clinical scientists work together to develop a systems medicine approach to study early and advanced liver disease. The aim of this unique research program is to use new experimental data and existing data bases to build computational models that facilitate decision making at the patient s bedside and to predict the actions of new medicines in the treatment of metabolic liver disease. Liverpool Drug Interactions Pembroke Place Liverpool L69 3GF United Kingdom Based at the University of Liverpool, UK, the Liverpool Drug Interactions team is a world-leading provider of clinically useful, reliable, comprehensive, up-to-date, evidence-based drug-drug interaction (DDI) resources for Hepatitis and HIV. INDUSTRY Our websites and org and companion apps enable rapid screening for DDIs and are freely available to healthcare workers, patients and researchers. Our mission is to support DDI education and promote safer prescribing, thereby improving quality of care and patient outcomes. Our websites received almost 800,000 visits from 188 countries in Our apps Hep ichart and HIV ichart have been downloaded over 100,000 times. THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 395

398 THE INTERNATIONAL LIVER CONGRESS 2018 PROGRAMME PSC Partners Seeking a Cure East Belleview Avenue, Suite 202 Greenwood Village, Colorado United States PSC Partners Seeking a Cure is a nonprofit patient organization whose mission is to provide education and support internationally to primary sclerosing cholangitis patients and caregivers, and to fund PSC research via its international competitive grant program and IRB-approved patient registry with over 1150 participants. PSC Partners holds annual patient and caregiver conferences throughout the United States in partnership with academic medical centers that treat and research PSC; the 2018 PSC Partners Conference will be held in conjunction with University of California Davis. PSC Partners also has active online support groups, a mentorship program and a comprehensive website, www. pscpartners.org. The Cochrane Hepato-Biliary Group 728 Tagensvej 22, Dept Copenhagen 2200 Denmark INDUSTRY The Cochrane Hepato-Biliary Group (The CHBG), part of The Cochrane Collaboration, is a non-profit, international clinical research group with more than 2000 members. Cochrane systematic reviews of interventions for hepatic and biliary diseases are our main product. In issue 1, 2018 of The Cochrane Library, we published 332 peer-reviewed protocols for systematic reviews and 207 systematic reviews. A CHBG Register with about references on randomised or controlled clinical trials is maintained in the CENTRAL database in The Cochrane Library. Cochrane reviews are not industry funded. You are welcome to work with us! Come to booth 728! 396 EASL THE HOME OF HEPATOLOGY

399 11-15 APRIL 2018 PARIS, FRANCE UEG- United European Gastroenterology 724 Wickenburggasse 1 Vienna 1080 Austria UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive health. Together, our member societies represent over 25,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Our mission is continually to advance gastroenterology care, to improve the prevention and care of digestive diseases in Europe through providing education, supporting research and improving clinical standards. Together, we are advancing gastroenterological care. Visit World Gastroenterology Organisation East Wells Street, Suite 1100 Milwaukee, WI United States The World Gastroenterology Organisation (WGO) is a federation comprised of over 100 member societies representing more than 50,000 individuals worldwide. WGO focuses on the improvement of standards in gastroenterology training and education globally. The WGO Foundation is the philanthropic resource for the WGO mission. INDUSTRY THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER 397

400

401 JOIN EASL COMMUNITY THE Reduced fees to The International Liver Congress TM and EASL meetings Journal of Hepatology LiverTree EASL Schools and Masterclass EASL Fellowships and Mentorship Funding support Discover more benefits on:

402

403 BRINGS LIVER DISEASE MANAGEMENT TO A NEXT LEVEL ENHANCE EXAM EFFICIENCY EXTEND PATIENT APPLICABILITY EXPAND CLINICAL CAPABILITIES Dedicated SPLEEN STIFFNESS module High-speed electronics Intuitive user interface Redesigned ergonomics Embedded ultrasound guidance system TOUCHSCREEN & TOUCH KEYBOARD Integrated barcode scanner BOOTH #251 NEW PRODUCT LAUNCH EASL 2018 COME & TRY FIBROSCAN DEVICES ECHOSENS.COM FibroScan is a class IIa medical device according to Directive EC/93/42 and is manufactured by Echosens. CE mark is in progress. FibroScan is indicated for the non invasive measurement of liver stiffness (E) and controlled attenuation parameter (CAP) in humans. It is expressly recommended to carefully read the guidance and instruction of the users guide and labeling of the device. Results obtained must be interpreted by a physician experienced in dealing with liver disease, taking into account the complete medical record of the patients. Our products are subject to regulatory requirements that vary from country to country and therefore may not be available for sale or distribution in all markets. Echosens TM, TM, are trademarks of Echosens Company Copyright Echosens all rights reserved All rights reserved - Advert EASL non-contractual pictures.

404 Oncology with Soul Date of Preparation: Feb 2018 EU0120c

405 INNOVATIVE COMPANY IN TREATMENT AND DIAGNOSIS OF METABOLIC & INFLAMMATORY DISEASES BOOTH #120 COME AND VISIT US TO LEARN MORE ABOUT GENFIT CONNECT TOGETHER GENFIT genfit_pharma

406 INTERCEPT PHARMACEUTICALS SPONSORED SATELLITE SYMPOSIUM AT THE EASL INTERNATIONAL LIVER CONGRESS Chair Professor Olivier Chazouilleres Professor of Hepatology, Saint Antoine Hospital, Paris THURSDAY 12 th APRIL 2018 WEST 1 PARIS CONVENTION CENTRE, PARIS EXPO PORTE DE VERSAILLES PAVILION 7 FLOOR 7.3 PRIMARY BILIARY CHOLANGITIS (PBC): OLD DISEASE, NEW PERSPECTIVES Welcome and introduction Professor Olivier Chazouilleres (FRA) PBC: evolving role of patients in disease self-management Achim Kautz (DEU) Enhanced understanding of farnesoid X receptor agonists Professor Michael Trauner (AUT) Obeticholic acid: clinical evidence through long-term treatment and real-world experience Professor Frederik Nevens (BEL) PBC Case Presentations: approaches to risk stratification, disease management and long-term monitoring of patients with PBC Professor Gideon Hirschfield (GBR) & Professor Vincent Leroy (FRA) Panel discussion and Q&A All speakers Summary and close Professor Olivier Chazouilleres (FRA) Prescribing information is available at this event. EU-PP-PB-0213 March 2018 For more information please visit interceptpharma.com or booth 810

407 Integrated Symposium of the International Liver Congress 2018, 53 rd Annual Meeting of the European Association for the Study of the Liver Advanced NASH and HCC - The New Frontiers Thursday, 12 April :30 20:00 Paris Expo Porte de Versailles Pavillon 7 Room: South 1 Paris, France Presentations include: GET INTERACTIVE! Download the app Welcome and Introductions Lawrence Serfaty, MD Hôpitaux Universitaires de Strasbourg Strasbourg, France Meeting Chair Advanced NASH: How Do We Take Action? Quentin M. Anstee, BSc(Hons), MB BS, PhD, MRCP(UK), FRCP Newcastle University Newcastle upon Tyne, United Kingdom Is There a Connection Between NASH and HCC? Peter Galle, MD, PhD Universitätsmedizin Mainz Mainz, Germany What Are the Latest Innovations in HCC Treatments? Bruno Sangro, MD Clínica Universidad de Navarra Pamplona, Spain 2018 Bristol-Myers Squibb Company IMSFR /18

408 Just because they re home, doesn t mean they re out of danger Please visit us on stand No. 840 For the reduction in recurrence of overt hepatic encephalopathy (OHE) Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at Please consult the Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to side-effects, precautions and contra-indications. Further Information is available on request from the marketing authorisation holder: Norgine Pharmaceuticals Ltd. Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex UB9 6NS, UK. Legal category: POM. Product licence number: PL20011/0020. ATC code: A07AA11. Company reference: GL/XIF/1214/0080(2). Product under licence from Alfasigma S.p.A. XIFAXAN and TARGAXAN Long-term secondary prophylaxis in OHE are registered trademarks of the Alfasigma group of companies, licensed to the Norgine group of companies. NORGINE and the sail logo are registered trademarks of the Norgine group of companies. GL/XIF/0118/0180a. Date of preparation: February Adverse events should be reported to your regulatory agency. Adverse events should also be reported to your local distributor or Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex UB9 6NS, United Kingdom. globalmedinfo@norgine.com XIFAXAN (registered in France under the name TARGAXAN ) is not marketed in France. XIFAXAN (enregistré en France sous la dénomination TARGAXAN ) n est pas commercialisé en France. Some disclaims and data presented may not be compliant with French/local regulation, please consult your local product information. Certaines informations et données présentées dans ce document peuvent ne pas suivre la réglementation française/locale, merci de vous référer au Résumé des Caractéristiques du Produit en vigueur dans votre pays. XIFAXAN /TARGAXAN has varying availability and licensing internationally. Before prescribing, consult your country approved prescribing information, available from your local distributor or Norgine Ltd.

409 COMING SOON Industry ad 7: MSD MSD EPIC Talks Visit Booth 310 for more details Copyright 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. INFC /18

410 Welcome to EASL The International Liver Congress 2018 ARE YOU READY TO MOVE FORWARD? VISIT BOOTH # AbbVie Inc. North Chicago, IL GBL/HGP/1217/1280a(1) November 2017

411 TOGETHER WE CURE Together, we have changed the lives of many. Together, we are making HCV elimination a reality. ABBREVIATIONS: HCV = hepatitis C virus HB&C/IHQ/17-07//1235b Date of preparation: February 2018